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General Introduction
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Iron metabolism, hepcidin and innate immunity
Iron is by mass the most common element on earth, it not only forms most of the earth’s inner 
core which gives it its magnetic field, but it also is the 4th most abundant element of the earth’s 
crust, comprising approximately 5 to 6% of its mass. Its abundant presence is the consequence of 
chemical reactions that occurred long before the earth even started to exist: Iron is formed by the 
decay of radioactive nickel-56, which is formed by nuclear fusion in exploding high-mass stars called 
supernovas. Upon explosion, star debris is scattered through the universe, providing the elements 
from which future planets are built. 
Iron is not only highly abundant: being a transition metal that can easily accept or donate 
electrons, it is also capable of catalyzing numerous chemical reactions. Not surprisingly, virtually all 
living organisms have evolved ways to use this metal to their advantage. As such, all kinds of organisms, 
from small unicellular to large ones use iron as a nutrient. 
Iron: essential and dangerous
Iron is one of the most important nonorganic substances that make life possible. Iron plays major 
roles in oxygen transport, short-term oxygen storage, and energy generation.1 Although iron is vital 
for many basic cellular processes like respiration and DNA replication, there is also another side to 
iron. As Chapter 2 of this thesis points out in more detail, iron homeostasis in the human body needs 
to be carefully maintained, as iron handling poses two major threats. First, being a metal catalyst, iron 
is capable of catalyzing oxidative stress reactions that can cause harm to cells and tissues. Second, 
pathogens require iron for replication and growth, so any available iron will promote infection. 
Therefore, practically all iron within the body is bound to specific proteins and the uptake and storage 
of iron is tightly regulated. 
Iron regulation by hepcidin
Until recently, it was not well understood how systemic iron homeostasis is maintained. In 2000, two 
separate groups discovered the small peptide hormone later called ‘hepcidin’.2,3 Being a member of 
defensin-like peptides, hepcidin was initially reported to have an anti-microbial function.2,3 However, 
when a coincidental knockdown of the hepcidin gene in mice resulted in severe iron overload,4 it 
turned out to be the master regulator of iron homeostasis. Synthesized mainly by the liver, hence 
its name, hepcidin maintains systemic iron homeostasis by binding to the cellular iron exporter 
ferroportin, which is expressed on duodenal enterocytes, hepatocytes, and reticuloendothelial 
macrophages. By binding ferroportin, hepcidin causes its internalization and degradation,5 thereby 
downregulating iron absorption and iron export from storage sites into in the extracellular 
compartment. The net effect is a redistribution of iron from the blood into macrophages of the 
reticulo-endothelial system. Although no absolute shortage of body iron exists, due to the low 
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serum iron levels in the plasma, the bone morrow is restricted from iron, leading to iron-restricted 
erythropoiesis. The discovery of hepcidin gave an enormous impulse to the field of iron biology,6 and 
since then many investigators have reported on the several ways hepcidin is regulated and how it 
exerts its function. This leap forward in the understanding of iron homeostasis has led to better insight 
in existing diseases (e.g. hereditary hemochromatosis) and the discovery of new diseases, such as 
iron refractory iron deficiency anemia (IRIDA), which is the result of inadequately high hepcidin levels 
due to defective hepcidin signaling.7 Moreover it holds the promise for the development of improved 
therapies for patients with anemia, among which is anemia of inflammation.
Anemia
Anemia, the clinical entity that is characterized by a low plasma concentration of hemoglobin, is one of 
the major public health burdens worldwide. In a systematic analysis using data from 1990 to 2010 The 
World Health Organization estimated that the global prevalence of anemia affected 2 billion people, 
indicating that anemia is present in more than 30% of all people.8 The causes of anemia can essentially 
be divided in two groups: anemias caused by loss or destruction of erythrocytes (e.g. due to bleeding 
or hemolysis), and anemia caused by a reduction in the production of new erythrocytes. The latter 
can result from disorders of the bone marrow itself (e.g. aplastic anemia, bone marrow malignancy, 
myelofibrosis), or from deficiencies of hormones (e.g. erythropoietin) or essential nutrients (vitamin B-12, 
or iron). Iron deficiency anemia is the most frequent form of anemia, typically due to nutritional deficiency 
or chronic blood loss and is characterized by decreased serum iron levels and tissue iron stores, while 
regulation of iron homeostasis is intact. Anemia of inflammation is the second most common form of 
anemia, and the most common form encountered in hospitalized patients.9 A retrospective analysis of a 
study in approximately 40000 patients from 28 European nations on preoperative anemia revealed that 
27% of women and 31% of men were anemic.10 Anemia of inflammation is associated with significant 
morbidity and mortality, and increases healthcare costs dramatically, e.g. as a result of a prolonged 
hospital stay, and higher frequency of admission to the intensive care unit compared with patients that 
do not suffer from anemia.10 Investigating the causes of anemia of inflammation, and developing new 
treatments for anemia of inflammation is therefore is of high clinical relevance.
Anemia of inflammation
In anemia of inflammation, acute or chronic inflammatory diseases, including infections, cause an 
immune response characterized by release of inflammatory cytokines. In turn, cytokine release results 
in increased levels of hepcidin. Next to a reduced erythropoietin production and a decreased erythroid 
response of the bone marrow during inflammation, this hepcidin-induced iron restriction ultimately 
causes the development of anemia of inflammation.11-13 Anemia of inflammation is also known as 
‘anemia of chronic disease’. However, as this form anemia also occurs during acute inflammatory 
states as well, e.g. during sepsis (see also chapter 5), anemia of inflammation is the preferred term.
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In intensive care medicine, anemia is highly prevalent. Nearly all patients develop anemia during their 
stay on the intensive care unit (ICU).14,15 Related to this, 40 to 50% of patients receive one or more 
blood transfusions during their ICU stay, although transfusions are independently associated with 
worse outcome.14 It was initially hypothesized that erythropoiesis-stimulating agents may be beneficial 
in the ICU setting, however, several clinical trials with these agents have proven ineffective in intensive 
care patients, possibly because erythropoiesis is impaired due to inflammatory cytokines and reduced 
iron availability.16 The same holds true for intravenous iron supplementation.17,18 At the same time, 
changes  in parameters of iron metabolism in critically ill patients, are strongly related ICU outcome,19 
suggesting that iron homeostasis may offer targets for therapy. This underscores the need for 
increased understanding of anemia of inflammation in ICU patients, the role of hepcidin, and the need 
for alternative therapies.
Iron withholding strategy
Most microbes thrive on iron, as they need it for their replication and growth. The human plasma is a 
particularly hostile environment for microbes. Although as much as 20-25 mg of iron is transported 
from the bloodstream to the bone marrow every day, the freely available iron in plasma is extremely 
low, in the order of magnitude of 10-18 mol/L. As the antibacterial effect of plasma in vitro can 
be attenuated by adding iron, whereas it can be mimicked in vitro by the iron binding molecules 
transferrin and lactoferrin, iron binding molecules are held responsible for the anti-microbial effects 
of plasma.20 It is theorized that during acute infection, several mechanisms interact to further deprive 
microbes from iron. If these mechanisms are compromised, e.g. in the case or iron overload secondary 
to iron supplementation, blood transfusions, or hereditary hemochromatosis, infections with a variety 
of microbes, including viruses and bacteria, occur more often and are more severe.21-23 At the same 
time, infections may be less frequent and less severe in iron-deficient patients, e.g. in malaria,24,25 and 
treating iron deficiency in these cases may be harmful, rather than beneficial.26,27 
Several proteins in the human host are involved in withholding iron from pathogens. Most 
importantly, inflammatory signaling leads to the induction of hepcidin by hepatocytes, which, as 
described earlier, leads to the degradation of ferroportin, resulting in abrogation of iron release 
from macrophages and duodenal cells thereby further reducing iron availability in the plasma. 
Simultaneously, also other processes are activated. Lactoferrin, a glycoprotein similar to transferrin 
that is found in high concentrations in neutrophils and mucosal secretions, can chelate iron also 
at acidic pH, often present in infected areas.28 Neutrophil gelatinase-associated lipocalin (NGAL) 
is released in large amounts during sepsis, and has a bacteriostatic effect through inactivating 
siderophores, which are chelators used by microbes to acquire iron from their environment.29 Natural 
resistance-associated macrophage protein-1 (Nramp1) depletes iron from the phagosome and directs 
it out of the cell,30 thereby starving intracellular (phagosomal) microbes. Transferrin receptor-1 (TfR1), 
the receptor that mediates tranferrin-bound iron uptake in many cell types including macrophages, is 
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reduced in activated macrophages, thereby limiting intracellular iron content.31 Finally, systemic as well 
as local production of hepcidin and expression of ferroportin are regulated on several levels to reduce 
iron availability for pathogens. 
These different processes that represent the iron withholding strategy makes sense from an 
evolutionary point of view, as infections are more likely to determine survival than sterile inflammatory 
diseases. However, with the increasing incidence of (auto-)inflammatory diseases and our ability to 
treat infectious diseases using specific antibiotic treatments, the iron restriction has become more 
harmful than protective for most patients. Therefore, in the last decade much effort has been put in 
elucidating the mechanisms underlying anemia of inflammation and in developing new therapeutic 
strategies. Antagonizing hepcidin seems particularly interesting, given its dominant role in iron 
regulation.
Development of new therapies targeting hepcidin
Ever since its discovery, researchers have attempted to identify means to inhibit hepcidin and/or 
its effects. If hepcidin expression can be inhibited or biologically inactivated, iron trafficking during 
inflammation can be restored and anemia could be prevented or treated. Currently, several therapies 
are being developed to counteract the effects or the expression of hepcidin. Basically, these can be 
divided into three groups: 
1)  Compounds that suppress the production of hepcidin by suppressing the inflammatory 
response (anti-TNF-α or anti-IL-6) or by inhibiting the two major pathways of hepcidin 
production, the BMP6-HJV-SMAD pathway and the IL-6-STAT pathways, e.g. using anti-BMP6 
antibodies, BMP-receptor antagonists, soluble hemojuvelin Fc fusion protein (sHJV.Fc), 
heparins, or STAT3 inhibitors.32-37 
2)  Compounds that neutralize hepcidin after it has been produced. Examples are anti-hepcidin 
antibodies, anticalines, and RNA-based spiegelmers.38-40 
3)  Compounds that inhibit the hepcidin-ferroportin interaction, including cardiac glycosides 
and fursaltiamine.39,41
Next to the direct targeting of hepcidin, iron homeostasis and hepcidin expression can be influenced 
through hypoxia-mediated pathways, such as the stabilization of hypoxia-inducible factors (HIFs) by 
prolyl hydroxylase domnain-2 inhibitors. HIFs stimulate erythropoietin production and directly and 
indirectly reduce hepcidin expression and increase iron absorption at the same time.
As iron redistribution during inflammation is a very basic, primary mechanism plausibly aimed 
at protecting the host by depriving pathogens from iron, the question emerges whether intervening 
in this pathway is a viable therapeutic strategy. Most data on iron metabolism have been obtained 
from interventional studies in animals and observational studies in patients. However, up till now, 
pathophysiological studies into the effects of iron homeostasis modulation in humans in vivo are 
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lacking. In the studies described in this thesis, we have made use of the experimental human 
endotoxemia model, which enabled us to study iron metabolism during acute inflammation in humans 
in vivo. 
Direct immunomodulatory effect of iron and hepcidin
Apart from the effect of inflammation on iron homeostasis and the associated clinical consequences, 
key players of iron homeostasis might also exert direct immunomodulatory effects. Most importantly, 
iron itself is thought to influence the innate immune response through both direct and indirect 
mechanisms. Iron may catalyze oxidative stress reactions, thereby enhancing the innate immune 
response. On the other hand, as will be explained in Chapter 2, many conflicting obervations, mostly 
from in vitro and animal studies, have been reported with regard to NF-ĸB,42 HIF,43 and iNOS signaling,44 
which can be either enhanced or suppressed by altered iron concentrations, suggesting that both 
iron overload and iron deficiency can lead to enhanced inflammatory signaling. In Chapter 3 the direct 
effect of iron loading and iron chelation on innate immunity in humans are described. Also hepcidin 
has been reported to have both pro- and anti-inflammatory effects in vitro and in vivo.45,46 Therefore, 
the direct effect of hepcidin was further investigated, as reported in Chapter 4. 
Experimental human endotoxemia
Historical development of the model
The experimental human endotoxemia model, consists of the intravenous administration of a low 
dose of bacterial endotoxin (also known as lipopolysaccharide [LPS]), which is a constituent of the 
outer-membrane of Escherichia Coli, a Gram negative bacterium. Administration of LPS results in a 
controlled and reproducible systemic inflammatory response that lasts for several hours. Endotoxin 
administration was originally described as a fever-inducing therapy that was used to treat several 
infectious diseases, such as syphilis, in the last decades of the 19th century. William Coley, a surgeon 
who had observed a spontaneous regression of a malignancy in one of his patients who had 
developed erysipelas, developed a mixture of heat-killed bacteria called ‘Coley’s toxin’, and used it for 
the treatment of malignancies. Later, Carswell and colleagues identified a molecule, tumor necrosis 
factor (TNF), which was responsible for the tumoricidal activity that Coley had observed.47 The use of 
Coley’s toxin gained popularity and was used until the mid-20th century. However, the preparations, 
dosages and routes of administration of Coley’s toxin varied, and controlled trials were lacking. 
After it had become clear in the 1940s, that is was the endotoxin present in the outer leaflet of 
the bacterial cell membrane that induced the generalized or non-specific immune response, endotoxin 
was purified from several bacteria and administered to humans to induce febrile reactions, first as a 
treatment for several diseases, but later also for the study of systemic inflammatory responses under 
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controlled conditions. As the potency of the several endotoxin preparations varied, standardization 
of the endotoxin preparation was warranted. In 1976 a large batch of endotoxin from Escherichia 
coli O113 became available through the FDA, designated EC-5, which since then served as standard 
reference material.48 After the EC-5 batch ran out in 1999, a new lot of reference Escherichia coli O113 
endotoxin was prepared by the National Institute of Health, designated Clinical Center Reference 
Endotoxin (CCRE), followed by another batch in 2005.49 The latest batch is currently running out of date 
and a new batch of GMP-certified reference endotoxin is expected to be released in 2016. 
Effects of endotoxin administration
Endotoxin is the ligand for Toll-like receptor 4 (TLR-4), a pattern recognition receptor that is expressed 
on many cell-types, most importantly on macrophages. Upon administration of endotoxin, ligation of 
TLR-4 on macrophages results in initiation of an innate immune response. Initially, this is characterized 
by release of various pro-inflammatory cytokines into the bloodstream and subsequent activation 
of circulating leucocytes. Furthermore, fever is induced, and subjects usually experience flu-like 
symptoms such as headache, nausea, chills, back pain, and muscle aches. Symptoms typically peak 
around 90 minutes following endotoxin administration and gradually subside in the following hours. 
The systemic inflammatory response induced by endotoxin administration results in several effects 
which are also observed in patients that suffer from acute systemic inflammation, including a decrease 
in blood pressure and a compensatory rise in heart rate, reduced vascular sensitivity to vasoactive 
drugs like norepinephrine,50 subclinical kidney injury,51 and activation of the coagulation cascade.52 
Moreover, endotoxemia is accompanied by major shifts in iron homeostasis. Although it can be 
considered a logical consequence of inflammation, it was not until 2005 that Kemna et al. showed 
that urinary hepcidin concentrations were increased during experimental human endotoxemia, 
peaking 6 hours after endotoxin administration, which was accompanied by a major decrease in 
serum iron levels.53 Although the experimental human endotoxemia model has proven to be safe and 
reproducible over the years, several methodological considerations need to be taken into account. 
These are pointed out in the second part of this thesis.
In summary, the experimental human endotoxemia model can serve as a valuable tool to 
investigate the pathophysiology of inflammatory syndromes such as Systemic Inflammatory Response 
Syndrome (SIRS) or sepsis, and to evaluate new immunomodulatory therapies. Moreover, as pointed 
out in the first part of this thesis, it is a suitable model to study changes in iron homeostasis during 
acute inflammation and investigate putative therapies to treat anemia of inflammation . 
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Outline of this thesis
This thesis comprises two parts: the first part focuses on iron metabolism during acute systemic 
inflammation and therapies to target hepcidin during inflammation in humans in vivo. 
This part of the thesis is based on 4 main research questions:
1)  Does iron supplementation or iron chelation have a direct effect on the innate systemic 
inflammatory response in humans?
2) Does hepcidin have a direct effect on the innate immune response?
3) Is hepcidin associated with the development of anemia in sepsis patients?
4) Can hepcidin be pharmacologically targeted in the setting of acute systemic inflammation?
The second part focuses on the experimental human endotoxemia model, and addresses several 
methodological aspects of the model.
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Introduction
Critically ill patients represent a heterogeneous group of patients with a broad array of (co)
morbidities. Although highly divers, there is one characteristic that applies to practically all critically 
ill patients, being that iron homeostasis is greatly disturbed. Iron redistribution is one of the key 
factors contributing to the development of anemia, which is quite common on the intensive care. 
Nearly all patients develop anemia during their stay on the intensive care.1,2 While transfusions are 
independently associated with worse outcome, 40 to 50% of patients receive one or more blood 
transfusions during ICU stay.1 This underscores the need for understanding ICU related anemia and 
finding alternative therapies. The field of iron biology has experienced an enormous impulse since the 
discovery of hepcidin in 2001, the key regulator of iron homeostasis.3 Since then, many investigations 
have focused on iron homeostasis and its interactions with inflammation, which are numerous. 
Although most of the pathophysiological mechanisms have been clarified in animal models and 
chronically inflamed patients, studies in critically ill are limited. However, while anemia on the intensive 
care is frequently encountered, the awareness of the great changes in iron balance that accompany or 
underlie these anemias is low. This review provides an overview of iron biology during inflammation, 
and clarifies its relation with microbial virulence, immunity, and oxidative stress reactions. In addition, 
consequences for the critically ill patient are discussed. 
Iron biology
Undeniably, iron is essential to vertebrate life. It is the fourth most abundant element in the earth’s 
crust, and a lot of species depend on its constant availability, as iron is needed for many basic 
cellular processes like respiration and DNA replication. Although the essence of iron for physiological 
processes is evident, iron is considered a double edged sword, as at the same time iron handling is 
both difficult and dangerous. Difficult because iron is practically insoluble, both in and outside the 
body, as under physiologic conditions iron is readily oxidized to the insoluble ferric (Fe3+) form, and 
dangerous because most microbes thrive well on iron, as they need it for their replication and growth. 
In addition, because iron can catalyze oxidative stress reactions that can cause harm to cells and 
organelles the host may be harmed by iron, while on the other hand oxidative stress reactions are 
necessary to kill invading micro-organisms. To overcome these problems, humans as well as most 
other species, have evolved in a way that enables them to take-up iron and utilize it safely by making 
use of specific protein complexes, such as transferrin, lactoferrin, ferritin and heme proteins, while 
keeping iron away from microbes and not letting it take part in oxidative stress reactions. In addition, 
the major iron transporting molecule transferrin is normally only partly saturated (30-40%), so iron is 
readily bound to transferrin once it appears in the plasma. As a consequence, although as much as 20-
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25 mg of iron is transported through the blood to the bone marrow every day,  the freely available iron 
in plasma is extremely low, in the order of magnitude of 10-18 M.4 
Within the body, most of the iron is stored intracellularly. The total quantity of iron in the human body 
is normally maintained at approximately 50 mg/kg body weight in males and approximately 40 mg/kg 
in females, distributed among functional, transport, and storage compartments. The largest amount 
of iron is present in the erythrocytes, where approximately two-thirds of the total body iron supply is 
build in heme proteins. Another 300-500 mg of iron is conveyed by erythroid progenitor cells of the 
bone marrow. The other major iron storage protein is ferritin, accounting for approximately 500 mg 
of iron, being primarily deposited in hepatocytes and macrophages of the reticuloendothelial system. 
Normally not more than 0.1 percent of the body’s iron (approximately 3 mg) can be found in the 
plasma compartment, where almost all iron is bound to transferrin while it gets transported to cells in 
need for iron, primarily erythroid progenitor cells. 
As iron is a transition metal, it can exist in either a ferric form (Fe3+) or a ferrous form (Fe2+). In 
general, iron within the body exist as ferric iron, bound to molecules that ensure its solubility. Free 
ferrous iron can be found in small amounts within the cytosol, which is referred to as the ‘labile iron 
pool’. In the plasma, iron can also be bound to other molecules than transferrin, among which are 
citrate and albumin. These molecules generally have a much lower affinity for iron, and therefore iron 
which is not bound to transferrin - i.e. non-transferrin-bound-iron (NTBI) - is more likely to participate 
in chemical reactions.5 This is especially the case for ‘labile plasma iron’ (LPI), a fraction of NTBI that is 
involved in oxidative stress reactions, and which will be discussed separately. 
Regulation of iron homeostasis
Hepcidin controls iron homeostasis
The uptake of iron is tightly regulated to meet the systemic iron requirements. Since humans have 
no physiologic mechanism for the active elimination of iron, total body iron is controlled almost 
exclusively by the rate of iron absorption from the duodenum. Two major sources exist via which 
iron can enter the bloodstream (Figure 1). A small quantity of iron (approximately 1-2 mg per day)  
is taken up from duodenal enterocytes, that absorb iron from the gut. But more importantly, most 
of the iron (20-25 mg per day) is recycled by macrophages of the reticuloendothelial system that 
retrieve iron from phagocytized senescent red blood cells.6 Iron enters the cytosol of enterocytes 
and macrophages through divalent metal transporter 1 (DMT1), from where it can either be stored in 
ferritin, or gets exported through iron exporter ferroportin. Once in the plasma, iron is bound primarily 
to transferrin and is taken up by cells expressing the type 1 transferrin receptor (TfR1). Most of the iron 
is transported to the bone marrow, but practically all cell types including immune cells, carry TfR1, as 
they are all dependent on iron to some extent.
41481 van Eijk.indd   25 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
26
The expression of ferroportin on the cell surface of macrophages and duodenal enterocytes is strictly 
controlled by peptide hormone hepcidin, which is produced in the liver in response to a wide range of 
signals. By binding to ferroportin, hepcidin induces the internalization and degradation of ferroportin,7 
thereby downregulating the iron efflux. In circumstances of increased iron demands, the hepcidin 
production is decreased, leading to higher expression of ferroportin and an increase in circulating iron. 
Figure 1. Systemic iron regulation. 
Adapted from Swinkels et al.50, with permission of the authors.
Iron can enter the plasma from duodenal enterocytes, and from macrophages of the reticuloendothelial system, that 
recycle iron from senescent erythrocytes. From the plasma, iron is mainly transported to the bone marrow, where it 
is used for the production of new red blood cells. Hepcidin attenuates the release of iron from macrophages, and the 
uptake of iron from the gut, thereby leading to decreased serum iron levels. Hepcidin is produced in the liver, and 
is induced by increased iron supply and inflammtion, whereas is it down regulated by low iron supply, hypoxia and 
increased erythropoiesis. 
Hepcidin regulation
Four main factors exist that regulate hepcidin expression by hepatocytes; iron status, oxygen tension, 
erythropoietic activity and inflammation (among others reviewed by Fleming et al.8 and Zhao et al.9). 
Iron status regulates hepcidin both through liver iron stores and circulating transferrin bound 
iron. Increased liver iron stores stimulate the hepatic expression of bone morphogenetic protein 6 
(BMP-6). Binding of BMP to its receptor on hepatocytes together with coreceptor hemojuvelin, lead 
to activation of transcription factor SMAD4 (sons of mothers against decapentaplegic homologue 
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protein 4), thereby stimulating hepcidin transcription. Circulating iron-transferrin complexes lead to 
the dissociation of iron sensing molecule HFE from TfR1, after which it complexes with TfR2, leading to 
hepcidin transcription through a signaling cascade that is not yet entirely elucidated, but may involve 
hemojuvelin–induced hepcidin expression via SMAD signaling.
Decreased oxygen tension leads to the increased intracellular levels of transcription factor 
hypoxia inducible factor 1α (HIF1α), that prevents BMP-induced hepcidin production through the 
upregulation of matriptase-2, which cleaves BMP-coreceptor hemojuvelin from the hepatocellular 
surface. Increased erythropoietic activity markedly decreases hepcidin through a mechanism 
that is not entirely clarified. It probably requires one or more soluble signaling molecules. Growth 
differentiation factor 15 (GDF15), and twisted gastrulation protein homolog 1, may be two of these 
factors, but others have yet to be discovered. Inflammation induced hepcidin production is mediated 
through pro-inflammatory cytokines, mainly IL-6, that leads to activation of signal transducer and 
activator of transcription 3 (STAT3) through the IL-6 receptor, thereby activating hepcidin transcription. 
In addition the hepatic expression of activin B, a cytokine of the transforming growth factor- β (TGF-β) 
superfamily, is increased by inflammation, which also activates the BMP receptor pathway and 
increases hepcidin expression.
In summary, hepcidin is induced by increased iron supply and inflammation, and downregulated 
by iron deficiency, hypoxia and erythropoietic activity.
Inflammation induced changes in iron homeostasis
A profound change in body iron distribution is one of the key features of anemia of critical illness, 
diverting iron from the circulation to storage sites. Iron is shifted from the extracellular to the 
intracellular compartment as a results of inflammation by induction of hepcidin production in the 
liver. This leads to the subsequent internalization and degradation of ferroportin on iron exporting 
cells, especially macrophages of the reticuloendothelial system.  The resultant iron restriction leads 
to attenuation of erythropoiesis, a process which is already hampered by the inflammatory process 
through the downregulation of transferrin receptors on erythroid progenitor cells, and the decreased 
production of erythropoietin (EPO), either as a direct effect of inflammatory cytokines, or as a 
consequence from impaired renal function. These mechanism are identical to those that cause anemia 
of chronic disease, and therefore ‘anemia of inflammation’ has been suggested as a better name for of 
anemia that develops in both chronic and acute systemic inflammatory diseases.10
Typical laboratory changes during anemia of inflammation are a lowered serum iron and 
transferrin saturation, and an increased ferritin level. As ferritin may be elevated in a variety of 
conditions, including infection, inflammation and malnutrition, normal or high ferritin does not 
exclude iron deficiency.  Low transferrin saturation in combination with high ferritin level may indicate 
functional iron deficiency. Reticulocyte counts are typically low compared to the grade of anemia, 
and the reticulocyte hemoglobin content is also diminished. Less common laboratory parameters 
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include zinc-protoporpherin, which is elevated in the case of iron restricted erythropoiesis, and 
hepcidin, that is usually augmented in the case of inflammation, whereas suppression of hepcidin 
during inflammation is indicative of absolute iron deficiency. Interestingly, iron deficiency can also exist 
without anemia. However, the relevance of this for critically ill patients is currently not know.
Effects of iron on microbes
Iron affects virulence of pathogens 
It is theorized that the shifts in iron distribution during inflammation contribute to innate immunity by 
withholding iron from pathogens. Iron acquisition is a major determinant for survival and replications 
of microbes within the host. Human plasma is normally a hostile environment for pathogens. As the 
antibacterial effect of plasma in vitro can be attenuated by adding iron, whereas it can be mimicked in 
vitro by transferrin and lactoferrin, iron binding molecules within the plasma are held responsible for 
its anti-microbial effect.11
In vivo series of experiments have demonstrated that animals injected with various forms of 
iron are much more susceptible to infection. Its clinical relevance is substantiated by the observation 
that patients suffering from iron overload are more likely to become infected and experience worse 
outcome.12 In addition, iron supplementation during malaria infection has been related to increased 
mortality.13 
The importance of iron for microbes is further illustrated by the fact that many bacteria and 
fungal strains possess capabilities for the acquisition of iron. Three main strategies of microbes to 
attain iron are 1) the expression of receptors for host iron-binding proteins, such as transferrin, 
lactoferrin and heme, 2) reductive elemental uptake of iron through cell surface reductases, and 3) the 
utilization of siderophores that act as high affinity iron chelators that can scavenge iron from host iron-
carrying molecules. Several hundreds of microbial siderophores have been identified. Exploiting these 
strategies, microbes can survive in the host even at sites where iron concentrations are quite low. 
In addition, animal studies have shown that iron loading worsens experimental sepsis.14 This is 
not only related to the fact that microbes can utilize this iron for growth, but mainly because iron can 
attribute to oxidative stress induced organ damage. In contrast, iron chelation has been shown to 
protect against bacterial growth as well as oxidative stress induced organ damage, and has proven 
beneficial in animal models of sepsis.15 
Intracellular versus extracellular pathogens
As explained above, infection and inflammation lead to intracellular iron sequestration which is 
considered part of innate immunity. However, intracellularly living and dividing pathogens might 
benefit from increased intracellular iron. Indeed, blocking iron efflux by hepcidin or a mutation of 
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ferroportin has a promoting effect on the growth of intracellular pathogens such as Salmonella 
typhimurium, Mycobacterium tuberculosis, Chlamydia psittaci, Chlamydia trachomatis and Legionella 
pneumophila, whereas lowering cellular iron levels by the expression of ferroportin has the opposite 
effect.16 Another striking observation is that iron chelators can inhibit malaria growth in vitro and in 
vivo 17 and iron deficiency in patients may protect against malaria probably because the intracellular 
labile iron pool is significantly reduced during iron deficiency. So, in contrast to the beneficial effect of 
decreased plasma iron in most infections, in case of intracellular infections the opposite may occur. In 
this context, the local transcriptional up-regulation of ferroportin that occurs following infection with 
Salmonella typhimurium or Mycobacterium tuberculosis, could be considered as a innate anti-microbial 
defense mechanism based on iron deprivation.18
Effects of iron on the host 
Innate immunity
Much effort has put in elucidating the effects of iron on the different aspect of immunity. Many 
observations seem conflicting, and illustrate the complexity of the effects of iron. 
With regard to innate immunity, it has been shown that elevated intracellular iron promotes 
NF-ĸB mediated cytokine production,19 while it inhibits expression of the important anti-microbial 
molecule inducible nitric oxide synthase (iNOS).20 On the other hand, low intracellular iron inhibits 
NF-ĸB activity, and iron chelation increases iNOS. Another important transcription factor that is 
affected by iron status is HIF-1α, a molecule that gets degraded swiftly under physiologic conditions.21 
When intracellular iron concentrations are low, HIF-1α is spared from degradation, so it can act as a 
transcription factor for several pro-inflammatory cytokines. Therefore it seems that both iron overload 
and iron deficiency can lead to enhanced inflammatory signaling, either through NF-ĸB or HIF-1α.
The fact the intracellular iron concentrations affect the transcription of inflammatory cytokines 
suggests that ferroportin and hepcidin could also have an immune modulating effect. For hepcidin 
an anti-inflammatory effect has been reported in vitro and in vivo.22,23 But as these findings are not yet 
reproduced, the immune modulating effects of hepcidin are still the subject of debate. 
Less is known about the influence of iron overload on innate immunity. Macrophages from 
HFE-knockout mice, that have high ferroportin levels and therefore low intracellular iron levels due 
to a lack of hepcidin, produced lower amounts of TNF-α and IL-6 compared to wild-type, in response 
to Salmonella typhimurium infections. In vivo this was associated with attenuated inflammation, but 
increased pathogen burden,24 which could be corrected by administration of hepcidin or ferrous 
sulphate. 
Available evidence comes from animal data that show an aggravated immune response and 
associated mortality in murine models of sepsis after iron loading,14 whereas iron chelation appears 
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to attenuate inflammation and improve outcome.15 Direct effects of iron loading and iron chelation 
therapy on innate immunity in humans are yet unknown.
Adaptive immunity
In contrast to innate immunity, the activation of the adaptive immune response is characterized 
by an extensive proliferation of B and T lymphocytes, that rely on their capability of acquiring iron 
through TfR1. Polyclonal proliferation of human B and T lymphocytes can be inhibited by antibodies 
against TfR1.25 Absence of TfR1 results in the complete arrest of T cell differentiation, whereas the 
development of IgM positive B cells is severely attenuated 26. Nutritional iron deficiency is associated 
with impaired lymphocyte function.27 Furthermore, the profile of cytokine expression by lymphocytes 
may be altered by iron deficiency 28 and iron overload.29 
Oxidative stress
Labile plasma iron or poorly liganded iron  have the potential to catalyze Haber-Weiss and Fenton 
reactions,30 whereby superoxide radical and hydrogen peroxide yield the highly reactive hydroxyl 
radical, causing damage to cells and organelles. These reactive oxygen intermediates are inevitable 
byproducts of aerobic respiration and are also generated during several enzymatic reactions. In 
addition, they are produced by the membrane-bound NADPH oxidase complex, which is primarily 
expressed in phagocytic neutrophils and macrophages, serving as a tool for antimicrobial defense.31 
During infection it is used to generated high levels of superoxide in a “respiratory burst” in which 
several species of potent oxidants are formed that enhance microbial killing. 
An increase in the steady state levels of reactive oxygen (and nitrogen) species beyond the 
antioxidant capacity of the organism, called oxidative (and nitrosative) stress, is encountered in many 
pathological conditions, such as systemic inflammation. Although the respiratory burst is needed for 
effective pathogen eradication, oxidative stress causes damage to vital organs and may contribute 
to the development of multiple organ failure.  The kidney may be especially vulnerable as an acid 
environment such as tubular urine enhances the formation of reactive hydroxyl radicals. Concordantly, 
iron and heme-induced oxidative stress caused by cardiopulmonary bypass during cardiac surgery was 
associated with the development of acute kidney injury.32 
The role of NTBI and labile plasma iron in critical illness, and their putative role in oxidative stress 
induced organ injury needs to be further investigated. A practical problem in these investigations is 
that the methods currently available for the measurement of NTBI and labile plasma iron, are not yet 
analytically and clinically validated.  
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Consequences for critical care
Anemia on the intensive care
Anemia is highly prevalent in critically ill and injured patients. Two-third of patients are already anemic 
at admission to the intensive care 1, increasing to 97% of patients by day 8.1,2 ICU-related anemia is 
not only very frequent among critically ill patients, it is also associated with increased transfusion rates 
and worse outcome, including weaning failure,33 myocardial infarction,34 and increased risk of death.35 
More than one-third of all ICU patients receive transfusions sometime during their ICU stay, increasing 
to more than 70% when ICU stay exceeds one week.1 At the same time, the number of transfusions 
is independently associated with longer ICU stay, increased risk of complications and increased 
mortality,1 stressing the importance of understanding the pathofysiology of ICU related anemia and 
finding alternative therapies. In addition, the problem of anemia extends far beyond ICU admission, as 
approximately 50% of patients with anemia at ICU discharge were still anemic 6 months later.36
The development of anemia can be attributed to two main reasons: first erythrocyte lifespan 
is extensively shortened due to hemolysis, the increased clearance of erythrocytes by macrophages, 
diagnostic phlebotomy, tissue injury, invasive procedures and gastrointestinal bleeding. Second, red 
cell production is attenuated during inflammation, due the decreased EPO production and signaling 
and the aforementioned alterations in iron metabolism.
Decreased erythrocyte lifespan
Blood loss due to tissue injury, invasive procedures (drainage, catheter placement, renal replacement 
therapy), gastrointestinal bleeding and systemic inflammation associated hemolysis are obvious 
reasons reduced red cell survival on the intensive care. Less obvious is the loss of blood through 
diagnostic phlebotomy, which represents a mean daily loss of 40 to 70 ml of blood, while under 
physiological conditions only 2-3 ml of new erythrocytes are formed per day. This phenomenon, 
termed the “anemia of chronic investigation”,37 has been reported to account for 30% of required 
blood transfusions. Including other reasons for blood loss the median total loss of blood for anemic 
critically ill patients has been calculated to be as high as 128 ml per day,38 representing a daily iron loss 
of 64 mg, exceeding normal iron intake more than 20 fold. When considering that during inflammatory 
states hardly any iron is absorbed due to the actions of hepcidin, the imbalance in iron uptake and iron 
loss is even greater.  
An increased clearance of erythrocytes by macrophages during the inflammatory process has 
gained more attention in the last decade. It seems that inflammation leads to stress on erythrocytes 
that may be mediated through cytokines, hypoxia, disturbances in acid-base balance, endothelial 
damage, oxidative stress or alterations in lipid metabolism, resulting in damage to the red cells and 
increased phosphatidylserine expression on red cell membranes, flagging them for removal by 
macrophages of the reticuloendothelial system.39 In addition, a sudden and continued drop in EPO 
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production as can be observed during acute inflammatory states, may promote the clearance of a 
subset of young erythrocytes by macrophages.40
Attenuation of red cell production during inflammation
A decreased erythrocyte production during inflammatory states is the result of three main 
mechanisms.41 First, EPO concentrations fall quickly and remain inappropriately low during 
inflammation, probably as a result of  a combination of decreased renal function and proinflammatory 
cytokine inhibition. Second, the response of erythroid progenitor cells to EPO is attenuated as well, as 
a result of direct effects of cytokines, and down regulation of EPO receptors. Third, as described earlier, 
several cytokines such as IL-1β, IL-6 and TNF-α induce hepcidin production, leading to less serum iron 
available for the bone marrow. This limits iron availability for erythroid progenitor cells and impairs 
heme biosynthesis, leading to iron restricted erythropoiesis.41 This pathway has indeed been shown 
to be relevant for the anemia observed in sepsis patients,42 as hepcidin levels correlated with the 
extend of anemia and blood transfusions needed. The impaired iron homeostasis and EPO signaling is 
worsened by medication that is often used on the intensive care. Norepinephrine and phenylephrine 
directly inhibit hematopoietic precursor maturation. Furthermore, EPO release is suppressed by ACE 
inhibitors, angiotensin receptor blockers, calcium channel blockers, theophylline, and β-adrenergic 
blockers. 
Erythropoiesis-stimulating agents
As the impaired production of EPO and the blunted response to EPO together with iron restriction 
are central to the anemia of inflammation, some studies have attempted to stimulate erythropoiesis 
with exogenously administrated EPO in critically ill patients. In a meta-analysis the odds of a patient 
receiving a blood transfusion was significantly reduced and the number of units of blood transfused 
per patient was decreased. However, no statistically significant effect on length of stay in hospital of 
intensive care, nor on overall mortality was found.43
 
Iron supplementation for the critically ill
Low serum iron  and high ferritin levels constitute the typical iron profile of critically ill patients and are 
indicative of an inflammatory iron profile. Despite generally high ferritin levels, iron deficiency often 
coexist with inflammation and may concern up to 40% of critically ill patients. Therefore, it has been 
suggested that iron supplementation, alone or in combination with erythropoiesis-stimulating agents 
may be beneficial also in the setting of the intensive care.  As mentioned earlier, iron has been shown 
to promote the growth and virulence of a number of microbes responsible for nosocomial infections. 
As a result, concern exists for greater infection rates and (oxidative stress induced) organ injury with 
iron supplementation. Although this outcome is biologically plausible, evidence from human studies 
is lacking. Multiple studies have failed to show any increased risk of infection associated with iron 
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therapy in chronic hemodialysis patients.44 Few studies have examined iron supplementation in the 
critical care population. Available observational studies in postoperative or critically ill patients show no 
association between intravenous iron administration and risk of infection.45 In 863 patients undergoing 
cardiopulmonary bypass surgery who were subsequently treated with both intravenous iron and 
erythropoietin or with blood transfusions, there was no difference in subsequent infection rate.46 In a 
trial of 200 patients receiving care in a surgical ICU,47 it was shown that enteral iron supplementation 
(ferrous sulfate 325 mg three times daily) reduced transfusion rate in patients with baseline iron 
deficiency. Finally, intravenous iron therapy with and without erythropoietin administration reduces 
allogeneic blood transfusions in surgical patients.48 Apparently, iron appears to be effective in 
correcting anemia, despite inflammation. Moreover, none of these studies has shown a clear adverse 
effect on infection rates, which is compatible with the notion that especially the NTBI fraction is 
important for the risk of infection, whereas this fraction is usually low in iron deficient patients even 
after iron treatment. Currently a multicenter randomized clinical trial of intravenous iron for the 
treatment of anemia in critically ill trauma patients is being performed (ClinicalTrials.gov identifier 
NCT01180894). 
In addition to the absence of clear evidence that iron administration is harmful to the iron 
deficient critically ill patient, iron deficiency is also associated with impaired immunity and increased 
susceptibility to infection, as well as being associated with increased length of stay in the ICU,49 
providing an extra reason to further examine the possible role of iron administration in the setting of 
intensive care medicine.
Future perspectives
Although iron homeostasis is particularly complicated, it is clear that iron can play a crucial role during 
infection of inflammation in critically ill patients. However, although the discovery of several novel 
players in iron metabolism, including hepcidin and its interaction with ferroportin have resulted in an 
enormous impulse in research on iron biology, still a lot has to be learned, especially with regard to 
the setting of the intensive care. Future research should clarify whether iron plays a detrimental role 
in the development of organ failure or not. Most notably, the occurrence of labile plasma iron during 
operative procedures and during intensive care stay, and its relation with the occurrence of organ 
dysfunction should be investigated. In addition iron could play a decisive role in infections, where for 
some reason pathogens are not fully eradicated, despite optimal antimicrobial treatment and hold 
potential for therapeutic intervention. 
Furthermore, in the case of iron deficiency, the possibility of treating anemia with intravenous 
iron supplementation in critically ill patients should be further examined, either in combination with 
erythropoiesis-stimulating agents or not. Especially in elective large surgical procedures like coronary 
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artery surgery, early iron fortification can probably accelerate recovery, and prevent complications 
from anemia. Finally therapies directed against the action of hepcidin are being developed, which may 
be useful in the future treatment of anemia of critical illness. 
Conclusion
Profound changes in iron metabolism occur in critically ill patients. This is predominantly the result 
of both blood loss and the inflammatory process. These changes are relevant to the intensive care 
patient for three reasons: 1) anemia is frequently observed in critically ill patients, is associated with 
impaired immunity and worse outcome, and cannot be adequately compensated by transfusions or 
erythropoietin stimulating agents, whereas there might be an additive role for iron supplementation. 2) 
Iron homeostasis may determine the fate of an infection, as iron is an essential nutrient for pathogens, 
and therefore future research should clarify the exact role of bound and unbound iron and in critically 
ill patients suffering from infections. 3) Iron can catalyze oxidative stress reactions that cause organ 
damage, especially when non-transferrin-bound or labile iron exists. This is especially relevant to the 
critically ill patients as they are likely to suffer from oxidative stress and organ failure, whereas at the 
same time  increased labile iron concentrations are more likely to be present. Future studies should 
further clarify the role of iron in critical illness and organ dysfunction, as the prevention of non-
transferrin-bound or labile iron could attribute to the prevention of organ dysfunction, whereas at the 
same time, iron supplementation or counteracting the actions of hepcidin, may represent an adjuvant 
therapy to prevent anemia of critical illness. 
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Abstract
In this double-blind randomized placebo-controlled trial in 30 healthy male volunteers we investigated 
the acute effects of iron loading (single dose of 1.25 mg/kg iron sucrose) and iron chelation therapy 
(single dose of 30 mg/kg deferasirox) on iron parameters, oxidative stress, the innate immune 
response and subclinical organ injury during experimental human endotoxemia. 
The administration of iron sucrose induced a profound increase in plasma malondialdehyde 1 
hour after administration (433±37% of baseline,  p<0.0001), but did not potentiate the endotoxemia-
induced increase in malondialdehyde, as was seen 3 hrs after endotoxin administration in the placebo 
group (p=0.34) and the iron chelation group (p=0.008). Endotoxemia resulted in an initial increase in 
serum iron levels and transferrin saturation that was accompanied by an increase in labile plasma iron, 
especially when transferrin saturation reached levels above 90%. Thereafter, serum iron  decreased 
to 51.6±9.7% of baseline at T=8 hrs in the placebo group , versus  84±15% and 60.4±8.9% of baseline 
at 24 hrs in the iron sucrose and deferasirox treated groups, respectively. No significant differences in 
the endotoxemia-induced cytokine response (TNF-α, IL-6, IL-10 and IL-1RA), subclinical vascular injury 
and kidney injury were observed between groups. However, vascular reactivity to noradrenalin was 
impaired in the six subjects in which labile plasma iron was elevated during endotoxemia as opposed 
to those in which no labile plasma iron was detected  (p=0.029). 
In conclusion, a single dose of iron sucrose does not affect the innate immune response in a 
model of experimental human endotoxemia, but may impair vascular reactivity when labile plasma iron 
is formed. (clinicaltrials.gov identifier: NCT01349699)
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Introduction
Systemic inflammation is accompanied by profound changes in iron distribution, mainly under the 
influence of hepcidin, leading to sequestration of iron in macrophages of the reticuloendothelial 
system, and ultimately anemia of inflammation.1 This redistribution of iron may represent an 
effective defense mechanism against a variety of pathogens, that need iron for replication and 
growth. The fact that iron withholding strategy is such a highly conserved part of the innate 
immune response illustrates that iron homeostasis and immunity are closely related. Concordantly, 
several studies in animal models have revealed immune modulatory effects of both iron and iron 
chelation: Iron sucrose has been shown to potentiate the inflammatory response and associated 
mortality,2 while iron chelation appears to attenuate inflammation and improve outcome in murine 
models of inflammation and sepsis.3-6 The immune modulatory effects of iron supplements and 
chelators are mainly attributed to their ability to potentiate or reduce the formation of reactive 
oxygen species (ROS). A subfraction of non-transferrin bound catalytically active iron, labile plasma 
iron, is thought to be responsible as this free iron is able to easily donate or accept electrons, 
thereby fueling redox reactions. Oxidative stress is associated with propagation of the immune 
response,7 endothelial dysfunction,8,9 and contributes to the organ damage that occurs during 
systemic inflammation.10 In accordance, anti-oxidants exert anti-inflammatory effects.11,12 As such, 
iron chelation has been suggested to be a valuable adjuvant therapy during infection for two 
distinct reasons: inhibition of bacterial growth and protection of organs against inflammation 
induced oxidative stress. 
Effects of iron status on the immune response has up till now mainly been investigated in in vitro 
and in animal models, often using supra-therapeutic dosages of iron donors or iron chelators. Data 
on the effect of iron loading and iron chelation during systemic inflammation in humans are lacking. 
The objectives of the present study were to investigate the acute effect of therapeutic dosages of iron 
loading and iron chelation therapy on iron homeostasis, oxidative stress, the innate immune response, 
and subclinical organ injury during systemic inflammation induced by experimental endotoxemia in 
humans in vivo. 
Methods 
Design 
This double-blind, randomized, placebo-controlled trial (clinicaltrials.gov identifier: NCT01349699) 
was approved by the local ethics committee, and carried out according to GCP standards and the 
declaration of Helsinki. After they gave written informed consent, thirty healthy non-smoking male 
subjects were randomly treated with either iron loading (iron sucrose), or iron chelation (deferasirox) 
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or placebo, prior to the intravenous administration of 2 ng/kg purified E.Coli endotoxin as described in 
detail in the Online supplementary Design and Methods.
Iron loading and iron chelation therapy
At T=-2 hrs (2 hours before endotoxin administration), iron chelation therapy (deferasirox [Exjade®], 
Novartis, Netherlands) or placebo (starch powder) was administered orally. A commonly applied 
dose of 30 mg/kg of deferasirox 13 was dissolved in water and was stirred until the moment of 
intake. Subjects drank the suspension within 1 minute. The time point of deferasirox administration 
was chosen so that maximal plasma levels were achieved between 0 and 2 hrs after endotoxin 
administration, just before and during the expected peak of the pro-inflammatory cytokine response. 
At T=-1 hr, a generally applied therapeutic dose 14 of 1.25 mg/kg iron sucrose (Venofer®, Vifor 
Nederland BV, Netherlands), or placebo (NaCl 0.9%), was intravenously administered through blinded 
syringes and lines. Because the two therapies had different administration routes, a double dummy 
was used to ensure adequate blinding.
Iron homeostasis analysis
Serum iron, ferritin, transferrin and soluble transferrin receptor (sTfR), hepcidin, GDF-15 and labile 
plasma iron were determined as described in the supplementary Design and Methods. 
Oxidative stress and cytokine measurements
Oxidative stress (malondialdehyde) and plasma levels of pro-inflammatory cytokines TNF-α and IL-6, 
the anti-inflammatory cytokines IL-10 and IL-1ra, and markers of endothelial activation Vascular Cell 
Adhesion Molecule (VCAM) and Intercellular Adhesion Molecule (ICAM) were determined as described 
in the Online supplementary Design and Methods. 
Subclinical organ injury 
Subclinical endothelial injury was assessed by measuring the changes in response of the forearm 
vasculature to the infusion of vasoactive medication into the brachial artery, using venous occlusion 
plethysmography. For the determination of subclinical renal tubular damage, urinary Glutathione 
S-Transferase Alpha-1-1 (GSTA1-1) and Glutathione S-Transferase-Pi-1-1 (GSTP1-1) were determined. A 
detailed description is provided in the Online supplementary Design and Methods.
Stastistical analysis
Data are expressed as mean±SEM, or median[25th-75th percentile], depending on their distribution. A 
p-value of 0.05 was considered statistically significant. For all outcome variables, the intervention groups 
were compared to the placebo group in two separate analyses.  Group means or medians were tested 
using students T-test for parametric data and Mann Whitney–U test for non-parametric data. Changes 
41481 van Eijk.indd   42 18-08-16   16:17
The effect of iron loading and iron chelation on the innate immune
response and subclinical organ injury during human endotoxemia, a randomized trial
43
3
over time for each treatment group were analyzed by one-way ANOVA-repeated measures and post-hoc 
testing was performed with Dunnett’s Multiple Comparison Test. Differences over time between groups 
were analyzed using two-way ANOVA-repeated measures (interaction term: time*treatment). Peak levels 
of cytokines were correlated to oxidative stress levels using Spearman’s correlation coefficients. The 
analysis of forearm blood flow (FBF) and a power calculation are described in the Online supplementary 
Design and Methods. 
Results
No significant differences between the intervention groups with respect to demographic data and anti-
oxidative status were found (Table 1). 
Symptoms and hemodynamic sequelae
Iron sucrose and deferasirox treatment were well tolerated. Experimental endotoxemia resulted in 
flu-like symptoms (shivering, headache, backache, muscle ache and nausea), that gradually declined 
to baseline values at the end of the experiment (T=8 hrs). There were no differences between the 
treatment groups, measured by a cumulative subjective symptom scoring list that was described 
previously 15 (data not shown). Body temperature in the three treatment groups increased with 
2.2±0.1°C,  no differences were observed between groups. Also, the hemodynamic response to 
endotoxemia (increase in heart rate of 25.6±1.7 bpm and decrease in mean arterial pressure of 
11.5±1.5 mmHg) was not influenced by iron loading or iron chelation treatment (Table 2).
Table 1. Demographic data and anti-oxidative status
Iron sucrose
(n=10)
Deferasirox
(n=10)
Placebo
(n=10)
p-value
Demographic data
Age (yrs) 21.4 ± 0.6 21.7 ± 1.3 22.7 ± 0.9 0.63
Weight (kg) 75.7 ± 2.0 74.8 ± 4.4 79.0 ± 2.4 0.61
BMI kg/m2) 22.3 ± 0.4 22.5 ± 0.7 23.3 ± 0.8 0.53
Forearm volume (mL) 1115 ± 48 1066 ± 70 1119 ± 38 0.74
Anti-oxidative status
Vitamin A (μmol/L) 2.4 ± 0.2 2.2 ± 0.1 2.2 ± 0.1 0.54
Vitamin C (μmol/L) 51.0 ± 2.0 57.8 ± 4.9 46.5 ± 1.4 0.052
Vitamin E (μmol/L) 23.9 ± 1.4 23.6 ± 1.6 23.1 ± 1.1 0.92
Bilirubin (μmol/L) 14.0 ± 1.4 11.5 ± 2.1 12.1 ± 1.1 0.53
Total cholesterol 
(mmol/L)
4.4 ± 0.2 4.0 ± 0.2 4.2 ± 0.1 0.28
Anti-oxidative status was measured at screening. Data expressed as mean±SEM. No differences between groups 
were detected by one-way ANOVA.
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Table 2. Hemodynamic changes during experimental endotoxemia
Iron sucrose
(n=10)
Deferasirox
(n=10)
Placebo
(n=10)
p-value
ΔHR (bmp) + 24.5 ± 2.9 + 26.9 ± 3.7 + 25.3 ± 2.3 0.85
ΔSBP (mmHg) - 15.9 ± 2.7 - 10.6 ± 2.3 - 16.9 ± 3.6 0.27
ΔMAP (mmHg) - 12.6 ± 2.2 - 7.9 ± 2.7 - 14.2 ± 2.4 0.19
ΔDBP (mmHg) - 6.5 ± 2.0 - 4.0 ± 3.3 - 9.2 ± 1.7 0.33
Difference (Δ: delta) between mean value of T=-4 to T= -2 hrs and T=4 and T=6 hrs after the administration of 
endotoxin. HR: Heart Rate, MAP: Mean Arterial Pressure, DBP Diastolic Blood Pressure. Data are expressed as 
mean±SEM. No differences between groups were detected by one-way ANOVA.
Iron parameters
Administration of iron sucrose resulted in a profound increase of serum iron to 218±17% of baseline 
(Figure 1A). Serum iron levels initially increased during LPS-induced systemic inflammation in all three 
groups, reaching peak levels at approximately 3 hrs after LPS administration, followed by a gradual 
decrease, reaching its lowest values at T=8 hrs in the placebo group (51.6±9.7% of baseline) and 24 hrs 
in the iron sucrose and deferasirox treated groups (84±15 % and 60.4±8.9% of baseline, respectively). 
Transferrin saturation showed the same profile (data not shown), peaking at T=3 hrs. Iron chelation 
did not reduce serum iron levels, which can be explained by the fact that in the serum iron analysis, 
the total of both chelated and unchelated iron is determined.16 When serum iron was elevated, 
transferrin saturations of >90% were reached in 5 out of 10 iron sucrose treated subjects, whereas 
this was observed in none of the deferasirox treated and 1 of the placebo treated subjects. Ferritin 
was increased at 3 hrs after LPS administration, after which it reached a plateau in the placebo- and 
deferasirox treated group, while further increasing in the iron sucrose treated group (Figure 1B). 
TIBC was increased at T=24 hrs (Figure 1C), as was sTfR (Figure 1D). GDF-15 peaked at 6 hrs post-LPS 
(Figure 1E). The latter three parameters were not influenced by iron loading or chelation treatment. 
Hepcidin was markedly induced by LPS-induced inflammation, reaching its peak levels at 6 hrs following 
LPS administration (Figure 1F). Again, no differences between the treatment groups were observed. 
Treatment with iron sucrose did not result in measurable LPI levels at T=0 (Figure 2A). However, at T=2  
and 3 h, simultaneous with the endotoxin-induced rise in serum iron and transferrin saturation, LPI was 
increased in 5 out of 10 iron sucrose treated subjects, compared to 1 placebo treated subject (Figure 
2A-B). Importantly, LPI formation most notably occurred when transferrin saturation was >90% (Figure 
2C).
Oxidative stress
The administration of iron sucrose induced a profound increase in plasma lipid peroxidation products 
(MDA) at T=0 h (433±37% of baseline,  p<0.0001) (Figure 3). In this group MDA remained elevated in 
comparison with the other two groups until 3 hrs after LPS administration. Three hrs after endotoxin
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Figure 1. Iron parameters. 
IS: iron sucrose. DFX: deferasirox. Plac: placebo. NS: Not significant. Arrows indicate the time points of deferasirox 
and iron sucrose administration. Changes over time for each treatment group were analyzed by one-way ANOVA-
repeated measures followed by Dunnett’s post-hoc test: †: significant change from baseline in iron sucrose 
group; *: significant change from baseline in deferasirox group. # significant change from baseline in placebo 
group. Differences between groups were analyzed using two-way ANOVA-repeated measures (interaction term: 
time*treatment). The intervention groups were compared to the placebo group in separate analyses. Significant 
interactions between treatments are depicted within each graph. Data are represented as mean±SEM. 
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administration a similar inflammation-induced increase in MDA was observed in the placebo 
group (p=0.34) and the iron chelation group (p=0.008). Iron-administration did not potentiate the 
endotoxemia-associated increase in oxidative stress at T=3 hrs. MDA increases were not related to LPI 
formation in any way. 
Figure 2. Labile plasma iron and transferrin saturation. 
(A) Mean labile plasma iron levels in the three treatment groups. Changes over time for each treatment group were 
analyzed by one-way ANOVA-repeated measures followed by Dunnett’s post-hoc test: †: significant change from 
baseline in iron sucrose group. No significant changes were detected in the other treatment groups. IS: iron sucrose. 
DFX: deferasirox. Data are expressed as mean±SEM. (B) Transferrin saturation of the subjects in the iron sucrose 
treated group. Open dots: samples in which no labile plasma iron was detected, black dots: samples in which labile 
plasma iron was detected. Note that in general, labile iron was only positive in subjects where transferrin saturation 
increased above 90%. (C) Labile plasma iron in relation to transferrin saturation in iron sucrose treated subjects at 
T=2h and T=3h.
Plasma cytokines
Endotoxemia resulted in increased plasma levels of pro-inflammatory cytokines (Figure 4A- 4B). The 
TNF-α response was similar in the different groups. The increase in IL-6 tended to be potentiated in 
the iron sucrose treated group compared with the other treatment groups (p=0.052). No correlations 
between iron parameters and pro-inflammatory cytokines were found. In particular, no correlation was 
found between LPI or MDA and pro-inflammatory cytokine production. 
The anti-inflammatory response, illustrated by plasma levels of IL-10 and IL-1ra, was similar 
in all three groups (Figure 4C-D). For the three groups combined, plasma levels of ICAM and VCAM 
gradually increased after the endotoxin challenge from 84±5 and 164±7 pg/mL to peak levels of 
161±12 (p<0.0001) and 259±10 ng/mL (p<0.0001), respectively at T=24 hrs (data not shown). Again, no 
differences were observed between the treatment groups and no correlations were found with iron 
parameters.
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Figure 3. Oxidative stress. 
Malondialdehyde (MDA) concentrations as a measure of oxidative stress. IS: iron sucrose. DFX: deferasirox. Plac: 
placebo. NS: Not significant. Arrows indicate the time points of deferasirox and iron sucrose administration. # Effect 
of endotoxin administration on oxidative stress. Changes over time for each treatment group were analyzed by 
one-way ANOVA-repeated measures followed by Dunnett’s post-hoc test: †: significant change from baseline in iron 
sucrose group; *: significant change from baseline in deferasirox group. # significant change from baseline in placebo 
group. Changes over time were significant in the iron sucrose group (P<0.0001) and the deferasirox group (p=0.008), 
but not in the placebo group. Differences between groups were analyzed using two-way ANOVA-repeated measures. 
The intervention groups were compared to the placebo group in separate analyses. Significant interaction between 
treatments are depicted within the graph. Data are represented as mean±SEM. †: significant change from baseline in 
iron sucrose group; *: significant change from baseline in deferasirox group.
Subclinical organ injury
Vascular reactivity as measured by changes in forearm blood flow in response to intrabrachial infusion 
of vasoactive drugs was reduced after endotoxemia (Figure 5). Elevated MDA levels caused by infusion 
of iron sucrose prior to endotoxemia were not associated with the inflammation-induced vascular 
hyporesponsiveness, and iron chelation had no ameliorating effects. However, subjects in which 
elevated LPI levels were found 2 or 3 hrs after endotoxin administration (5 subjects in iron sucrose 
group and 1 in placebo group), did show a more pronounced inflammation-induced reduction of 
vascular reactivity to noradrenalin compared with those that showed no LPI increase (48.5[19.7 – 
80.8] % of baseline response in LPI positive subjects vs 84.3[61.7 – 121.1] % in LPI negative subjects, 
p=0.029). No correlation between MDA and vascular dysfunction was observed.
The excretion of markers of subclinical kidney injury GSTA1-1 (proximal tubule injury) and GSTP1-
1 (distal tubule injury) was increased after endotoxin administration in all three groups. Treatment with 
either iron sucrose or deferasirox had no effect on the urinary excretion of GSTA1-1 and GSTP1-1 in 
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comparison to the placebo group. Furthermore, excretion of these markers was not related to LPI or 
oxidative stress. For the three groups combined, median GSTA1-1 excretion increased from 234[87-
452] ng/mmol creatinine at baseline, to 1123[611-2194] ng/mmol creatinine at T=12 hrs after LPS 
treatment, and returned to baseline levels at T=24 hrs (189[52-309] ng/mmol). GSTP1-1 increased 
from 85[32-209] ng/mmol creatinine at baseline, to 1120[414-1442] ng/mmol creatinine at T=12 hrs 
and also normalized at T=24 (154[84-338] ng/mmol). 
Figure 4. Cytokine production during endotoxemia. 
Data are represented as median with interquartile range. Changes over time for each treatment group were analyzed 
by one-way ANOVA-repeated measures followed by Dunnett’s post-hoc test: Changes over time were significant in 
all subgroups for all parameters. †: significant change from baseline in iron sucrose group; *: significant change from 
baseline in deferasirox group. # significant change from baseline in placebo group. Differences between groups were 
analyzed using two-way ANOVA-repeated measures. The intervention groups were compared to the placebo group 
in separate analyses. No significant interactions between treatments were detected. As there was a trend towards a 
higher IL-6 in the iron sucrose group, peak levels for this parameter were additionally compared to the placebo group 
using the Mann Whitney U test: p=0.052.
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Figure 5. Vascular dysfunction. 
Vascular dysfunction measured by Forearm Blood Flow (FBF) measurements before endotoxin administration (open 
circles) and 4-6 hrs after endotoxin administration (closed circles). In panels A, B and C dose response curves to 
Achetylcholine (Ach), Nitroglycerin (NTG), Norepinephrine (NE) are presented, respectively. Increases and decreases in 
FBF were expressed as percentage change from baseline. The results of all 30 subjects are combined in these three 
graphs, showing that the vascular responsiveness to Ach, NTG and NE were significantly attenuated after endotoxin 
administration. Data are presented as mean±SEM. In panel D, E and F, the relative response after LPS administration 
is expressed as a percentage of the response before endotoxin administration by comparing the area under the 
curve (AUC) before and after endotoxemia to enable the evaluation of differences between the treatment groups. 
Data in these graphs are expressed as median and interquartile range. No differences in relative decrease in vascular 
responsiveness were present between the three groups.
Discussion
This study shows that administration of a single dose of iron sucrose results in an increase in oxidative 
stress, while it does not significantly modulate the acute innate immune response or inflammation-
induced end-organ dysfunction in humans in vivo. In line with these findings, iron chelation with 
a single dose of deferasirox did not alter acute effects of  experimental endotoxemia in healthy 
volunteers with regard to inflammation-induced oxidative stress, the innate immune response, and 
subclinical end-organ dysfunction. However, when transferrin becomes saturated following iron 
sucrose infusion, formation of redox active labile plasma iron during endotoxemia is associated with 
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a more pronounced inflammation-induced reduction in vascular reactivity to noradrenalin, indicating 
that in a subgroup of subjects infused with iron sucrose, iron does exert deleterious vascular effects 
during inflammation.
In accordance with previous studies,17,18 the administration of iron sucrose resulted in an 
increase in oxidative stress, as reflected by the markedly elevated amount of lipid peroxidation 
product MDA. In the present study we found that while systemic inflammation elicited by endotoxemia 
increased oxidative stress, iron administration does not potentiate the inflammation-induced 
oxidative stress response or release of pro-inflammatory cytokines, despite the increment in labile 
plasma iron that was observed in a subgroup of iron sucrose treated individuals. These findings 
during systemic inflammation in humans in vivo are in contrast with previous findings in animals. 
Iron sucrose administered together with heat killed E.Coli in rats was shown to significantly enhance 
cytokine production and was associated with increased mortality.2 It was speculated that the iron 
sucrose-mediated increase in oxidative stress was responsible for amplification of the inflammatory 
response. Importantly, supra-pharmacological doses of iron sucrose were used in the animals, 
being approximately 40 times higher than the dose generally administered in humans 19 and used in 
the present study. Furthermore, the dose used in rats elicited a significant increase in TNF-α in the 
absence of E. Coli,2 therefore, the difference in iron dosages may explain the difference in results. 
Although we found a trend towards increased endotoxemia-induced IL-6 peak levels in iron-treated 
subjects, no effect on the production of TNF-α was observed, indicating that pharmacological doses 
of iron do not relevantly influence the innate immune response in humans in vivo. Our findings 
correspond to clinical observations of patients suffering from inflammatory bowel disease that 
are dependent of intra-venous iron supplementation to restore inflammation-associated anemia. 
The majority of these patients experience no effects or even a beneficial effect on inflammation-
related disease activity.20 However, since experimental endotoxemia is a model of acute and short-
lived systemic inflammation in which we treated the subjects with a single bolus of iron sucrose or 
deferasirox, we do acknowledge that  the absence of an acute immune modulating effect of iron in the 
present study, does not necessarily exclude a possible effect of iron in chronically iron loaded patients, 
such as those suffering from sickle cell disease, thalassemia or chronic kidney disease. Furthermore, 
our study does not rule out a possible immune modulating role of hepcidin during these chronic 
diseases.21
We determined vascular reactivity and excretion of markers of tubular damage in the urine as 
parameters of inflammation-induced subclinical end-organ dysfunction. In accordance with previous 
studies of our group 22 and others,23 experimental endotoxemia resulted in vascular hyporeactivity. 
Overall, iron sucrose treatment  did not directly exacerbate inflammation-induced endothelial 
dysfunction. In a previous study in human volunteers in the absence of systemic inflammation, 
it was found that endothelial dysfunction of the brachial artery occurred following iron sucrose 
administration, but had restored at 4 hrs after administration.8 Therefore, in our study, the endothelial 
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damage that may have occurred due to the oxidative stress caused by iron sucrose itself could have 
subsided by the time inflammation-induced endothelial dysfunction occurred.23 However, iron sucrose 
treatment contributed to the saturation of transferrin that occurred at T=2 to 3 h after endotoxin 
administration thereby contributing to LPI formation. LPI formation was shown to be associated with 
increased vascular dysfunction caused by inflammation. We confirmed our previous findings that 
endotoxemia induces subclinical renal damage of both the proximal tubule and the distal tubule.24 Iron 
loading before LPS administration did not modify the urinary excretion of the tubular injury markers, 
indicating that iron does not exert a direct toxic effect on tubular cells, and does not exacerbate 
inflammation-induced tubular damage. 
Of interest, labile plasma iron levels did not correlate with MDA. Possibly this is the result of a 
large difference in plasma half life; where LPI only exists shortly, whereas MDA products are eliminated 
more gradually. Therefore, as LPI was not measured directly following iron sucrose treatment, we 
cannot exclude the possibility that a correlation between LPI and MDA levels is present directly 
following iron sucrose infusion.
Beneficial effects of iron chelator deferrioxamin on both inflammatory parameters and outcome 
in rodent models of sepsis have been reported.4-6 Moreover, iron chelation therapy has been shown 
to work synergistically with antibiotics in the treatment of murine sepsis.25,26 Several explanations for 
the differences with our findings in humans can be put forward. First of all, the majority of studies in 
which a beneficial effect of iron chelation therapy was found were performed in rodents or in vitro. 
Besides the fact that extrapolation to humans may be problematic, there are important differences 
in routes of administration and dosages administered. In animals, the iron chelator deferrioxamin 
is usually given as bolus injection, whereas in humans, it is needs to be administrated as a slow 
infusion over 8 to 24 hrs, to avoid possible toxicity associated with high plasma levels. For this proof 
of principle study we aimed to reach a high concentration of iron chelator between 0 and 2 hrs after 
endotoxin administration, the time window in which the inflammatory cascade is being activated  and 
pro-inflammatory cytokines reach their peak levels. Therefore, we chose to administer deferasirox, 
a relatively new iron chelator that can be administered orally at once, has a good bioavailability of 
approximately 70%, with peak plasma levels between 2 and 4 hrs after ingestion,27 and has  been 
shown to protect against oxidative stress-induced damage in patients.28-31 We chose a relatively high 
dosage of 30 mg/kg.32 Although deferasirox has roughly the same characteristics as deferrioxamin 
with regard to the chelation of iron, there might be a difference in anti-oxidative capacity between 
the two compounds. While deferasirox exerts anti-oxidative effects in animals models and patients,33 
deferrioxamin exerts anti-oxidative effects even after pre-saturation of the deferrioxamin-molecule 
with iron,6 suggesting an anti-oxidative effect of the molecule itself, while this has not yet been 
established for deferasirox. The fact that deferasirox may not exert anti-oxidative effects by itself may 
in part explain why no effect on the inflammation-induced oxidative stress was observed. The fact that 
inflammation-induced oxidative stress was not attenuated by deferasirox may also explain why no 
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effect on inflammation-induced endothelial dysfunction was found. Furthermore, LPI formation could 
only be shown in one subject of the placebo group, so apparently, there was not much catalytically 
active iron present in the plasma for deferasirox to chelate during experimental endotoxemia.  Finally, 
oxidative stress is only one of the factors that may lead to vascular hyporeactivity during endotoxemia. 
Other, local factors that are not influenced by anti-oxidant therapy may also play a role, such as the 
upregulation of inducible nitric oxide synthase,34 and the activation of potassium channels on vascular 
smooth muscle cells.22 
It is generally known that inflammation results in a reduction of serum iron. Herein, we report 
for the first time that serum iron initially increases in the acute phase of systemic inflammation, which 
is accompanied by LPI formation once serum transferrin becomes saturated. Although we did not 
investigate the mechanism underlying the increase in serum iron in the present study, we speculate 
that the acute release of pro-inflammatory cytokines depresses the erythropoiesis in the bone 
marrow, while an iron flux from storage cells to the plasma is still present, as hepcidin is not elevated 
yet. Previous studies indicate that pro-inflammatory cytokines, mainly TNF-α, are able to suppress 
hematopoiesis in vitro and in vivo.35-39 As the utilization of iron is attenuated, serum iron increases, and 
only decreases after the induction of hepcidin, and the decrease of TNF- α. In accordance, the rate by 
which serum iron increased in the present study roughly resembles the rate by which iron is normally 
utilized by the bone marrow (5 μmol/l/hr ≈ 22 mg iron per day for an average person).40 GDF-15 has 
been reported both as a marker of innate immunity,41 and a humoral factor connecting increased or 
ineffective erythropoiesis in the bone marrow to a  reduction of hepatocyte hepcidin production.42 We 
observed a peak of GDF-15 at 6 hrs post-LPS, that is most likely attributed to the endotoxin-related 
inflammation. Interestingly, and in agreement with recent findings in mice suggesting that GDF-15 is 
not essential for systemic iron homeostasis,43 this increase in GDF-15 did not prevent the increase of 
hepcidin after LPS administration. Surprisingly,  iron loading had no effect on serum hepcidin levels, 
despite a clear effect of serum iron and transferrin saturation. This finding suggests that during the 
acute inflammatory phase, transferrin bound-iron induced hepcidin production does not add to 
cytokine-dependent hepcidin induction.
In conclusion, a single dose of iron sucrose or deferasirox, does not exert relevant effects 
on the innate immune response in a model of experimental human endotoxemia. Acute systemic 
inflammation is associated with an initial rise in serum iron and transferrin saturation, that is 
associated with LPI formation once transferrin saturations >90% are reached. Labile plasma iron 
formation during experimental human endotoxemia is associated with more pronounced vascular 
dysfunction, but not with other measures of subclinical end organ injury.
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Supplementary design and methods
Experimental human endotoxemia
All subjects gave written informed consent before participation and were thoroughly screened, 
including a full medical history, physical exam, ECG, and routine laboratory blood tests including 
markers of kidney and liver function and HIV and Hepatitis-B serology. 
Subjects had refrained from the ingestion of alcohol and caffeine for 24 hrs prior to the test, 
and had fasted since 10 pm the night before. Subjects were placed in a bed in supine position, and 
received a venous catheter in an antecubital vein, and an arterial catheter in the brachial artery that 
enabled continuous arterial pressure monitoring, blood sampling, and the infusion of vasoactive 
medication for the assessment of vascular reactivity by forearm blood flow measurements. 
Heart rate was continuously monitored throughout the entire experiment using a 5 lead ECG. 
Subjects were pre-hydrated with 1.5 L NaCl 0.45%/glucose 0.45%.1  At T=0, 2 ng/kg purified E.Coli 
endotoxin (Escherichia coli O:113, Clinical Center Reference Endotoxin, National Institute of Health 
(NIH), Bethesda, MD, USA) was administered intravenously, followed by 5 mL NaCl 0.9% to ensure 
complete delivery.
Blood sampling for the measurement of oxidative stress (malondialdehyde, MDA), iron 
parameters, cytokines and leukocyte count was carried out at baseline (before the start of iron or iron 
chelation therapy), and serially after the administration of endotoxin. From the morning of the test 
until 24 hrs after endotoxin administration all urine was collected for the measurement of markers of 
subclinical renal injury. 
At T=8 hrs, after the final blood sampling, arterial and venous canulas were removed and subjects 
left the hospital. The following morning, subjects returned for final blood sampling by vena puncture 
and collection of urine samples. 
Iron homeostasis analysis
Serum iron, ferritin and transferrin were automatically determined (Immulite 2000, Siemens healthcare 
Diagnostics, Deerfield, USA) at baseline (T=-2 h) and serially thereafter. Total iron binding capacity 
(TIBC) was calculated as: TIBC(μmol)=25.0 x transferrin (g/L). Serum concentration of soluble transferrin 
receptor (sTfR) was measured immunonephelometrically on a BN II System (Dade Behring Marburg 
GmbH, Marburg, Germany) at -2, 0, 3, 6 and 24 h post LPS. 
Serum hepcidin concentrations were measured by  a combination of weak cation exchange 
chromatography and time-of-flight mass spectrometry (WCX-TOF MS) using an internal standard 
(synthetic hepcidin-24; Peptide International Inc., Louisville, Kentucky USA) for quantification. Peptide 
spectra were generated on a Microflex LT matrix-enhanced laser desorption/ionisation TOF MS 
platform (Bruker Daltonics, Billerica, Massachusettes, USA). Serum hepcidin-25 concentrations were 
expressed as nmol/L(nM) with a lower limit of detection of 0.5 nM.2,3 
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Growth differentiation factor 15 (GDF-15) concentrations were measured with DuoSet (R&D Systems, 
Minneapolis, MN, USA) enzyme linked immunosorbent assay (ELISA) for human GDF15 according to 
the manufacturer’s protocol.
Labile plasma iron (LPI) was quantified by measuring the iron-specific redox activity in serum 
(FeROSTM LPI kit, Aferrix Ltd., Tel-Aviv, Israel) as was essentially described before.4 Briefly, a reducing 
agent (ascorbic acid) and an oxidizing agent  (atmospheric O2), cause labile iron in the tested sample 
to oscillate between its oxidized (Fe3+) and reduced (Fe2+) forms, generating Reactive Oxygen Species 
(ROS) via the Fenton reaction. The ROS are detected by an oxidation-sensitive probe (DHR), which 
becomes fluorescent when oxidized by ROS.
Oxidative stress 
Plasma concentrations of malondialdehyde (MDA), were measured in duplicate as a measure of 
lipid peroxidation as previously described.5 Briefly, 50 µL of lithium heparin anti-coagulated plasma, 
or standard solution was added to 1 mL reagens, consisting of 10 mmoI/L  2-thiobarbituric acid 
in phosphate buffer (0.1  mol/L, pH 3). The solution was vortexed  and incubated for 1 hr at 96°C. 
Thereafter, samples were placed on ice for 5 min, after which 2 mL of butanol was added. The mixture 
was shaken twice for 1 min to extract the TBA-MDA adduct, and then centrifuged at 1500x g for 5 
min at 4°C.  For fluometric measurement of the supernatant a Shimadzu RFF-500 spectrofluorometer 
(Shimadzu Scientific Instruments Inc., Columbia, MD, USA ) was used (excitation 515 nm and 
emission 552 nm). The results were quantified by comparison with the standard curve obtained with 
1,1,3,3-tetramethoxy-propane (TMP; Fluka  Chemika/Biochemika  Buchs , Switzerland) ranging from 
0-10 μmol/L. The CV for this assay was <10 % for both intra- and interassay variations.
Cytokines
To determine the concentration of the various cytokines, EDTA anti-coagulated blood was processed 
immediately by centrifugation at 2000×g at 4°C for 10 min and was stored at -80°C until analysis. 
Concentrations of the pro-inflammatory cytokines TNF-α and IL-6, the anti-inflammatory cytokines 
IL-10 and IL-1ra, and markers of endothelial activation Vascular Cell Adhesion Molecule (VCAM) 
and Intercellular Adhesion Molecule (ICAM) were determined using a simultaneous Luminex assay 
(Milliplex, Millipore, Billerica, MA, USA). 
Subclinical organ injury 
Subclinical endothelial injury was measured by the changes in response of the forearm vasculature 
to the infusion of vasoactive medication into the brachial artery. Changes in forearm blood flow (FBF) 
were measured by venous occlusion plethysmography according to methods described previously.6 
Briefly, after having received the prehydration fluid, and before iron (chelation) treatment and 
endotoxemia, the baseline response of the forearm vasculature to acetylcholine, nitroglycerin and 
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norepinephrine was determined. Venous occlusion was achieved by inflating a cuff around the upper 
arm to 45 mmHg. A strain gauge was placed on the forearm and connected to a plethysmograph 
(Filtrass Angio; Domed, Munich, Germany) to measure changes in forearm volume in response to 
inflation of the venous-congesting cuff. From the changes in forearm volume, the blood flow in the 
forearm was derived using specifically designed software (Filtrass Angio; Domed, Munich, Germany). 
FBF measurements were carried out before and during the incremental intra-arterial administration of 
acetylcholine (0.5; 2; 8 µg·min-1·dL-1 ), nitroglycerine  (0.125; 0.25; 0.5 ug·min-1·dL-1 ) and norepinephrine 
(3; 10; 30 ng·min-1·dL-1) to assess vascular reactivity, as a measure of vascular function. FBFs and drug 
infusions were normalized to forearm volume as measured with the water displacement method 
and expressed in mL per min per deciliter forearm volume (mL·min-1·dL-1). Each dose-response curve 
started with a 5-min period of baseline measurements, followed by 2 min intra-arterial infusion, and 4 
min of recording FBF. FBF data are the mean of measurements obtained during the last 3 min of each 
infusion (steady state). Four hrs after LPS administration, the analysis was repeated to determine the 
LPS-induced effects on vascular reactivity.
For the determination of subclinical renal tubular damage, urinary Glutathione S-Transferase 
Alpha-1-1 (GSTA1-1) and Glutathione S-Transferase-Pi-1-1 (GSTP1-1) were determined, reflecting 
proximal and distal tubular damage, respectively.7,8 Immediately following collection, urine was stored 
in a 10% (v/v) buffer solution, containing 1M HEPES, pH 7.5, containing 5% (w/v) bovine serum albumin, 
1% (w/v) sodium azide, 1% (v/v) Tween-20 and 10% (v/v) glycerol. The urine samples were stored at 
4°C after collection. Within 12 hrs urine samples were frozen at -80°C until assayed. Urinary GSTA1-1 
and GSTP1-1 levels were measured in duplicate by ELISA, as previously described.7,8  The CV for these 
assays was < 10 % for both intra- and interassay variations.
Statistical analysis
Forearm blood flow (FBF) results are expressed as relative changes in FBF in the infusion arm 
compared with baseline measurement. The FBF-ratios are plotted as dose-response curves for each 
vasoactive agent. These dose-response curves were repeated 4 hrs after endotoxin administration. 
The endotoxin-induced differences on vascular reactivity were analyzed by comparing the curve 
before and after endotoxemia using repeated measures two way ANOVA. Differences between 
groups were analyzed by calculating AUCs of the dose response curve before and after endotoxemia 
for each subject. Relative changes of the AUCs during endotoxemia were expressed as percentage 
from baseline for each subject. These percentages were compared between the treatment groups to 
investigate the treatment effects. A p-value<0.05 was considered to indicate significant differences.
We performed a power calculation showing that with a relevant difference of 30% in peak levels 
of TNF-α, an expected standard deviation of 25% and a power of 80-90%, nine to twelve subjects were 
needed per group to find a statistically significant difference.
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Abstract 
Background
Hepcidin-25 is the principle regulator of iron homeostasis in the human body. Next to iron regulation, 
several immune modulatory properties have been attributed to hepcidin. However, the direct effect of 
hepcidin on the innate immune response has not been firmly established.  
Methods
Three experimental setups were used to investigate the immune modulatory effect of hepcidin. 
First, the effect of hepcidin on the cytokine response to LPS challenge in mice was investigated. Four 
groups of eight mice were treated with synthetic human hepcidin or placebo, followed by the i.p. 
administration of LPS (5 mg/kg) or placebo two hours later. Mice were sacrificed at 90 minutes after 
LPS administration. Plasma concentrations of TNF-α, IL-6, and IL-10 were measured. Second, the 
dose-effect relation of hepcidin on the cytokine production in human whole blood was investigated. 
To this end, whole blood of 6 healthy volunteers was incubated with human synthetic hepcidin-25 in a 
concentration range of 0-500 nM. One hour later E. Coli lipopolysaccharide (LPS) was added in a final 
concentration of 10 ng/ml and samples were left to incubate for 24 hours. Production of IL-6, TNF-α 
and IL-10 was measured. In a final experiment, 10 healthy volunteers were subjected to phlebotomy 
(withdrawal of 500 ml of blood) to down-regulate systemic hepcidin production. LPS-stimulated 
cytokine production of whole blood was investigated up to 21 days following phlebotomy and 
correlations between changes in hepcidin and ex vivo cytokine production were explored.
Results
In mice, cytokines were not significantly induced by hepcidin administration alone. In contrast, LPS 
administration resulted in markedly increased plasma cytokine concentrations at t=90 min after 
injection (TNF: 1185±72 pg/ml, IL-6: 59.9±5.2 ng/ml, KC: 62.4±3.0 ng/ml,  IL-10: 3041±401 pg/ml), but 
cytokine plasma concentrations were not modulated by the administration of hepcidin. Stimulation 
of human whole blood with LPS resulted in the production of cytokines (TNF-α: 3.7±0.3 pg/103 
monocytes, IL-6: 24.0±3.3 pg/103 monocytes, IL-10: 496±90 pg/106 monocytes,). Again, no effect of 
hepcidin on the ex vivo cytokine production of whole blood was found at any concentration. After 
phlebotomy, hepcidin markedly decreased from 5.53±1.63 to 1.46±0.14 nmol/L over the first 3 days 
and stayed suppressed throughout the follow-up period. Ex vivo cytokine production of LPS-stimulated 
whole blood, did not change over time for all cytokines measured. No significant correlations 
were found between changes in hepcidin and ferritin plasma concentrations and ex vivo cytokine 
production.
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Conclusion
In conclusion, human hepcidin-25 does not exert immune modulatory effects in three different ex vivo 
and in vivo experiments in mice and man.
 
Introduction 
 
Systemic iron homeostasis is primarily regulated through the production of hepcidin in the liver. This 
principal iron-regulatory hormone induces the degradation of iron exporter ferroportin on duodenal 
cells and macrophages of the reticulo-endothelial system, leading to decreased cellular iron export 
and increased intracellular iron retention.1-3 In addition, immune modulatory properties have been 
attributed to hepcidin for several reasons. First hepcidin is a β-defensin-like peptide with antimicrobial 
effect in high concentrations.4,5 Second, hepcidin impairs the growth of pathogens by the restriction 
of iron availability, as these need iron for replication and growth.6-8 Third, hepcidin affects intracellular 
iron concentration, which may lead to altered cellular functions, including the ability to produce oxygen 
radicals, in turn affecting intracellular killing capacity of immune cells.9 Finally, hepcidin has been 
suggested to directly suppress cytokine production during acute inflammation.10-13
As inflammation-induced hepcidin production is one of the primary causes of anemia of 
inflammation,14 several hepcidin-targeted therapies are currently being developed.15 The possible 
immune modulatory effects of hepcidin, may implicate that antagonizing hepcidin during inflammation 
may also affect the systemic inflammatory response, with potentially deleterious effects for the patient. 
However, the putative direct effects of hepcidin on the innate immune response have not been firmly 
established. Moreover, the data from reference 10 supporting anti-inflammatory effects of hepcidin 
are clouded by scientific misconduct (paper # 3  in the report by McCormack et al. 2013).16 The recent 
observation that antagonizing inflammation-induced hepcidin with lexaptepid pegol  does not affect 
plasma cytokine levels during human endotoxemia (lipopolysaccharide [LPS] administration in healthy 
volunteers),17 suggests that hepcidin does not affect the acute systemic inflammatory response to a 
relevant extent. However, direct evidence of the immune modulatory properties of hepcidin is scarce.
The objective of the current study was to investigate the effects of hepcidin on the innate 
immune response in three ways. First we evaluated the effects of hepcidin administration on the 
cytokine response during murine endotoxemia. Second, the effects of hepcidin on whole blood 
cytokine production was assessed. Finally, we investigated the effects of phlebotomy on suppression of 
hepcidin production and ex vivo whole blood cytokine production. 
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Materials and methods
Effects of hepcidin on the systemic cytokine response during murine 
endotoxemia
Animals
All procedures described were in accordance with the requirements of the Dutch Experiments on 
Animals Act, the EC Directive 86/609 and approved by the Animal Ethics Committee of the Radboud 
University Nijmegen Medical Centre.  A total of 24 male C57Balb/6 mice (Charles River Laboratories 
International, Inc., L’Arbresle Cedex, France), aged six to eight weeks were used.
Reagents
Synthetic human hepcidin-25 (Peptide Institute, Inc. Minoh-shi Osaka, Japan. Lot number 610715) was 
dissolved in sterile water for injection at a concentration of 1 mg/mL. LPS (E.Coli, serotype 0111:B4) 
was obtained from Sigma–Aldrich ( St Louis, MO, USA) and dissolved in sterile water for injection at a 
concentration of 1.25 mg/mL. We used sterile water for injection as placebo.  
Experimental protocol
Mice were randomly divided in four groups (n=8 per group): 1) mice that received an intraperitoneal 
injection with placebo followed by another intraperitoneal injection with placebo two hours later. 2) 
mice that received an intraperitoneal injection with hepcidin (100 µg) followed by an intraperitoneal 
injection with placebo two hours later. 3) mice that received  an intraperitoneal injection with placebo 
followed by intraperitoneal injection of LPS (5 mg/kg) two hours later. 4) mice that received  an 
intraperitoneal injection with hepcidin (100 µg) followed by intraperitoneal injection of LPS (5 mg/
kg) two hours later. Mice were sacrificed 210 minutes after placebo/hepcidin administration (90 
minutes after LPS administration in the corresponding groups), and EDTA anti-coagulated blood was 
centrifuged (14000g, 5 minutes) after which plasma was stored at -80°C until batchwise analysis.
Cytokine analysis
Concentrations of TNF-α, IL-6, KC, and IL-10 were measured using a simultaneous Luminex assay 
(Milliplex, Merck Millipore, Billerica, MA, USA) according to the manufacturer’s instructions., 
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Effects of hepcidin on whole blood cytokine production
Subjects
Six healthy young non-smoking male volunteers provided written informed consent to donate blood 
(single venapuncture) for these experiments. The procedures were approved by the local ethics 
committee (Commissie Mensgebonden Onderzoek regio Arnhem-Nijmegen) and were performed 
according to Good Clinical Practice guidelines and the declaration of Helsinki.
Reagents
RPMI culture medium (RPMI 1640 Dutch modification, Gibco, Invitrogen, Life Technologies Europe 
BV, Bleiswijk, The Netherlands) was supplemented with gentamycin 50 µg/ml, 1 mM pyruvate and 2 
mM glutamax. Details of the hepcidin used are provided in the description of the animal experiments 
above. LPS (E.Coli, serotype O55:B5) was obtained from Sigma–Aldrich and further purified as 
described previously.18
Experimental protocol
Lithium-heparin anticoagulated blood was diluted 1 to 5 in culture medium. Diluted blood was 
incubated in 24-well plates in the presence of absence of hepcidin (0-500 nM), and plates were placed 
in an incubator (37 oC, 95% O2, 5% CO2) for 1 hour. Subsequently, LPS (final concentration of 10 ng/mL) 
or culture medium (negative control) was added and plates were returned to the incubator. After 24 
hours, plates were centrifuged for 10 minutes at 2000g and supernatants were stored at -80°C until 
batchwise analysis. 
Cytokine analysis
Concentrations of TNF-α, IL-6, and IL-10 were measured by enzyme-linked immunosorbent assays 
(ELISA) according to the instructions of the manufacturer (TNF-α: R&D systems, Minneapolis, MN, 
USA; IL-6 and IL-10: Sanquin, Amsterdam, The Netherlands). As monocytes are the main producers of 
cytokines in whole blood stimulations,19 cytokine production was normalized for monocyte counts.
Leukocyte counts and iron parameters
To ensure all subjects had normal iron and hematological parameters, hemoglobin, hematocrit, and 
white blood cell counts (Sysmex EX 5000, Sysmex Corp., Kobe, Japan),  serum iron and transferrin 
(Architect c16000, Abbott Diagnostics, Lake Forest, USA), and ferritin (Immulite 2000, Siemens 
Healthcare Diagnostics, Deerfield, USA) were determined.
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Effect of phlebotomy on hepcidin levels and ex vivo whole blood 
cytokine production
Subjects
Ten healthy male non-smoking volunteers provided written informed consent to participate in this part 
of the study The procedures were approved by the local ethics committee and carried out according to 
the declaration of Helsinki and good clinical practice guidelines. This part of the study was registered at 
www.clinicaltrials.gov (NCT02031614). 
Experimental protocol
500 ml of blood was obtained on day 0, according to standard methods of phlebotomy as practiced 
at blood banks. On days -1, 1, 3, 5, 7, 14 and 21 relative to the day of phlebotomy, blood was obtained 
for the determination of iron parameters, hepcidin, and for ex vivo whole blood stimulation. Whole 
blood stimulation with LPS was performed by adding 0.5 mL of whole blood to pre-filled blood tubes 
containing 2 mL culture medium supplemented with 12.5 ng/mL LPS (final concentration of LPS: 10 ng/
mL), as described in detail previously.20 Cultures were incubated at 37°C for 24 hours, centrifuged, and 
supernatants were stored at -80⁰C until cytokine analysis by ELISA (see cytokine analysis in previous 
section). Cytokine production was normalized for monocyte counts.
Leukocyte counts, iron parameters and hepcidin analysis
Leukocyte counts and iron parameters were determined as described in the previous section. 
Total iron binding capacity (TIBC) was calculated as: TIBC (μmol/L)=25.0 (µmol/g) x transferrin (g/L). 
Transferrin saturation (TSAT) was calculated as: TSAT (%) = serum iron (μmol/L) / TIBC (μmol/L) x 100%. 
Plasma hepcidin concentrations were measured using a specifically designed competitive ELISA using 
rabbit anti-hepcidin antibody,21 with a lower limit of detection of 0.51 nM.
Statistical analysis 
Data are expressed as mean±SEM, or median [25th-75th percentile], depending on their distribution. 
Differences over time were analyzed with either one-way analysis of variance (ANOVA) with Bonferroni 
post-hoc tests, or Friedman with Dunns comparison post-hoc tests, depending on the distribution of 
the data. Differences in group means were analyzed with one-way ANOVA with Bonferroni post-hoc 
tests. Correlation analysis was performed using Spearman correlation analysis.
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Results 
Effects of hepcidin on the cytokine response during murine 
endotoxemia
Administration of hepcidin was well-tolerated, exerted  no clinical effects, and did not increase 
plasma cytokine levels in the absence of LPS administration (Figure 1). LPS administration resulted in 
markedly increased plasma cytokine concentrations, which were however not affected by hepcidin 
pre-treatment. 
Figure 1. Effect of hepcidin on plasma cytokine concentrations during murine endotoxemia. 
Plasma concentrations of  (A) TNF-α, (B) IL-6, (C) KC, and (D) IL-10  210 minutes after hepcidin/placebo administration 
(90 minutes after LPS administration in the corresponding groups). Values are depicted as mean ± SEM pg/mL. * 
indicates a p<0.05 compared with  mice that did not receive LPS or hepcidin (one-way ANOVA with Bonferroni post-
hoc test).  
41481 van Eijk.indd   67 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
68
Effects of hepcidin on whole blood cytokine production
All six donors had normal red and white blood cell counts and a normal iron status (Table S1). 
Microscopic evaluation of the blood samples directly after incubation, revealed normal cellular 
morphology and no signs of toxicity with hepcidin in high concentrations. As expected, stimulation of 
whole blood with LPS resulted in robust production of cytokines. However, no effects of hepcidin in 
any concentration on ex vivo cytokine production was found (Figure 2). 
Figure 2. Effect of hepcidin on LPS-induced whole blood cytokine production. 
Production of (A) TNF-α, (B) IL-6, and (C) IL-10 in whole blood (pg/mL), corrected for the number of monocytes (*106/
mL). Cells were incubated with a increasing hepcidin concentrations with and without LPS (10 ng/mL). Concentrations 
of hepcidin on the x-axis are in nM. As no cytokine production was observed after incubation with hepcidin alone for 
all dosages, only hepcidin 0 nM and 500 nM are depicted for reasons of clarity. * indicates p<0.05 compared with 
RPMI (one-way ANOVA with Bonferroni post-hoc test).
Effect of phlebotomy on parameters of iron homeostasis, hepcidin 
concentrations, and ex vivo whole blood cytokine production
Baseline characteristics of the volunteers subjected to phlebotomy are described in Table S2. 
Phlebotomy resulted in a decrease in hemoglobin concentration that reached its nadir at day 7 (from 
9.3±0.1 at baseline to 8.5±0.1 mmol/L at day 7, Figure 3A). Serum iron levels and transferrin saturation 
initially tended to increase on day 1, followed by a decrease that was most pronounced on day 7 
(serum iron: from 18.2±1.3 at baseline to 14.4±1.3 µmol/l; TSAT: from 29.2±2.4% to 22.2±2.2%, Figure 
3B). Ferritin levels also gradually decreased over time, reaching their nadir at day 21 (from 109.6±14.4 
at baseline to 56.4±9.7 µmol/L at day 21) suggesting that at this point, intracellular iron stores were 
lowest (Figure 3C). Hepcidin markedly decreased over the first 3 days after phlebotomy and remained 
suppressed throughout the follow-up period (Figure 3D). 
Phlebotomy did not result in significant changes in total white blood cell counts (data not shown) 
or monocytes (Figure 4A). LPS-induced ex vivo whole blood cytokine production did not change 
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significantly over time for all cytokines measured (Figure 4B-D). Furthermore, Spearman correlation 
analysis revealed no significant correlations between the change in cytokine production and the 
change in hepcidin plasma concentrations on day 21 for any of the cytokines measured (Table 1). 
Similarly, no significant correlations were found between the change in ferritin concentrations on day 
21 and LPS-induced ex vivo cytokine production at this time-point (Table 1).
Figure 3. Effects of phlebotomy on parameters of iron homeostasis. 
Changes over 21 days following phlembotomy in (A) hemoglobin and hematocrit, (B) transferrin saturation, (C) plasma 
ferritin concentration, and (D) plasma hepcidin. P-values indicate changes over time (repeated measures one-way 
ANOVA).. * indicates p<0.05 compared with day -1 (Bonferroni post-hoc test). 
41481 van Eijk.indd   69 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
70
Figure 4. Effects of phlebotomy on monocyte counts and ex vivo whole blood cytokine production. 
Monocyte counts (A), and ex vivo production of (B) TNF-α, (C) IL-6, and (D) IL-10 of whole blood (pg/ml), corrected for 
monocyte count(*106/mL). Data were depicted as median with 25th-75th percentile (A) or mean ± SEM (B-D) according 
to their distribution. P-values indicate changes over time (Friedman test in panel A, repeated measures one-way 
ANOVA in panels B-D).
Table 1. Correlation between change in hepcidin en ferritin concentrations  
and ex-vivo cytokine production 
Delta TNF-α 
production 
day 21
Delta IL-6 
production 
day 21
Delta IL-10 
production 
day 21
Delta hepcidin concentration day 21 Spearman R 0.53 0.09 -0.59
P-value 0.12 0.81 0.08
Delta ferritin concentration day 21 Spearman R 0.63 -0.07 -0.47
P-value 0.054 0.87 0.17
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Discussion 
The present study does not support the previously suggested effects of hepcidin on the innate 
immune response. We draw this conclusion based on three separate experiments. First, hepcidin 
did not affect the systemic cytokine response in a murine endotoxemia model. Second, we found 
no effects of hepcidin on LPS-induced cytokine production in human whole blood. Third, although 
phlebotomy resulted in profound reduction of plasma hepcidin levels in healthy volunteers, it did not 
modulate cytokine production by whole blood ex vivo stimulated with LPS. Furthermore, no relation 
was found between hepcidin concentrations and ex vivo cytokine responses. 
Our results are in contrast with previous animal data. In mice subjected to iron starvation, 
resulting in suppression of systemic hepcidin levels, an enhanced innate immune response was 
found after LPS administration.12 This was prevented by treatment with hepcidin 2 hours before the 
LPS challenge. Other work showed that hepcidin knockout mice have a higher cytokine response 
and mortality following LPS administration and exogenous hepcidin administration rescues hepcidin-
knockout mice from a otherwise lethal LPS challenge.10 Furthermore, hepcidin has been reported to 
reduce LPS-induced inflammation, liver injury and lethality in a murine model of cholestasis.11 As such, 
the observation that iron deficiency confers resistance to a variety of pathogens,22 has been suggested 
to be the result of a more robust innate immune response due to suppression of hepcidin.12 
The immune modulatory effect of hepcidin appears to be independent of its pivotal role in iron 
metabolism, because iron-deficient mice with suppressed hepcidin have an enhanced inflammatory 
response compared with iron-deficient mice with increased hepcidin levels due knockout of the 
Tmprss6 gene.12 Hepcidin has been reported to confer its anti-inflammatory effects through activation 
of JAK2, thereby leading to phosphorylation of the transcription factor STAT3, which negatively 
modulates IL-6 and TNF-α transcription,10 although JAK2 involvement has been debated by others.23,24 
The findings of reference 10 have been clouded by scientific misconduct,16 and therefore the putative 
immunomodulatory effect of hepcidin is all but unequivocally proven. Based on our findings, we 
suggest that hepcidin does not independently affect the innate immune response to a relevant extent. 
This is in accordance with our recent finding that antagonizing hepcidin with an hepcidin-binding 
Spiegelmer during  experimental endoxemia in humans did not result in an altered immune reponse.17 
We used three different models in our study, each with its own limitations. A drawback of the 
murine study is that synthetic human hepcidin was used, although the structure of hepcidin is highly 
conserved throughout species and others have shown that human hepcidin induces degradation 
of ferroportin in a mouse macrophage cell line.25 In the whole blood stimulation experiments with 
increasing concentrations of hepcidin, we pre-incubated blood with hepcidin for 1 hour. It could be 
argued that this is not long enough.  However this appears highly unlikely, as hepcidin was shown to 
exert immune modulatory effects without pre-incubation.10,12 Also, we used hepcidin concentrations 
up to supra-physiological levels, ruling out the possibility of a too low dose. The model of phlebotomy-
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induced decreases in hepcidin is limited by the fact that it also exerts effects on iron stores, making 
is more difficult to study the effect of hepcidin alone. Nevertheless, as the observed lack of effects 
was in line with the  whole blood experiments using different concentrations of exogenous hepcidin,  
this appears unlikely. Finally, whole blood stimulations, as used in two of our experiments, is not 
necessarily representative of  the in vivo situation. Although monocytes express ferroportin and TLR-4, 
we cannot exclude the possibility that hepcidin could exert effects on resident macrophages, but not 
on monocytes. Again, this is not very plausible given the complete absence of effects in mice.
In conclusion, our data show that hepcidin does not exert significant effects on the innate 
immune response. These findings are of special relevance to anti-hepcidin therapies that are currently 
being developed for the treatment of anemia of inflammation, because theoretically, abrogating the 
putative anti-inflammatory effects of hepcidin in patients could augment the inflammatory disease 
underlying the anemia in patients. Our study does not support these concerns.
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Supplemental tables
Table S1. Baseline characteristics of volunteers that donated blood for whole  
blood stimulation experiments
Mean ± SEM
Age (years) 28 ± 1
Hemoglobin concentration (mmol/L) 9,38 ± 0.29
Hematocrit (L/L) 0.43 ± 0.01
Total leucocytes (*109/L) 5.35 ± 0.26
Monocytes (*109/L) 0.48 ± 0.03
Serum iron (µmol/L) 22.3 ± 2.5
Transferrin saturation (%) 35.5 ± 3.6
Ferritin (µg/L) 148 ± 25
Table S2. Baseline characteristics of volunteers subjected to phlebotomy
Mean ± SEM
Age (years) 23 ± 1
Hemoglobin concentration (mmol/L) 9.3 ± 0.1
Hematocrit (L/L) 0.43 ± 0.01
Total leucocytes (*109/L) 5.5 ± 0.65
Monocytes (*109/L) 0.59 ± 0.08
Serum iron (µmol/L) 18.2 ± 1.3
Transferrin saturation (%) 29.2 ± 2.4
Ferritin (µg/L) 110 ± 14
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Abstract
Introduction
Anemia is a frequently encountered problem during inflammation. Hepcidin is an IL-6-induced key 
modulator of inflammation-associated anemia. Human sepsis is a prototypical inflammatory syndrome, 
often complicated by the development of anemia. However, the association between inflammation, 
hepcidin release and anemia has not been demonstrated in this group of patients. Therefore, we 
explored the association between hepcidin and sepsis-associated anemia. 
Methods
92 consecutive patients were enrolled after presentation on the emergency ward of a university 
hospital with sepsis, indicated by the presence of  a proven or suspected infection and ≥ 2 extended 
SIRS criteria. Blood was drawn at day 1, 2 and 3 after admission for the measurement of IL-6 and 
hepcidin-25. IL-6 levels were correlated with hepcidin concentrations. Hemoglobin levels and data 
of blood transfusions during 14 days after hospitalisation were retrieved and the rate of hemoglobin 
decrease was correlated to hepcidin levels. 
Results
53 men and 39 women with a mean age of 53.3±1.8 yrs were included. Hepcidin levels were highest 
at admission (median[IQR]): 17.9[10.1-28.4]nmol/l and decreased to normal levels in most patients 
within 3 days (9.5[3.4-17.9]nmol/l). Hepcidin levels increased with the number of extended SIRS 
criteria (p=0.0005). Highest IL-6 levels were measured at admission (125.0[46.3-330.0]pg/ml) and  
log-transformed IL-6 levels significantly correlated with hepcidin levels at admission (r=0.28, p=0.015), 
day 2 (r=0.51, p<0.0001) and day 3 (r=0.46, p<0.0001). Twelve patients received one or more blood 
transfusions during the first 2 weeks of admission, not related to active bleeding. These patients 
had borderline significant higher hepcidin level at admission compared to non-transfused patients 
(26.9[17.2-53.9] vs 17.9[9.9-28.8]nmol/l, p=0.052). IL-6 concentrations did not differ between both 
groups. Correlation analyses showed significant associations between hepcidin levels on day 2 and 3 
and the rate of decrease in hemoglobin (Spearman’s r ranging from -0.32, p=0.03 to -0.37, p=0.016, 
respectively).
Conclusion
These data suggest that hepcidin-25 may be an important modulator of anemia in septic patients with 
systemic inflammation.
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Introduction 
Inflammation-associated anemia represents an important and highly prevalent clinical problem. In 
2000 Krause et al. described a peptide that was later called  ‘hepcidin’ based on its hepatic expression 
and antimicrobial activity.1,2 This β-defensin-like peptide, turned out to be a principle regulator of 
systemic iron homeostasis. In concordance with this dual function its expression is modulated by 
systemic iron requirements and inflammatory stimuli, as it is induced by cytokines such as IL-6.3 Its 
role in the development of anemia was first suggested in 2001.4 Since then, it has been demonstrated 
that hepcidin is a central modulator of inflammation-associated anemia, not only by controlling the 
expression of ferroportin on intestinal cells and macrophages,5 but also via a direct inhibitory effect 
of hepcidin on erythropoiesis.6 In humans, increased concentrations of hepcidin were detected in 
patients with chronic infections and severe inflammatory diseases 7 and the association with anemia 
has been determined in patients suffering from chronic inflammation,8 chronic kidney disease,9 and 
cancer.10 In addition, acute systemic inflammation evoked by experimental endotoxemia in humans 
resulted in an increase in hepcidin release, associated with a decrease in serum iron.11 Nevertheless, 
the association between the innate immune response, hepcidin release and consequent decrease in 
hemoglobin has not been established in patients with an acute systemic inflammation. 
Human sepsis is a prototypical acute inflammatory syndrome frequently complicated by the 
development of anemia. As the incidence of sepsis is high,12 determination of this putative pathway of 
the development of anemia is of clinical importance. Therefore, we explored the correlation between 
IL-6 and hepcidin, and the subsequent rate of hemoglobin decrease and number of blood transfusions 
received in septic patients.
Materials and methods
Subjects and sampling
This is an explorative observational study in which data of the subjects were retrieved from a 
prospectively aggregated database of patients with sepsis. After approval of the local ethics committee 
92 consecutive septic patients were enrolled after presentation on the emergency ward and  subsequent 
hospital admission.  Sepsis was defined by the presence of ≥2 extended criteria for systemic 
inflammation (body temperature >38.3 or <36°C, acutely altered mental status, shivering, heart rate > 
90bpm, systolic blood pressure <90mmHg or mean arterial pressure <65mmHg, respiratory rate >20/min, 
hyperglycemia in absence of diabetes) and a proven or suspected source of infection.13 The total number 
of extended Systemic Inflammatory Response Syndrome (SIRS) scores were calculated. Patients were 
given usual care according to the guidelines of the Surviving Sepsis Campaign.14 Blood was drawn at day 
1, 2 and 3 of admission for the measurement of IL-6 and hepcidin-25. Hemoglobin (Hb) measurements 
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were not protocolized, but Hb levels that were determined as part of standard hospital care during 
14 days after hospital admission were retrieved and used for further analysis. Also the accompanying 
indices of mean corpuscular volume (MCV), mean cell hemoglobin (MCH), and red cell distribution width 
(RDW) were analyzed. Blood transfusions during hospital stay were recorded. We hypothesized that the 
effect of sustained elevated levels of hepcidin could be firstly seen in the hemoglobin level after a period 
of 7 to 14 days. This was based on the assumption that erythrocytes circulate for approximately 120 
days. If erythropoiesis would be abrogated by hypoferremia due to an increased hepcidin level, it would 
therefore take approximately 12 days to reduce the hemoglobin levels with 10%. A decrease of 10% 
was considered a clinically relevant and reliably detectable difference. However, due to a possible direct 
inhibitory effect of hepcidin on erythropoiesis, and a reduced erythrocyte half-life during inflammation a 
detectable reduction of hemoglobin from day 7 onwards was anticipated.
Laboratory measurements
IL-6 levels were measured on an Immulite 2500 (Siemens, Breda, The Netherlands), based on a solid 
phase, enzyme labelled, chemiluminescent sequential immunometric method. Serum hepcidin-25 
measurements were performed by a combination of weak cation exchange chromatography and 
time-of-flight mass spectrometry (TOF-MS), using a Microflex LT matrix-enhanced laser desorption/
ionisation TOF-MS platform (Bruker Daltonics, Bremen, Germany). An internal standard (synthetic 
hepcidin-24; Peptide International Inc., Louisville, Kentucky, USA) was used for quantification.15,16 
Calculations and statistical analysis
Log-transformed IL-6 concentrations were correlated with hepcidin-25 concentrations using Pearson’s 
correlation coefficient. Hepcidin-25 was correlated with the rate of decrease of Hb between day 1 and 
day 14, using Spearman’s correlation coefficient. The rate of decrease of Hb was calculated per patient by 
linear regression using all available Hb-measurements. If Hb levels were not measured at day 7-14, or if 
patients received a blood transfusion during their stay, they were excluded for this analysis. Hepcidin levels 
at admission (prior to any transfusion) of patients who received a blood transfusion during the first 14 days 
of hospitalization were compared to patients who did not. To test whether the presence of comorbidity 
affected the rate of hemoglobin decrease we divided different forms of comorbidity over 8 categories 
(chronic kidney disease, hematologic, malignancy, pulmonary, rheumatic/autoimmune, cardiologic, urologic 
and other) and performed a step-wise multi-variate analysis in which hepcidin levels and the 8 categories of 
comorbidity were added to the model. If a comorbidity was found to significantly attribute to the prediction 
of Hb decrease, it was left in the model, but otherwise discarded. Data are expressed as mean±standard 
error of the mean(SEM) or median [25th -75th percentile] depending on their distribution. Correlations were 
expressed as Spearman’s correlation coefficient, except for the correlations between hepcidin and log-
transformed IL-6 concentrations that were expressed as Pearson’s r. Paired observations over time were 
tested with Wilcoxon matched pairs test and unpaired observations with a Mann-Whitney test.
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Results
Demographic data
Demographic data of the subjects are displayed in Table 1. Two patients died during hospitalization. 
Blood culture results are presented in table 2. Twenty percent of the patients had a positive blood 
culture. This relatively low percentage is probably due to the fact that in most cases the general 
practitioner had already initiated antimicrobial therapy before admission to the hospital.
Table 1. Demographic data of the subjects
Number (%)
Total 92 (100)
Male/female 53/39 (58/42)
Age (yrs) 53.3 ± 1.8
ICU admissions 3 (3)
Deaths 2 (2)
Median hospital length of stay (days) 6 [4-11]
Number of SIRS criteria present 2.5 ± 0.9
Number of patients transfused 12 (13)
Site of infection 
Lung 28 (30)
Abdomen 12 (13)
Urinary tract 24 (26)
Skin/soft tissue 4 (4)
Bone/joint 3 (3)
Blood 2 (2)
Cerebral 1 (1)
Other 3 (3)
Unknown 9 (10)
No infectious focus 6 (7)
Comorbidity 
None 36 (39)
Chronic kidney disease 13 (14)
Hematologic disease 7 (8)
Malignancy 8 (9)
Lung disease 6 (7)
Rheumatic / auto immune disease 2 (2)
Cardial disease 1 (1)
Urological disease 5 (5)
Other 14 (15)
Data are expressed as absolute numbers and percentages of total, Mean±SEM or Median [25th -75th percentile]. 
Multivariate analysis demonstrated that comorbidities were not independently associated with Hb-decrease.
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Table 2. Organisms and culture sites
Number of patients
Organisms
Aeromonas species 1
Candida species 2
Citrobacter species 1
Corynebacterium jeikeium 1
Coxiella species 4
Enterobacter species 1
Enterococcus species 5
Escherichia coli 10
Haemophilus influenzae 1
Klebsiella species 2
Morganella species 1
Pseudomonas species 3
Salmonella species 1
Staphylococcus species 2
Streptococcus species 3
Viral infection (positive serological test) 6
No pathogen cultured 50
Sites
Blood 18
Urine 18
Other 4
Multiple organisms 2
Multiple sites 2
IL-6 and hepcidin
IL-6 was highest at admission (125.0 [46.3-330.0] pg/ml), and decreased on day 2 (37.2 [16.8-112.8.0] 
pg/ml) and 3 (19.5 [7.4-55.7] pg/ml]). A similar pattern was observed for hepcidin levels, being 
highest at admission (17.9 [10.1-28.4] nmol/l) and declining to 9.5 [3.4-17.9] nmol/l on day 3, which 
is still increased compared to control values. Log-transformed IL-6 levels correlated significantly with 
hepcidin levels on admission, day 2 and 3, (Pearson’s r=0.28, p=0.015; r=0.512, p<0.0001; r=0.458, 
p<0.0001 respectively,Figure 1A). Also, the number of extended SIRS criteria present correlated with 
hepcidin levels (Figure 1B).
Hepcidin and hemoglobin
Hb was 12.0 [11.2-13.4] g/dl at admission and decreased to an average of 11.3 [10.3-12.8] g/dl at 
day 7 to 14 (p=0.004) in patients who did not receive a blood transfusion. During hospitalization the 
hemoglobin levels decreased at least 0.8 g/dl in 69 (86%) of 80 patients who did not receive a blood 
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transfusion. There was no correlation between hepcidin levels and hemoglobin levels at admission 
(r=0.21, p=0.07). Hepcidin levels on day 1 of admission did not correlate with the rate of decrease 
in Hb, (r=-0.13, p=0.39). Hepcidin on day 2 and 3 significantly correlated with the rate of decrease of 
hemoglobin (r=-0.32, p=0.03 and r=-0.37, p=0.016, Figure 1C).
Figure 1. Association between IL-6, Hepcidin and hemoglobin decrease. 
(A) Humoral relation between inflammation and hepcidin levels: Pearson’s correlation between the natural logarithm 
(Ln) of IL-6 and hepcidin-25 on day 2 (black diamonds, uninterrupted line), and 3 (grey dots, dashed line. The 
correlation on day 1 (r=0.28, p=0.015), was omitted for reasons of clarity. The median reference level of serum 
hepcidin-25 is 4.2 nM, range 0.5-13.9 nM.15 (B) Clinical relation between inflammation and hepcidin levels: hepcidin-25 
levels according to the number of extended SIRS criteria at presentation at the emergency ward.13 Differences 
were tested with Kruskal-Wallis. (C) Spearman’s correlation between rate of hemoglobin decrease and hepcidin-25 
concentration on day 2 (black dots, uninterrupted line) and day 3 (open triangles, dashed line). The rate of decrease 
was only calculated in patients that did not receive a blood transfusion and of whom Hb was measured at least once 
between day 7 and 14 of hospital admission (n=44). (D) Relation between hepcidin-25 levels at admission and the 
number of blood transfusions received during 14 days of follow-up. Boxes represent median and interquartile range, 
whiskers represent 5th and 95th percentile. Difference between transfused and non transfused patients was tested 
with a Mann Whitney test.
41481 van Eijk.indd   83 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
84
Twelve patients received one or more blood transfusions during the first 2 weeks of admission, not 
related to active bleeding. These patients had borderline significant higher hepcidin level at admission 
(preceding any blood transfusion) compared to non-transfused patients (26.9[17.2-53.9] vs 17.9[9.9-
28.8]nmol/l, p=0.052, Figure 1D).
MCV slightly increased during hospital admission from 86.0[84.0-90.0] to an average of 88.5[85.7-
92.6]fl at day 7 to 14 (p=0.011). RDW increased from 13.9[13.1-15.4] to an average of 15.9[14.2-
17.0]% (p=0.002). MCH remained unchanged during 14 day of follow-up (from 1.84[1.75-1.90]fmol 
to an average of 1.82[1.76-1.90]fmol at day 7 to 14 (p=0.39)). None of the changes in red cell indices 
correlated with the hepcidin levels on day 1-3.
Discussion
In the present study 3 novel findings emerged. This is the first study to show that i), hepcidin-25 is 
increased during human sepsis, ii) in septic patients the degree of inflammation, indicated by IL-6 
levels and number of SIRS criteria present, is associated with the elevated concentrations of hepcidin, 
and iii) persistently increased levels of hepcidin-25 at day 2 and 3 after admission are associated with 
a decrease in hemoglobin during hospitalization. Naturally, in patients who received a transfusion the 
effect of hepcidin on Hb could not be determined and these patients were excluded from this part 
of the analysis. In a separate analysis we showed that transfused patients showed a trend towards 
higher hepcidin levels than those who were not. These findings combined suggest that the observed 
association between elevated hepcidin and a decrease in Hb is likely an underestimation. 
This study does not necessarily indicate a causal relation between elevated hepcidin and Hb 
decrease in septic patients. However, the causal relation of the induction of hepcidin by IL-6 and 
the development of anemia by sustaining elevated hepcidin levels has been shown by others in 
separate experiments.3,5,6,17 This study is the first study that addresses the combined measurement 
of hepidin, IL-6 and hemoglobin levels in patients and shows that hepcidin probably plays a role in 
sepsis associated anemia. One may argue that the correlation between inflammation, hepcidin and 
anemia is an epiphenomenon, as more severly affected patients release higher levels of inflammatory 
parameters and also receive more fluids during their volume resuscitation, resulting in the more 
pronounced decrease in Hb. This appears not to be the case, since hepcidin concentrations at 
admission did not predict the decrease in Hb, in contrast to more prolonged elevations in hepcidin 
during the first 3 days. Moreover, the decrease in Hb was determined during 14 days, a period in 
which effects of volume resuscitation should have diminished. Nevertheless, it is important that 
in addition to the physiological role of hepcidin, several other factors that lead to anemia during 
infection have been described, such as iatrogenic blood loss, inhibition of erythropoietin production,18 
blunted erythropoietic response,18,19 and a decreased lifespan of erythrocytes, mediated by increased 
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adherence to the vascular wall and phagocytosis by macrophages.20 In addition, in these patients 
the presence of different comorbidities and the severity of the disease could have influenced the 
development of anemia. However, we were not able to express these variables in size and number, 
and therefore could not include these parameters as a continuous variable into a multivariate 
regression analysis. This may explain the relatively low correlation coefficients we found between 
hepcidin and Hb decrease.
There are two known ways by which hepcidin can result in inflammation associated anemia. First, 
hepcidin can abrograte erythroid colony formation in situations where erythropoietin concentrations 
are reduced, as is the case during sepsis.6 Furthermore, inflammation leads to sequestration of iron 
in cells resulting in a blocked transport of iron to the bone marrow. Considering the fact that the 
lifespan of erythrocytes of approximately 120 days might be shortened due to inflammation and the 
fact that hepcidin suppresses erythropoiesis itself, we hypothesized that if hepcidin is upregulated by 
inflammation and thereby suppresses serum iron levels, a measurable effect on Hb level was expected 
from 7 days onwards after the diagnosis of sepsis. Furthermore, we anticipated a swift decrease in 
inflammation in treated septic patients. For these reasons we determined IL-6 and hepcidin for 3 days 
and the rate of Hb decrease within 7-14 days.
We were not able to demonstrate a relation of Hb decrease with a change in MCV, MCH and 
RDW. This does not invalidate the hypothesis that increased hepcidin attributes to the development 
of anemia in these patients. It was previously shown that erythrocyte progenitor cells carry iron 
transporter ferroportin1B on their cell membrane.21 During inflammation systemically elevated 
hepcidin down-regulates ferroportin on these cell, thereby preventing a loss of intracellular iron and 
the microcytic anemia that is seen in iron deficiency anemia. Therefore, inflammation-associated 
anemia is not typically microcytic.22 Moreover, the observed effect of hepcidin on the development on 
anemia may have been mediated by a direct inhibitory effect on erythropoiesis, rather than by blocking 
iron transport to the bone marrow by sequestration.
Interestingly, hepcidin at day 1 did not predict the rate of Hb decrease. Probably persistently 
elevated hepcidin levels are necessary to exert a relevant effect on hemoglobin concentrations. The 
association we found may be an underestimation, because the patients in this study were already 
anemic at the time of presentation on the emergency ward and likewise it is possible that prior 
to presentation hepcidin levels were even more pronounced. Nevertheless, although statistically 
significant, the observed association between hepcidin and hemoglobin levels is modest, indicating 
that other previously mentioned factors that influence Hb are likely to play a role.
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Conclusions
Anemia during acute systemic inflammation evoked by sepsis is a frequently encountered clinical 
problem. Up to now, human data concerning the effect of hepcidin release on the development of 
anemia during sepsis were absent. Our study demonstrates that inflammation in septic patients is 
associated with increased hepcidin-25 concentrations. Moreover, the elevated hepcidin concentrations 
observed in early sepsis negatively correlated with hemoglobin levels during the hospital stay of these 
patients. These human in vivo correlations suggest that hepcidin release is a modulator of anemia in 
septic patients with systemic inflammation.
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Abstract
Anemia of chronic inflammation is the most prevalent form of anemia in hospitalized patients. A 
hallmark of this disease is the intracellular sequestration of iron. This is a consequence of hepcidin-
induced internalization and subsequent degradation of ferroportin, the hepcidin receptor and only 
known iron-export protein. This study describes the characterization of the novel anti-hepcidin 
compound NOX-H94, a structured l‑oligoribonucleotide that binds human hepcidin with high affinity 
(KD=0.65±0.06 nmol/L). In J774A.1 macrophages, NOX-H94 blocked hepcidin-induced ferroportin 
degradation and ferritin expression (IC50=19.8±4.6 nmol/L). In an acute cynomolgus monkey model 
of interleukin-6-induced hypoferremia, NOX-H94 inhibited serum iron reduction completely. In a 
subchronic model of interleukin-6-induced anemia NOX-H94 inhibited the decrease in hemoglobin 
concentration. We conclude that NOX-H94 protects ferroportin from hepcidin-induced degradation. 
Therefore, this pharmacological approach may represent an interesting treatment option for patients 
suffering from anemia of chronic inflammation.
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Introduction
Hepcidin,1-3 a small 2.8 kDa peptide, is regarded as the central mediator of iron homeostasis.4 The 
increased production of hepcidin during inflammatory conditions is a cornerstone of the pathogenesis 
of anemia of chronic inflammation (ACI).5,6 The pathophysiologic effects of hepcidin are central to the 
development of anemia in several groups of patients, for example those with chronic kidney disease, 
cancer, and inflammatory bowel disease. Therefore, inhibition of hepcidin represents a potentially 
attractive therapeutic target to improve the utilization of iron from intracellular stores in patients 
suffering from ACI. The efficacy of pharmaceutical hepcidin inhibition has already been demonstrated 
with an anti-hepcidin antibody in mice7 and by other less specific approaches with an indirect effect on 
hepcidin expression.8-11 
NOX-H94 (supplemental Figure 1) is a structured mirror-image l-oligoribonucleotide, a so called 
Spiegelmer,12 conjugated to 40 kDa polyethylene glycol (PEG), that blocks its target hepcidin in a 
manner similar to aptamers or protein-based scaffolds. In the described studies we aimed to confirm 
that the high binding affinity of NOX-H94 for human hepcidin (huHep) translates into functional 
inhibition of hepcidin-induced ferroportin degradation and ferritin expression in two in vitro bioassays 
in macrophages, and finally to evaluate efficacy in two in vivo models in cynomolgus monkeys.
Methods
Surface plasmon resonance (SPR) experiments
NOX-H94 binding to huHep was characterized using SPR analysis as described in supplemental 
methods.
Hepcidin-induced ferroportin degradation and ferritin expression
The effect of NOX-H94 on hepcidin-induced ferroportin degradation and ferritin expression was 
examined in J774A.1 mouse macrophages (DSMZ, Braunschweig, Germany). Cells were cultivated 
at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s medium with Glutamax (Invitrogen, Karlsruhe, 
Germany) containing 10% fetal bovine serum, 100 units/mL penicillin, and 100 µg/mL streptomycin.
For the ferroportin degradation assay macrophages were seeded in 24-well plates (7.3x105 cells/
well), loaded with iron by addition of iron-nitrilotriacetic acid solution and incubated overnight. Cells 
were incubated with huHep (100 nmol/L, Peptides International Inc., Louisville, USA) in combination 
with Spiegelmers (NOX-H94 or NOX-H94002, without PEG modification) for 3 hours, washed once and 
lysed in lysis-buffer (20 mM Tris (tris(hydroxymethyl)aminomethane)/HCl (pH 7.5), 150 mM NaCl, 1 mM 
ethylenediaminetetraacetic acid, 1% Triton X-100) including protease inhibitors (Roche, Mannheim, 
Germany). Lysate mouse ferroportin levels were determined by Western Blot analysis (rabbit anti-
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mouse ferroportin antibody, Alpha Diagnostics, San Antonio, USA) as described under supplemental 
methods. 
For the ferritin expression assay cells were seeded in 96-well plates (4.5x104 cells/well). After 
incubation with huHep in combination with NOX-H94 for 24 hours, cells were washed twice and 
lysed in M-PER buffer (Thermo Fisher Scientific, Waltham, USA) including protease inhibitors (Roche). 
Lysates were quantified for mouse ferritin levels by ELISA (ICL Inc., Newberg, USA) according to the 
manufacturer’s instructions.
IL6-induced hypoferremia and anemia
Male cynomolgus monkeys (Macaca fascicularis) were housed and handled according to the guidelines 
set by the animal welfare regulations enacted in Germany in the ‘Tierschutzgesetz’. Monkeys (n=3/
group) were injected with NOX-H94 (10 mg/kg (1 mL/kg), intravenously, t=0.5 hours) followed by a 
single subcutaneous injection of human IL6 (0.3 µg/kg (1 mL/kg), t=0 hours, Miltenyi Biotec, Bergisch-
Gladbach, Germany) to induce hypoferremia. Control groups received NOX-H94 or IL6 and the 
corresponding vehicle (vehicle A: 5% glucose, vehicle B: 1% autologous heat inactivated serum). In the 
subchronic IL6-induced anemia model monkeys were injected with IL6 (daily, 0.3 µg/kg) and NOX-H94 
(daily, 10 mg/kg) for up to eight days. Blood samples were taken by punctation from the vena cephalica 
or saphena magna at the indicated timepoints. Iron parameters were determined colorimetrically by 
Konelab 30i (Thermo Fisher Scientific, Dreieich, Germany) using Konelab kits. Blood cell parameters 
were determined with an ADVIA120 hematology analyzer (Siemens, Fernwald, Germany).
Results and discussion
Different Spiegelmer-based hepcidin-binders (data not shown) were identified following a process 
essentially described in Purschke et al.13. The best binding Spiegelmer, modified at its 5’-end with 
40 kDa PEG, showed a dissociation constant of 0.65±0.06 nmol/L (supplemental Figure 2) and was 
selected for further in vitro and in vivo studies. 
Incubation of J774A.1 macrophages with 100 nmol/L huHep clearly reduced ferroportin 
expression. This effect was almost completely inhibited with 200 nM of the l-oligonucleotide itself 
(NOX-H94002) as well as with its PEGylated variant NOX-H94 (Figure 1A). Another more sensitive 
in vitro assay based on hepcidin-induced iron retention in macrophages showed a substantial 
concentration-dependent upregulation of ferritin with an EC50 of 9.4±1.2 nmol/L (Figure 1B). NOX-H94 
inhibited the induction of ferritin expression with an IC50 of 19.8±4.6 nmol/L (Figure 1C). 
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Figure 1. Anti-hepcidin Spiegelmer inhibits hepcidin effects in vitro. 
A) Ferroportin Western Blot analysis of lysates obtained from mouse J774A.1 macrophages after stimulation 
with human hepcidin (huHep) alone or in combination with different concentrations of the l-oligoribonucleotide 
NOX-H94002 or its PEGylated variant NOX-H94. B) Ferritin content of lysates obtained from macrophages after 
stimulation with different concentrations of huHep (one representative experiment of three) or C) after stimulation 
with 20 nM huHep and different concentrations of NOX-H94 (one representative experiment of six). Ferritin content 
was analyzed with a mouse ferritin ELISA (two lysates, each tested twice in the ELISA, mean ± standard deviation). The 
amount of ferritin was normalized to total protein. 
To translate the in vitro inhibitory effects into an in vivo situation, NOX-H94 was tested for its ability 
to prevent the reduction of serum iron in an IL6-induced hypoferremia model. The cross-reactivity of 
human IL6 with the cynomolgus monkey IL6-receptor and the induction of hepcidin were shown in an 
initial study (supplemental Figure 3). Cross-reactivity of NOX-H94 with cynomolgus monkey hepcidin 
was demonstrated in competition studies (supplemental Figure 4). In the hypoferremia study three 
treatment groups were compared; i) NOX-H94, ii) combination of IL6 and NOX-H94 and iii) IL6 alone 
(Figure 2A). In the IL6-treated group serum iron dropped from 18.0±3.5 µmol/L to 9.8±0.2 µmol/L 
(P<0.05) at eight hours and returned to baseline within 48 hours. Pre-treatment with NOX-H94 
(10 mg/kg) prevented this decrease for up to 24 hours (predose, 8 h, 24 h: 23.4±3.7, 24.0±9.3, 
26.3±5.2 µmol/L, respectively). In the NOX-H94 control group iron levels increased from 19.3±0.4 
to 40.7±6.9 µmol/L at eight hours (P<0.05), 43.3±3.5 µmol/L at 24 hours (P<0.01) and returned to 
predose levels at 48 hours. 
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Figure 2. Inhibition of IL6-induced hypoferremia and anemia by NOX-H94 treatment in cynomolgus monkeys.
A) Treatment with IL6 induced a non-sustained hypoferremia. The serum iron decrease was prevented by 10 mg/kg 
NOX-H94 (vehicle A: 5% glucose, vehicle B: 1% autologous heat inactivated serum). In the control group without IL6 
NOX-94 treatment induced a temporal hyperferremia (n=3/group, mean±SEM). Statistical analysis was performed 
with the unpaired t-test comparing the different time points of each group with the respective predose values. The 
dotted line indicates the mean pre-dose serum iron concentration. B) Repeated subcutaneous injections of human 
IL6 (0.3 µg/kg, daily) reduced hemoglobin concentration. This effect was ameliorated in NOX-H94 (10 mg/kg, daily) 
treated animals (mean - SEM, n = 4/group, individual levels describe the difference compared to pre-dose levels). 
Statistical analysis was performed with Dunnett’s Multiple Comparison Test. Statistical significance was indicated with 
* P<0.05, ** P<0.01, *** P<0.001.
In a subchronic model of IL6-induced anemia (supplemental Table 1) NOX-H94 (10 mg/kg) ameliorated 
the hemoglobin reduction produced by IL6, but was not able to block it completely (Figure 2B). Thus, 
on day 8 the hemoglobin concentration was reduced by 1.1±0.3 mmol/L (P<0.01) in the IL6 group, 
in contrast to the NOX-H94 group in which no significant reduction (0.6±0.3 mmol/L) compared to 
baseline was observed. In this model NOX-H94 treated animals also exhibited a smaller reduction 
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in reticulocyte hemoglobin content, erythrocyte counts, and hematocrit on day 8. No difference was 
observed for reticulocyte counts, which increased in both groups (supplemental Table 2). 
The aim of the current work was to characterize NOX-H94 in preclinical experiments. We have 
demonstrated that NOX-H94 is a high affinity huHep binder and inhibits ferroportin degradation 
in two in vitro models. In cynomolgus monkeys we confirmed the rapid induction of hepcidin and 
hypoferremia in response to IL6 that had been reported in human volunteers receiving IL6 or 
endotoxin infusions14,15 and demonstrated efficacy of NOX-H94 in this in vivo model of acute systemic 
inflammation. Repeated administration of IL6 has been reported to induce anemia in several 
studies16-18. Our results suggest that NOX-H94 may attenuate the inflammation-induced decrease in 
hemoglobin, but a larger study would be needed to further substantiate this observation. Strikingly, 
the clearest differences were observed for reticulocyte hemoglobin content. This could be explained 
by improved supply of hemoglobin synthesis with iron in reticulocytes due to NOX-H94-mediated 
hepcidin neutralization.
We conclude that NOX-H94 may provide a new therapeutic option for the treatment of ACI. To 
enable a Phase IIa study in anemic myeloma and lymphoma patients, two human clinical trials19,20 are 
currently being conducted to evaluate safety and pharmacokinetics and to determine if the described 
effects of NOX-H94 during systemic inflammation can be reproduced in humans.
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Supplemental methods 
Surface plasmon resonance analysis
Binding studies were performed using a BIAcore 2000 biosensor system (GE Healthcare, Freiburg, 
Germany). Human hepcidin (huHep, Peptides International Inc., Louisville, USA) was immobilized on 
a carboxy-dextran-coated sensor chip (CM4 chip, GE Healthcare) using a 1:1 mixture of EDC (0.4 M, 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide) and NHS (0.1 M, N-hydroxysuccinimide). HuHep 
(300-400 response units) was immobilized in HBS-EP buffer (GE Healthcare) at a flow of 10 µL/min. 
The respective flow cell was washed, the reference flow cell was activated with NHS/EDC and all flow 
cells were blocked with ethanolamine (1 M). Measurements were performed at 37 °C and a flow of 
30 µL/min. Data analysis was performed with the BIAevaluation 3.1.1 software (BIACORE AB, Uppsala, 
Sweden) using a modified Langmuir 1:1 stoichiometric fitting algorithm. For the dissociation constant 
(KD) the mean ± SEM was calculated based on n = 3 experiments.
Immunodetection of ferroportin 
Total protein concentrations were determined using the bicinchoninic acid method (Pierce BCA 
Protein assay Kit, Thermo Scientific, Bonn, Germany). Protein samples (20 µg each) were separated 
on 10% Novex® Tris-Glycin gels (Invitrogen, Karlsruhe, Germany) and transferred on Amersham 
Hybond™-PVDF membranes (GE Healthcare). Equal loading and transfer were confirmed by staining 
with Ponceau Red Solution. Immunodetection was performed using the Snap i.d. Detection system 
in accordance with the manufacturer’s recommendations (Millipore, Schwalbach, Germany). After 
blocking with 0.5% non-fat dry milk in Tris-buffered saline and 0.1% Tween, mouse ferroportin 
was detected using a rabbit anti-mouse ferroportin antibody (1:300, Alpha diagnostics, MTP11-A) 
as primary antibody and incubated with horseradish peroxidase conjugated anti-rabbit-IgG (New 
England Biolabs, Frankfurt am Main, Germany) as secondary antibody. Ferroportin was finally detected 
using LumiGlo® chemiluminescent reagent (New England Biolabs, Frankfurt am Main, Germany) and 
Hyperfilm™ ECL films (GE Healthcare).
IL6-induced hepcidin and hypoferremia in cynomolgus monkeys
Male monkeys were injected with a single subcutaneous dose of human IL6 [10 µg/kg]. Repeated 
blood withdrawals were taken at the indicated timepoints. Hepcidin levels were determined with an 
enzyme-linked immunoassay using a commercially available kit (human hepcidin EIA, Bachem, Saint 
Helens, United Kingdom). Iron parameters were determined colorimetrically by Konelab 30i (Thermo 
Fisher Scientific, Dreieich, Germany) using Konelab kits. 
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Competition pull-down binding assays
Pull-down assays with radioactively labeled Spiegelmer were established to evaluate cross-
reactivity to related hepcidin variants from other species. In order to enable enzymatic labeling 
with T4 polynucleotide kinase (Invitrogen, Karlsruhe, Germany) and [γ-32P]ATP (Hartmann Analytic, 
Braunschweig, Germany), the Spiegelmer sequence of NOX-H94 was modified at its 5’-end with two 
consecutive d-guanosine nucleotides instead of the PEG residue, that is normally coupled to the 5’-end. 
The radiolabeled Spiegelmer [5’-32P]-d-Gp-d-Gp-NOX-H94001 at a concentration of approximately 
50 pmol/L and 5-fold dilutions ranging from 32 pmol/L to 500 nmol/L of non-biotinylated human, 
cynomolgus, or marmoset hepcidin competitor molecules was incubated with 550-600 pmol/L 
of biotinylated human hepcidin in selection buffer (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, 0.1 % Tween-20, 20 mM Tris pH 7.4, 10 µg/mL Yeast ribonucleic acid, 10 µg/mL bovine serum 
albumin) at 37 °C for 135 minutes. Biotinylated peptide-Spiegelmer complexes were immobilized on 
Streptavidin Plus Ultralink matrix (Thermo Fisher Scientific, Rockford, USA). After appropriate washing 
the immobilized complexes of radiolabeled Spiegelmer and biotinylated peptide were subjected 
to scintillation counting (LS 6500 multi-purpose scintillation counter, Beckman Coulter, Fullerton, 
USA) and the normalized percentage of bound Spiegelmer was plotted against the corresponding 
competitor concentration. KD values (mean±SEM, based on two experiments) were calculated 
employing the data analysis software GraFit (Erithacus Software Ltd., Horley, UK) assuming a 1:1 
stoichiometry. 
IL6-induced anemia in cynomolgus monkeys
Male monkeys were injected with a daily subcutaneous dose of human IL6 [0.3 µg/kg] or vehicle (1% 
autologous cynomolgus monkey heat-inactivated serum in 0.9% sodium chloride solution). Repeated 
blood withdrawals were taken at the indicated timepoints. Iron parameters were determined 
colorimetrically by Konelab 30i (Thermo Fisher Scientific, Dreieich, Germany) using Konelab kits. 
Hematology parameters were determined by the automated analyzer ADVIA 120 (Siemens Diagnostics, 
Fernwald, Germany).
Statistics
Statistical analysis was performed with GraphPad Prism software (GraphPad Software). For the data 
analysis in the IL6-induced anemia model an unpaired t-test was used to compare the effects with 
predose levels. A paired t-test was used if appropriate. Dunnett’s Multiple Comparison Test was used 
for comparison of more than two groups. Statistical significance was indicate with * P<0.05, ** P<0.01, 
*** P<0.001.
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Supplemental tables and figures
Table S1: Hematological features of IL6-induced anemia in cynomolgus monkeys
Parameter Changes compared to
predose levels (%)
Serum iron - 37 ± 10 **
Hemoglobin - 11 ± 2 **
Erythrocytes - 10 ± 2 **
Hematocrit - 8.1 ± 2.5 **
Reticulocyte hemoglobin content - 5.1 ± 1.5 *
Reticulocytes + 172 ± 31 ***
Mean ± SEM values in the table were calculated based on individual change at day eight after daily interleukin-6 (IL6) 
treatment in % compared to individual predose levels (n = 8, two independent experiments). * P<0.05, ** P<0.01, 
*** P<0.001
Table S2: Effects of NOX-H94 in IL6-induced anemia in cynomolgus monkeys
Parameter Day 4 Day 8
IL6 + vehicle IL6 + NOX-H94 IL6 + vehicle IL-6 + NOX-H94
Hemoglobin (mmol/L) -0.60 ± 0.28 -0.38 ± 0.32 -1.08 ± 0.26** -0.58 ± 0.31
Erythrocytes  (1012/L) -0.48 ± 0.19 -0.28 ± 0.23 -0.68 ± 0.19* -0.38 ± 0.21
Hematocrit (%) -2.50 ± 1.04 -2.00 ± 1.29 -4.00 ± 1.00** -1.50 ± 1.32
Reticulocyte hemoglobin 
content (fg)
-45.0 ± 21.01* -20.0 ± 0 -62.5 ± 24.6** -5.00 ± 9.57
Reticulocytes, 1010/L 4.74 ± 0.60*** 4.74 ± 1.36*** 6.25 ± 1.52*** 6.12 ± 0.51***
Mean ± SEM values in the table were calculated based on individual change at day 4 and 8 compared to predose 
levels. For statistical analysis predose values were compared with values on day 4 and 8 with Dunnett’s Multiple 
Comparison Test (n = 4, * P<0.05, ** P<0.01, *** P<0.001).
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Figure S1. Chemical structure of NOX-H94. 
The chemical name of the NOX-H94 is: l-RNA,(5’-G-C-G-C-C-G-U-A-U-G-G-G-A-U-U-A-A-G-U-A-A-A-U-G-A-G-G-A-G-U-
U-G-G-A-G-G-A-A-G-G-G-C-G-C-3’), 5’-ester with N-[w-methoxypoly(oxy-1,2-ethanediyl], N’-[w-methoxypoly(oxy-1,2-
ethanediyl]-acetyl 9-amino-8-oxo-7-aza-nonyloxy phosphate, sodium salt. C, A, U and G code for l-cytidylic, l-adenylic, 
l-uridylic and l‑guanylic acid, respectively.
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Figure S2. Binding of NOX-H94 to human hepcidin by SPR.
Concentration-dependent binding of NOX-H94 to immobilized human hepcidin at 37 °C. The figure shows 
representative sensorgrams of indicated NOX-H94 concentrations (one representative experiment of three). Grey 
line: raw data, black line: fitted data (stoichiometric 1:1 Langmuir binding reaction).
Figure S3. IL6-induced hepcidin increase and serum iron decrease in cynomolgus monkeys. 
Subcutaneous injection of human IL6 [10 µg/kg] induced a rapid increase in hepcidin, starting at four hours post 
treatment and reaching peak levels at six and eight hours after administration (p = 0.001). Correspondingly, serum 
iron concentration declined continuously and significantly starting six hours post treatment. Results are shown as 
mean ± SEM, n = 3. Statistical analysis was performed with Dunnett’s Multiple Comparison Test and predose values 
were selected as control groups, ** P<0.01, *** P<0.001).
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Figure S4. Reciprocal competition of hepcidin from different species binding to  
Spiegelmer [5’-32P]-d-Gp-d-Gp-NOX-H94001. 
Binding of [5’-32P]-d-Gp-d-Gp-NOX-H94001 to biotinylated human hepcidin was competed by hepcidin from 
cynomolgus monkey (cynoHep, dotted line with open squares, n = 1), marmoset monkey (marmoHep, dashed line 
with full triangles, n = 2), and human (huHep, solid line with full circles, n = 2). The radioactively labeled Spiegelmer 
shows cross-reactivity to hepcidin from cynomolgus (KDcomp = 2.0 nmol/L) and marmoset monkeys (KDcomp = 7.7±1.4 
nmol/L). As expected, the dissociation constant of the Spiegelmer to cynomolgus hepcidin which carries a 
conservative exchange of one amino acid (lysine to arginine at position 24) compared to human hepcidin is almost 
indistinguishable from the dissociation constant to human hepcidin (KDcomp = 1.6±0.1 nmol/L). 
41481 van Eijk.indd   102 18-08-16   16:17
The effects of the anti-hepcidin Spiegelmer NOX H94 on inflammation-induced anemia in cynomolgus monkeys
103
6
41481 van Eijk.indd   103 18-08-16   16:17
41481 van Eijk.indd   104 18-08-16   16:17
CHAPTER 7a
Effect of the anti-hepcidin
Spiegelmer® lexaptepid on 
inflammation-induced decrease 
in serum iron in humans
Lucas T van Eijk, Aaron SE John, Frank Schwoebel, Luciana Summo, 
Stéphanie Vauléon, Stefan Zöllner, Coby M Laarakkers, Matthijs Kox, 
Johannes G van der Hoeven, Dorine W Swinkels, Kai Riecke, Peter Pickkers
Blood. 2014;124(17):2643-6
41481 van Eijk.indd   105 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
106
Abstract 
Increased hepcidin production is key to the development of anemia of inflammation. We investigated 
whether lexaptepid, an anti-hepcidin l-oligoribonucleotide, prevents the decrease in serum iron during 
experimental human endotoxemia. This randomized, double-blind, placebo-controlled trial was carried 
out in 24 healthy males. At T=0 hours, 2 ng/kg Escherichia coli lipopolysaccharide was intravenously 
administered, followed by an intravenous injection of 1.2 mg/kg lexaptepid or placebo at T=0.5 hours. 
The lipopolysaccharide-induced inflammatory response was similar in subjects treated with lexaptepid 
or placebo regarding flu-like symptoms, body temperature, C-reactive protein, leucocyte counts and 
cytokine concentrations. 
At T=9 hours, serum iron had increased by 15.9±9.8 µmol/L from baseline in lexaptepid-treated 
subjects compared with a decrease of 8.3±9.0 µmol/L in controls (P<0.0001). This study delivers proof 
of concept that lexaptepid achieves clinically relevant hepcidin inhibition enabling investigations in the 
treatment of anemia of inflammation. This trial was registered at www.clinicaltrial.gov #NCT01522794. 
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Introduction 
Anemia of inflammation is the most prevalent form of anemia in a hospital setting,1 occurring in a 
variety of acute and chronic inflammatory diseases.2 The dysregulation of iron homeostasis is central 
to the pathogenesis of anemia of inflammation.1,3 A redistribution of iron to the cells of the reticulo-
endothelial system occurs, with hepcidin as a central mediator.3 Hepcidin induces internalization and 
degradation of the iron exporting channel ferroportin on duodenal enterocytes and iron storing cells,4 
thereby preventing the export of iron into the circulation and causing iron-restricted erythropoiesis.5 
Hence, hepcidin inhibition may be an attractive therapeutic intervention to improve the utilization of 
iron from intracellular stores.
Lexaptepid (international nonproprietary name: lexaptepid pegol), a non-natural mirror-image 
l-nucleotides modified at its 5´-end with a branched 40 kDa monomethoxy-polyethylene-glycol, 
inactivates hepcidin in a mode conceptually similar to antibodies. Lexaptepid, as well as other 
pharmaceutical interventions inhibiting hepcidin, have been shown to prevent ferroportin degradation 
in vitro, and also to prevent and correct anemia of inflammation in animal models.6-13 However, the 
efficacy in humans remains to be determined. In a first-in-human trial, lexaptepid was well tolerated 
and effective in elevating serum iron.14  
The primary aim was to investigate the effectiveness of lexaptepid in preventing the serum iron 
decrease observed during systemic inflammation in healthy volunteers. The secondary objective was 
to assess the effects of lexaptepid on the innate immune response.
Materials and methods
Experimental human endotoxemia
This double-blind, randomized, placebo-controlled trial was approved by the local ethics committee 
and carried out according to GCP standards and the declaration of Helsinki including current revisions. 
The study was registered under ClinicalTrial.gov: #NCT01522794. 
Experimental human endotoxemia is a generally accepted way of studying systemic inflammation 
in a controlled manner.15 Following written informed consent and screening, 24 healthy male subjects 
were pre-hydrated with 1.5 L NaCl 0.45%/glucose 2.5%.16 At T=0 hours, 2 ng/kg purified standard 
reference Escherichia coli O:113 LPS (Clinical Center Reference Endotoxin, National Institutes of 
Health, Bethesda, MD, USA) was administered intravenously. Lexaptepid (NOXXON Pharma AG, Berlin, 
Germany) was diluted in glucose 5%, according to the manufacturer’s instructions. At T=0.5 hours 
1.2 mg/kg lexaptepid or placebo (glucose 5%) was administered intravenously over 15 minutes in a 
randomized, double-blind fashion. See Supplemental Data File 2 for details.
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Inflammatory and iron parameters
C-reactive protein, total white blood cell count and iron parameters were determined by the local 
laboratory of clinical chemistry, see also Supplemental Data File 2 for details. For cytokines (TNF-α, 
IL-6, IL-10 and IL-1RA), ethylenediaminetetraacetic acid (EDTA) anti-coagulated blood was immediately 
processed and plasma was stored at -80°C until batch wise analysis (Luminex, Merck Millipore, Billerica, 
MA, USA). Plasma hepcidin concentrations were measured with time-of-flight mass-spectrometry as 
described in Supplemental Data File 2. As it is currently technically impossible to discriminate between 
lexaptepid-bound and free hepcidin, the total of bound and unbound hepcidin is reported. 
Pharmacokinetics
Lexaptepid plasma concentrations were determined using a fully validated sandwich hybridization 
assay specific for the full-length sequence of the oligonucleotide.  See Supplemental Data File 2 for 
details.
Statistical analysis 
Data are expressed as arithmetic mean±SD, or median [25th-75th percentile], depending on their 
distribution. Differences in group means or medians were tested with Student’s t-test for parametric 
data or Mann-Whitney U test for non-parametric data, as appropriate. The primary endpoint was the 
change from baseline in serum iron at T=9 hours after LPS administration. See Supplemental Data File 
2 for details.
Results and discussion 
As hepcidin is the principal regulator of iron homeostasis, it has become a target for the development 
of novel therapeutics for iron disorders.17 Lexaptepid has proven effective in counteracting hepcidin’s 
effects in animal models, including an IL 6-induced anemia model in cynomolgus monkeys.11 In the 
present study we extend the concept of hepcidin inhibition to humans for the first time.  
No differences in baseline parameters between the treatment groups were found (Table S1). 
Lexaptepid was well tolerated. Maximum lexaptepid plasma concentrations (Cmax) of 1.96±0.19 μmol/L 
were measured at 0.7±0.4 hours after administration (Figure 1A), after which levels declined in a 
biphasic manner (initial elimination half-life of 9.7±3.6 hours, mean terminal elimination half-life of 
22.5±4.3 hours).
In placebo-treated subjects, LPS administration resulted in an increase in plasma hepcidin, 
peaking at T=6 hours with maximum concentrations of 23.0±5.2 nmol/L, followed by a gradual 
decrease reaching baseline levels at T=24 hours (Figure 1B). In the lexaptepid-treated group, total 
hepcidin levels increased more rapidly and extensively (maximum levels: 547±117 nmol/L, peak at T=9 
41481 van Eijk.indd   108 18-08-16   16:17
Effect of the anti-hepcidin Spiegelmer® lexaptepid on inflammation-induced decrease in serum iron in humans
109
7a
hours). This may largely be attributed to a reduced elimination of the lexaptepid-hepcidin complex 
through the kidney due to increased size and charge as also reported for an anti-hepcidin antibody.12 
In a previous Phase 1 study, constant concentration increases of hepcidin after increasing doses 
of lexaptepid from 0.3 to 4.8 mg/kg, indicated that the administration of lexaptepid did not induce 
hepcidin production by itself.14 In addition, hepcidin production may have been influenced by the major 
changes in serum iron as observed throughout the experiment. 
There was a marked induction of serum iron in both the lexaptepid-treated and placebo group 
at 3 and 6 hrs after endotoxin administration (rise to 203±13 and 221±22 % from baseline respectively 
in the lexaptepid treated group, versus 181±14 and 146±14% in the placebo (Figure 1C-D and Figure 
S1).  This immediate increase was previously observed during experimental endotoxemia,18 and may 
be due to an acute inflammation-induced abrogation of erythropoiesis and iron uptake by the bone 
marrow, whereas the export of iron from iron storing cells persists as long as ferroportin is expressed. 
In concordance, serum iron levels were comparable in both groups at T=3 hours and started to 
decline in the placebo-treated subjects concurrent with the increase of hepcidin concentrations. 
In contrast, lexaptepid administration resulted in a prolonged increase in serum iron, peaking 
at T=6 hours. The transient LPS-induced hypoferremia was effectively prevented by lexaptepid. 
Accordingly, the predefined primary endpoint, change in serum iron concentration 9 hours after LPS 
administration, was met (P<0.0001). At this time point, no differences between groups  were found 
in changes in hematological parameters and cytokine levels (Table S2). Twenty-four to 48 hours after 
LPS administration, serum iron was actually lower in the lexaptepid-treated group compared with 
controls. We suspect that the prolonged and strongly elevated serum iron concentrations may have 
stimulated hepcidin production to overcome the effect of lexaptepid, eventually resulting in hepcidin-
induced hypoferremia. We do not anticipate that treatment of patients with anemia of chronic disease 
and functional iron deficiency, who typically have serum iron concentrations below 10 µmol/L, would 
react with similarly high increases in serum iron concentrations when treated with lexaptepid and we 
therefore do not consider this observation as predictive for actual patients. Currently, a Phase 2 trial 
(ClinicalTrials.gov: #NCT01691040) investigates whether lexaptepid is able to elevate hemoglobin in 
cancer patients and initial results from a pilot phase are encouraging.19  
Although an increase over time was noted for both total iron binding capacity and plasma 
ferritin concentration after endotoxin administration, no differences between groups were observed 
(Figure S2A-B). No effect of lexaptepid was observed on innate immunity. Laboratory parameters of 
inflammation (Figure 2A-F) and inflammatory signs and symptoms (Figure S3A-B) caused by LPS were 
not different between the groups.
In conclusion, the anti-hepcidin treatment with lexaptepid was well tolerated and effective in 
blocking the inflammation-induced reduction in serum iron during systemic inflammation in humans. It 
therefore represents an interesting compound for the future treatment of anemia of inflammation. 
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Figure 1. Plasma lexaptepid and iron parameters during experimental human endotoxemia. 
(A) Drug concentration in lexaptepid-treated subjects only. (B) Concentration of hepcidin in lexaptepid- and placebo-
treated subjects. (C) Serum iron concentrations. Black arrow indicates the primary endpoint: change in serum iron 
levels at 9 hours after LPS administration.  (D) Transferrin saturation. Data are expressed as mean±SD. Changes in all 
parameters over time were analyzed with two-way ANOVA repeated measures, interaction term. Interaction terms 
are displayed within each graph. In the lexaptepid-treated subjects, hepcidin levels were still elevated at T=168 hours 
(day 8) compared with baseline values (Student’s paired T-test: P=0.005).
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Figure 2. Inflammatory parameters.
(A) C-reactive protein, (B) white blood cell count. Values in panel A and B are depicted as mean and SD. Differences 
over time were analyzed with two-way ANOVA repeated measures. The p-value of the interaction terms are depicted 
in the respective panels. Plasma concentrations of TNF-α (C), IL-10 (D), IL-6 (E) and IL-1RA (F) are displayed for the 
treatment groups. As cytokine concentrations were not normally distributed, only median cytokine concentrations 
are depicted. Area’s under the concentration-time curve were calculated for each individual and compared between 
groups as depicted in the inserted bar charts. Differences in AUCs between groups were tested with Mann-Whitney U 
test. No significant differences in cytokine concentrations between the treatment groups were observed. 
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Supplemental file 1: Treatment regimen
1.  Drug name 
 Drug name: Lexaptepid
 International nonpriority name: Lexaptepid pegol
 Chemical name: L-RNA,(G-C-G-C-C-G-U-A-U-G-G-G-A-U-U-A-A-G-U-A-A-A-U-G-A-G-
  GA-G-U-U-G-G-A-G-G-A-A-G-G-G-C-G-C), 5’-ester with N-[ω-methoxypoly(oxy-1,2-ethanediyl], 
N’-[ω-methoxypoly(oxy-1,2-ethanediyl]-acetyl 9-amino-8-oxo-7-aza-nonyloxy phosphate, 
sodium salt. C, A, U and G code for L-cytidylic, L-adenylic, L-uridylic and L-guanylic acid, 
respectively.
2. Dose 
 1.2 mg/kg body weight
3. Route 
 Intravenously. No central venous access required.
4. Type and volume of diluent 
 1 dose volume of lexaptepid was added to 4 volumes of glucose 5% solution.
 The prepared volume was infused over 15 minutes, using an automated syringe pump.
5.  Cycle length and number of cycles, or criteria for 
discontinuation
 Not applicable in this proof of concept study in which a single dose was administered only.
6. Premedications and concurrent medications 
  At T=0 hours, 2 ng/kg purified standard reference Escherichia coli O:113 LPS (Clinical Center 
Reference Endotoxin, National Institutes of Health, Bethesda, MD, USA) was administered 
intravenously. 
  All subjects received 1.5 L NaCl 0.45%/glucose 2.5%  as pre-hydration, followed by 150 ml/hr 
NaCl 0.45%/glucose 2.5%  until T= 6 hours and then 75 ml/hr to T=8 hrs.
7.  Patient monitoring parameters (frequency of visits and blood draws during 
therapy)
  Subjects received an arterial catheter in the radial artery that enabled continuous arterial 
pressure monitoring. Heart rate was continuously monitored throughout the experiment 
using a 5 lead ECG. 
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  Follow up visits took place on T=24 hrs (day 2), T=48 hrs (day 3), day 8 and day 15. Blood 
was drawn for monitoring of liver enzymes, electrolytes, renal function and hematology 
parameters.
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Supplemental file 2: Supplemental methods,  
tables and figures
Methods
Iron parameters
Serum iron and transferrin were automatically determined (Architect c16000, Abbott Diagnostics, Lake 
Forest, USA) as was ferritin (Immulite 2000, Siemens Healthcare Diagnostics, Deerfield, USA). Total iron 
binding capacity (TIBC) was calculated as: TIBC (μmol/L)=25.0 (µmol/g) x transferrin (g/L). Transferrin 
saturation (TSAT) was calculated as: TSAT (%) = serum iron (μmol/L) / TIBC (μmol/L) x 100%. 
Plasma hepcidin concentrations were measured by matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) following a weak-cation-exchange bead-based 
hepcidin enrichment according to methods described previously.1 The method underwent a validation 
under conditions that ensure the quantification of total hepcidin even in the presence of excess 
lexaptepid. The assay lower limit of quantification was 0.74 nmol/L and the upper limit of quantification 
was 13.2 nM. Above this level samples were diluted 10-1000 times. Currently it is technically impossible 
to discriminate between lexaptepid-bound and free hepcidin, so the total of bound and unbound 
hepcidin was reported. 
Lexaptepid dose administration and pharmacokinetics
Lexaptepid was administered in a dose of 1.2 mg/kg. This dose was chosen based on findings from 
a phase 1 trial in which 1.2 mg/kg proved to be the highest tolerable dose that showed no adverse 
effects related to the study medication.2
Lexaptepid plasma concentrations were determined using a fully validated sandwich 
hybridization assay specific for the full-length sequence of the oligonucleotide. Briefly, an 
amino modified l-RNA capture probe which is complementary (base-pairing) to one end of the 
oligonucleotide was covalently coupled to a 96-well plate by amino coupling. A biotinylated l-RNA 
detect probe was added to the sample for hybridization to the opposite end of the oligonucleotide. 
The complex of analyte and detect probe was then added to the capture probe-coated plate. After 
unbound sequences were removed, the complex of capture probe, Spiegelmer, and detect probe 
was quantified by a streptavidin/alkaline phosphatase conjugate converting a chemiluminescence 
substrate. The assay is not influenced by hepcidin binding to lexaptepid, as a high temperature 
step (5 min, 95 °C) necessary for the complete unfolding of the oligonucleotide releases and 
denatures all hepcidin present in the sample. Quantification was done via a five parameter logistic 
fitted calibration curve. The assay has a limit of quantification of 3.42 nmol/L in plasma. Dilution 
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linearity has been validated up to 1 in 50,000, corresponding to a plasma concentration of 10 µmol/L 
lexaptepid.
Pharmacokinetic (PK) parameters were derived from the PK population data by non-
compartmental analysis using SAS®Software version 9.1.3. (SAS Institute Inc., Cary, NC, USA).
Statistical analysis 
In addition to the analyses of differences in group means or medians (Student’s t-test or Mann-
Whitney U test, as appropriate), changes over time were analyzed using two-way ANOVA repeated 
measures, interaction term, in the case of normally distributed data. For the analysis over time of data 
that were not normally distributed, the area under the concentration-time curve (AUC) for each subject 
was calculated. Areas were compared between groups using a Mann-Whitney U test. For data analysis, 
Graphpad Prism 5.0 (Graphpad Software, San Diego, CA, USA) was used. 
We performed a power analysis showing that with a relevant difference in serum iron 
concentration of 8.5 μmol/L, an expected standard deviation of 7 µmol/L and a power of 80%, twelve 
subjects were needed per group to find a statistically significant difference.
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Supplemental tables 
Table S1. Demographic and baseline characteristics
Lexaptepid Placebo p-value
Age ( years) 21.4 ± 1.2 22.0 ± 2.6 0.48
BMI (kg/m2) 24.6 ± 2.0 24.0 ± 3.3 0.58
Serum iron (μmol/L) 18.0 ± 6.8 19.0 ± 7.6 0.74
TIBC (μmol/L) 55.3 ± 6.1 53.8 ± 6.6 0.55
Transferrin saturation (%) 33.2 ± 14.4 35.4 ± 13.8 0.70
Ferritin (μg/L) 83.8 ±29.7 77.9 ± 38.4 0.68
Hepcidin (nmol/L) 2.19 [0.91-5.17] 1.88 [0.83-3.25] 0.49
Hemoglobin (mmol/L) 13.9 ± 0.8 14.4 ± 0.7 0.27
Hematocrit (L/L) 0.40 ± 0.03 0.41 ± 0.02 0.52
MCV (fl) 88.0 ± 2.8 87.1 ± 2.5 0.40
MCH (fmol) 1.91 [1.83-1.94] 1.89 [1.85-1.90] 0.66
Reticulocyte hemoglobin content (fmol) 2.16 ± 0.08 2.15 ± 0.07 0.70
Date expressed as mean ± SD or median [interquartile range], depending on their distribution. Differences in means 
or medians were tested using Student’s t-test for parametric data or Mann-Whitney U test for non-parametric data, 
as appropriate. BMI, body mass index; TIBC, total iron binding capacity; MCV, mean corpuscular volume; MCH, mean 
corpuscular hemoglobin.
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Table S2. Change in hematological and cytokine parameters from baseline to T=9 hours
Lexaptepid Placebo
P
T=0 T=9 T=0 T=9
Hematologic parameters
Hemoglobin, mmol/L 8.63 ± 0.15 8.64 ± 0.16 8.85 ± 0.12 8.97 ± 0.11 0.66
Hematocrit, L/L 0.43 ± 0.01 0.40 ± 0.01 0.45 ± 0.01 0.40 ± 0.01 0.70
Leucocytes, x 109/L 6.19 ± 0.51 11.84 ± 0.70 4.96 ± 0.30 12.08 ± 0.81 0.19
Lymphocytes, x 109/L 1.64 ± 0.12 0.96 ± 0.12 1.52 ± 0.11 0.86 ± 0.06 0.64
Neutrophils, x 109/L 3.82 ± 0.53 10.02 ± 0.71 2.73 ± 0.27 10.42 ± 0.80 0.25
Monocytes, x 109/L 0.57 ± 0.03 0.80 ± 0.08 0.42 ± 0.28 0.73 ± 0.06 0.36
Eosinophils, x 109/L 0.13 ± 0.02 0.04 ± 0.01 0.15 ± 0.03 0.06 ± 0.01 0.71
Basophils, x 109/L 0.03 ± 0.00 0.02 ± 0.00 0.03 ± 0.01 0.02 ± 0.00 0.59
Cytokines
TNF-α, pg/ml 1.97 
[1.97 – 3.27]
15.94 
[9.92 – 9.33] 
1.97 
[1.97 – 2.16]
14.17 
[5.58 – 7.26]
0.34
IL-6, pg/ml 0.55 
[0.55 – 0.58]
2.76 
[0.86 – 5.29]
0.55 
[0.55 – 0.55]
4.02 
[2.12 – 6.13]
0.66
IL-10, pg/ml 2.16 
[2.16 – 2.16]
3.15 
[2.16 – 6.60]
2.16 
[2.16 – 2.16]
5.61 
[3.08 – 8.37]
0.38
IL-1RA, pg/ml 8.48 
[6.38 – 29.69]
118.1 
[66.7 – 149.1]
10.58 
[4.29 – 23.31]
118.1 
[62.9 – 152.9]
0.89
Date expressed as mean ± SD or median [interquartile range], depending on their distribution. Differences between 
treatment groups were analyses by comparing the difference from T=0 to T=9 between the treatments groups using 
a Mann Whitney U test. No significant difference in the change from baseline at T=9 hours were found between the 
treatment groups.
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Supplemental figures
Figure S1. Changes in serum iron of individual subjects.
Changes in serum iron are identical for the treatment groups until the T=3 hour time point, at which iron 
concentrations are clearly elevated compared to baseline in each individual subjects. From this time point onwards, 
iron starts to decrease in placebo treated subjects, whereas iron stays elevated for a prolonged period and even rises 
further in most lexaptepid treated subjects.
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Figure S2. Total iron binding capacity and ferritin.
(A) total iron binding capacity (TIBC), (B) serum ferritin. Total iron binding capacity is expressed as mean ± SD.  Although 
no significant interaction between groups was found, two-way ANOVA repeated measures showed a significant time 
effect (P<0.0001). Ferritin concentrations were not normally distributed. For reasons of clarity, only median ferritin 
concentrations are depicted. Area’s under the concentration-time curve were calculated for each individual and 
compared between groups as depicted in the inserted bar chart. Differences in AUCs between groups were tested with  
Mann-Whitney U test. No significant differences in ferritin between the treatment groups was observed.
Figure S3. Clinical symptoms and body temperature.
(A) Total symptom score. Subjects rated the severity of 5 items (headache, chills, nausea, back ache, muscle ache) 
on a 0 to 5 anchored Likert scale. These scored were added up to a total symptom score. AU, arbitrary units. As 
symptom scores were not normally distributed, scores are depicted as median. The inserted bar chart within the 
graph shows the median and interquartile ranges of the area under the curve (AUC) of total symptom scores. 
Differences in AUCs between groups was tested with a Mann-Whitney U test. No significant difference between the 
treatment groups was observed. (B) Body temperature. Values are depicted as mean and SD. Differences over time 
were analyzed with two-way ANOVA repeated measures. The p-value of the interaction term is depicted in the panel. 
Again, no difference between the treatment groups was observed.
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CHAPTER 7b
Hepcidin as a target of 
therapy in the treatment 
of anemia after trauma
Lucas T van Eijk, Matthijs Kox, Peter Pickkers
Crit Care Med. 2015;43(1):e36-7
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Abstract of the original article
A multicenter, randomized clinical trial of IV iron supplementation for anemia of traumatic critical 
illness. 
Fredric M Pieracci, Robert T Stovall, Brant BA Jaouen, Maria BA Rodil, Anthony MD Cappa, Clay Cothren 
Burlew, Daniel N Holena, Ronald MD Maier, Stepheny MD Berry, Jerry MD Jurkovich, Ernest E Moore. 
Critical Care Medicine. 2014;42(9):2048–57
Objective
To evaluate the efficacy of IV iron supplementation of anemic, critically ill trauma patients.
Design
Multicenter, randomized, single-blind, placebo-controlled trial.
Setting
Four trauma ICUs.
Patients
Anemic (hemoglobin < 12 g/dL) trauma patients enrolled within 72 hours of ICU admission and with an 
expected ICU length of stay of more than or equal to 5 days.
Interventions:
Randomization to iron sucrose 100 mg IV or placebo thrice weekly for up to 2 weeks.
Measurements and main results
A total of 150 patients were enrolled. Baseline iron markers were consistent with functional iron 
deficiency: 134 patients (89.3%) were hypoferremic, 51 (34.0%) were hyperferritinemic, and 64 
(42.7%) demonstrated iron-deficient erythropoiesis as evidenced by an elevated erythrocyte zinc 
protoporphyrin concentration. The median baseline transferrin saturation was 8% (range, 2–58%). 
In the subgroup of patients who received all six doses of study drug (n = 57), the serum ferritin 
concentration increased significantly for the iron as compared with placebo group on both day 7 
(808.0 ng/mL vs 457.0 ng/mL, respectively, p < 0.01) and day 14 (1,046.0 ng/mL vs 551.5 ng/mL, 
respectively, p < 0.01). There was no significant difference between groups in transferrin saturation, 
erythrocyte zinc protoporphyrin concentration, hemoglobin concentration, or packed RBC transfusion 
requirement. There was no significant difference between groups in the risk of infection, length of stay, 
or mortality.
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Conclusions
Iron supplementation increased the serum ferritin concentration significantly, but it had no discernible 
effect on transferrin saturation, iron-deficient erythropoiesis, hemoglobin concentration, or packed 
RBC transfusion requirement. Based on these data, routine IV iron supplementation of anemic, 
critically ill trauma patients cannot be recommended (NCT 01180894).
To the editor:
With great interest, we read the article by Pieracci et al.1 on iron supplementation as a treatment for 
anemia in critically ill trauma patients. Administration of 100 mg iron sucrose thrice weekly for 2 weeks 
did not affect transferrin saturation, erythropoiesis, hemoglobin concentration, or need for transfusion 
of RBCs over a period of 42 days in a trial with 150 trauma patients. As the authors point out, the lack 
of effects of iron sucrose is probably due to inflammation-induced production of hepcidin, the master 
regulator of iron homeostasis. The release of danger-associated molecular patterns after trauma 
triggers a systemic inflammatory response, leading to increased hepcidin levels and the abrogation of 
iron release from cells through degradation of the iron exporting protein ferroportin. This in turn leads 
to a redistribution of iron out of the circulation into iron storing cells, primarily macrophages of the 
reticuloendothelial system. Next to a reduced production of erythropoietin and a blunted response of 
the bone marrow to erythropoietin, hepcidin therefore plays a key role in the development of anemia 
of inflammation. Indeed, hepcidin has previously been shown to be markedly induced following trauma, 
remaining elevated for 28 days,2 and possibly even longer. The study by Pieracci et al.1 indicates that 
treatment with iron is not useful as long a hepcidin is elevated through ongoing inflammation. In addition, 
in patients who need transfusion in the absence of active bleeding, the amount of iron in the body may 
actually exceed normal values as a result of the repetitive red cell transfusions, illustrated by increased 
ferritin concentrations during hospital stay, which were also observed in this study. As such, instead of 
increasing iron levels, a therapeutic modality directed against hepcidin would be more viable. 
The authors briefly suggest that hepcidin could serve as a potential target for therapy. Of 
interest, several pharmacological approaches of antagonizing hepcidin, its receptor, or its expression 
are currently under investigation. Our group has recently demonstrated that one of these agents, 
lexaptepid pegol, a PEGylated anti-hepcidin l-RNA oligonucleotide, is effective in antagonizing the 
inflammation-induced increase in hepcidin levels induced by the systemic administration of a low 
dose of Escherichia coli endotoxin in healthy volunteers.3 The systemic inflammatory response during 
experimental endotoxemia is similar to that observed after trauma 4 and results in the release 
of cytokines and increased levels of hepcidin, in turn causing hypoferremia and a reduction in 
transferrin saturation. We showed that treatment with lexaptepid pegol 30 minutes after endotoxin 
administration prevents these inflammation-induced effects on iron variables. In addition, the first 
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data from a proof-of-concept study testing this compound in patients with anemia of inflammation are 
promising,5 and additional studies are underway (#NCT02079896). We propose that pharmacological 
modulation of hepcidin may represent a complementary treatment for anemia of inflammation in 
critically ill trauma patients or patients suffering from anemia after major surgery. Therefore, a trial 
investigating the efficacy of such a compound after trauma or major surgery is warranted. 
Lucas T van Eijk, Matthijs Kox and Peter Pickkers
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We thank van Eijk et al.1 for their thoughtful comments regarding our article.2 Indeed, standard 
dosing of iron, whether enteral 3 or parenteral,2 appears only to accumulate as ferritin within the 
reticuloendothelial system of anemic, critically ill surgical patients. Consequently, both irondeficient 
erythropoiesis and anemia persist despite an increase in total body iron. van Eijk et al.1 are correct to 
suggest that hepcidin mitigation is a natural next step toward achieving iron-sufficient erythropoiesis 
during the inflammatory state associated with both trauma and surgery. One additional avenue of 
investigation involves goal-directed, as opposed to standardized, iron dosing. In the outpatient dialysis 
setting, iron is administered to target transferrin saturation (TSAT). Using such a strategy, IV iron 
supplementation was able to overcome the functional iron debt of dialysis patients with low TSAT and 
high ferritin (suggesting functional iron deficiency).4 Similarly, IV iron was able to improve hemoglobin 
in a mouse model of anemia of inflammation in the absence of hepcidin inhibition.5 It is likely that 
the optimal treatment of inflammation-induced functional iron deficiency will involve a combination 
of hepcidin mitigation and goal-directed iron supplementation. We thank van Eijk et al.1 for their 
contributions to this field and look forward to their continued research. 
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Abstract 
Background
Inflammation is a strong inducer of hepcidin, whereas hypoxia suppresses hepcidin production. 
Inflammation and hypoxia often coincide in patients, especially during critical illness. The objective 
of the current study was to study the interplay of hypoxia and systemic inflammation on hepcidin 
production and iron homeostasis, using the experimental endotoxemia model in healthy volunteers.
Methods
20 healthy male subjects participated in an open-label, randomized, parallel group intervention study. 
Hypoxia was induced for 3.5 hours using a respiratory non-invasive ventilation helmet, in which the 
fraction of inspired oxygen (FiO2) was adjusted to achieve a peripheral oxygen saturation between 
80 and 85% (n=10). The normoxia group (n=10) was exposed to room air (FiO2 21%). After 1 hour of 
hypoxia/normoxia, an i.v. bolus of 2ng/kg E. Coli endotoxin was administered. Blood was drawn serially 
for the measurement of plasma erythropoietin, cytokines , hepcidin, and serum iron concentrations.  
Results
Hypoxia resulted in increased plasma erythropoietin levels, peaking 6 hours after endotoxin 
administration (7.8±0.7 mlU/L vs. 3.8±0.3 mlU/L at baseline). Plasma cytokine levels markedly increased 
as a result of endotoxin administration. In the hypoxia group, TNF-α and IL-8 were significantly 
attenuated compared with the normoxia group (reduction of the AUC of the concentration*time curve 
of 35%, p=0.007 and 47%, p=0.003, respectively), while IL-6 showed a similar trend (38%, p=0.08). 
In contrast, IL-10 showed a trend towards increased levels in the hypoxia group (increase of 92% 
compared with the normoxia group, p=0.06). Plasma hepcidin concentrations increased, peaking 6 
hours after endotoxin administration, but no differences between the groups were observed (p=0.11). 
Serum iron levels showed a biphasic pattern: an initial increase, peaking at 3 hours after endotoxin 
administration, followed by a decrease below baseline values that was most pronounced 8 hours after 
endotoxin administration. This response was similar in both groups (p=0.45).
Conclusion
In this experimental model of systemic inflammation, hypoxia exerted distinct effects on the immune 
response, but not on hepcidin or iron homeostasis. These findings indicate that acute inflammation-
induced hepcidin production overrules hypoxia-induced suppression of hepcidin.
This trial was registered at www.clinicaltrial.gov #NCT01978158. 
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Introduction 
Hepcidin is the central mediator of iron homeostasis. It binds to the iron exporter ferroportin 
expressed on macrophages and duodenal enterocytes, leading to its internalization and degradation, 
thereby attenuating iron export into the extracellular compartment.1 Systemic hepcidin levels are 
regulated through several mechanisms, and new pathways are still emerging.2 Next to body iron 
status, systemic inflammation is another major inducer of hepcidin production in the liver. Binding of 
cytokines to their receptors on hepatocytes leads to activation of the JAK-STAT3 pathway, resulting 
in increased transcription of the hepcidin-encoding HAMP gene.3 The redistribution of iron into iron 
storing reticulo-endothelial cells as a result of increased hepcidin production during inflammation or 
infection is regarded to be part of the innate immune response against invading pathogens, as iron is a 
vital nutrient for microbial growth and replication. 
In sharp contrast with inflammation, hypoxia is a strong suppressor of hepcidin production.4 
Hypoxia facilitates increased transport of iron from storage sites and the enterocytes to the bone 
marrow, where it is used for erythrocyte production. It suppresses hepcidin through various 
mechanisms mediated by induction of hypoxia inducible factors (HIFs). First, hepcidin expression may 
by directly regulated by the binding of HIFs on the hepcidin promoter,5 although this remains to be 
confirmed. Second, HIF induction results in increased erythropoietin production and erythropoiesis, 
which are known suppressors of hepcidin production.6,7 Third, hypoxia decreases hepatic hepcidin 
expression via induction of platelet derived growth factor-BB, which inhibits hepcidin transcription.8 
Finally, HIF induction  increases levels of furin, a protease that cleaves hemojuvelin, resulting in soluble 
hemojuvelin. This is a natural inhibitor of the BMP-SMAD pathway, one of the major hepcidin-inducing 
pathways.9  
In case of pronounced systemic inflammation, e.g. during sepsis, inflammation and severe 
tissue hypoxia frequently occur at the same time.  Data obtained in mice models suggest that 
hypoxia can override the upregulation of hepcidin during liver inflammation and interleukin-6 
production.5 However,  Currently it is not known whether, and if so, to what extent hypoxia suppresses 
inflammation-induced hepcidin production in man. The objective of the current study was to study 
the effect of hypoxia on hepcidin production and iron homeostasis during systemic inflammation in 
healthy volunteers, using the experimental endotoxemia model.
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Materials and methods
Design and subjects
This study was part of larger trial investigating the effects of oxygen status on inflammation.  It was 
designed as an open-label, randomized, parallel group interventional study. The trial was approved by 
the local ethics committee and carried out according to GCP standards and the declaration of Helsinki 
including current revisions. The study was registered under ClinicalTrial.gov: #NCT01978158. 
After written informed consent was obtained and subjects were declared eligible based on a screening 
including a full medical history, physical examination, ECG and routine laboratory tests, 30 healthy male 
non-smoking subjects, between 18 and 35 years of age, were randomized to receive either hypoxia, 
normoxia, or hyperoxia during experimental endotoxemia. For the current study, only the data of the 
hypoxia group and the normoxia group were analyzed.
Experimental protocol
At the morning of the experiment, subjects were admitted to the research unit of the department of 
intensive care medicine of a university hospital, situated 20 meters above sea level. They had refrained 
from the ingestion of alcohol and caffeine for 24 hours prior to the study, and were fasted from the 
preceding night. Subjects received a venous catheter in an antecubital vein and an arterial catheter in 
the radial artery (BD Angiocath, Becton Dickinson, Infusion therapy systems, Sandy, USA) that enabled 
continuous arterial pressure monitoring and blood sampling. Heart rate was continuously monitored 
throughout the experiment using a 5-lead ECG. Subjects were pre-hydrated with 1.5 L NaCl 0.45%/
glucose 2.5%,10 followed by the infusion of 150 ml/hour 0.45%/glucose 2.5% during the rest of the 
experimental day.10
Oxygen status was modulated from 1 hour before, until 2.5 hours after endotoxin administration. 
Oxygen modulation was achieved by making use of a transparent, plastic, air-tight respiratory non-
invasive ventilation helmet (CaStar R Next, StarMed, Mirandola, Italy), covering the entire head of the 
subject. In the hypoxia group, subjects were exposed to a mixture of nitrogen and room air with a 
variable fraction of inspired oxygen (FiO2) that was titrated individually to achieve an arterial  oxygen 
saturation between 80 and 85% (measured by a pulse oxymeter placed on one of the fingers). In the 
normoxia group, subjects were exposed to room air (FiO2 21%) using the same helmet. The O2 and 
CO2 contents of the gas mixture inside the respiratory hood were constantly monitored to enable O2 
titration and to ensure an adequate flow to prevent rebreathing of exhaled gas. The exhaled air left 
the helmet through a one-way valve, set to open at a low pressure to prevent the hood from collapsing 
upon inhalation.
Purified standard reference Escherichia coli O:113 LPS (Clinical Center Reference Endotoxin, 
National Institutes of Health, Bethesda, MD, USA) was diluted in NaCl 0.9% and vortexed for a 
minimum of 20 minutes before administration. At T=0, endotoxin was administered intravenously in 
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a dosage of 2 ng/kg body weight over 1 minute, followed by 5 cc normal saline to ensure complete 
delivery. Blood samples were obtained from the arterial catheter repeatedly throughout the 
experiment for various determinations.  
Plasma erythropoietin levels
To investigate whether that hypoxia treatment resulted in tissue hypoxia and HIF stabilization, 
plasma concentrations of EPO, a known downstream HIF target,11 was assessed. Measurements were 
performed using an enzyme-linked immunosorbent assay (ELISA) for quantitative detection of human 
EPO (eBioscience, Bender MedSystems BmbH, Vienna, Austria) according to the instructions of the 
manufacturer. 
Plasma cytokine levels
The magnitude of the inflammatory response was quantified by serial determination of plasma 
cytokine concentrations. To this end, EDTA-anti-coagulated blood was immediately centrifuged 
at 2000 g at 4°C for 10 minutes after which plasma was stored at -80°C until batchwise analysis. 
Concentrations of the pro-inflammatory cytokines tumor-necrosis-factor-α (TNF-α), interleukin-6 
(IL-6), and IL-8, as well as the anti-inflammatory cytokine IL-10 were determined using a simultaneous 
Luminex assay (Merck Millipore, Billerica, MA, USA) according to the manufacturer’s instructions. 
Iron homeostasis parameters
Plasma hepcidin concentrations were measured from lithium-heparin plasma that was handled and 
stored identical to the aforementioned EDTA plasma. Hepcidin was measured using an in house 
developed and validated  competitive ELISA using rabbit anti-hepcidin antibody,12 with a lower limit of 
detection of 0.42 nM in the current study. Serum iron and transferrin were determined using routine 
analysis methods also used for patient samples (Architect c16000, Abbott Diagnostics, Lake Forest, 
USA), as was hemoglobin and hematocrit (Sysmex XE 5000, Sysmex Corp., Kobe, Japan) and ferritin 
(Immulite 2000, Siemens Healthcare Diagnostics, Deerfield, USA). Total iron binding capacity (TIBC) was 
calculated as: TIBC (μmol/L)=25 (µmol/g) x transferrin (g/L). Transferrin saturation (TSAT) was calculated 
as: TSAT (%) = (serum iron (μmol/L) / TIBC (μmol/L)) x 100%. 
Statistical analysis 
Data are expressed as mean ± SEM, or median [25th-75th percentile], depending on their distribution. 
Differences over time between groups were analyzed with repeated measures two-way analysis 
of variance (ANOVA), providing that data were normally distributed. In the case of not-normally 
distributed data, area’s under the concentration-time curve were compared using Mann-Whitney U 
tests. Differences in group means or medians were tested with Student’s t-tests for parametric data or 
Mann-Whitney U tests for non-parametric data. 
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Results 
Wearing of the respiratory helmet and hypoxia were well-tolerated by the subjects. Endotoxin 
administration typically resulted in flu-like symptoms that peaked 90 minutes after endotoxin 
administration and slowly subsided within the following hours. All symptoms subsided before the end 
of the experiment (8 hours after endotoxin administration). 
Targets of hypoxic treatment
In the hypoxia group, the targeted oxygen saturation of 80-85% was reached within approximately 
15 minutes and was maintained throughout the period that the subjects wore the respiratory helmet  
(Figure 1A).  A mean FiO2 of 11.4±0.1 % was required to reach the target saturation. After removal 
of the respiratory helmet 2.5 hours after endotoxin administration, peripheral saturation quickly 
recovered. 
Hypoxia resulted in increased plasma EPO levels, starting 90 minutes after endotoxin 
administration (Figure 1B). In normoxic subjects, EPO levels were increased only at 24 hours after 
endotoxin administration, to similar levels as found in hypoxic subjects at that time-point. 
Figure 1. Targets of hypoxia treatment. 
(A) Peripheral oxygen saturation  (B) Concentration of erythropoietin (EPO). Data are expressed as mean ± SEM. 
Between-group  differences over time were analyzed with repeated measures two-way ANOVA (interaction term 
displayed in each panel). 
Plasma cytokines
Following endotoxin administration, plasma cytokine levels markedly increased and showed a typical 
pattern: an increase of pro-inflammatory cytokines (TNF-α, IL-6 and IL-8) followed by increased levels 
of the anti-inflammatory  IL-10 (Figure 2A-D).  The increase in pro-inflammatory cytokines TNF-α and 
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IL-8 was significantly attenuated in the hypoxia group (reduction of the AUC of the concentration*time 
curve of 35%, p=0.007 and 47%, p=0.003) while IL-6 showed a similar trend (38%, p=0.08). In contrast, 
the anti-inflammatory IL-10 showed a trend towards increased levels in the hypoxia group (increase of 
92%, p=0.06). 
Figure 2. Cytokine concentrations. 
Concentrations of the pro-inflammatory cytokines TNF-α (A), IL-6 (B) and IL-8 (C), and the anti-inflammatory IL-10 (D). 
For reasons of clarity only median cytokine concentrations are depicted. Area’s under the concentration-time curve 
were calculated for each individual and compared between groups as depicted in the inserted bar charts. Differences 
in AUCs between groups were tested with Mann-Whitney U test (p-value displayed within each chart). 
Iron homeostasis parameters
In both groups, plasma hepcidin concentrations increased from 2.5 hours post-endotoxin onwards, 
peaking 6 hours after endotoxin administration, and had normalized 24 hours after endotoxin 
administration (Figure 3A). Although peak levels appeared slightly lower in the hypoxia group, the 
increase in hepcidin over time was similar in the both groups. Baseline serum iron concentrations 
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were similar in both groups (mean ± SEM levels of 21 ± 2.3 µmol/l vs. 17.4 ± 1.9 µmol/l in the normoxia 
group, p=0.23). Endotoxemia resulted in an initial increase in serum iron, peaking 3 hours after 
endotoxin administration, followed by a decrease below baseline values that was most pronounced 8 
hours after endotoxin administration (Figure 3B). This response was similar in both groups. Transferrin 
saturation showed the same profile as serum iron concentrations with no differences between the 
treatment groups (Table 1). Furthermore, no significant changes over time between groups were noted 
in hemoglobin, hematocrit, and TIBC (Table 1). 
Figure 3. Hepcidin and iron concentrations. 
Concentrations of hepcidin (A) and serum iron (B). For reasons of clarity only median hepcidin concentrations are 
depicted. Area’s under the concentration-time curve were calculated for each individual and compared between 
groups as depicted in the inserted bar chart. Differences in AUCs between groups were tested with Mann-Whitney 
U test. Changes in serum iron over time are expressed as mean ± SEM and were analyzed with repeated measures 
two-way ANOVA (interaction term displayed in the panel). 
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Discussion 
The present study is the first to examine the effect of acute hypoxia on hepcidin production during 
systemic inflammation in humans. We show that exposure of healthy volunteers to hypoxic conditions 
from 1 hour before to 2.5 hours after LPS administration does not suppress hepcidin production or 
influence other parameters of iron homeostasis to a relevant extent. These data indicate that during 
a state of acute systemic inflammation, the inflammation-induced hepcidin production overrules 
hypoxia-induced hepcidin suppression.
Since its discovery in 2000,13 many regulatory pathways concerning hepcidin production have 
been discovered. The main pathways that are known to enhance hepcidin production are the BMP-
SMAD pathway, activated by high iron stores, and the JAK-STAT3 pathway, activated by inflammation/
infection. Known hepcidin-suppressors include HIF-1α, EPO, erythroferrone and erythropoiesis.4,14 
There is extensive interaction between these various pathways to ensure adequate iron stores and 
optimal erythropoiesis, while at the same time restricting iron availability for invading pathogens. 
However, in case of ongoing systemic inflammation, increased hepcidin production ultimately leads 
to anemia of inflammation.15,16 Anemia of inflammation occurs in both chronic as well as in acute 
inflammatory diseases, e.g. during severe sepsis or septic shock on the intensive care.17  The latter 
conditions are often complicated by tissue hypoxia, which may further contribute to organ injury and 
failure. Previous studies revealed that hepcidin levels are increased in septic patients, associated 
with the development of anemia on the intensive care,17 However, hitherto it was unclear to what 
extent hypoxia and inflammation, which are opposite signals for hepcidin production, interact with 
each other in humans in vivo. In the present study we demonstrate that the marked changes in 
hepcidin and iron homeostasis following intravenous endotoxin administration are not significantly 
influenced by hypoxia. These findings are in agreement with the hypothesis that hepcidin-induced 
redistribution of iron during inflammation or infection is an important part of the innate immune 
response.18 Apparently mild tissue hypoxia is subordinate to acute inflammation with regard to 
hepcidin signaling. 
Although a trend towards reduced peak levels of hepcidin was observed in the hypoxia group, 
this was most likely due to the fact that the inflammatory insult in the hypoxia group was significantly 
less pronounced: hypoxia led to a marked suppression of pro-inflammatory cytokines, whereas anti-
inflammatory IL-10 tended to be higher in these subjects. As such, hypoxia exerts anti-inflammatory 
effects, of which a detailed discussion is beyond the scope of the current study. Although the pro-
inflammatory cytokine response was importantly suppressed by hypoxia, hepcidin production was 
only marginally affected, indicating that the suppressive effect of hypoxia on hepcidin production is 
minor during systemic inflammation. Furthermore, the decrease in serum iron as a result of hepcidin 
induction was similar in both treatment groups, indicating that the slight attenuation in peak hepcidin 
concentrations in the hypoxia group lacks clinical relevance. 
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This study has several limitations. First, subjects were exposed to hypoxia for a period of 3.5 hours, 
starting 1 hr before LPS administration. One could argue that this may have been too short to down-
regulate hepcidin levels and downstream effects. Hypoxia results in reduced hepcidin production 
both through direct and indirect mechanisms. The direct mechanism involves HIFs that are stabilized 
under hypoxic conditions and bind to hypoxia responsive elements (HREs) on target genes, one of 
which is the HAMP gene.5 The fact that we and others,19 found a marked increase of erythropoietin 
plasma concentrations within 2.5 hours following initiation of hypoxia indicates that the hypoxic 
condition was pronounced and sustained enough to result in HIF stabilization at tissue level, and 
therefore also to suppress hepcidin production. Still, we cannot rule out the possibility that hepcidin 
concentrations would have been affected by a longer hypoxic stimulus. Physiologically, hypoxia would 
be accompanied by an increase in erythropoiesis, which is a strong indirect suppressor of hepcidin.6 
We acknowledge that 3.5 hours of hypoxia is probably not long enough to increase erythropoiesis to 
a relevant extent, and more importantly, erythropoiesis is greatly suppressed during acute systemic 
inflammation.20-23 The presence of (mild) tissue hypoxia alone may thus be insufficient to affect 
hepcidin production, but this does not exclude that long-term hypoxia might influence inflammation-
induced hepcidin production. A second drawback of the current study is the fact that the endotoxin-
induced inflammatory response was not equal in both treatment groups. Hypoxia exerted a marked 
immunosuppressive effect, which makes it hard to distinguish between effects directly resulting from a 
suppressed inflammatory response and those resulting from hypoxia per se. Unfortunately the small 
treatment groups do not allow for co-variate- or multiple regression analyses. 
In conclusion, we have investigated the effect of hypoxia on hepcidin and iron kinetics in a 
setting of acute controlled systemic inflammation in healthy volunteers. In this model no relevant 
effects of hypoxia on endotoxin-induced changes in hepcidin or iron were found, indicating that acute 
inflammation-induced hepcidin production overrules hypoxia-induced suppression of hepcidin. These 
findings may be of special relevance to patients on the intensive care, in whom inflammation and 
tissue hypoxia often coincide. As hypoxia appears unable to down-regulate hepcidin during inflamed 
circumstances and these patients are likely to suffer from a low hemoglobin level that may further 
compromise oxygen transport, pharmacological inhibition of hepcidin to prevent the development of 
anemia of inflammation may prove to be a valuable adjuvant therapy.  
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Abstract
Background
Reduced erythrocyte survival and deformability may contribute to the so-called anemia of 
inflammation observed in septic patients. Erythrocyte structure and function are affected by both the 
membrane lipid composition and the organization. Wetherefore aimed to determinewhether these 
parameters are affected during systemic inflammation. 
Methods
A sensitive matrix-assisted laser desorption and ionization time-of-flight mass spectrometric method 
was used to investigate the effect of plasma components of 10 patients with septic shock and of 
10 healthy volunteers subjected to experimental endotoxemia on erythrocyte membrane lipid 
composition. 
Results
Incubation of erythrocytes from healthy control donors with plasma from patients with septic shock 
resulted inmembrane phosphatidylcholine hydrolysis into lysophosphatidylcholine (LPC). Plasma 
fromvolunteers undergoing experimental human endotoxemia did not induce LPC formation. The 
secretory phospholipase A2 IIA concentrationwas enhanced up to 200-fold in plasma of septic patients 
and plasma fromendotoxin-treated subjects, but did not correlate with the ability of these plasmas to 
generate LPC. Erythrocyte phosphatidylserine exposure increased up to two-fold during experimental 
endotoxemia.
Conclusions
Erythrocyte membrane lipid remodeling as reflected by LPC formation and/or PS exposure occurs 
during systemic inflammation in a secretory phospholipase A2 IIA-independent manner. General 
significance: Sepsis-associated inflammation induces a lipid remodeling of the erythrocyte membrane 
that is likely to affect erythrocyte function and survival, and that is not fully mimicked by experimental 
endotoxemia.
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Introduction
In patients with inflammation, anemia is associated with poor patient outcome. Next to changes in 
iron homeostasis and defective erythropoiesis,1,2 reduced erythrocyte lifespan contributes to “anemia 
of  inflammation”.3-5 This condition is common in patients suffering from sepsis.6 Erythrocyte shape, 
deformability, and aggregability were shown to be altered in these patients.7,8 Such structural and 
functional changes may contribute to the microcirculatory alterations that are linked to untimely 
erythrocyte removal in the spleen 9 and to a poor outcome.8 
Erythrocyte structure and function depend on plasmamembrane lipid composition.10,11 Sepsis-
associated alterations in membrane lipid composition may contribute to alterations in erythrocyte 
function. Indeed, incubation of erythrocytes from healthy volunteers with plasma of septic patients has 
been shown to induce phosphatidylserine (PS) exposure and membrane ceramide formation,12 both 
with functional consequences.10,13 
Phospholipids constitute the majority of the erythrocyte membrane lipids, with the 
glycerophospholipid (GPL) phosphatidylcholine (PC) and the sphingolipid sphingomyelin (SM) 
dominating the outer membrane of the lipid bilayer.10,11 Secretory phospholipase A2 (sPLA2) and 
sphingomyelinase (SMase) catalyze the hydrolysis of GPLs into lysophospholipids (LPLs) and free 
fatty acids, and SM into ceramide and choline, respectively. The activity of both lipases is enhanced 
in the plasma of patients with sepsis,14,15 and the lipids they generate are involved in the pathology of 
inflammation.16 In vitro, erythrocyte deformability and survival are negatively influenced by sPLA2 and 
SMase, and by the incorporation of their products into the membrane.9,13,17,18
The aim of the current study was to investigate the involvement of lipase activity in the 
erythrocyte-related pathophysiology during systemic inflammation in patients with sepsis and in 
experimental human endotoxemia. Using sensitive matrix-assisted laser desorption and ionization 
time-of-flight (MALDI-TOF) mass spectrometry (MS), we investigated the lipid composition of 
erythrocytes after incubation with the plasma of patients suffering fromseptic shock andwith plasma of 
subjects undergoing experimental endotoxemia. A mechanistic explanation for the observed changes 
was explored by measuring plasma sPLA2 IIA levels and erythrocyte PS exposure.
Material and methods
Septic patients
Anticoagulated blood (4 mL) was collected from 10 septic shock patients who resided in the 
department of Intensive Care Medicine of the Radboud University Medical Center, Nijmegen, the 
Netherlands, and from ten healthy volunteers. Septic shock was defined as having two or more 
systemic inflammatory response syndrome criteria,19 in combination with a proven or suspected 
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infection and the need for vasopressor therapy following adequate fluid resuscitation. The study was 
carried out in accordance with the applicable rules on review by ethics committees and informed 
consent. Blood from all patients was drawn within 24 h after starting vasopressor therapy. Plasma, 
erythrocytes and erythrocyte membrane fractions were obtained by differential centrifugation.
Human endotoxemia trial
This study was part of a larger endotoxemia trial (clinicaltrials.gov identifier: NCT01349699).20 Our 
analyses were performed on data of the ten placebo-LPS-treated subjects only. The trial was approved 
by the local ethics committee, and carried out according to GCP standards and the declaration of 
Helsinki. A detailed protocol of the human endotoxemia trial was previously described.20 Blood was 
collected at various time points after the injection of purified endotoxin (LPS) prepared from E. coli 
O:113 (Clinical Center Reference Endotoxin, National Institute of Health (NIH), Bethesda, MD, USA).20 
sPLA2 IIA and cytokine measurements 
sPLA2 IIA concentrationswere determined by ELISA (Cayman Chemical, Ann Arbor, MI, USA). Tumor 
necrosis factor (TNF)-α and interleukin-6 (IL-6) were measured by Luminex (Bio-Plex cytokine assay, 
Bio-Rad, Hercules, CA, USA). 
Erythrocyte isolation from blood group O, Rhesus-negative donors 
EDTA-anti-coagulated bloodwas collected fromseveral blood group O, Rhesus-negative volunteers, and 
erythrocytes were isolated using Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation.
Plasma incubation
Blood group O, Rhesus-negative erythrocytes were incubated in the plasmaof patients or healthy 
volunteers at 10% hematocrit in a final volume of 500 μL, for 20 h at 37 °Cwith gentle agitation. 
Erythrocytes incubated with calcium-containing (2.5 mM CaCl2) Ringerwith or without bee venom 
sPLA2 type III (Cayman Chemical, Ann Arbor, MI, USA) served as positive and negative controls. 
Absorption at 415 nm was determined to assess the extent of hemolysis.
Flow cytometry
Erythrocytes were probed for PS exposure with Annexin V-FLUOS (Roche, Basel, Switzerland). Flow 
cytometry was performed as described previously.21
MALDI-TOF MS detection of membrane lipids 
Erythrocytes (50 μL) were lysed and the membrane fractions were washed. Membrane lipids were 
extracted and analyzed by MALDI-TOF MS.22-26
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Thin layer chromatography (TLC)
Lipids were separated using high performance TLC silica gel 60 plates, lipidswere visualized andMALDI 
mass spectrawere recorded directly from the TLC plate as described previously.26,27
Statistical analysis
Differences in the percentages of total membrane lysophosphatidylcholine (LPC) between two 
groups were determined using Fisher’s exact test. A repeated measures one-way ANOVA was used 
in combination with Tukey’s post-test to assess changes in erythrocyte PS exposure over time. 
Differences between two groups of continuous datawere determined using the Mann–Whitney U 
test. The relation between two parameters was assessed by Pearson correlation. Reported values are 
two-sided, and a P-value of b0.05 was used for statistical significance. Additional details of the methods 
used are given in the Supplemental Information.
Results
Demographic characteristics
Characteristics of the septic patients are provided in Table 1, and characteristics of the volunteers who 
participated in the endotoxemia trial (trial subjects) and of the control donors that served as controls 
for the septic patient group are presented in Table 2.
Enhanced LPC generation in erythrocytes incubated with septic 
patient plasma
Lipid analysis of erythrocytes from patients with septic shock and fromcontrol donors did not 
reveal the presence of lysolipids such as ceramide and LPC (Fig. 1A). These observationsmay yield 
a skewed picture due to the loss of compromised cells by lysis or phagocytosis in the circulation. 
Therefore, incubation of erythrocyteswith plasma of septic patients was used to investigate sepsis-
associated lipid remodeling in the circulation. The number of PS-exposing erythrocytes was within 
the normal range observed in vivo 21 after incubation with patient (0.39%±0.11) and with control 
donor (0.43%±0.07) plasma samples. Incubation with septic patient plasma, and to a much lesser 
extentwith control donor plasma, caused the formation of LPC (Fig. 1B). Ceramide and reactive 
oxygen species-generated LPLs were not observed (Fig. 1B), even though they are readily detectable 
by MS [28].28 The observed LPC percentages were within the same range as observed after 
incubation with sPLA2 (Fig. 1C). LPC formation was significantly enhanced in erythrocytes treated 
with plasma from septic patients, but not in erythrocytes treated with plasma from control donors 
(Fig. 1D). The percentage of LPC in the total plasma PC pool was much lower for the septic patients 
(0.63 ± 0.35, n = 3) than for the control donors (4.91 ± 0.49, n = 3), making the incorporation of LPC 
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from the plasma into the erythrocyte membrane an unlikely cause of the increase observed after 
incubation with patient plasma. 
Table 1. Demographic characteristics of septic patients
Pt Nr. Sex
(M/F)
Age
(years)
Diagnosis APACHE 
II
Hb
(mmol/l)
Transfusion history
1 V 54 pneumosepsis 28 4.9 None
2 M 68 abdominal sepsis 
after intestinal 
ischemia
5.1 Day before blood drawing :
     3 thrombocyte transfusions
     3 plasma transfusions
Day of blood drawing:
     2 thrombocyte transfusions
     8 plasma transfusions
     9 erythrocyte transfusions
3 V 81 abdominal sepsis in 
ulcerative colitis
28 6.0 None
4 M 59 infected hip 
prosthesis
4.9 Day before blood drawing :
     1 erythrocyte transfusion
Day of blood drawing:
     1 erythrocyte transfusion
5 M 75 cholangitis 23 8.6 Day before blood drawing :
     2 thrombocyte transfusions
     2 plasma transfusions
Day of blood drawing:
     1 thrombocyte transfusion
6 M 82 abdominal sepsis 
after intestinal 
ischemia
23 7.5 Day before blood drawing :
     3 erythrocyte transfusions
7 M 34 pneumosepsis 14 7.8 None
8 M 84 urosepsis 16 6.3 None
9 V 51 pneumosepsis 27 5.9 None
10 V 65 toxicodermia 23 6.6 None
Mean 
± SD
66.3 
± 16.1
22.8 
± 5.3
6.4 
± 1.3
 
Table 2. Characteristics of healthy subjects
Endotoxemia subjects Healthy volunteers
N 10 10
Age (years ± SD) 22.7 ± 2.8 34.7 ± 14.8
Sex (M/F) 10 / 0 8 / 2
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Enhanced LPC generation does not correlate with the sPLA2 IIA 
plasma concentration
The enzyme sPLA2 type IIA is the only member of the sPLA2 family that is increased in the plasma 
of septic patients.29 Indeed, all our septic patients had enhanced plasma sPLA2 IIA concentrations 
(50.2–1654.0 ng/mL) as compared to the control donors (1.3–9.3 ng/mL) (Fig. 1E), corroborating earlier 
observations.15,29 However, there was no correlation between the observed degree of LPC formation 
and the sPLA2 IIA concentration (Fig. 1F). Also, no correlations were observed between the percentage 
of LPC and the sPLA2 IIA concentration
with the patient parameters sex, age, weight, length, focus of infection, APACHE II, temperature, 
mean arterial pressure, heart rate, fluid balance,Glasgow coma scale, PaO2, FiO2, thrombocytes, 
bilirubin, creatinine or leukocytes (data not shown).
LPC generation and sPLA2 IIA plasma concentration in human 
endotoxemia
In order to overcome the heterogeneity in origin of infection, bacteriology and progression of 
sepsis,30 we investigated the effect of sepsis on erythrocyte lipid composition using a human 
endotoxemiamodel.20 After LPS infusion, the sPLA2 IIA concentrations increased in almost all trial 
subjects (Fig. 2A). A strong correlation (r=0.89, P b 0.001) was observed between sPLA2 IIA levels 
before and 8 h after LPS infusion (Fig. 2B). Furthermore, the sPLA2 IIA concentration at t = 0 correlated 
(r=0.68, P = 0.032) with the rise in body temperature after LPS infusion. However, in contrast to that 
of septic patients, the plasma of the trial subjects did not induce LPC formation in erythrocytes (Fig. 
2C), even though its sPLA2 IIA levels overlappedwith those of septic patients (cf. Figs. 1D and 2A). This 
corroborates our finding that, in septic patients, sPLA2 IIA concentration is not related with the LPC 
formation (Fig. 1E).
Erythrocyte PS exposure is induced during the initial phase of 
human endotoxemia
In vivo, LPC is rapidly converted into lysophosphatidic acid (LPA), whichmay induce the exposure of the 
removal signal PS in erythrocytes.31 In trial subjects, the number of PS-exposing erythrocytes increased 
strongly at 6 and 8 h after LPS infusion, to return to baseline level at 24 h (Fig. 2D). This increase in 
PS-exposing erythrocytes was observed after the onset of inflammation, as indicated by the TNF-α 
and IL-6 plasma levels (Fig. 2E, F). There was a strong positive correlation (r = 0.91, P = 0.002) between 
erythrocyte PS exposure before and at 6 h after LPS infusion.
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Figure 1a-b. Septic patient plasma-induced LPC formation in the erythrocyte membrane. 
Five representative examples of positive-ion MALDI-TOF MS spectra of membrane lipid extracts of erythrocytes from 
septic patients, healthy controls (A), or control donor erythrocytes incubated overnight at 37°C with i) plasma from 
septic patients, ii) plasma from healthy controls, and iii) Ringer solution (B). All peaks are labeled according to their 
mass-to-charge (m/z) ratios and assignments of the most prominent peaks are given directly in the figure. Also, the 
m/z ratios of LPC and ceramide are indicated in panel A en panel B, respectively. 
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Figure 1c-f. Septic patient plasma-induced LPC formation in the erythrocyte membrane. 
The percentage of hydrolyzed PC (LPC) was determined by comparing the proton and sodium adducts of LPC 16:0 
(m/z 496.3 and 518.3), to the combined pool of LPC 16:0 and PC 16:0/18:2 (m/z 758.6 and 780.6). LPC formation 
after incubation of erythrocytes from three different donors with Ringer containing 20 and 100 ng/mL sPLA2 (C). LPC 
formation after overnight incubation with plasma from 10 septic patients and 10 healthy controls (D). The human 
sPLA2 IIA concentration in all plasma samples was determined using an ELISA (E). The sPLA2 IIA concentrations 
measured in patients did not correlate (r = -0.44, P = 0.22) to the observed LPC percentage (F). Means are shown; *: P 
< 0.05. Abbreviations: Cer = Ceramide, LPC = lysophosphatidylcholine, PC = phosphatidylcholine, SM = sphingomyelin.
Figure 2. Erythrocyte lipid remodeling during human experimental endotoxemia-induced inflammation. 
Allogeneic erythrocytes were incubated overnight at 37°C with plasma obtained from 10 endotoxemia trial 
subjects just prior to (t=0) and eight hours after (t=8) the administration of 2 ng/kg clinical grade LPS. The sPLA2 
IIA concentration in all plasma samples was determined using an ELISA (A). The sPLA2 IIA concentrations at t=0 
were correlated to the concentrations at t=8 (r = 0.89, P < 0.001) (B). The percentage of hydrolyzed PC (LPC) was 
determined by positive-ion MALDI-TOF MS, by comparing the intensities of the proton and sodium adducts of LPC 
16:0 (m/z 496.3 and 518.3) with the combined pool of LPC 16:0 and PC 16:0/18:2 (m/z 758.6 and 780.6) (C). Of the 
same 10 trial subjects, the percentage of PS-exposing erythrocytes was determined by flow cytometry detection of 
Annexin V-FLUOS staining (D), and TNF-α (E) and IL-6 (F) plasma concentrations were assessed by Luminex. In panel 
A, C and D means are shown; *: P < 0.05; error bars in panel D represent SEM. In panel E and F median values are 
shown, and the error bars represent the inter-quartile range.
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Figure 3. Detection of lysophospholipids. 
Allogeneic erythrocytes were incubated overnight at 37°C with plasma of a septic patient. Both positive and negative-
ion MALDI-TOF MS of isolated membrane lipids were performed (A). All peaks are labeled according to their m/z 
ratios. Note that there are intense signals of LPC, but no signals of other LPL species. TLC was performed using the 
identical lipid extract (B) to verify the absence of LPL other than LPC. Lipid standards were included to delineate the 
different lipid species. The pale white band in the TLC is caused by the presence of small amounts of hemoglobin that 
could not be completely removed during the extraction process.33 Abbreviations: LPC = lysophosphatidylcholine, LPE 
= lysophosphatidylethanolamine, PA = phosphatidic acid, PC = phosphatidylcholine, PE = phosphatidylethanolamine, 
PG = phosphatidylglycerol, PI = phosphatidylinositol, PL = phospholipid, PS = phosphatidylserine, SM = sphingomyelin.
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The observed lipase activity selectively targets PC in the erythrocyte
sPLA2 phospholipases may not only hydrolyze PC, but also other glycerophospholipids such as 
PS and phosphatidylethanolamine (PE).32 Incubation of control donor erythrocytes with septic 
patient plasma generated high levels of LPC, but no other LPLs such as lysoPE (LPE), lysoPS, or 
lysophosphatidylinositol (Fig. 3A, B). Also, incubation in Ringer that had been spikedwith recombinant 
sPLA2 did not generate any LPLs other than LPC (data not shown). Most likely the plasma 
phospholipases are unable to attack other phospholipids in situ because of their location in the inner 
leaflet of the erythrocyte membrane.
Discussion
sPLA2 phospholipases are the principal catalysts of the hydrolysis of GPLs into LPLs and fatty acids, 
while SMases catalyze the hydrolysis of SM into ceramide and phosphorylcholine. Both activities are 
enhanced in patients with severe sepsis,14,15 and LPLs and ceramide have been shown to play a role 
in the pathology of various inflammatory diseases.16 sPLA2 has attracted attention as a therapeutic 
target in atherosclerosis.32,34 Here, we report that the plasma of patients with severe sepsis triggers 
erythrocyte membrane lipid remodeling, as shown by enhanced LPC formation. This LPC formation 
was similar to that observed after incubation with sPLA2 (Fig. 1). sPLA2 IIA is the only sPLA2 family 
member of which the secretion is significantly promoted during sepsis.29 Indeed, the sPLA2 IIA 
concentration was strongly enhanced in our septic patient plasma samples. The lack of a statistically 
significant correlation between sPLA2 concentration and LPC formation is likely due to the involvement 
of other sPLA2 phospholipases.29 Interestingly, we did not detect an increase in LPC generation using 
the plasma of subjects undergoing experimentally induced endotoxemia, even though inflammation 
and a subsequent rise in plasma sPLA2 IIA were observed. Thus, experimentally-induced acute 
endotoxemia may constitute a useful model for several aspects of sepsis, but does not fullymimic the 
effects of sepsis on erythrocytes. This could be due to the human endotoxemia model mimicking only 
the initial phase of septic shock.20 The absence of LPC formation in the endotoxemia model suggests 
that additional factors, or the exposure of PS, direct sPLA2 IIA towards compromised erythrocytes. 
sPLA2 IIA has been implicated in the activation of the inflammatory processes responsible for 
multiple organ failure in sepsis,30,35 and its plasma level correlated with the rate of mortality.15,36 In 
the human endotoxemia trial subjects, we noticed that sPLA2 IIA status at baseline was predictive for 
the sPLA2 IIA response upon LPS infusion. This suggests that there is a pre-existing, inter-individual 
variability in the sPLA2 IIA response to systemic inflammation. Our MS method enables both specific 
and sensitive detection of different ceramide species inmembrane lipid preparations.37 However, 
and in contrast to earlier findings,12 we did not observe ceramide after erythrocyte incubationwith 
septic patient plasma. As we could detect ceramide after sphingomyelinase treatment in vitro 12 this 
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discrepancy may be caused by patient heterogeneity in the stage and cause of sepsis. The absence 
of LPLs other than LPC may be due to the inability of the responsible plasma lipases to attack their 
substrate GPLs, since the latter primarily reside in the inner leaflet of the plasma membrane.10,11 LPC 
acts as a substrate for lysophospholipase D and LPC acyltransferase, to produce the pro-inflammatory 
lipid mediators LPA and plateletactivating factor.38 Enhanced activity of these enzymesmight explain 
why LPC levels are reduced in the plasma of septic patients.39 We observed a small increase in the 
percentage of PS-exposing erythrocytes in the trial subjects after LPS infusion. Since PS-exposing 
erythrocytes are rapidly removed from the circulation, the increase in PS-exposing erythrocytes 
observed in endotoxemia subjects presumably does not represent the actual number of erythrocytes 
that expose PS after LPS infusion. In addition, significant LPC build-up in the erythrocytemembrane 
can induce hemolysis,18,40 altermorphology, induce microparticle release, and reduce deformability 
leading to splenic retention ex vivo.9 Both the removal and metabolism hypotheses may explain our 
inability to detect LPC in the erythrocytes from the septic patients. PS exposure and PC hydrolysis 
in the erythrocyte membrane may contribute to the reduced erythrocyte lifespan in “anemia of 
inflammation”.3-5 This might also affect erythrocyte transfusion in septic patients, as blood bank 
erythrocytes are prone to expose PS.41 We found that, in trial subjects, erythrocyte PS exposure 
prior to LPS infusion was predictive for the extent of erythrocyte PS exposure upon LPS-induced 
inflammation. This is in line with our previous finding that PS exposure on stored erythrocytes predicts 
their extent of PS exposure after the application of osmotic stress.21 Therefore, determination of the 
PS exposure in erythrocyte concentrates might allow the selection of products for the transfusion 
of septic patients. Since blood bank erythrocytes were also found to be more susceptible for SMase 
activity, it would be interesting to assess whether this also applies to sPLA2s.13 
Conclusions
We here provide evidence for erythrocyte membrane lipid remodeling during systemic inflammation, 
as illustrated by enhanced LPC formation and PS exposure during sepsis. The enhanced LPC formation 
in erythrocytes could not be attributed to sPLA2 IIA alone, and was not observed in experimentally 
induced endotoxemia. As membrane lipid remodeling affects erythrocyte integrity, it is necessary 
to focus future research on elucidating the identity of the phospholipase(s) responsible, including 
erythrocyte-associated forms.42,43 Comparing the endotoxemia model with septic patients would be 
helpful in shortlisting relevant candidates.
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Supplemental information
Methods
Septic patients
Plasma was obtained by centrifugation (2000´g, 4°C) under sterile conditions. Erythrocytes were 
isolated using Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation and washed with 
calcium-free Ringer’s solution (125 mM NaCl, 5 mM KCl, 1 mM MgSO4, 32 mM HEPES, 5 mM glucose, 
pH 7.4). Plasma and erythrocyte membranes were snap-frozen and stored at -80°C following isolation. 
Healthy volunteers
Ten healthy volunteers donated 4 mL of lithium–heparin anticoagulated blood to serve as control, 
after having provided written informed consent to the study protocol. Plasma was obtained by 
centrifugation (2000´g, 4°C) under sterile conditions. Erythrocytes were isolated and processed as 
described above. 
Human endotoxemia trial
A detailed protocol of the human endotoxemia trial was previously described.1 Briefly, a venous 
cannula was placed for administration of fluids to ensure an optimal hydration status,2 and an 
arterial catheter was placed in the radial artery to permit the continuous measurement of blood 
pressure, as well as blood drawing. Heart rate, arterial blood pressure, and temperature were 
monitored throughout the experiment and the subjects were supervised at all time. They received 
1.5 L 2.5% glucose/0.45% saline solution in 1 h immediately before LPS infusion (pre-hydration), 
followed by 150 mL/h until 6 h after LPS infusion, and 75 mL/h until the end of the experiment. E. 
coli endotoxin (Escherichia coli O:113, Clinical Center Reference Endotoxin, National Institute of 
Health, Bethesda, MD) was reconstituted in 0.9% NaCl for injection and vortex-mixed for at least 
10 min. At t=0 hours, 2 ng/kg E. coli endotoxin was injected intravenously. Blood was collected 
at various time points thereafter. Plasma from lithium–heparin anticoagulated (Vacutainer, BD 
Biosciences, San Jose, CA, USA) blood was obtained by centrifugation, snap-frozen and stored at 
-80°C under sterile conditions. Erythrocytes from 4 mL of EDTA anticoagulated (Vacutainer, BD 
Biosciences, San Jose, CA, USA) blood were isolated using Ficoll (GE Healthcare, Waukesha WI, USA) 
density centrifugation and washed with calcium-free Ringer for flow cytometry analysis within 4 
hours after collection.
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sPLA2 IIA and cytokine measurements
Plasma sPLA2 IIA concentrations were determined using an sPLA2 ELISA assay (sPLA2 (human Type IIA) 
EIA Kit, Cayman Chemical, Ann Arbor, MI, USA) according to the manufacturer’s instructions. Plasma 
concentrations of tumor necrosis factor (TNF)-α and interleukin-6 (IL-6) were determined at various 
time points using a simultaneous Luminex assay (Bio-Plex cytokine assay, Bio-Rad, Hercules, CA, USA) 
according to the manufacturer’s instructions.
Erythrocyte isolation from blood group O, Rhesus negative donors
Healthy volunteer EDTA-anti-coagulated (Vacutainer, BD Biosciences, San Jose, CA, USA) blood was 
collected from several blood group O, Rhesus-negative donors, and erythrocytes were isolated using 
Ficoll (GE Healthcare, Waukesha WI, USA) density centrifugation.
Plasma incubation
The allogeneic blood group O, Rhesus-negative erythrocytes were incubated in the plasma of patients 
or healthy volunteers at 10% hematocrit in a final volume of 500 µL, for 20 h at 37°C with gentle 
agitation. Incubation of the erythrocytes with calcium-containing (2.5 mM CaCl2) Ringer with or without 
bee venom sPLA2 type III (Cayman Chemical, Ann Arbor, MI, USA) served as positive and negative 
controls for (sPLA2-induced) lysophospholipid formation, respectively. The absorption at 415 nm of the 
supernatant was determined to assess hemolysis. After incubation, the erythrocytes were washed with 
calcium-free Ringer prior to flow cytometry and membrane lipid analyses. 
Flow cytometry
Flow cytometry was performed on a FACSCalibur system (BD Biosciences, Franklin Lakes NJ, USA) using 
Cellquest Pro software version 6.0. Per sample, 100,000 cells were measured and data analysis was 
performed using Cyan Summit software version 4.3.
MALDI-TOF MS detection of membrane lipids
Erythrocytes (50 µL) were lysed and the membrane fractions were washed repeatedly with lysis 
buffer (10 mM HEPES, 1 mM EDTA, 1 m EGTA, pH 8.0) by centrifugation at 21,000´g for 10 min to 
remove free hemoglobin. Membrane pellets were re-suspended and transferred to glass tubes 
and 500 µL methanol and 250 µL dichloromethane were added. After vortexing, another 250 
µL dichloromethane and 400 µL 0.5% acetic acid were added and vortexed once more. After 
10 min centrifugation at 800´g, the bottom dichloromethane layer was isolated. Residual lipids 
were extracted from the aqueous layer by extraction with 250 µL dichloromethane. The two 
dichloromethane fractions were pooled and the solvent was evaporated. For some plasma samples, 
lipids were isolated directly from 100 µL plasma using the method described for membrane pellets 
above. The lipid fraction was analyzed by positive-ion (and in selected cases also negative-ion) 
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MALDI-TOF MS as described previously.3 Shortly, the lipid extract was mixed 1:1 (v/v) with the matrix 
solution (0.5 M 2,5-dihdyroxybenzoic acid in methanol) and 1 µl of this mixture was directly applied 
onto the MALDI target. For negative ion mass spectra, 9-aminoacridine (9-AA) (Fisher Scientific 
GmbH, Nidderau, Germany) as 10 mg/mL solution in 60/40 (v/v) isopropanol/acetonitrile 4 was used 
and mixed 1:1 (v/v) with the samples of the lipid extracts.
All MALDI-TOF mass spectra were acquired on an Autoflex I mass spectrometer (Bruker 
Daltonics, Bremen, Germany) with ion reflector. The system utilized a pulsed 50 Hz nitrogen laser, 
emitting at 337 nm. The extraction voltage was 20 kV and gated matrix suppression was applied to 
prevent the saturation of the detector by matrix ions. All spectra were acquired in the reflector mode 
using delayed extraction conditions. Peak identities were additionally confirmed by recording post 
source decay spectra as previously described.5 Quantitative data can be obtained with a standard 
deviation of ±10%.6
Thin layer chromatography (TLC)
Lipid extracts were applied onto high performance TLC silica gel 60 plates (10×10 cm in size, on 
aluminum backs; Merck, Darmstadt, Germany), using a Linomat 5 device (CAMAG, Berlin, Germany), 
and developed in vertical TLC chambers with CHCl3, ethanol, water, and triethylamine (30:35:7:35, 
v/v/v/v) as the solvent system. Lipids were visualized by spraying the plate with primuline (Direct Yellow 
59) as previously described.7 Upon illumination with UV light (366 nm), individual lipid classes were 
detected as colored spots. These spots were assessed using a digital image system in combination 
with the program Argus X1 (BioStep, Jahnsdorf, Germany). MALDI mass spectra were recorded directly 
from the TLC plate as described before.8
41481 van Eijk.indd   159 18-08-16   16:17
PART I  |  Iron metabolism and innate immunity
160
References
1.  Pickkers P, Dorresteijn MJ, Bouw MP, van der Hoeven JG, Smits P. In vivo evidence for nitric oxide-mediated 
calcium-activated potassium-channel activation during human endotoxemia. Circulation. 2006;114(5):414-
21.
2.  Dorresteijn MJ, van Eijk LT, Netea MG, Smits P, van der Hoeven JG, Pickkers P. Iso-osmolar prehydration 
shifts the cytokine response towards a more anti-inflammatory balance in human endotoxemia. J Endotoxin 
Res. 2005;11(5):287-93.
3.  Dannenberger D, Suss R, Teuber K, Fuchs B, Nuernberg K, Schiller J. The intact muscle lipid composition of 
bulls: an investigation by MALDI-TOF MS and 31P NMR. Chem Phys Lipids. 2010;163(2):157-64.
4.  Sun G, Yang K, Zhao Z, Guan S, Han X, Gross RW. Matrix-assisted laser desorption/ionization time-of-flight 
mass spectrometric analysis of cellular glycerophospholipids enabled by multiplexed solvent dependent 
analyte-matrix interactions. Anal Chem. 2008;80(19):7576-85.
5.  Fuchs B, Schober C, Richter G, Suss R, Schiller J. MALDI-TOF MS of phosphatidylethanolamines: different 
adducts cause different post source decay (PSD) fragment ion spectra. J Biochem Biophys Methods. 
2007;70(4):689-92.
6.  Bresler K, Pyttel S, Paasch U, Schiller J. Parameters affecting the accuracy of the MALDI-TOF MS 
determination of the phosphatidylcholine/lysophosphatidylcholine (PC/LPC) ratio as potential marker of 
spermatozoa quality. Chem Phys Lipids. 2011;164(7):696-702.
7.  White T, Bursten S, Federighi D, Lewis RA, Nudelman E. High-resolution separation and quantification of 
neutral lipid and phospholipid species in mammalian cells and sera by multi-one-dimensional thin-layer 
chromatography. Anal Biochem. 1998;258(1):109-17.
8.  Fuchs B, Schiller J, Suss R, Schurenberg M, Suckau D. A direct and simple method of coupling matrix-
assisted laser desorption and ionization time-of-flight mass spectrometry (MALDI-TOF MS) to thin-layer 
chromatography (TLC) for the analysis of phospholipids from egg yolk. Anal Bioanal Chem. 2007;389(3):827-
34.
41481 van Eijk.indd   160 18-08-16   16:17
Inflammation-associated changes in lipid composition and the organization of the erythrocyte membrane
161
9
41481 van Eijk.indd   161 18-08-16   16:17
41481 van Eijk.indd   162 18-08-16   16:17
CHAPTER 10
Turkish blonde turns brunette
after treatment of anemia
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Figure legend
A 19-year-old Turkish woman presented with an unexplained iron deficiency anemia since childhood. 
She had no other complaints than tiredness and had an obvious lighter hair color than her family 
members. Repetitive gastrointestinal examinations revealed no abnormalities and hematological 
diseases were ruled out. Her hemoglobin was 8.1mg/dl and transferrin saturation was 2.7% despite 
oral iron supplementation. Serum hepcidin turned out to be inadequately high in relation to the 
iron deficiency, suggesting a genetic disorder in iron metabolism. Genetic investigation revealed 
homozygosis for a mutation in the TMPSS6 gene encoding for matriptase-2. This is indicative of the 
diagnosis iron-refractory iron deficiency anemia (IRIDA) caused by matriptase deficiency.
Intravenous iron supplementation was started. Six months later her hemoglobin had risen to 
10.8mg/dl, the tiredness had vanished and her hair had started to grow dark (see panel A and B). Iron 
deficiency has previously been associated with mild alternating segmentation of hair into dark and light 
bands, called segmented heterochromia. But these are the first pictures thus far reported that show a 
dramatic and non-alternating change in hair color due to iron deficiency, that was completely reversed 
by intravenous iron supplementation therapy. 
Figure 1. change in hair color after iron supplementation.
photographs by Marcel Rekers
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CHAPTER 11
Severe vagal response after
endotoxin administration in man
Lucas T van Eijk, Peter Pickkers, Paul Smits,  
Martijn PWJM Bouw, Johannes G van der Hoeven
Intensive Care Med. 2004;30(12):2279-81
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Abstract 
Introduction
Endotoxin administration to humans has shown to be an appropriate tool to study the effects of 
systemic inflammation. Worldwide, thousands of volunteers have received endotoxin.  Adverse effects 
are reported rarely and the method is considered safe.
Objective: To increase awareness of specific risks of the intravenous administration of endotoxin to 
human volunteers.
Design
Report of four cases who developed a severe bradycardia or protracted asystole, approximately one 
hour after administration of endotoxin.
Setting: The research unit on the Intensive Care.
Cases
Four subjects developed a severe bradycardia or protracted asystole, approximately one hour 
after administration of endotoxin. Further analyses revealed that all subjects had fasted overnight 
and during the experiment, and were not prehydrated in advance of the experiment in contrast to 
approximately 600 subjects that were prehydrated in which no such cardiac events were seen.
Conclusions
These effects may be attributed to the cardio inhibitory Bazold Jarisch reflex. A thorough screening on 
vagal sensitivity and generous fluid suppletion prior to and during the endotoxin challenge appear to 
prevent such cardiac effects.
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Introduction
Sepsis is the leading cause of mortality in non-cardiac ICU’s resulting in an estimated mortality of 
200,000 patients per year in the United states alone.1 Endotoxin is one of the principal bacterial 
components that interacts with the host during Gram negative sepsis. Administration of endotoxin 
to humans has proven to be an appropriate tool to study acute inflammatory responses (activation 
of cytokines and coagulation pathways) and to evaluate novel therapeutic interventions.2 In the 
past three decades, thousands of volunteers have been included in endotoxin trials worldwide. 
Endotoxin administration (1-4 ng/kg) to human volunteers is demanding for the subjects, but generally 
considered safe. Serious adverse events have been reported only rarely. 
Endotoxin is known to cause a transient immune response, which is characterized by flue-like 
symptoms (headache, nausea, muscle aches, chills, fever). Volunteers that have been administered 
endotoxin show a decrease in arterial blood pressure and peripheral vascular resistance, accompanied 
by an increase in heart rate and cardiac output.3 These changes reach their maximum after 
approximately 3-5 hours. Apart from a case report of one patient, who experienced a severe vagal 
response to endotoxin (sinus arrest of 23 sec),4 bradycardia is not typically seen following endotoxin 
administration in humans. Here, we describe 4 cases of severe bradycardia or protracted asystole 
following 2-4 ng/kg reference endotoxin administration. 
Description of cases
Between 1980 and 2004 the subjects received endotoxin during different experimental protocols. All 
studies were approved by the local ethics committees, and written informed consent was given by all 
subjects that participated in these studies. Subjects who were taking prescription drugs or asprin or 
other non steroid anti inflammatory drugs were excluded. Screening of the subjects prior to the test 
revealed no abnormalities in medical history and physical examination. Routine laboratory tests and 
ECGs were normal. Routine laboratory tests and ECGs were normal. The experiments were performed 
after an overnight fast. None of the subjects was prehydrated prior to the administration of endotoxin 
(E. coli batch 0:113, United States Pharmacopeia Convention (Rockville, MD). Characteristics of the 
subjects that experienced severe bradycardia or prolonged sinus arrest are illustrated in table 1. All 
subjects had an uneventful recovery.
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Table 1. Details of subjects who experienced a severe vagal response after the administration of endotoxin. 
Gender, 
Age (yrs)
LPS 
dose 
(ng/kg)
Time 
till 
event 
(min)
Infusion 
protocol 
(cc/hr)
Sinus 
arrest 
during 
event 
(sec)
Therapy Chest 
compressions
Head 
tilt 
test
Vagal 
response 
in MH
Female, 23 2 60 75 4 Atropine - - -
Male, 28 2 65 75 22 Atropine + - +
Male, 33 4 15 75 45 Fluid 
challenge
- + +
Male, 28 4 73 75 23 Fluid 
challenge
- + +
All subject received the same endotoxin (E. coli batch 0:113  United States Pharmacopeia Convention (Rockville, MD)) 
HR heart rate, BP blood pressure, MH medical history.
Discussion
Administration of endotoxin to healthy volunteers is a generally approved model for systemic 
inflammation. Although the cardiovascular response to endotoxin is characterized by a decrease 
in arterial blood pressure, an increase in heart rate, and an increase in cardiac output, bradycardia 
was observed in four subjects in the first hours after endotoxin administration. These subjects were 
kept fasting prior to and during the study and they received the endotoxin without prehydration. 
Further analysis revealed that severe bradycardia did not occur in approximately 600 subjects that 
were parenterally prehydrated, and another 1600 subjects that were orally prehydrated (personal 
communications AF Suffredini, R. Noveck), so apparently, the relative hypovolemia plays an important 
role. Since the denominator is not certain and a considerable publication and investigator bias cannot 
be excluded, it is impossible to calculate an reliable odds ratio and to draw definitive conclusions about 
the pathophysiology.
It has been demonstrated previously that catecholamine levels are increasing approximately 
1-2 hours following endotoxin administration.5 In combination with the relative hypovolemia, we 
believe that a cardiac mechanoreflex accounts for the observed bradycardia and asystole. Because 
of multifactorial influences and the low incidence of the observed bradycardia, it is difficult, if not 
impossible to support our hypothesis with experimental proof.
Pathophysiological mechanism
Cardiac distension, streching or vigorous contraction may activate vagal afferent nerve ending in the 
left ventricle. This may lead to a cardiac mechanoreflex also known as Bezold Jarisch reflex, resulting 
in bradycardia and eventually vagal collapse in subjects sensitive to vagal stimulation.6 Our subjects 
may have responded the same way since a tide of mediators (pro-inflammatory cytokines, cortisol, 
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catecholamines) is starting to be released one hour after the administartion of endotoxin.7 This is 
accompanied by the onset of symptoms including malaise, headache, myalgias and anxiety. The 
decrease in ventricular preload resulting from a relative volume depletion, in combination with the 
enhanced inotropic state caused by the rise of catacholamines, may lead to a deformation of the 
ventricular wall during contraction, thereby stimulating vagal afferent nerve endings in the left ventricle. 
This results in bradycardia in a similar way to the Bezold-Jarisch reflex.8 Naturally, it is entirely possible 
that other mechanisms (e.g. IL-1beta- or 5HT-induced increase in vagal tone REF) can be responsible 
for the observed effects. Interestingly, the vagal reflex actions of ANP appear to be mediated by 
guanylyl cyclase,9 an enzyme also acivated by nitric oxide, which is also increased following endotoxin 
administration. However, prehydration and vagal sensitivity appear to play a crucial role. In accordance, 
we found a higher than normal vagal tone or vagal sensitivity in 2 of the 4 cases in which a head tilt test 
was performed. Also, after the experiment 3 out of 4 subjects admitted to have experienced syncopes 
previously, which apparently did not emerge during the screening.  
Advise for future endotoxin experiments in humans
In cases where volume depletion by hemorrhage presented with relative bradycardia, transfusion 
alone would reliably increase heart rate.6 Therefore, interventions can be based either on 
compensation of the volume depletion or on repressing vagal tonus by the administration of 
atropine. Depending on the preference of the investigator that conducted the experiment, our 
subjects were treated with volume loading or atropine. However, administration of atropine may have 
potential deleterious effects. In a study in 280 patients with hemorrhagic shock, 27 cases experience 
bradycardia succesfully treated with volume loading. Of the 2 patients that received atropine, 1 
patients developed ventricular fibrillation.10
Ideally, subjects who are likely to develope a vagal reaction should be excluded for endotoxin 
experiments. However, reliable provocation tests are lacking. Therefore it is imperative to obtain the 
subjects medical history concerning vagal collapse by proper screening. Since a pre-syncopal state 
cannot be reliably identified, we recommend generous fluid repletion prior and during the test in all 
subjects. Oral or parenteral prehydration preceding the infusion of endotoxin may decrease the risk of 
serious cardiac side effects dramatically.
The cardiac events described appear exceedingly rare. With the subjects prehydrated, 
continuously monitored and qualified personnel present, we consider it justified to continue endotoxin 
experiments in healthy volunteers. 
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Abstract
Clinical experience suggests that the administration of fluids in human endotoxemia reduces 
symptoms. In the present study, the effects of a standardized fluid protocol on symptoms, 
inflammatory and hemodynamic parameters in human endotoxemia are determined. With approval 
of the local ethics committee, 16 healthy volunteers received 2 ng/kg of Escherichia coli endotoxine 
(O:113). After an overnight fast, nine subjects received 1.5 l of 2.5% glucose/0.45% NaCl the hour prior 
to the endotoxin administration and 150 ml/h during the course of the experiment (‘prehydrated 
group’). Seven subjects only received a continuous infusion of 75 ml/h during the experiment (‘non-
prehydrated group’). The course of inflammatory parameters and symptoms were determined and 
mean arterial pressure, heart rate and forearm blood flow were measured. In the prehydrated 
group, TNF-α increased to 522 ± 63 pg/ml (mean ± SEM) while the maximum in the non-prehydrated 
group was 927 ± 187 pg/ml (P < 0.04). IL-10 increased similarly in both groups (non-prehydrated 
117 ± 18 pg/ml and prehydrated 99 ± 18 pg/ml; P = NS). The prehydrated group had a significantly 
lower (P < 0.004) symptom score and recovered sooner (P = 0.004). Endotoxin-induced changes in 
hemodynamics revealed no significant differences between groups. We demonstrate that prehydration 
in experimental human endotoxemia significantly shifts the cytokine balance towards a more anti-
inflammatory pattern. This effect is associated with a reduction in symptoms, whereas the changes in 
hemodynamic parameters are not influenced by prehydration.
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Introduction
Endotoxin administration to both animals and humans is a widely used model to investigate the  
pathophysiological characteristics of sepsis. Animal experiments indicate that the inflammatory 
response to endotoxin is affected by hydration status. Experiments in rats have demonstrated 
that in a state of dehydration, endotoxininduced fever is significantly higher, an effect that can be 
eradicated by the administration of a dose of sterilized water prior to the endotoxin.1 Both volume 
and osmolarity may play a role in the modulation of the immune system. In sepsis as well as in trauma 
patients, the infusion of hypertonic solutions is an accepted method for fast volume resuscitation 
that also exerts immunomodulatory effects.2,3 Interestingly, the administration of iso-osmolar fluids 
in human endotoxemia is widely applied since the clinical impression of experienced investigators 
suggests that it reduces endotoxininduced symptoms. This observation may indicate that besides 
the known immunomodulatory effects of hypertonic solutions, iso-osmolar fluids also exert an effect 
on the inflammatory response. However, the immunomodulatory effects of iso-osmolar solutions in 
humans have not been studied. In the present study, the effects of iso-osmolar prehydration on the 
inflammatory, clinical and hemodynamic response in human endotoxemia are determined. 
Patients and methods
Subjects
After approval from the local ethics committee, 16 nonsmoking subjects (8 females, 8 males) gave 
written informed consent to participate in these experiments. Subjects who were taking prescription 
drugs (except for oral contraceptives), aspirin or other non-steroid anti-inflammatory drugs were 
excluded. Screening of the subjects within 14 days prior to the test revealed no abnormalities in 
medical history and physical examination. Routine laboratory tests and ECG were normal. All subjects 
tested HIV and hepatitis B negative. They did not have a febrile illness in the 2 weeks preceding 
the study. Ten hours prior to the experiment, subjects refrained from caffeine, alcohol and food. 
The experiments were conducted as part of a vascular research investigation in which a local 
pharmacological intervention took place a t = 4 h after endotoxin administration. The subjects of the 
non-prehydrated group were part of a previously published study.4
Study design and procedures 
All subjects received a 20-gauge arterial catheter (Angiomat, Deseret Medical, Becton Dickinson, Sandy 
UT, USA) connected to an arterial pressure monitoring line (Viggo Spectramed, 5269-129 connected 
to Siemens S9000 monitor). This enabled continuous blood pressure monitoring as well as blood 
sampling. Mean arterial pressure (MAP) was determined by the electronically integrated area under 
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the arterial pulse wave curve. Heart rate was continuously monitored using a 3- lead ECG. Both heart 
rate and blood pressure monitoring started at ~2 h before endotoxin administration and continued 
until the end of the experiment. A canulla was placed in an antecubital vein to permit the infusion of a 
glucose/saline solution and endotoxin administration. Forearm blood flow (FBF) was measured in both 
forearms using venous occlusion plethysmography as previously described (Filtrass Domed, Munich, 
Germany).5,6 The endotoxin-induced temperature changes were determined every 30 min for the 
first 8 h after endotoxin administration using an infrared tympanic thermometer (Sherwood Medical, 
‘s-Hertogenbosch, The Netherlands). 
At t = 0 h, all subjects received a dose of purified lipopolysaccharide prepared from Escherichia 
coli (O:113, 2 ng/kg). The endotoxin was injected intravenously in 1 min, followed by 5 ml of normal 
saline to ensure complete delivery. To monitor onset and alterations of endotoxin-induced symptoms, 
subjects were asked to score the severity of nausea, headache, shivering, muscle and back pain every 
30 min until 8 h after the endotoxin was administrated. Symptoms were scored on a scale ranging 
from 0, (symptom not present) to 5 (worst ever experienced) and these scores were added up to form 
a ‘total symptom score’. The duration of symptoms was determined by assessing at which time point 
the total symptom score returned to baseline. 
Laboratory tests
All blood tests were performed on blood samples taken from the arterial line. Blood samples were 
taken at various times during the test in order to determine the time course and the peak values per 
individual. Leukocyte and CRP values were measured before endotoxin administration and at 1 h, 6, 
12 and 22 h after endotoxin. Leukocyte levels were determined in EDTA plasma using flow-cytometry 
(Sysmex XE-2100, Goffin Meyvis, Etten Leur, The Netherlands) and CRP was measured in Lithium 
Heparin plasma using immunological detection according to the instructions of the manufacturer 
(Aeroset, Abbott Laboratories, Abbot Park, IL, USA). 
To determine the concentration of the various cytokines, EDTA plasma was processed 
immediately by centrifugation at 2000 g at 4°C for 15 min and was stored at –80°C before analyses. 
Concentrations of TNF- α, IL-1β, IL-6, IL-8 and IL-10 were determined in samples taken at baseline and 
15, 30, 60 and 90 min and 2, 3, 4, 6, 8, and 22 h after endotoxin was administrated using simultaneous 
Luminex Assay.7
Protocol 1 – The non-prehydrated group 
Seven subjects (4 females, 3 males) received a continuous infusion of 75 ml/h of 2.5% glucose/0.45% 
saline solution. Infusion started directly after cannulation (~2 h before endotoxin administration). Total 
volume infused before endotoxin was administrated, therefore, was 150 ml per subject. Infusion was 
continued until the next morning (22 h after the administration of endotoxin, t = 22 h). 
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Protocol 2 – The prehydrated group 
In nine subjects (4 females, 5 males), 2.5% glucose/ 0.45% saline solution was administered at an 
infusion rate of 150 ml/h starting directly after cannulation and continued until t = 6 h. In the hour 
prior to the endotoxine administration, an extra 1.5 l of 2.5% glucose/0.45% saline solution was 
administered. Therefore, total volume infused before endotoxin administration was 1800 ml per 
subject. After t = 6 h, the infusion rate was decreased to 75 ml/h until the end of the experiment. 
Drugs and solutions 
All solutions were freshly prepared on the day of the experiment. Endotoxin (US Standard Reference 
Endotoxin E. coli O:113 retrieved from United States Pharmacopia Convention, Rockville, MD, USA) was 
dissolved in normal saline 0.9% to a concentration of 200 EU/ml, of which 0.1 ml/kg was administrated. 
Data analysis, calculations and statistics 
The MAP and heart rate were sampled every 5 min throughout the experiments. To determine the 
effect of the endotoxin, the group average of the 30 min before the administration of the prehydration 
and the group average of 30 min at the time where endotoxin induced effects were most dominant, 
are expressed. To assess changes in FBF, the flow of both forearms was averaged and expressed as 
absolute values and percentage change from baseline. All of the expressed peak values/concentrations 
are the group average of the highest value/concentration per subject, unless otherwise stated. 
Unpaired Student’s t-tests or ANOVA with repeated measures were used to compare the 
differences between the prehydrated and the non-prehydrated group, as appropriate. To determine 
changes over time (endotoxine-induced effects) the paired Student’s t-test was used. The Mann-
Whitney U-test was used to compare peak levels of IL-1β, because of the non-parametric distribution 
as a consequence of the lower detection limits. All data are expressed as mean ± SE unless otherwise 
stated. P < 0.05 was considered statistically significant. 
Results
There were no significant differences in demographic characteristics between both groups. 
Characteristics are shown in Table 1. 
Inflammatory parameters
Baseline leukocyte values did not differ between the two groups (4.9 ± 0.2 versus 5.0 ± 0.4 x109/l). 
Figure 1A demonstrates a drop in leukocyte count (due to sequestration) after which an endotoxin-
induced leukocytosis is observed. ANOVA repeated measures did not demonstrate significant 
differences between the two groups. However, the peak leukocyte count was significantly lower in the  
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Table 1. Demographic characteristics of the subjects
Non-prehydrated group Prehydrated group
n (M:F) 7 (3:4) 9 (5:4)
Age (years) 23.9 ± 3.1 22.2 ± 1.7
Height (cm) 175 ± 14 175 ± 9
Weight (kg) 69.9 ± 13.7 71.3 ± 9.1
BMI (kg/m2) 22.5 ± 1.8 23.2 ± 2.0
MAP (mmHg) 96 ± 6 91 ± 10
HR (bpm) 64 ± 10 61 ± 10
FAV (ml) 993 ± 281 1061 ± 216
Data are expressed as mean ± SD. n, number of subjects; M, male; F, female; BMI, body mass index; MAP, mean 
arterial blood pressure, measured with i.a. pressure monitoring line, averaged for 30 min; HR, heart rate, measured 
with 3-lead ECG averaged for 30 min; FAV, forearm volume, measured with water displacement method. There were 
no significant differences between groups.
Figure 1. Leukocyte count and CRP in human endotoxemia with and without  prehydration. 
Effects of 2 ng/kg endotoxin (administered at t = 0 h) in the non-prehydrated group (open circles) and the 
prehydrated group (filed circles) on leukocyte count (A) and CRP (B) over time. In both groups, endotoxin 
administration induced an increase in both leukocyte count and CRP. ANOVA repeated measures demonstrated no 
significant differences between the prehydrated and non-prehydrated group neither for leukocyte count nor for CRP. 
Data are expressed as mean ± SEM.
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Figure 2. TNF-α and IL-10 concentrations during human endotoxemia with and without prehydration. 
Effects of 2 ng/kg endotoxin (administered at t = 0 h) in the prehydrated group (filled circles) and the non-prehydrated 
group (open circles) on pro-inflammatory cytokine TNF-α (A) and anti-inflammatory cytokine IL-10 (B) over time. In 
both groups, TNF-α and IL-10 demonstrated a significant rise in response to the endotoxin. TNF-α was significantly 
lower in the group receiving prehydration (ANOVA, P = 0.046). IL-10 concentrations were not significantly different 
between groups (ANOVA, P = NS). The bar diagrams show the average of individual peak values per cytokine in the 
prehydrated group (filled squares) and the nonprehydrated group (open squares). TNF-α peak, P < 0.04; IL-10 peak, P 
= NS (Student’s t-test). Data are expressed as mean ± SEM.
prehydrated group, reaching a peak value of 12.7 ± 0.7 x109/l compared to a peak of 15.8 ± 1.1 x109/l 
(P < 0.05) in the non-prehydrated group; all peak values were reached between 6-12 h. As illustrated 
in Figure 1B, CRP values started to increase ~6 h after endotoxin administration and reached 
maximum values at t = 22 h. The peak CRP in the prehydrated group averaged 29 ± 4 mg/l. Although 
the rise in CRP in the non-prehydrated group tended to be higher (average of 39 ± 5 mg/l at t = 22 
h), this difference did not reach statistical significance (difference between peak values: P = 0.14). At 
baseline, cytokine levels did not differ between the prehydrated and the non-prehydrated group. After 
endotoxine administration, TNF-α increased to an average peak value of 522 ± 63 pg/ml at t = 90 min 
in the prehydrated group compared to 927 ± 187 pg/ml between 90–120 min in the non-prehydrated 
group (P < 0.04; ANOVA repeated measures, P = 0.046; Fig. 2A). In the prehydrated group, IL-1β stayed 
below the level of detection (8 pg/ml) during the entire experiment whereas IL-1β concentrations in 
the non-prehydrated group demonstrated an increase from below the level of detection to an average
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Figure 3. IL-1β, IL-6 and IL-8 concentrations during human endotoxemia with and without prehydration. 
Effects of 2 ng/kg endotoxin (administered at t = 0 h) in the prehydrated group (filled circles) and the non-prehydrated 
group (open circles) on IL-1β  (A), IL-6 (B) and IL-8 (C) over time. In both groups all three cytokines demonstrated 
a significant rise in response to the endotoxin. IL-1β  and IL-8 were significantly lower in the group receiving 
prehydration (ANOVA, P = 0.018 and P = 0.005, respectively). The difference between groups concerning the release 
of IL-6 did not reach statistical significance (ANOVA repeated measures P = 0.095). The bar diagrams show the 
average of individual peak values per cytokine in the prehydrated group (filled squares) and the non-prehydrated 
group (open squares). All three cytokines were significantly lower in the group receiving prehydration. IL-1β  peak, P < 
0.001; IL-6 peak, P < 0.03; and IL-8 peak, P < 0.002 (Student’s t-test). Data are expressed as mean ± SEM.
peak value of 25.6 ± 1.9 pg/ml between 2–4 h after endotoxin administration (Fig. 3A; P < 0.001; ANOVA 
repeated measures, P = 0.018). In addition, the concentrations of the pro-inflammatory cytokines, IL-6 
and IL-8, demonstrated an endotoxin-induced rise, in the group receiving prehydration this rise in 
cytokine-concentrations was almost halved (Fig. 3B,C). In contrast to the pro-inflammatory cytokines, IL-
10 concentrations showed a trend towards higher values in the prehydrated group; however, differences 
were not significant (prehydrated group 117 ± 18 pg/ml versus non-prehydrated group 99 ± 18 pg/ml, 
all peak times recorded between 2-3 h after endotoxin administration; P = NS; Fig. 2B). About 1 h after 
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endotoxin administration, body temperature started to rise in both groups. Subjects in the prehydrated 
group developed a significantly lower peak body temperature (average peak value of 38.1 ± 0.1°C versus 
38.8 ± 0.3°C in the non-prehydrated group; Student's t-test, P < 0.05).
Symptomatic parameters
The first endotoxin-induced symptoms occurred after about 1 h and usually started with headache 
and nausea. In the prehydrated group, subjects scored lower on all symptom items; however, due to 
variation, these effects did not reach statistical significance on each symptom item separately. The total 
symptom score was significantly lower in the prehydration-group (peak values of 5.9 ± 0.5 versus 10.0 
± 1.2; P < 0.004; ANOVA repeated measures, P = 0.036) and symptoms lasted significantly shorter (P < 
0.005) compared to the non-prehydrated group (Fig. 4).
Figure 4. Total symptom score during human endotoxemia with and without prehydration. 
Total symptoms score after 2 ng/kg E. coli endotoxin administration in the non-prehydrated (white bars) and the 
prehydrated (black bars) group. Subjects were asked to score the severity of nausea, headache, shivering, muscle 
and back pain on a scale from 0 (symptom not present) to 5 (worst ever experienced) every 30 min until 8 h after 
the endotoxin was administrated. Symptoms were scored on a scale ranging from 0, (symptom not present) to 5 
(worst ever experienced) and these scores were added up to form a ‘total symptom score’. All subjects experienced a 
significant rise in symptom score in response to the endotoxin. Expressed data are the average of the symptom score 
at baseline and the average of the highest score per individual. The total symptom score was significantly lower in the 
group receiving prehydration (P < 0.004, Student’s t-test). Data expressed are mean ± SEM.
Hemodynamic parameters
As illustrated in Figure 5, endotoxin-induced changes in hemodynamic parameters reached their 
zenith at ~4 h after endotoxin was administrated. MAP declined by 15% (from 91 ± 9 mmHg to 77 ± 
3 mmHg; P < 0.005) in the prehydrated group and by 15% (from 96 ± 2 mmHg to 81 ± 4 mmHg; P < 
0.001) in the non-prehydrated group. Heart rate increased by 50% from an average of 61 ± 3 bpm to 
92 ± 4 bpm in the prehydrated group (P < 0.0001) and by 47% from 64 ± 4 bpm to 94 ± 3 bpm in the 
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non-prehydrated group (P < 0.002). No significant differences for heart rate and MAP were observed 
between the prehydrated and the non-prehydrated group. Forearm blood flow increased in response 
to the endotoxin. In the prehydrated group, FBF was 3.4 ± 0.6 ml/min/dl at baseline and increased 
by 132% to 7.9 ± 1.2 ml/min/dl at t = 5 h (over time, P < 0.0005). In the non-prehydrated group FBF 
averaged 2.9 ± 0.5 ml/min/dl at baseline and increased by 103% to 5.9 ± 0.9 ml/min/dl (over time, P < 
0.03; difference between groups, P = NS). 
Figure 5. The time course of mean arterial pressure and heart rate during human endotoxemia  
with and without prehydration. 
Effects of 2 ng/kg E. coli endotoxin (administered at t = 0 h) on mean arterial pressure (MAP, A) and heart rate (HR, B) 
in the prehydrated (thick line) and the nonprehydrated group (thin line). MAP was determined using the intra-arterial 
catheter and an arterial pressure monitoring line, heart rate was determined by a 3-lead ECG. Both MAP and HR were 
sampled every 5 min throughout the experiments. Endotoxin administration induced a significant fall of MAP (non-
prehydrated group, P < 0.001; prehydrated group, P < 0.005, Student’s t-test) and heart rate increased in both groups 
(non-prehydrated group, P < 0.002; prehydrated group, P < 0.0001; Student’s t-test). Data expressed are the group 
averages over time. For reasons of clarity SEMs are omitted.
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Discussion
The main finding of the present study is that prehydration in human endotoxemia causes an 
attenuated endotoxininduced response of the pro-inflammatory cytokines including TNF-α. In contrast, 
the response of the anti-inflammatory cytokine IL-10 was not significantly altered by the prehydration 
and even demonstrated a trend towards higher concentrations in the group receiving prehydration, 
indicating that prehydration significantly shifts the cytokine balance towards a more anti-inflammatory 
pattern. This effect is associated with a reduction and faster recovery of symptoms and an attenuated 
endotoxin- induced fever, whereas the possible influence of prehydration on endotoxin-induced 
changes in forearm blood flow, blood pressure and heart rate were not detected. The shift in pro/anti-
inflammatory balance indicates that prehydration in human endotoxemia exerts immunomodulating 
properties. The endotoxin-induced hemodynamic effects are either not influenced by hydration status 
or compensated by counter-regulatory mechanisms. 
Previous studies concerning immunomodulation have mainly focused on the effects of 
hypertonic saline. It has been demonstrated that apart from an efficient method of volume 
resuscitation in sepsis,8,9 hypertonic saline also exerts immunomodulatory effects. These effects 
include suppression of neutrophil activation and modulation of pro- and anti-inflammatory 
cytokines.2,10,11 In vitro experiments demonstrate that hypertonic saline reduces endotoxin induced 
TNF-α production whereas IL-10 production is augmented and, therefore, helps to restore the pro/
anti-inflammatory balance.3 The immunomodulatory effects of hypertonic solutions show similarity to 
the effects of prehydration demonstrated in our experiments. However, the prehydration administered 
to our subjects was isotonic and it is, therefore, impossible that the effects on the immune response 
observed in our experiments are mediated by a change in osmolarity. This indicates that the increase 
in volume must be the main instigator of the effects found in this study. Animal experiments have 
shown that hypovolemia caused by dehydration increases Salmonella endotoxininduced fever and that 
the administration of fluid before endotoxin reduces this effect.3 Angiotensin II is believed to play a 
role in the induction of endotoxin-induced fever and cytokine production since both are reduced by an 
ACE-inhibitor.12,13 It could be argued that after an overnight fast, our subjects in the non-prehydrated 
group are relatively hypovolemic resulting in an activated renin–angiotensin–aldosterone system and 
an angiotensin II-mediated pro-inflammatory response. However, in humans this effect could not 
be confirmed as in experiments with volunteers receiving E. coli endotoxin after an overnight fast, 
administration of an ACE-inhibitor gave no significant differences in TNF-α concentrations.14 In addition, 
the mild hypovolemia may cause activation of the sympathetic nervous system leading to increased 
concentrations of circulating catecholamines. Interestingly, various cytokine producing cells express 
α- and β-adrenoreceptors and in subjects infused with adrenaline, endotoxin induces less TNF-α and 
more IL-10 compared to controls, indicating that β-adrenergic stimulation exerts anti-inflammatory 
effects.15 In contrast, in several in vitro studies, noradrenaline was demonstrated to exert pro-
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inflammatory properties. By stimulating the α-adrenoreceptors of macrophages and lung mononuclear 
cells, noradrenaline augmented TNF- α secretion in various inflammation-inducing models.16,17 It 
could be envisaged that, due to the limited infusion strategy after the overnight fast, the sympathetic 
activity and, therefore, noradrenaline concentrations in the non-prehydrated group are higher. The 
α-adrenoreceptor agonism by the increased noradrenaline concentrations may explain the more 
pro-inflammatory pattern found in this study group. Lastly, it could be hypothesized that prehydration 
improves the microcirculation in organs involved in cytokine release during human endotoxemia. This 
may result in an attenuated induction of pro-inflammatory cytokines after a similar inflammatory insult, 
thereby leading to a change in the pro/anti-inflammatory balance. Rivers et al.18 have demonstrated 
that in septic patients, fast and early volume therapy positively affects outcome. Furthermore, the 
(pre-operative) optimization of hemodynamic parameters has beneficial effects in high-risk surgical 
patients.19,20 It is thought that, during an infection, a moderate increase in pro-inflammatory cytokines 
is beneficial, but that severe induction of proinflammatory cytokines is deleterious and causes organ 
dysfunction.21 In view of our study, it is tempting to speculate that the better outcome after early goal 
directed therapy and pre-operative optimization are a not only a consequence of an improved oxygen 
delivery, but also a direct effect of a more balanced pro/anti-inflammatory pattern as a consequence of 
an improved microcirculation. At present, the human endotoxemia model is the only available in vivo 
human model to mimic Gram-negative sepsis. Future studies using human endotoxemia have to take 
into account that prehydration alters the pro/anti-inflammatory balance after the administration of 
endotoxin. Besides the decrease in symptoms, it is also believed that prehydration decreases the risk 
of a severe vagal response during human endotoxemia.22 It is advisable to administer prehydration in 
human endotoxemia experiments, but when used as a model to measure inflammation or the effects 
of therapeutic interventions on cytokine responses, a standardised protocol should be applied.
Conclusions
In human endotoxemia prehydration significantly attenuates the concentrations of pro-inflammatory 
cytokines, while the concentration of the anti-inflammatory cytokine IL-10 demonstrates a trend 
towards higher concentrations. We conclude that prehydration results in a shift towards a more 
anti-inflammatory cytokine pattern. This effect is associated with a reduction of endotoxin-induced 
symptoms and fever, while the endotoxin-induced changes in hemodynamic parameters remain 
unchanged. Since this effect is caused by the administration of an iso-osmolar fluid, this effect is most 
likely due to a volume effect.
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Abstract
A higher body mass index (BMI) appears to be associated with lower mortality in critically ill patients, 
possibly explained by an altered innate immune response. However, the precise relation between BMI 
and the innate immune response in humans in vivo is unknown. We investigated the relation between 
BMI and the systemic cytokine response during experimental human endotoxemia. Endotoxemia was 
induced in 112 healthy male volunteers by intravenous administration of 2ng/kg E. coli endotoxin. 
Plasma concentrations of TNF-α, IL-6, IL-10, and IL-1RA were serially determined. The relation between 
BMI and the cytokines response as well as body temperature was investigated. The BMIs of the 
subjects ranged from 18.3 to 33.6 kg/m2, (median: 22.7 kg/m2). All subjects showed a marked increase 
in plasma cytokine levels (median(IQR)) peak levels: TNF-α 509 (353-673)pg/ml, IL-6 757 (522-1098)pg/
ml, IL-10 271 (159-401)pg/ml, IL-1RA 4882 (3927-6025)pg/ml) and increase in body temperature (1.8 
(1.4-2.2)°C) during endotoxemia. No significant correlations were found between BMI and levels of any 
of the cytokines or body temperature. No relation between BMI and the cytokine response was found 
in healthy volunteers subjected to experimental endotoxemia. These data question the relationship 
between BMI and cytokine responses in critical illness.
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Introduction
Obesity is an epidemic disease in western society1 and a well-known risk factor for cardiovascular 
diseases, cancer, diabetes and asthma.2–4 However, among critically ill patients mostly beneficial effects 
of obesity have been reported,5–15 named ‘the obesity paradox’ 16 and a putative immunomodulatory 
mechanism has been suggested to explain these effects.17,18
Obesity leads to a chronic state of low grade inflammation. Levels of the pro-inflammatory 
cytokines TNF-α, IL6, IL-1β and the pro-inflammatory marker C-reactive protein (CRP) increase as 
the mass of adipose tissue increases,19 while weight loss results in reduction of pro-inflammatory 
markers.20 Interestingly, the profile of both pro- and anti-inflammatory cytokines and adipokines 
in the morbidly obese are generally comparable to critically ill patients.21 Possibly, the pre-existing 
pro-inflammatory state in obesity primes the immune system to mount a more pronounced immune 
response during systemic inflammation or sepsis. Accordingly, several animal studies have shown an 
increased inflammatory response during sepsis in obese animals compared to lean controls.22–24 This 
can partly be explained by the fact that fat tissue itself is reactive to exogenous triggering factors like 
lipopolysaccharide. It was shown that the intravenous injection of lipopolysaccharide in healthy adults 
results in expression of several adipocytokine and chemokine genes in subcutaneous fat tissue.25 
However, not only the adipose tissue itself may be responsible for the altered immune response in the 
obese, as blood drawn from obese women with a BMI>40 kg/m2 produced twice the amount of TNF-
alpha compared to patients with a BMI of 20-25 kg/m2 after in vitro stimulation with endotoxin.26
Considering that an ever increasing number of overweight patients are admitted to the ICU, it 
is of importance to gain more insight into the potential immunomodulatory effects of adipose tissue. 
Existing data are mainly derived from in vitro, ex vivo and murine models of systemic inflammation, 
while human in vivo data are lacking. The experimental human endotoxemia model, in which a low 
dose of E. coli endotoxin is administered intravenously to healthy volunteers, serves as a standardized 
way to investigate the innate response in vivo in humans. This study aims to investigate the effect 
of the body mass index on the pro- and anti-inflammatory cytokine production in vivo during 
experimental endotoxemia.
Materials and methods
Design and subjects 
In this study, data and plasma samples of seven double blind, randomized placebo controlled trials 
were used that were performed in our institution from 2005 to 2010. All 7 studies (NCT00246714, 
NCT00513110, NCT00783068, NCT00785018, NCT00916448, NCT01349699,  NCT01091571) 
investigated the effect of an intervention on the innate immune response elicited by endotoxin 
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administration using the exact same endotoxemia protocol. The samples from these studies were 
reanalyzed for cytokines in one batch for the current study, to prevent bias from inter-assay variability. 
Only the data of subjects that received LPS and placebo or LPS and an intervention that did not 
influence the immune response were used. We only studied male volunteers because of considerable 
differences in the LPS-induced cytokine response between males and females and possible effects of 
hormonal variations due to the menstrual cycle.27
The study protocols were approved by the Ethics Committee of the Radboud University 
Nijmegen Medical Centre and complied with the Declaration of Helsinki including current revisions 
and the Good Clinical Practice guidelines. All subjects were carefully screened (height, weight, general 
physical examination, medical history, routine laboratory tests, hepatitis and HIV serology and an 
electrocardiogram in the 14 days preceding the LPS administration). Subjects that experienced febrile 
illness in the 4 weeks preceding the test were excluded. Only non-smoking individuals were included. 
The subjects abstained from caffeine and alcohol for 24 hours and did not drink or eat for 12 hours 
prior to the start of the experiment.  
Procedures
On the morning of the experiment, subjects were admitted to a research unit on the intensive care. 
Subjects received a 20-gauge arterial catheter (Angiomat, Becton Dickinson, Sandy, UT, USA) for 
continuous blood pressure monitoring and blood sampling. Hemodynamic data were continuously 
monitored for safety. A venous cannula was placed to permit infusion of 1.5 L 2.5% glucose/ 0.45% 
NaCl in one hour preceeding LPS infusion (prehydration), followed by 150 mL/h until 6 hours after LPS 
infusion and 75 mL/h until the end of the experiment to ensure an optimal hydration status. At t=0 hrs, 
the subjects received 2ng/kg U.S. Reference E. coli endotoxin intravenously over 1 minute, followed by 
5 ml of normal saline. (Escherichia coli O:113, Clinical Center Reference Endotoxin, National Institute of 
Health (NIH), Bethesda, MD, USA). The same batch of endotoxin was used for all studies.
Inflammatory parameters 
EDTA-anti-coagulated blood was drawn from the arterial catheter at T=0, 60, 90 minutes and 2, 4, and  
8 hours after LPS administration, for the measurement of pro-inflammatory cytokines TNF-α and  IL-6 
and the anti-inflammatory IL-10 and IL-1RA. Blood was processed immediately by centrifugation at 
2000xg at 4˚C for 10 minutes before being stored at -80˚C until further analysis. Concentrations of 
TNF-α, IL-6, IL-1ra and IL-10 were determined using a simultaneous Luminex assay, according to the 
manufacturer’s instructions (Milliplex, Millipore, Billerica, MA, USA). As a general clinical measure of 
inflammation, body temperature was measured every half hour.
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Data analysis and statistics
For all cytokines, peak levels and area under curve (AUC) values were determined. These values 
were related to the weight, body mass index (BMI), and body surface area (BSA) of the subjects using 
Spearman’s correlation analyses. Also the ratio of the AUCs of TNF-α/IL-10 as a measure of pro-anti 
inflammatory balance was analyzed. To increase the sensitivity to detect a possible relation between 
BMI and cytokine induction, subjects were stratified in three groups according to their BMI (<20, 
20-25,>25 kg/m2) and systemic cytokine levels were compared between the strata. For data analysis, 
Graphpad Prism 5.0 was used (Graphpad software, San Diego, CA, USA). All data are expressed as 
mean±SEM or median(interquartile range), depending on their distribution. A P<0.05 was considered 
statistically significant. According to methods described previously,28 we calculated that with a sample 
size of 112 subjects and an alpha a 0.05 this study had 80% power to detect a correlation between 
BMI and peak cytokine response with an r of 0.23 or higher.
Results
Demographic data
112 male subjects, aged 22.2±0.2 years, were enrolled. Subjects had an average height of 184±0.7 cm 
and weight of 77.2±0.9 kg resulting in a mean BMI of 22.8±0.2 kg/m2. BMI’s ranged from 18.3 to 33.6 
kg/m2 and were normally distributed (figure 1). Thirteen subjects had a BMI <20, 83 subjects had a BMI 
of 20-25, and 16 subjects had a BMI>25 kg/m2. Length was not statistically different between the strata 
(185±2.3 cm , 184±0.8 cm and  185±1.5 cm respectively, One-way ANOVA p=0.63).
Figure 1. Distribution of BMI’s of the study population.
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Figure 2. Body temperature, mean arterial pressure, heart rate and white blood cell count during 
experimental human endotoxemia. 
Left panels: Values are depicted as median with interquartile range. Right panels: maximal differences compared to 
baseline. Data were stratified according to BMI. Boxes represent interquartile ranges, whiskers represent the 10th and 
90th percentile. Differences between groups were analyzed with Kruskal-Wallis test for nonparametric data. No significant 
differences were found between the three groups. MAP  Mean arterial pressure, HR   heart rate, WBC  white blood cell 
count.
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Endotoxemia symptoms
Approximately 1 hour (T=1) after the administration of LPS, subjects began to show flu-like symptoms. 
The symptoms reached a maximum severity at T=90 minutes. Thereafter, symptoms gradually declined 
to normal values at the T=8 hrs (data not shown). There was a transient increase in body temperature 
of 1.8 (1.4-2.2) °C. (Figure 2) There were no differences in symptom scores and body temperature 
between the three different BMI strata.
Cytokine response
Endotoxemia led to a marked cytokine response, illustrated in figure 2. TNF-α peaked at T=1.5, while 
IL-6 was maximally induced at T=2 hrs. Peak levels of IL-10 and IL1ra were reached at T=2 and T=4, 
respectively (peak levels: TNF-α 509 (353-673) pg/ml, IL-6 757 (522-1098) pg/ml, IL-10 271 (159-401) 
pg/ml, IL-1RA 4882 (3927-6025) pg/ml).
Figure 3. Plasma cytokine levels during endotoxemia.
Values are depicted as median with interquartile range
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Correlation analyses
Peak plasma cytokine levels and AUCs were calculated and a possible correlation with weight, BMI and 
BSA of the subjects was investigated. We did not find a significant correlation of any of the parameters 
with weight, BMI and BSA (Spearman correlations are listed in table 1.) 
Furthermore, no significant differences were found between the three aforementioned strata, 
neither in cytokine peak levels (figure 3), nor in AUCs of the different cytokines, nor in the ratio of the 
AUCs of TNF-α/IL-10. One subject was a statistically significant outlier for IL-10 (peak level 3502 pg/
ml), and another for IL-1RA (peak level 56399 pg/ml), but they had normal BMI’s of 21.5 and 21.7 kg/
m2, respectively. In addition, the subject  with the highest BMI (33.6 kg/m2) had normal peak levels of 
TNF-α (616 pg/ml), IL-6 (1233 pg/ml), and IL-1RA (6384 pg/ml), while peak IL-10 was relatively, but not 
abnormally low (126 pg/ml).
Figure 4. Cytokine peak levels stratified according to BMI. 
Boxes represent interquartile ranges, whiskers represent the 10th and 90th percentile. Differences between groups 
were analyzed with Kruskal-Wallis test for nonparametric data. No significant differences were found between 
the three groups. AUCs of the cytokine responses stratified according BMI were not shown, but also showed no 
difference.
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Table 1. Spearman correlation analyses between indexes of body mass and cytokine levels
TNF-α IL-6 IL-10 IL-1RA TNF-α / IL-10
Peak AUC Peak AUC Peak AUC Peak AUC AUC
Weight -0.02 0.06 0.10 0.11 -0.14 -0.09 0.08 0.08 0.13
BMI -0.00 0.08 0.05 0.04 -0.13 -0.09 0.00 0.02 0.15
BSA -0.03 0.06 0.12 0.13 -0.14 -0.10 0.01 0.09 0.13
Data are expressed and Spearman’s r. No significant correlations were found (P-values not shown). BMI  Body Mass 
Index, BSA  Body Surface Area, AUC  Area Under Curve
Discussion
This is the first study that investigates the relation between body mass index and the innate immune 
response in humans in vivo during systemic inflammation. No correlation was found between BMI and 
the systemic inflammatory cytokine response after the intravenous administration of endotoxin to 
human volunteers. 
The debate on the existence of a beneficial effect of obesity in critically ill patients has been 
going on for decades, including several meta-analyses of which most conclude that obese patients 
have equivalent or improved survival compared to patients with a BMI between 20-25  kg/m2.13–15The 
findings of these studies have been subject of debate29–31 and the mechanism of action by which a 
higher BMI is associated with a better outcome is unclear. One of the supposed mechanisms by which 
obesity leads to a better prognosis is an altered immune response. In the current study we tested 
this hypothesis in an experimental human endotoxemia model. In contrast to data obtained from 
ICU patients, which are difficult to interpret due to differences in patient characteristics (age, gender, 
comorbidity, etc) and differences with regard to the inflammatory stimulus (type and site of infection, 
time of onset, disease severity etc), the experimental endotoxemia model makes it feasible to test 
the immune response in a standardized manner in a homogenous group of subjects. Our findings in 
humans do not correspond to the results from previous rodent studies of which most,22–24 but not all32 
report a pro-inflammatory effect of obesity. In humans, apart from more nutritional reserves, higher 
levels of pro-inflammatory19 and anti-inflammatory cytokines,17,18 and the higher cholesterol and lipid 
levels common in obese patients that bind endotoxin during critical illness and provide the precursors 
for adrenal steroid synthesis33have been related to the beneficial effects of a higher BMI. In addition, 
neutrophil dysfunction and attenuation of acute lung injury,34and diaphragmatic remodeling due to 
chronically increased weight35and chronically increased intra-abdominal pressure36are possibly related 
to a lower ARDS incidence in obese patients.37
While our study demonstrates the absence of a clear association between BMI and the cytokine 
response, we acknowledge several limitations. First,  we used data of 112 healthy volunteers from 7 
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previously conducted endotoxemia trials. Despite this relatively large sample size, our population does 
not comprise a large number of overweight and obese subjects and no massively obese subjects with 
a BMI>35 kg/m2, and therefore any interpretation of the effects of a BMI>30 kg/m2 is limited, especially 
when considering that a possible relation may not be linear, but rather be dependent on a certain 
BMI threshold. Nevertheless, ICU mortality has been shown to gradually decrease with increasing 
BMI, with beneficial effects already found in patients with a BMI of 25 to 30 kg/m2,14 suggesting that 
our sample population was appropriate to detect a possible difference.  Second, we only measured 
4 key cytokines, 2 of which are considered archetypal pro-inflammatory cytokines, and 2 that are 
regarded as classic anti-inflammatory cytokines. All four cytokines are induced relatively early in the 
inflammatory response. Late cytokines, like e.g. IFN-γ, HMGB-1, IL-8 and IL-17 were not measured. 
Therefore, we cannot rule out the possibility that a correlation exists between BMI and one of the 
unmeasured mediators, however, as early pro-inflammatory cytokines orchestrate the subsequent 
immune response, the panel of markers we chose is representative of the general inflammatory 
cytokine response induced by endotoxin administration. In accordance, also no BMI-dependent 
effects on inflammatory symptoms and fever were observed. Finally, BMI is only an indirect measure 
of obesity, as it assumes that overweight is attributed to excess body fat, while in fact well trained 
muscular subjects with low levels of body fat may actually have higher BMI’s. Previous studies have 
shown that, after adjustment for BMI, waist circumference and the waist-to-hip ratio were strongly 
associated with the risk of death for non-hospitalized patients,38 whereas a higher mortality rate was 
observed for adults with a thigh circumference less than 60 cm.39 Unfortunately, these measurements 
or more direct measures of body fat percentage, such as skin fold measurements or bioimpedance 
determinations were not available as  the primary aim of the individual trials in which these subjects 
participated was not to investigate the effect of body fat on innate immunity. 
In conclusion, we have studied the effect of BMI on the systemic cytokine response induced by 
endotoxin administration in a large group of healthy young males and found no relation between BMI 
and the cytokine response. Our data suggest that the better prognosis of obese patients during critical 
illness is unlikely to be mediated through an altered cytokine response. 
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Abstract
Objective
To determine gender differences in the innate immune response and vascular reactivity during human 
endotoxemia.
Design
Clinical experimental study.
Setting
University medical center intensive care research unit.Subjects: Fifteen female and 15 male volunteers.
Interventions: Intravenous injection of 2 ng/kg Escherichia coli lipopolysaccharide.
Measurements and main results
C-reactive protein, leukocytes, and cytokines were measured at regular time intervals as indicators of 
inflammation. Heart rate and blood pressure were continuously monitored. Forearm blood flow and 
the responsiveness of forearm vessels to the intrabrachial infusion of norepinephrine (1–3–10–30 ng/
min/dL) were measured before and 4 hrs after the administration of endotoxin using venous occlusion 
plethysmography. Differences were tested with repeated-measures analysis of variance.Females showed a 
more proinflammatory response to lipopolysaccharide than males, illustrated by a higher rise in C-reactive 
protein (42 ± 3 vs. 29 ± 3 mg/L, p = .002) and more leukocyte sequestration (leukopenia 1.8 ± 0.1 × 109 
vs. 2.4 ± 0.1 × 109, p = .003). The increase in cytokine levels showed a more proinflammatory pattern 
in females as reflected by a higher increase in tumor necrosis factor-α (965 ± 193 vs. 411 ± 35 pg/mL, 
p < .0001), whereas the increase of the anti-inflammatory interleukin-10 was not significantly different (95 
± 15 pg/mL in females vs. 129 ± 15 pg/mL in males, p = .288). Females exhibited higher baseline levels 
(9.9 ± 1.1 vs. 7.0 ± 0.8 pg/mL in males, p = .042) and an augmented increase in lipopolysaccharide-
binding protein, which may explain the more pronounced inflammatory response in females. The 
lipopolysaccharide-induced change in heart rate was not significantly different between the genders, 
whereas blood pressure decreased more in females (p < .0001). Lipopolysaccharide administration 
significantly attenuated the norepinephrine sensitivity in males (p = .002), whereas no lipopolysaccharide-
induced effect was observed in females (p = .552; difference between groups, p = .045).
Conclusions
During experimental human endotoxemia, females showed a more pronounced proinflammatory 
innate immune response associated with less attenuation of norepinephrine sensitivity. These findings 
may be relevant in view of the profound and incompletely explained differences in incidence and 
outcome of sepsis among male and female patients
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Introduction
Severe sepsis and septic shock are important causes of death in intensive care units. Although 
our understanding of the pathogenesis of inflammation and sepsis has improved exponentially 
over the past decades, some fundamental questions remain unanswered. One of the most striking 
observations that remain unexplained is the gender-based difference in mortality and morbidity of 
septic patients, to the advantage of women. Although females in general mount a more profound 
immune response following antigenic challenge, it is now well recognized that they also exhibit lower 
susceptibility to bacterial sepsis than their male counterparts.1-3 Significantly more males develop 
severe sepsis/septic shock than females,1,4 and significantly fewer female patients are referred to 
the intensive care unit.4 These differences mainly have been attributed to the immunomodulatory 
effects of sex hormones,5-7 but human in vivo data are lacking.Apart from the possible differences in 
innate immune response, the hemodynamic response to vasopressor therapy is of high importance in 
septic shock. Differences between males and females in vascular reactivity have been demonstrated 
in the absence of an inflammatory stimulus,8,9 but human data during systemic inflammation are 
not available. For these reasons, it is pivotal to study gender differences during experimentally 
controlled systemic inflammation in humans in vivo. The aim of the present study was to investigate 
gender differences in the innate immune response, clinical symptoms, and vascular reactivity 
following the administration of lipopolysaccharide (LPS) to human volunteers of both genders.The 
administration of a low dose of LPS to humans is a valuable way of studying the innate immune 
response and hemodynamic sequelae during systemic inflammation.10,11 LPS administration evokes 
a dose-dependent 12 and predictable increase in cytokines. Furthermore, it exerts several vascular 
effects, including a transient decrease in blood pressure of 15–20 mm Hg and a reduced sensitivity to 
vasopressor therapy with norepinephrine.11,13
Methods
Subjects
The subjects described in the present study participated in a larger endotoxin trial.14 After approval 
from the local ethics committee, 30 nonsmoking individuals (15 females, 15 males) gave written 
informed consent to participate in these experiments. Females were studied in the follicular phase. 
Nine females used oral contraceptives (five used ethinylestradiol 30 µg/levonorgestrel 150 µg, 
three used cyproteronacetat 2 mg/ethinylestradiol 35 µg, and one used ethinylestradiol 30 µg/
drospirenone 3 mg). Subjects who were taking prescription drugs, aspirin, or other nonsteroid 
anti-inflammatory drugs were excluded. Screening of the subjects within 14 days before the test 
revealed no abnormalities in medical history and physical examination. Routine laboratory tests and 
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electrocardiogram were normal. All subjects tested human immunodeficiency virus (HIV) and hepatitis 
B negative. They did not have a febrile illness in the 2 wks preceding the study. Ten hours before the 
experiment, subjects refrained from the consumption of caffeine, alcohol, and food. Study 
Design and procedures
On the morning of the test, subjects were admitted to the intensive care unit. All subjects received 
a 20-gauge arterial catheter (Angiomat, Becton Dickinson, Sandy, UT) in the brachial artery for 
continuous blood pressure monitoring, blood sampling, and intra-arterial infusion of norepinephrine. 
Both heart rate (three-lead electrocardiogram) and blood pressure were continuously monitored. 
A cannula was placed in an antecubital vein to permit the infusion of 1.5 L of 2.5%/0.45% glucose/
saline solution before and 150 mL/hr after the administration of endotoxin to ensure an optimal 
hydration status.15,16 At 0 hrs, all subjects received a dose of purified LPS prepared from Escherichia 
coli (O:113, 2 ng/kg). The endotoxin was injected intravenously in 1 min, followed by 5 mL of normal 
saline to ensure complete delivery.EDTA-anticoagulated blood samples were taken from the arterial 
catheter at baseline and 15, 30, 60, and 90 mins as well as 2, 3, and 4 hrs after the administration of 
LPS to determine the time course and the peak values of several cytokines (tumor necrosis factor-α, 
interleukin [IL]-1[beta], IL-6, IL-10, interferon-[gamma]). Other variables of inflammation (C-reactive 
protein, leukocyte count, and differential) were measured in blood that was drawn at baseline and at 
3, 6, 12, and 22 hrs. For the determination of LPS-binding protein (LBP), blood was sampled at baseline 
and at 1, 2, 3, 4, 6, 8, and 22 hrs. Body temperature was measured every 30 mins for the first 8 hrs 
after endotoxin administration using an infrared tympanic thermometer (Sherwood Medical, DeLand, 
FL). Subjects were asked to score the severity of the endotoxin-induced flulike symptoms (nausea, 
headache, shivering, muscle, and back pain) every 30 mins up to 8 hrs after the administration of 
endotoxin. Symptoms were scored on a scale ranging from 0 (symptom not present) to 5 (worst 
ever experienced) and these scores were added, forming an arbitrary total symptom score. Because 
five symptoms were scored, the maximum score was 25. Because not all symptoms occur at the 
same time (the initial headache and nausea are followed by shivering as well as muscle and back 
pain), the cumulative score was not very high at any given point in time.Forearm blood flow and the 
responsiveness of forearm vessels to the intra-arterial infusion of norepinephrine (1–3–10–30 ng/min/
dL) were measured before and 4 hrs after the administration of endotoxin using venous occlusion 
plethysmography (Filtrass Domed, Munich, Germany) using methods described previously.17,18
Laboratory tests
To determine the concentration of the various cytokines and LBP, plasma was processed 
immediately by centrifugation at 2000× g at 4°C for 15 mins and was stored at -80°C before analyses. 
Concentrations of tumor necrosis factor-α, IL-1[beta], IL-6, IL-10, and interferon-[gamma] were 
determined using a simultaneous Luminex assay.19 LBP levels were determined using Immulite 
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(Diagnostic Products, Los Angeles, CA). Leukocyte levels and differentials were determined using flow-
cytometry (Sysmex XE-2100, Goffin Meyvis, Etten Leur, The Netherlands), and C-reactive protein was 
measured using immunologic detection (turbidimetric method) according to the instructions of the 
manufacturer (Aeroset, Abbott Laboratories, Abbott Park, IL).
Drugs and solutions
All solutions were freshly prepared on the day of the experiment. LPS of E. coli (O:113, lot G2B274) 
was obtained from U.S. Pharmacopeia Convention (Rockville, MD) and dissolved in normal saline 0.9% 
to a concentration of 200 EU/mL. Norepinephrine was obtained from Centrafarm BV (Etten Leur, The 
Netherlands) and dissolved in normal saline.
Data analyses and statistics
Differences between males and females over time in cytokine levels, inflammation variables, and 
responsiveness of the forearm vessels to norepinephrine were analyzed with analysis of variance with 
repeated measures. Differences in paired data (within each subject) were tested with paired Student’s 
t-tests. All data are expressed as mean ± sem of n subjects unless otherwise stated. A p < .05 was 
considered statistically significant.
Results
Demographic data are shown in Table 1.
Table 1. Demographic data
Males
(n=15)
Females
(n=15)
P-value
Age (years) 22.8±0.7 20.7±0.3 0.024
Height (cm) 183±2 169±2 <0.0001
Weight (kg) 79.7±2.5 65.5±1.6 0.0001
BMI (kg/m2) 23.8±0.5 23.0±0.5 0.345
FAV (ml) 1158±42 837±36 0.0002
MAP (mmHg) 95±3 98±2 0.529
HR (bpm) 60±3 77±2 <0.0001
BMI, body mass index; FAV, forearm volume; MAP, mean arterial pressure; HR, heart rate.
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Differences in clinical variables
The onset of flu-like symptoms began approximately 1 hr after LPS administration. Symptoms were at 
their maximum 90 mins after LPS infusion (Fig. 1). This resulted in a total subjective symptom score of 
4.5 ± 0.4 for female and 4.7 ± 0.5 for male subjects (difference between groups, p = .85). All symptoms 
disappeared within 8 hrs. In both groups, the increase in temperature was 1.5 ± 0.2°C (p = .9) (Table 2).
Figure 1. Total subjective symptoms score after 2 ng/kg Escherichia coli endotoxin administration in male (filled circles) 
and female (open circles) subjects. Subjects were asked to score the severity of nausea, headache, shivering, and 
muscle and back pain on a scale from 0 (symptom not present) to 5 (worst ever experienced) every 30 mins until 
8 hrs after the endotoxin was administrated, and these scores were added up to form a total symptom score. All 
subjects experienced a significant increase in symptom score in response to the endotoxin. There was no significant 
difference between the male and female subjects. Data expressed as mean ± SEM (n = 15 + 15). AU, arbitrary units; 
NS, not significant.
Table 2. Inflammatory parameters
Males
(n=15)
Females
(n=15)
P-value
Tempbaseline (°C) 36.3±0.1 36.6±0.1 0.031
Tempmax 37.8±0.1 38.2±0.1 0.031
∆Temperature 1.5±0.2 1.5±0.2 0.938
Leucocytes (*109/L) 
     T=0 hr 5.9±0.6 5.9±0.4 0.937
     T=1 hr 2.4±1.1 1.8±0.7 0.003
     T=6 hrs 14.4±0.8 12.5±0.7 0.091
CRP (mg/L) 
      T=0 hr <5 <5 1.0
      T=12 hr 19.3±2.0 25.8±2.6 0.076
      T=22 hr 28.9 ± 2.7 41.8 ± 3.1 0.005
Temp, temperature; T, time after endotoxin administration; CRP, C-reactive protein.
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Differences in inflammatory variables
At baseline, C-reactive protein levels were below the detection limit in all subjects. Female subjects 
showed a more pronounced increase in C-reactive protein compared with males (41.8 ± 3.1 mg/L vs. 
28.9 ± 2.7 mg/L at 22 hrs, complete curve over time, repeated-measures analysis of variance, p = .002) 
and more leukocyte sequestration (leukopenia 1.8 ± 0.1 × 109 vs. 2.4 ± 0.1 × 109, unpaired Student’s 
t-test, p = .003), whereas the complete leukocyte curve over time was not significantly different 
between groups (p = .095) (Table 2). Baseline leukocyte differentials showed small differences between 
males and females. Neutrophils were lower in males at baseline (p = .005), whereas lymphocytes and 
monocytes were higher (p = .018 and p = .04, respectively) (Table 3).
Table 3. Leukocyte counts and differentials during human endotoxemia
T=0 hr T=1 hr T=6 hr T=12 hr T=22 hr
Males
Leukocytes (*109/L) 5.9±0.6 2.4±0.1 14.3±0.8 13.7±1.0 8.6±0.7
     Neutrophils (%) 52.8±3.3* 51.4±5.3 89.9±2.9 81.9±1.1 69.0±1.8
     Lymphocytes (%) 36.3±3.4** 42.9±5.5 4.4±1.8 11.0±0.8 20.5±1.2
     Monocytes (%) 8.3±1.0 0.7±0.2 4.3±1.1 6.6±0.7 8.3±1.0
     Eosinophils (%) 2.3±0.4 3.9±0.6 0.2±0.1 0.6±0.2 2.2±0.4
     Basophils (%) 0.6±0.2 1.0±0.3 0.0±0.0 0.0±0.0 0.1±0.1
Females
Leukocytes (*109/L) 5.9±0.4 1.8±0.1 12.5±0.7 13.7±0.8 9.0±0.7
     Neutrophils (%) 65.7±1.6* 41.9±3.8 94.7±0.3 86.6±1.1 75.3±2.7
     Lymphocytes (%) 25.4±1.6** 53.6±3.7 3.2±0.4 7.7±0.8 16.7±2.2
     Monocytes (%) 6.4±0.4 0.6±0.2 2.0±0.3 5.0±0.4 6.4±0.6
     Eosinophils (%) 2.0±0.3 3.0±0.6 0.1±0.1 0.2±0.1 1.3±0.3
     Basophils (%) 0.1±0.1 1.1±0.3 0.0±0.0 0.0±0.0 0.0±0.0
T, time after endotoxin administration.
As illustrated in Figure 2, at baseline, all cytokine levels were below the detection limit in all subjects. 
Females exhibited a more profound proinflammatory response after administration of endotoxin. 
Tumor necrosis factor-α peak levels in women were more than twice as high as in males (965 ± 193 
pg/mL vs. 411 ± 34.6 pg/mL, p < .0001), and IL-1[beta] was slightly elevated in females, whereas 
the increase was absent in males (12 ± 1.6 pg/mL vs. 8 ± 0.1 pg/mL, p = .005). Interferon-[gamma] 
increased in females to 136 ± 31.7 pg/mL at 90 mins and in males to 60 ± 10.4 pg/mL (p = .001). The 
increase of IL-6 levels was not significantly different between genders as tested by repeated-measures 
analysis of variance (p = .177).
In contrast to the proinflammatory cytokines, the increase in the anti-inflammatory cytokine IL-10 
was not significantly different between males and females (129 ± 14.6 pg/mL in males vs. 95 ± 15.3 pg/
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mL in females, p = .288). LBP concentrations were higher in females at baseline (9.9 ± 1.1 pg/mL vs. 
7.0 ± 0.8 pg/mL in males, p = .042). In females, LBP continued to rise until 22 hrs after administration 
to a maximum of 32.9 ± 4.2 pg/mL, whereas in males a plateau concentration of 21.1 ± 1.9 pg/mL was 
reached at 8 hrs that remained unchanged at 22 hrs (21.4 ± 1.8 pg/mL; difference in increase, p = 
.004).
Figure 2. Effects of 2 ng/kg lipopolysaccharide (administered at 0 hrs) in the male (filled circles) and the female (open 
circles) subjects on tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-10, and interferon (IFN)- γ over time. In both 
groups, administration of 2 ng/kg Escherichia coli lipopolysaccharide resulted in a marked increase in TNF-α, IL-6, 
IFN-γ, and IL-10 concentrations. TNF- α and IFN-γ were significantly higher in the female subjects. The difference 
between groups in the release of IL-6 and IL-10 did not reach statistical significance. Data are expressed as mean ± 
SEM (n = 15 + 15). P values refer to differences between males and females tested by repeated-measures analysis of 
variance.
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Figure 3. Effects of 2 ng/kg Escherichia coli endotoxin (administered at 0 hrs) on mean arterial pressure (MAP) 
and heart rate (HR) in female (open circles) and male (filled circles) subjects. MAP was determined using the intra-
arterial catheter and an arterial pressure monitoring catheter, and heart rate was monitored by a three-lead 
electrocardiogram; both were sampled every 5 mins throughout the experiments. Endotoxin administration induced 
a significant decrease of MAP in both groups (p < .0001), and heart rate increased in both groups (p < .0001). 
MAP significantly decreased more in the female subjects (p < .0001 compared with males), whereas there was no 
significant difference between the groups concerning the increase in heart rate as tested with repeated-measures 
analysis of variance. Data expressed as mean ± SEM (n = 15 + 15). NS, not significant.
Differences in cardiovascular variables
After the administration of LPS, forearm blood flow increased from 3.4 ± 0.4 mL/min/dL to 7.7 ± 1.0 
mL/min/dL in males, compared with 2.4 ± 0.3 mL/min/dL to 6.3 ± 0.6 mL/min/dL in females (both 
groups, p < .0001), resulting in a decrease in blood pressure and an increase in heart rate (Fig. 3). 
Females showed a more pronounced decrease in blood pressure (p < .0001). The LPS-induced 
increase in heart rate was comparable in males and females (p = .831, Fig. 3).
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Administration of norepinephrine in the absence of endotoxin induced vasoconstriction in both 
groups (p < .0001), but this tended to be less pronounced in females (p = .110, Fig. 4). The sensitivity 
to norepinephrine was decreased during endotoxemia in male subjects (p = .002) but did not change 
significantly after the administration of endotoxin in females (p = .552, Fig. 4).
Figure 4. Dose-response curve of intrabrachial norepinephrine (1–3–10–30 ng/min/dL) on forearm blood flow 
(FBF) before (filled diamonds, open triangles) and 4 hrs after (filled squares, open circles) the administration of 2 ng/kg 
Escherichia coli lipopolysaccharide in females (open symbols) and males (filled symbols). Lipopolysaccharide significantly 
attenuated the vasoconstrictor response to norepinephrine in male subjects, whereas this effect was not present in 
female subjects. The p values refer to the statistical difference between the dose-response curves within females/
males as analyzed with repeated-measures analysis of variance. Percentages of baseline FBF ratio (intervention/
control arm) are presented as mean ± SEM (n = 15 + 15).
Discussion
The present in vivo study is the first to report that females show a more pronounced proinflammatory 
response compared with males during systemic inflammation following the administration of E. coli 
endotoxin. Interestingly, the response of the anti-inflammatory cytokine IL-10 was not significantly 
different and even tended to be lower in females, indicating that the proinflammatory/anti-
inflammatory balance demonstrates a clear shift to a more proinflammatory pattern in females. This 
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pattern was accompanied by a higher baseline level of LBP and a higher increase in LBP in females. 
The more proinflammatory pattern in females was not associated with an increase in symptoms or 
a more attenuated vascular response to norepinephrine. In contrast, our study confirms previous 
reports that endotoxemia reduces the sensitivity to vasopressor agents, such as norepinephrine, in 
males, whereas this effect was absent in female subjects. The augmented innate immune response 
combined with the preserved norepinephrine sensitivity may explain the previously observed better 
outcomes for female septic patients.
Male-female differences in innate immunity
Many animal experiments demonstrate an augmented innate immune response in female animals 
combined with a lower susceptibility to endotoxic shock.20,21 Previous in vivo human studies have 
reported a lower,1,22,23 similar,22 or higher 24 proinflammatory cytokine response in female surgical and 
septic patients. Although the male-female differences in incidence and outcome of sepsis are clear 
from large population-based studies, the interindividual variability of the onset and course of the septic 
syndrome makes it difficult to compare the innate immune response in relatively small groups of septic 
patients. In contrast, the human endotoxemia model offers a standardized systemic inflammatory 
stimulus suited to examine gender-related inflammatory differences in vivo. With this model of 
sepsis, the amount and exact moment of purified LPS administration are clear, so that a precise and 
quantitative measure of the innate immune response can be obtained to compare different groups.
Influence of sex hormones
The influence of sex hormones on the host innate immune response has been proposed as an 
explanation for the unequal gender distribution in sepsis.25-27 Sex hormone receptors are present on 
immunologically relevant cells 28 and correlate with the activity of cytokine-secreting cells in vivo.29 For 
example, estrogens increase tumor necrosis factor-α and IL-6 expression and stimulate the cytokine 
production in response to LPS.30
In murine models of sepsis, sex hormones exert immunomodulatory effects, as estrogen 
treatment protects mice from death induced by endotoxic shock,31 and recently a distinct survival 
advantage was reported by the administration of a selective estrogen receptor [beta]-agonist in 
septic rats and mice.32 Human studies concerning estrogen suppletion and innate immunity are 
sparse. One study investigated the innate immune response in postmenopausal women challenged 
with endotoxin with and without estrogen replacement.33 Replacement therapy resulted in a 
markedly suppressed inflammatory response as reflected by less IL-6, IL-1ra, and tumor necrosis 
factor-α production. This observation is in contrast with the results obtained in animal experiments 
34 and our present study and may be explained by the relatively small number of women studied (n 
= 6) and the fact that the study was performed in a paired fashion in which LPS antibody formation 
may have influenced the results.35
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In our study, we found no gender differences in leukocyte differential that could explain the differences 
in cytokine production. The observation that monocyte count was significantly lower in females while 
their systemic cytokine release was higher is in accordance with the notion that circulating leukocytes 
appear not to play an important role in systemic cytokine production, as LPS-treated leukopenic mice 
achieve higher cytokine concentrations compared with controls.36 In contrast, the difference in serum 
LBP between females and males may offer an explanation of the observed effects. LBP mediates 
the transfer of endotoxin to CD14 and signaling of Toll-like receptor 4 on leukocytes, leading to the 
initiation of the immune response and the production of inflammatory cytokines,37 resulting in a 
lower susceptibility to bacterial infections. In accordance with this hypothesis, LBP-/- mice showed a 
dramatically reduced survival compared with heterozygous controls after the injection of Salmonella 
typhimurium,38 and in an E. coli peritonitis model of sepsis, LBP knockout mice showed higher 
mortality, earlier bacterial dissemination into the bloodstream, and impaired bacterial clearance as 
compared with wild-type mice.39 In the present study, we found a small but significant difference 
in baseline LBP levels accompanied by a more pronounced increase in LBP in females, which may 
account for their augmented cytokine response. Interestingly, estrogen treatment increases LBP 
messenger RNA,40 which provides another link between sex hormones and innate immunity.
Male-female differences in cardiovascular response to LPS
The more proinflammatory innate immune response in females was not associated with a more 
pronounced vascular hyporeactivity. During baseline conditions, we confirmed the previously reported 
observation that the norepinephrine-mediated vasoconstriction is less pronounced in women, an 
effect associated with an altered [beta]2-adrenergic function.
9,41 The reported increased sensitivity 
to [beta]2-adrenergic receptor stimulation may offset the vasoconstrictive effects of α-adrenergic 
receptor stimulation. Also, estrogen replacement therapy reduces the vasoconstrictive response to 
norepinephrine,42 possibly due to increased basal nitric oxide synthesis.43 These effects may play a 
role in the observed absence of an LPS-induced decrease in norepinephrine sensitivity and beneficial 
hemodynamic response to inflammation in females.
Clinical importance
We have previously suggested that with an aggressive initial response to an infection, bacterial 
growth can be contained and controlled in an early stage of the disease, and sepsis is less likely to 
occur.44 However, if the early response to an infection is inadequate, the bacteria have the chance 
to multiply and spread, resulting in disseminated infection and dysregulation of cytokine levels. This 
theory supports the idea of proinflammatory cytokines being of benefit, rather than being something 
from which the patient must be protected. Thus, a strong initial proinflammatory response may be 
an explanation for the lower incidence and mortality of sepsis observed in females. Moreover, the 
vascular sensitivity to norepinephrine during LPS-induced inflammation was preserved in female 
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subjects, possibly adding to the observed survival advantage in septic women, as refractory shock 
is the main cause of its mortality.45 Despite these important differences and the beneficial effects of 
estrogen treatment in septic animal experiments, this area is not yet exploited in human treatment 
strategies, and up to now the treatment for male and female septic patients has been the same. The 
immune-modulating effects of androgens and estrogen, however, are undisputed, rendering them a 
possible future therapeutic target.
Conclusions
We have demonstrated that females exert a more proinflammatory pattern of cytokine release during 
E. coli endotoxemia compared with males. This difference is associated with higher levels of LPS-
binding protein in females, which facilitates Toll-like receptor 4 signaling. In male subjects, systemic 
inflammation induces an attenuated vascular sensitivity to norepinephrine, whereas this effect is 
not observed in females. These findings may be relevant in view of the profound and incompletely 
explained differences in incidence and outcome of male and female septic patients.
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Abstract of the original article
Gender-specific differences in severely injured patients between 2002 and 2011: data analysis with 
matched-pair analysis.
Schoeneberg C, Kauther MD, Hussmann B, Keitel J, Schmitz D, Lendemans S
Crit Care. 2013;17(6):R277
Introduction
Previous studies reported divergent results concerning the effect of gender on patient outcome after 
severe injury. Results suggest that women have better outcomes because they have lower rates of 
sepsis and multi-organ failure. The objective of this analysis was to study gender differences in a Level 
1 trauma center in Germany.
Methods
Patients who were admitted to hospital between 2002 and 2011 with an Injury Severity Score (ISS) 
≥16 were included. Data were collected from the Trauma Registry of the German Society for Trauma 
Surgery and from hospital records. The effects of gender on a variety of parameters were investigated. 
To eliminate the influence of differences in ISS, an analysis of groups with similar ISS was performed. 
Also, a matched-pair analysis of 422 patients was performed.
Results
A total of 962 patients met the inclusion criteria. The mortality rate was lower in male patients (25.4% 
versus 36.59%). Female patients had more severe head injuries, received less fluid volume and had a 
lower rate of sepsis. Men were more frequently involved in motorcycle accidents and sustained more 
penetrating trauma. Women were more frequently involved in pedestrian accidents and sustained 
more falls from under 3 m. The effects of gender were reduced when the data were analyzed by 
matching ISS. The mortality rate was significantly different in the ISS 26 to 35 group but in mostly 
all groups, the mortality rate was higher in women. In the matched-pair analysis, the rate of sepsis 
and the length of the ICU stay were significantly lower in women and the mortality rate showed no 
significant difference (28.1% for male patients versus 33.01% for female patients). Women died after 
an average of 5.22 days, and men died after an average of 9.02 days.
Conclusions
Gender-based differences in patient outcome after severe trauma were observed in this study. 
Women are more likely to die in the first days after trauma. Upon extended hospital stay, women had a 
better survival rate because they had a lower rate of sepsis. No significant differences in mortality rate 
could be found, but there was a trend towards a higher rate in female patients.
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Letter
With great interest we read the article by Dr Schoeneberg and colleagues regarding gender-specific 
differences with respect to outcome in patients with severe traumatic injury. The authors show 
that, apart from the acute phase after trauma, women have a more favorable trauma severity-
adjusted outcome, with shorter ICU and hospital stay and lower sepsis rates.1 However, a possible 
mechanism of action behind this difference was not suggested. We hypothesize that, in view of the 
fact that morbidity and mortality in the post-acute phase after trauma are often caused by infectious 
complications,2 gender differences in immunity might explain the observed differences. 
In the general population, women show a lower sepsis incidence compared with men. This 
difference may be related to a shorter and more pronounced initial innate immune response in 
females, as we have previously demonstrated during experimental human endotoxemia,3 resulting 
in more effective bacterial killing 4 and less pronounced immunoparalysis, which is increasingly 
recognized as the overriding immune dysfunction in sepsis.5 In turn, this response results in decreased 
susceptibility towards secondary infections. As sex hormones have been suggested to play a crucial 
role in the observed gender difference, several trials with estrogens in trauma patients have been 
completed recently but are not yet published (NCT00973674; NCT00973102). 
A better clearance of septic foci and protection against secondary infections may thus account 
for the shorter ICU stay observed in women. This theory supports the currently prevailing idea that an 
adequate proinflammatory cytokine response is of benefit, rather than harmful, especially after the 
initial resuscitation phase of trauma. 
Lucas T van Eijk, Matthijs Kox and Peter Pickkers
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Authors’ response
We are very pleased that our article attracted interest. We would like to thank van Eijk and colleagues 
for presenting a possible explanation for the finding of lower sepsis rates in women. We are looking 
forward to results of the trials with estrogens in trauma patients, because different results could 
be found in the literature. For example, Sperry and colleagues reported that factors other than sex 
hormones are responsible for the lower sepsis rate in women.6 
In our view, the most interesting result of our research was that women died more frequently 
soon after trauma compared with men.1 A possible explanation for this observation might be that 
women are more vulnerable to hemorrhagic shock. Perhaps this finding is also associated with 
hormone differences. 
We believe more investigation is necessary to understand gender-specific differences. This 
understanding might result in different strategies in treatment of women and men. Women may need 
a more aggressive treatment for hemorrhage. 
Carsten Schoeneberg, Max Daniel Kauther, Björn Hussmann, Judith Keitel, Daniel Schmitz  
and Sven Lendemans 
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Abstract
Introduction
Septic shock is associated with increased microvascular permeability. As a model for study of 
the pathophysiology of sepsis, endotoxin administration to humans has facilitated research into 
inflammation, coagulation and cardiovascular effects. The present study was undertaken to determine 
whether endotoxin administration to human volunteers can be used as a model to study the sepsis-
associated increase in microvascular permeability.
Methods
In an open intervention study conducted in a university medical centre, 16 healthy volunteers 
were evaluated in the research unit of the intensive care unit. Eight were administered endotoxin 
intravenously (2 ng/kg Escherichia coli O113) and eight served as control individuals. Microvascular 
permeability was assessed before and 5 hours after the administration of endotoxin (n = 8) or placebo 
(n = 8) by three different methods: transcapillary escape rate of I125-albumin; venous occlusion strain-
gauge plethysmography to determine the filtration capacity; and bioelectrical impedance analysis to 
determine the extracellular and total body water.
Results
Administration of endotoxin resulted in the expected increases in proinflammatory cytokines, 
temperature, flu-like symptoms and cardiovascular changes. All changes were significantly different 
from those in the control group. In the endotoxin group all microvascular permeability parameters 
remained unchanged from baseline: transcapillary escape rate of I125-albumin changed from 7.2 ± 
0.6 to 7.7 ± 0.9%/hour; filtration capacity changed from 5.0 ± 0.3 to 4.2 ± 0.4 ml/min/100 ml/mmHg × 
10-3; and extracellular/total body water changed from 0.42 ± 0.01 to 0.40 ± 0.01 l/l (all differences not 
significant).
Conclusion
Although experimental human endotoxaemia is frequently used as a model to study sepsis-associated 
pathophysiology, an endotoxin-induced increase in microvascular permeability in vivo could not be 
detected using three different methods. Endotoxin administration to human volunteers is not suitable 
as a model in which to study changes in microvascular permeability.
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Introduction
Sepsis is the leading cause of mortality in noncardiac intensive care units, resulting in an estimated 
mortality of 200,000 patients per year in the USA alone.1 Sepsis is notably characterized by an increase 
in microvascular permeability, which accounts for the extravasation of macromolecules and fluid from 
the plasma to the tissues. The impaired diffusion of oxygen to cells as a result of the extracellular 
oedema appears to be a critical factor in the development of multiple organ failure.2,3 Few studies have 
been conducted in humans to examine the mechanism that underlies the sepsis-associated increase 
in microvascular permeability.
Endotoxin is among the principal bacterial components that interacts with the host during 
Gram-negative sepsis.4 Administration of endotoxin to humans is an appropriate model in which to 
investigate acute inflammatory responses (activation of cytokines and coagulation pathways) and to 
evaluate novel therapeutic interventions.5 In vitro, exposure of human endothelial cells to endotoxin 
induces an increase in permeability,6 and in vivo an increase in microvascular permeability is among 
the major manifestations observed in animal endotoxaemia.7-12 In humans, microvascular permeability 
can be assessed by plasma disappearance of a tracer (e.g. I125-albumin), changes in tissue volume 
caused by an imposed hydrostatic pressure and changes in bio-impedance. These methods were 
validated for the detection of a modest increase in microvascular permeability in patients with various 
diseases 13-17 and, more relevant to our study, patients with sepsis or septic shock.18-20 In septic 
patients, transcapillary escape rate of albumin varies from 6.7%/hour 21 to 13.4%/hour,18 whereas 
permeability measured using venous congestion plethysmography (VCP) ranged from 6.1 ml/min per 
100 ml mmHg × 10-3 to 9.3 ml/min per 100 ml mmHg × 10-3.19,22
The present study was undertaken to determine whether endotoxin administration to 
human volunteers can be employed as a model in which to study the sepsis-associated increase in 
microvascular permeability.
Materials and methods
Subjects
After approval had been granted by the local ethics committee, 16 nonsmoking individuals gave written 
informed consent to participate in the study. Those who were taking prescription drugs or asprin 
or other nonsteroidal anti-inflammatory drugs were excluded (except for oral anticontraceptives). 
Screening of the participants before the test revealed no abnormalities in medical history or physical 
examination. Routine laboratory tests and electrocardiograms were normal. All participants were HIV 
and hepatitis B negative. They had not suffered a febrile illness within the 2 weeks preceding the study. 
Ten hours before the experiment, the participants refrained from consuming caffeine, alcohol and food.
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Study design and procedures
Heart rate was continuously monitored using a three-lead electrogradiograph. An intra-arterial 
catheter in the radial artery permitted arterial blood sampling as well as continuous monitoring of 
blood pressure throughout the experiment. Forearm blood flow was measured in both arms using 
VCP, as described previously.23 All participant received an intravenous infusion of a glucose/saline 
solution (2.5% glucose, 0.45% saline; 75 cm3/hour) via a cannula in an antecubital vein. At baseline, 
purified lipopolysaccharide (LPS) prepared from Escherichia coli O113 was injected intravenously (2 
ng/kg) over 1–2 min in eight individuals, followed by 5 ml normal saline to ensure complete delivery. 
Another eight served as control individuals and received NaCl 0.9% instead of endotoxin in an 
equivalent volume. Because of obvious symptomatic changes after infusion of endotoxin, neither the 
volunteers nor the staff members were blinded to the study protocol.
The course over time of temperature, C-reactive protein, and plasma levels of tumour necrosis 
factor (TNF)-α and interleukin (IL)-1β 24 were monitored to confirm the inflammatory effects of 
endotoxin administration.
Transcapillary escape rate of I125albumin
Microvascular permeability determined by the transcapillary escape rate of I125-albumin (TER-alb) was 
measured at baseline and 5 hours after endotoxin administration, when haemodynamic changes 
are at their maximum.25 I125 labelled albumin solution of 2 μCi (baseline) and 6 μCi (at 5 hours) in 5 
cm3 normal saline were given as an intravenous bolus injection followed by 5 cm3 normal saline. The 
second dose is higher to overcome the background signal of the first dose. Arterial blood samples 
were drawn at baseline, and at 5, 10, 15, 20, 30, 45 and 60 min. Plasma radioactivity was measured in 
each sample using a scintillation detector (automatic γ-counter; 1480 Wizard 3”, Wallac, Turku, Finland).
Venous congestion plethysmography
Microvascular permeability was also determined by VCP, in accordance with methods fully described 
previously.26,27 Microvascular filtration capacity (Kf) – an index of vascular permeability – was measured 
using a protocol in which a series of eight small (10 mmHg) cumulative pressure steps were applied to 
venous congestion cuffs placed around both upper arms. Kf was estimated from alterations in forearm 
circumference due to the pressures applied, using the Filtrass strain gauge plethysmograph (Filtrass 
Angio, DOMED, Munich, Germany).27 Using this system, no change in the recorded signal is observed 
until ambient venous pressure in the arm is exceeded. At congestion cuff pressures greater than 
this value, each additional pressure increment causes a change in forearm volume that is attributed 
to vascular filling. When the congestion cuff pressure exceeds the isovolumetric venous pressure, 
a steady state change in volume is observed, reflecting fluid filtration. Kf reflects the product of the 
area available for fluid filtration and the permeability per unit surface area. Computer-based analysis 
enables differentiation between volume and filtration responses.28 The value of Kf is determined by 
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linear regression of the fluid filtration as a function of the cuff pressure. The slope of this relationship 
is Kf and the units are expressed as KfU (ml/min/100 ml/mmHg × 10
-3).28 The files were recorded and 
saved for subsequent offline analysis. Kf measurements were conducted before, and 4.5 hours and 22 
hours after the administration of endotoxin or normal saline.
Bioelectrical impedance analysis
In septic patients, fluid shifts from intracellular water to extracellular water (ECW) and an increase 
in total body water (TBW) occur because of an altered cellular membrane function, resulting in 
the formation of oedema. Bioelectrical impedance analysis (BIA) can estimate body composition 
parameters and has been used to estimate body water distribution and cellular membrane function 
in healthy individuals 29 and intensive care patients.20,30-33 The principles of bioelectrical impedance 
postulate that resistance (R) is the opposition of TBW and electrolytes to the flow of an alternating 
current of low amplitude (800 μA) and high frequency (50 kHz). Reactance is the capacitance produced 
by tissue interfaces and cell membranes. An increase in microvascular permeability and an altered 
membrane function result in the formation of oedema, which decreases the resistance and reactance 
to an alternating electric current throughout the body. ECW will increase in relation to TBW, and 
reactance/resistance will decrease. BIA was performed using a body composition analyzer (Akern 
Srl, Florence, Italy). This device employs four-electrode polarization and measures the resistance 
and reactance of a conductor to application of an alternating electric current of 800 μA and 50 kHz. 
All measurements were made with the patient supine, with their arms relaxed at their sides but not 
touching their body, and with their thighs slightly separated. Electrodes were placed on the dorsal 
surface of the skin of the wrist and ankle, with the detector electrodes applied along the articulation 
bisecting line of both joints. BIA was performed at baseline and 4, 6, 8 and 22 hours after endotoxin 
administration.
Drugs and solutions
All solutions were freshly prepared on the day of the experiment. Endotoxin from Escherichia coli (batch 
0:113, lot G2B274) was obtained from US Pharmacopia Convention (Rockville, MD, USA) and dissolved 
in normal saline 0.9% to a concentration of 200 EU/ml (0.1 ml/kg). I125-albumin (Iodinated [125I] 
Human Serum Albumin; code IM 17 P) was obtained from Amersham International (Amersham, UK).
Data analysis, calculations and statistics
Power analysis was based on clinically relevant changes in TER-Alb. In a previous study using the TER-
alb method, we found a standard deviation ranging from 1.5% to 2.5%. An increase in transcapillary 
escape rate of 2.5% was considered clinically relevant. With an estimated standard deviation of 2% and 
α = 0.05, we calculated that a sample size of seven individuals per group would be needed to achieve a 
power of 95%. Therefore, eight individuals per group were included.
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TER-alb was calculated and expressed as the percentage disappearance per hour. Fluid filtration 
capacity (Kf) was determined by venous occlusion plethysmography in both forearms and averaged. 
The mean Kf was used for further calculations. A change in the ratio of ECW/TBW was taken to give an 
impression of microvascular permeability, using BIA.
Student’s t-tests or analysis of variance with repeated measures were used for the assessment 
of the effects of endotoxin on microvascular permeability parameters. All data are expressed as mean 
± standard error of the mean of n experiments unless otherwise stated. P < 0.05 was considered 
statistically significant.
Results
Demographic characteristics of the participants are presented in Table 1. There were no significant 
differences between the groups.
Tabel 1. Demographic characteristics of the participants
Endotoxin group Control group
n (male/female) 8 (4/4) 8 (4/4)
Age (years) 23.9 ± 1.0 22.5 ± 0.8
Length (cm) 176 ± 5 183 ± 3
Weight (kg) 71.8 ± 4.9 70.1 ± 3.6
BMI (kg/m2) 23.0 ± 0.7 20.9 ± 0.8
SBP/DBP (mmHg) 127 ± 2 / 80 ± 3 119 ± 3 / 73 ± 3
Forearm volume (ml) 1019 ± 95 931 ± 67
Data are expressed as mean ± standard deviation. There were no significant differences between the groups. BMI, 
body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure
Changes in clinical and inflammatory parameters
The first flu-like symptoms (headache, nausea, chills) occurred in the endotoxin-treated group 
between 55 and 90 min after LPS injection. Body temperature started to rise 1 hour after endotoxin 
administration to a maximum of 38.7 ± 0.3°C at 4 hours versus 36.9 ± 0.2°C in the control group (P < 
0.001). At 8 hours all clinical symptoms had declined to control values. The clinical onset of inflammation 
was accompanied by a sudden rise in TNF-α plasma levels at 60 min (373 ± 71 pg/ml), which reached its 
zenith at 90 min (856 ± 158 pg/ml), closely followed by a rise in IL-1β that was maximal at 120 min (23.9 ± 
2.2 pg/ml). C-reactive protein increased from under 5 mg/ml at baseline to 22.3 ± 1.4 mg/ml at 12 hours 
after endotoxin administration and reached its maximum at 22 hours (38.9 ± 3.0 mg/ml). In the control 
individuals no elevations in temperature (from 36.9 ± 0.1 to 37.0 ± 0.1°C), clinical symptoms, cytokine 
levels (TNF-α <8 pg/ml, IL-1β <8 pg/ml) or C-reative protein (<5 mg/ml) were observed (Fig. 1).
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Figure 1. Changes in inflammatory parameters. 
Administration of endotoxin (n = 8; 2 ng/kg) resulted in a marked increase in tumour necrosis factor (TNF)-α (closed 
squares, left axis) and IL-1β (open squares, right axis). In control individuals cytokine levels remained below the 
detection limit (n = 8; data not shown). Cytokine release was associated with fever and an increase in C-reactive 
protein (CRP; endotoxin group, closed squares; control group, open circles). Data are expressed as means ± standard 
error of the mean. The P values in the figure refer to the difference between endotoxin and control groups as 
analyzed using analysis of variance with repeated measures over the complete curve.
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Changes in haemodynamic parameters
Figure 2 shows the course of heart rate, mean arterial pressure and forearm blood flow in the 
endotoxin and control group. In the control group the mean arterial blood pressure decreased 
from 88 to 80 mmHg at 6 hours (P = 0.035); the blood pressure decreased significantly more in the 
individuals administered LPS (from 96 ± 3 mmHg to 79 ± 4 mmHg at 6 hours, P < 0.0001; difference 
from control individuals: P = 0.002). Heart rate remained unchanged in the control group (from
Figure 2. Changes in haemodynamic parameters. 
Administration of endotoxin (2 ng/kg; n = 8; closed squares) resulted in a significant increase in heart rate (HR; 
measured using electrocardiography; P < 0.0001), a significant decrease in mean arterial pressure (MAP; measured 
intra-arterially; P < 0.0001) and a significant increase in forearm blood flow (FBF; measured using venous occlusion 
plethysmography; P = 0.018). HR and FBF did not change significantly in the control group (open circles; n = 8), 
whereas MAP decreased (P = 0.035). MAP decreased significantly more in the endotoxin group than in the control 
group (P = 0.002). These changes demonstrate that endotoxin induces a vasodilatory state. Data are expressed as 
means ± standard error of the mean. The P values in the figure refer to the difference between endotoxin and control 
group as analyzed using analysis of variance with repeated measures over the complete curve.
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66 ± 4 to 65 ± 2 beats/min; not significant) and increased from 63 ± 3 to 91 ± 3 beats/min at 6 hours 
in the LPS group (P < 0.0001). Forearm blood flow increased from 3.7 ± 0.6 to 6.8 ± 1.1 ml/min per dl 
at 6 hours (P = 0.018) in the endotoxin group, but remained unchanged in the control group (3.8 ± 0.8 
versus 4.4 ± 0.9 ml/min per dl; not significant).
Changes in microvascular permeability parameters
In neither the endotoxin group nor the control group were significant alterations in microvascular 
permeability parameters detected. In the endotoxin group TER-alb was 7.2 ± 0.6%/hour before and 7.7 ± 
0.9%/hour at 4.5 hours after endotoxin administration (not significant); Kf remained unchanged (from 5.0 
± 0.3 to 4.2 ± 0.4 ml/min/100 ml/mmHg × 10-3; not significant); and ECW/TBW, as measured by BIA, did not 
change (from 0.42 ± 0.01 l/l to 0.40 ± 0.01 l/l; not significant). Also, no significant changes in microvascular 
permeability parameters were found in the control group (all not significant: TER-alb from 9.08 ± 1.28 to 
10.38 ± 0.63%/hour; Kf from 4.14 ± 0.42 to 5.17 ± 0.39 ml/min/100 ml/mmHg × 10
-3; and ECW/TBW from 
0.43 ± 0.01 l/l to 0.42 ± 0.01 l/l). The effect of endotoxin on microvascular parameters is shown in Fig. 3.
Figure 3. Changes in microvascular permeability parameters. 
Microvascular permeability parameters were measured using transcapillary escape rate of I125-albumin (TER-alb), 
venous congestion plethysmography (VCP) and bioelectrical impedance analysis (BIA). There were no changes in 
microvascular permeability as measured using all three parameters in either the endotoxin group (n = 8; 2 ng/kg; 
closed squares) or in the control group (n = 8; open circles). Data are expressed as means ± standard error of the 
mean. ECW, extracellular water; TBW, total body water. 
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Discussion
Although administration of endotoxin to human volunteers has facilitated sepsis-associated research, 
the present study demonstrates that human experimental endotoxaemia is not a suitable model in 
which to study sepsis-induced changes in microvascular permeability. In a negative study the first issue 
to address is methodology. We conducted the present study with all three methods that are available 
for human in vivo experiments. Differences in microvascular permeability have been detected in 
various other diseases with these methods.13-17 In septic patients an increase in Kf was demonstrated 
with TER-alb,18 VCP 19 and BIA.20 In view of the ability of these methods to detect differences in 
microvascular permeability and the consistently negative findings of all three methods used in this 
endotoxin study, we believe our results are valid.
There are several possible reasons for our negative findings. First, the inflammatory stimulus 
might not have been sufficiently powerful. Endotoxin is known to stimulate the immune system in 
a dose-dependent manner.25 Indeed, a marked increase in permeability in vivo has previously been 
shown in, for example, cats after intravenous administration of 1 mg/kg endotoxin.10 On one occasion, 
an autointoxication with 1 mg of Salmonella endotoxin resulted in profound vasodilatory shock and a 
15 l cumulative fluid balance over 72 hours in a laboratory worker.34 This demonstrates unequivocally 
that high doses of endotoxin can cause shock and vascular leakage. In human volunteers an endotoxin 
concentration of 4 ng/kg is considered the maximal tolerable dose. The concentration of 2 ng/kg is 
widely applied and results in systemic inflammation, activation of coagulation pathways and distinct 
haemodynamic changes. Although the rise in proinflammatory cytokines is dose dependent, studies 
that used 4 ng/kg LPS found changes in clinical parameters similar to those reported here (e.g. rise 
in body temperature and fall in blood pressure).35 In the individuals included in the present study 
(who received 2 ng/kg) the flu-like symptoms, rise in body temperature, rise in heart rate, fall in blood 
pressure and rise in C-reactive protein were considerable; we therefore believe that the inflammatory 
stimulus was adequate. Also, the TNF-α and IL-1β concentrations in these individuals exceeded 
considerably the threshold levels of 50 pg/ml and 20 pg/ml, respectively, that are necessary to increase 
permeability significantly in vitro.6
Naturally, it remains difficult for many reasons to compare an in vitro study in endothelial cells of 
large vessels with our in vivo experiment. The human endotoxaemia model is currently the only available 
in vivo human model that mimics Gram-negative sepsis. Whereas in experimental endotoxaemia the 
stimulus is restricted to LPS, other (non-LPS) bacterial components are also of importance for the 
induction of cytokines and the inflammatory response 36 and possibly the induction of vascular leakage. 
These differences could represent the reason why therapies directed at endotoxaemia itself are not of 
benefit in patients with septic shock.37 However, as a model, the changes in haemodynamics that occur 
during human endotoxaemia are similar to those observed in septic shock, and suggest that endotoxin is 
a major mediator of the cardiovascular dysfunction that occurs in this condition.35 
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A second possible reason for our negative findings is that not only the peak concentration of cytokines 
but also the duration of the increased level of the inflammatory mediators may be important in the 
pathophysiology of oedema formation in sepsis. The stimulus caused by a single bolus injection 
of endotoxin may be too short to induce an increase in microvascular permeability. The induction 
of capillary leakage in vitro was accomplished after incubation with endotoxin or cytokines for 6 
hours.6 Also, in pre-eclampsia a sustained rise in plasma cytokines is associated with an increase in 
microvascular permeability, suggesting a causal relationship.38 However, although in some cases of 
sepsis in humans (e.g. meningococcal disease) elevated serum levels of TNF-α have been found in up 
to 90% of patients,39 several other clinical studies in septic patients reported only minimally elevated 
or undetectable levels of TNF-α.40,41 Because these patients exhibit an overt increase in microvascular 
permeability, sustained high cytokine levels are apparently not mandatory for the development of 
oedema.
A third reason is that the timing of the measurements might not have been optimal for the 
detection of changes in permeability. In previous studies maximal changes in haemodynamic 
parameters were found between 2 and 6 hours after administration of endotoxin.35 Because these 
vascular changes can partly be accounted for by endothelial dysfunction,42 we opted to measure 
microvascular permeability in the same time window. The possibility that an increase in permeability 
occurred outside the time window of interest appears unlikely because BIA was unchanged at five time 
points during the experiment, and Kf was also unaltered at 22 hours after endotoxin administration. 
Timing may be of critical importance because an accelerated plasma efflux of albumin was only 
observed during the early phase of sepsis in rats.43 Also, late-acting cytokines (e.g. high mobility group 
protein 1) remain elevated for 16–32 hours after the administration of endotoxin and may play a role 
in the capillary leak found in septic patients. This and possibly other mediators were not measured 
during our experiment. Again, BIA and VCP measurements after 22 hours did not reveal an increase 
in vascular permeability in our experiments, suggesting that a possible late increase in vascular 
permeability was not missed.
Finally, oedema formation may differ from tissue to tissue and from organ to organ. In human 
endotoxaemia increases in intestinal permeability 44 and alveolar epithelial permeability 45 were 
previously demonstrated. In contrast, human endotoxaemia did not induce an increase in the ocular 
blood–aqueous barrier.46 With the TER-alb and BIA whole body permeability is assessed, whereas 
the Filtrass strain gauge plethysmograph focuses on the forearms. An increase in microvascular 
permeability in, for example, the lungs was not specifically assessed, but if it was present it was 
insufficient to affect whole body permeability. Administration of iodated albumin as a measure of 
capillary leak may vary with hydration status, and albumin molecules might be too large to be useful 
as a sensitive permeability marker. However, these problems are overcome with the use of VCP. We 
believe that fluid loading would not have altered transcappilary leakage, because with the VCP method 
a venous occlusion pressure is applied to the forearms, so that vascular permeability is measured 
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independent of the volume status of the subject. The suggestion that permeability might have been 
increased for smaller molecules than albumin can be ruled out for the same reason.
In summary, we do not believe that the methods used, the timing of the permeability 
measurements, or the absolute maximal cytokine concentrations can account for the observed lack of 
effect of endotoxin on microvascular permeability in humans. However, the short duration of cytokine 
increase possibly played a role.
Conclusion
Although endotoxin administration to humans has proven to be a valuable model for studying systemic 
inflammation and coagulation, this model cannot be used to investigate the pathophysiological 
mechanisms that underlie capillary leakage in sepsis or to evaluate pharmacological interventions 
aimed at attenuating the increase in microvascular permeability.
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Abstract
To gain insight in the pathogenesis of increased vascular permeability during sepsis, we studied 
the effect of plasma obtained during human experimental endotoxemia on the permeability of 
cultured endothelial monolayers. Eight healthy subjects received an i.v. dose of 2 ng/kg Escherichia 
coli O:113 lipopolysaccharide (LPS). The concentration of various plasma mediators that supposedly 
induce vascular permeability was measured over time. Plasmas that were obtained before, and 2 
and 4 h after the administration of LPS were added to human umbilical venular endothelial cells 
that were cultured on semipermeable membranes. The permeability of the endothelial monolayers 
to fluorescein isothiocyanate-labeled bovine serum albumin was determined and expressed as the 
relative concentration of fluorescein isothiocyanate-bovine serum albumin when compared with that 
measured across empty Transwell-COL (Corning Life Sciences B.V., Schiphol-Rijk, The Netherlands) 
membranes (i.e., without endothelial monolayers). The permeability levels were correlated with the 
concentrations of various mediators. Experimental endotoxemia resulted in elevated levels of tumor 
necrosis factor α (TNF-α), interleukin (IL) 1β, IL-6, IL-8, IL-10, and vascular endothelial growth factor and 
a moderate increase of IL-12 and IFN-γ (all P values < 0.01). Incubation of human umbilical venular 
endothelial cells with plasma obtained 2 and 4 h after the administration of LPS increased the relative 
permeability from a baseline level (median) of 17% (range, 14%-31%) to 23% (range, 12%-39%; P = not 
significant) and 28% (range, 11%- 40%; P < 0.05), respectively. Plasma levels of vascular endothelial 
growth factor and IL-10, but not TNF-α or any other mediators, significantly correlated with the 
increase in endothelial permeability (r = 0.47, P = 0.038; r = 0.43, P = 0.038, respectively). The data 
presented here demonstrate that plasmas obtained from experimental human endotoxemia increase 
endothelial albumin permeability in vitro. Thus, cultured human endothelial monolayers provide a 
model to study sepsis-associated vascular changes.
Introduction
Sepsis and septic shock represent the most serious forms of infection and result in approximately 
200,000 fatalities each year in the United States alone.1 One of the key steps in the development 
of shock is increased microvascular permeability leading to massive edema formation, organ 
hypoperfusion, and tissue hypoxia. Impaired diffusion of oxygen to cells as a result of the extracellular 
edema may explain sepsis-induced organ injury.2 Several plasma mediators involved in sepsis increase 
vascular permeability including not only tumor necrosis factor (TNF)-α and interleukin (IL) 1β,3 but also 
IL-6,4 IL-8,5 interferon (IFN)-γ,6 leptin,7 complement,8 and vascular endothelial growth factor (VEGF).9 
These and other mediators may also act in synergy. For example, it was shown that endothelial 
permeability induced by VEGF could be abrogated by anti-TNF antibodies,10 whereas differences in 
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the systemic TNF-α response are modulated by the terminal complement component C5.11 Bacterial 
endotoxin or lipopolysaccharide (LPS) is a key initiator of the inflammatory cascade during sepsis. 
The administration of LPS to human volunteers is an established model to investigate the release of 
these cytokines and other inflammatory mediators.12 However, in contrast to patients with sepsis, 
experimental human endotoxemia was not associated with an increase in microvascular permeability 
in vivo.13 This may be explained by the limited duration of high levels of circulating cytokines and other 
mediators in human endotoxemia when compared with those in patients with sepsis and previous ex 
vivo studies.
Stimulation of human whole blood ex vivo with LPS has been used to mimic the release of 
sepsis-associated inflammatory mediators and results in a massive production of TNF-α And IL-1β. 
We have previously demonstrated that plasma obtained after these stimulations induced a marked 
increase in the permeability of cultured monolayers of human umbilical venular endothelial cells 
(HUVEC). Furthermore, the permeability increase of HUVEC monolayers seemed to be mediated by 
TNF-α and IL-1β.3 However, the ex vivo timulation of whole blood does not necessarily reflect the in 
vivo inflammatory response, which - in addition to blood - is predominantly regulated by several other 
organs. Therefore, despite the important role of TNF-α and IL-1β in our previous in vitro  studies and 
the key function these cytokines may have in the pathogenesis of sepsis, the clinical relevance of these 
findings remains unclear. Nevertheless, cultured human endothelial monolayers may yet provide a 
more sensitive model to study the changes in permeability when compared with the methods that 
can be used in humans. We have used this model to investigate the permeability-inducing capacity of 
plasma obtained from human experimental endotoxemia. In addition, we simulated the short in vivo 
exposure to high levels of plasma cytokines during human experimental endotoxemia by comparing 
short and long incubations of endotoxic plasma on the monolayers. Furthermore, we studied the 
possible correlations between the plasma concentrations of TNF-α, IL-1β, and several other mediators 
and endothelial permeability. These analyses may help identify possible targets for the future 
treatment of sepsis.
Materials and methods
Human endotoxemia
With approval from the local ethics committee and written informed consent of the volunteers, we 
have previously determined the effect of LPS administration on microvascular permeability measured 
in vivo in healthy volunteers.13 The investigation conformed with the principles outlined in the 
Declaration of Helsinki.14 Citrate-anticoagulated blood was drawn from 8 subjects (4 men, 4 women) for 
determination of several cytokines and other possible mediators of vascular permeability immediately 
before and serially after (time [t] = 15, 30, 60 min and 2, 4, 6, 8, 12, and 22 h) infusion of 2 ng/kg LPS. 
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The plasma samples obtained at t = 0, 2, 4 h after the administration of LPS were used to conduct the 
permeability experiments for the present study. 
Screening of the subjects before the LPS challenge revealed no abnormalities in medical history, 
physical examination, routine laboratory tests, and electrocardiogram. Heart rate was continuously 
monitored using a 3-lead electrocardiogram, and blood pressure was measured intra-arterially 
throughout the experiment. All subjects received an i.v. infusion of a glucose/saline solution (2.5% 
glucose/0.45% saline, 75 mL/h) through a cannula in an antecubital vein. At t equals 0 h, Standard 
Reference LPS (E. coli O:113; US Pharmacopeia, Rockville, Md) was injected intravenously (2 ng/kg). 
Detection of permeability mediators
Blood was drawn fromthe arterial cannula and immediately centrifugated at 2000g at 4-C for 15 
min and stored at j80-C until use. Concentrations of TNF-α, IL-1β, IL-6, IL-8, IL-10, IL-12, and IFN-γ 
were determined using a simultaneous Luminex Assay.15 A commercially available enzyme-linked 
immunosorbent assay (ELISA) for the measurements of VEGF (DuoSet ELISA Development System, 
lower limit of detection of 16 pg/mL) and leptin (Quantikine DLP00, lower limit of detection of 8 pg/mL) 
was purchased from R&D Systems Inc (Minneapolis, Minn). Complement activation was measured by 
determining the concentration of soluble terminal complement complexes using an in-house ELISA.16
Isolation and culture of HUVEC
Endothelial cells were isolated and cultured as previously described, with minor modifications.3 
Fresh umbilical cords were obtained after delivery and informed consent from healthy women at the 
Department of Obstetrics and Gynaecology in our hospital. Briefly, endothelial cells were harvested 
from the umbilical vein by proteolytic detachment using collagenase type I (Sigma Chemical Co, St 
Louis, Mo). The isolates were seeded on gelatinized culture flasks (Corning, Cambridge, Mass), and 
cultured in medium M199 (containing 25 mmol/L 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid, 
Earle salts, and L-Glutamate; Life Technologies, Paisley, Scotland) with 10% heat-inactivated newborn 
calf serum (Life Technologies), 10% heat-inactivated normal human serum (ICN, Costa Mesa, Calif), 50 
U/mL penicillin, 50 2g/mL streptomycin, 150 2g/mL endothelial cell growth factors and 5 U/mL heparin. 
A crude fraction of endothelial cell growth factors was extracted from bovine brain and kindly provided 
by the Department of Paediatrics, University Medical Center, Nijmegen, The Netherlands. The cultures 
were grown in a humidified incubator at 37-C under 5% carbon dioxide/95% air atmosphere. A split 
ratio of 1:3 was applied for subculturing. All experiments were performed on HUVEC that had been 
subcultured by trypsinization for 3 times.
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Incubation of HUVEC with plasma and conduction of albumin 
permeability studies
Plasma obtained before and 2 and 4 h after the administration of LPS was diluted to 20% vol/
vol in medium M199 without other serum components. The diluted plasma samples were added 
in quadruplet aliquots of 500 µL to confluent HUVEC monolayers subcultured on Transwell-COL 
membrane inserts (filter area, 1 cm2; pore diameter size, 0.4 µm; Corning) and incubated for 6 h at 
37-C. After the incubation, the albumin permeability of endothelial cultures to macromolecules was 
measured as previously described.3 Briefly, a tracer solution containing fluorescein isothiocyanate 
(FITC)-labelled bovine serum albumin (BSA, 250 µg/mL) in complete medium was added to the upper 
compartment of the Transwell-COL insert. After 2 h of equilibration of the tracer solution, duplicate 
100 µL aliquots were drawn from the lower compartment and the fluorescence of the samples was 
measured on a Wallac Victor II platereader (Perkin Elmer, Boston, Mass) at an emission/excitation 
wavelength of 495/520 nm. 
The amount of FITC-BSA in the samples was calculated according to a diluted series of FITC-
BSA in culture medium. To allow quantitative comparison between multiple experiments, data are 
expressed as the relative concentration of FITC-BSA when compared with that measured across empty 
Transwell-COL membranes (i.e., without endothelial monolayers). 
In a separate experiment, plasma samples (n = 3) were selected that induced the largest 
permeability increase in the previous experiment (i.e., after 6 h of incubation) but were now incubated 
for shorter periods (0.45, 2, and 6 h, respectively) and followed by incubation with control plasma of 
the same donor to complete a total incubation time of 6 h. The albumin permeability was compared 
with that induced by 6 h of incubation with baseline (unstimulated) plasma of the same individuals.
Statistical analysis
Student paired t test was used to analyze the effects of LPS on the peak levels of cytokines and other 
permeability mediators. Differences in the permeability between stimulated and control monolayers 
were analyzed using analysis of variance and Dunnett Multiple Comparisons post hoc test, and 
correlations between permeability and plasma mediator concentrations were analyzed by making use 
of the Spearman rank correlation test using GraphPad InStat (GraphPad Software Inc., San Diego, Ca) 
v3.05 software. A P value of less than 0.05 was considered to indicate statistical significance. Data are 
expressed as medians with 25th and 75th percentile and range (in parentheses) or mean ± SEM of n 
observations, as appropriate.
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Results
Human endotoxemia
The age, height, and weight of the subjects averaged 23.9 ± 1.0 yrs, 176 ± 5 cm and 71.8 ± 4.9 kg, 
respectively. After the administration of LPS, body temperature was raised to a maximum of 38.7 ± 
0.3°C at t equals 4 h (P < 0.0001). Mean arterial blood pressure decreased from 79.4 ± 3.6 to 69.2 ± 
2.7 mmHg at t equals 6 h (P < 0.0001), and heart rate increased from 63.0 ± 2.7 to 90.6 ± 3.0 beats per 
minute at t equals 6 h (P < 0.0001).
Detection of permeability mediators
As shown in Table 1 and Figure 1, A-C, LPS infusion induced a significant increase in the pro-
inflammatory and anti-inflammatory cytokines and VEGF. Plasma concentrations of IL-12 and IFN-γ 
were only marginally but significantly elevated, whereas complement activation and leptin plasma 
levels were not increased. Because the LPS-induced increase in pro-inflammatory mediators typically 
peaked between 2 to 4 h, baseline samples and samples drawn 2 and 4 h after LPS administration 
were incubated on HUVEC monolayers. 
Table 1. Inflammatory mediators during human endotoxemia
Mediator Baseline value 
(pg/mL)
Peak 
concentration 
(pg/ml)
Time of Peak
(hrs [range])
P-Value
TCC 0.32 ± 0.05* 0.69 ± 0.11* NA NS
TNF-α <8 856 ± 158 1.5 [ 1.5-2] 0.0009
IL-1β <8 23.9 ± 2.2 2 [2-6] <0.0001
IL-6 <8 10086 ± 2516 3 [2-6] 0.0036
IL-8 <8 1400 ± 192 3 [2-3] 0.0002
IL-10 <8 94 ± 20 3 [2-3] 0.0018
IL-12 <8 8.2 ± 1.3 3 [2-6] 0.0074
IFN-γ 101 ± 58 145 ± 59 2 [1.5-4] 0.0044
VEGF 36.1 ± 5.9 80.9 ± 8.0 4 [4-12] 0.0002
Leptin
     Males 2079 ± 674 2573 ± 701 NA NS
     Females 20898 ± 2881 31194 ± 669 NA NS
Plasma concentrations of inflammatory mediators during experimental human endotoxemia. Baseline values and 
peak concentrations are expressed as mean T SEM. Levels lower than the detection limit are expressed as less than 
8. The time at which the peak occurred is expressed as mode (range). *TCC indicates terminal complement complex 
and is expressed in arbitrary units per milliliter. NA indicates not applicable; NS, not significant.
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Figure 1. Plasma cytokine levels and plasma-induced endothelial permeability during the first 4 h  
after endotoxin administration. 
The endotoxin-induced increases in plasma TNF-! (A), IL-10 (B), and VEGF (C) were all significant. Data are expressed 
as mean with SEM. The box whisker plots in panel D illustrate endothelial permeability, induced by plasmas obtained 
0, 2, and 4 h after the administration of LPS. The relative permeability is represented by medians (bars), interquartile 
ranges (boxes), and ranges (whiskers).
Endothelial albumin permeability measurements 
When incubated with control plasma (obtained before the administration of LPS), cultured HUVEC 
monolayers restricted the passage of FITC-BSA into the lower compartment to approximately 1.84 µg/
mL or 17.2% (range, 13.5%-30.9%) of the amount that diffused across empty filters without HUVEC. 
Incubation of HUVEC monolayers with plasma that was drawn 2 h after the in vivo administration of LPS 
resulted in a non-significant increase of endothelial permeability to 23.1% (range, 12.4%-39.2%; P = not 
significant) (Fig. 1D). Plasma samples that were drawn 4 h after administration of LPS induced a larger 
and significant increase in the albumin permeability to 28.2% (range, 10.8%-40.3%; P < 0.05). A moderate 
but significant positive correlation with the increase in endothelial albumin permeability was observed 
with plasma levels of VEGF (r = 0.47, P = 0.038) and IL-10 (r = 0.43, P = 0.038) but not of the other 
mediators (Table 2). Plasma samples of the 3 subjects that induced the largest albumin permeability 
increase in the first experiment induced a similar response in a second experiment where shorter 
incubation times were applied (Fig. 2). Whereas control plasma of these subjects induced an albumin 
permeability of 18.8% (range, 11.0%-31.4%), plasma obtained after the LPS challenge and incubated for 
only 45 min on the monolayers, increased the albumin permeability to 29.3 % (range, 18.2%-46.2%; P = 
0.0038). This increase was quite similar to that induced by 2 and 6 h of incubation with the same plasma 
(29.5% [range, 22.6%-40.5%], P = 0.0011, and 32.1% [range, 16.6%-38.1%], P = 0.0051, respectively).
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Table 2. Correlation between inflammatory mediators and permeability
Parameter Spearman r P-Value
TNF-α 0.13 NS
IL-1β 0.19 NS
IL-6 0.22 NS
IL-8 0.22 NS
IL-10 0.43 0.0376
IL-12 0.11 NS
IFN-γ -0.19 NS
VEGF 0.47 0.379
Spearman correlation between levels of inflammatory mediators and endothelial permeability.
Figure 2. Effect of short exposure of endothelial monolayers to endotoxic plasma. 
Box whisker plots represent the relative permeability after different incubation times (hour) of endotoxic plasma. 
Short incubations with endotoxic plasma were followed by incubation with control plasma to complete a total 
incubation time of 6 h. Permeability between treatments were compared with that obtained after incubation with 
control plasma (baseline) for 6 h. Data are expressed as medians (bars), interquartile ranges (boxes), and ranges 
(whiskers).
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Discussion
Although plasma levels of several cytokines and other inflammatory mediators are increased during 
sepsis, it remains unclear which of these mediators play a decisive role in edema formation and shock 
during systemic inflammation in humans in vivo. We exposed healthy subjects to a single i.v. dose of 
LPS and induced a significant increase in the plasma levels of various mediators that may alter vascular 
permeability. Indeed, plasma obtained after the LPS challenge increased the albumin permeability of 
cultured endothelial monolayers. This response correlated with the plasma levels of VEGF and IL-10 
but, surprisingly, not with the pro-inflammatory cytokines TNF-α, IL-1β, or IL-6.
Experimental endotoxemia is an established model to study cardiovascular changes and 
coagulation that occur during systemic inflammation. In contrast with the present study, we were 
unable to demonstrate a significant change of microvascular permeability in vivo during human 
endotoxemia.13 Differences between the exposure time to inflammatory mediators and the sensitivity 
of the 2 permeability models may explain this inconsistency. We speculated that the LPS-induced peak 
levels of pro-inflammatory mediators could be sufficient to increase endothelial permeability in vitro , 
but the limited exposure to these cytokines during human experimental endotoxemia was insufficient 
to cause a permeability increase in vivo. 
Previous in vitro  permeability studies were conducted with plasma obtained from ex vivo 
LPS-stimulated whole blood, which contained relatively high levels of inflammatory cytokines and 
which was incubated on the endothelial monolayers for several hours to induce a full permeability 
response. In the present study, we show that, even at relatively short incubations of 45 min, plasma 
obtained from human endotoxemia significantly increased endothelial albumin permeability in vitro. 
We therefore conclude that cultured endothelial monolayers may represent a more sensitive model 
to study the effect of LPS-induced vascular permeability than our previous in vivo measurements. The 
sensitivity may result from the fact that cultured endothelial monolayers lack the influence of several 
factors present in their original environment such as circulating inflammatory cells, fibroblasts, and 
other soft tissue components. In addition, endothelial function in vivo is regulated by the integrated 
response of the immune, coagulation, and endocrine systems, which may prevent or down regulate 
the permeability increase induced by plasma obtained during experimental human endotoxemia. 
During the first hours after LPS administration, the concentrations of some cytokines, such as TNF-α, 
highly exceed the levels measured in plasma of patients with septic shock.17 Various other mediators 
of microvascular permeability were not (complement activation, leptin) or only moderately (IL-12, 
IFN-γ) increased during human endotoxemia. Plasma concentrations of the potent pro-inflammatory 
cytokines TNF-α and IL-1β did not correlate with endothelial permeability. In fact, the strongest 
albumin permeability response was induced by plasma that was obtained 4 h after the administration 
of LPS (i.e., when the concentration of these mediators had returned to baseline levels). This 
observation excludes the possibility that, in human experimental endotoxemia, these cytokines act 
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as direct mediators of vascular permeability and indicates that other molecules are involved in this 
phenomenon. This is a quite surprising finding because we have previously demonstrated that both 
TNF-α and IL-1β mediated the permeability increase induced by plasma obtained from LPS-stimulated 
whole blood.3 This inconsistency may be explained by the fact that the stimulation of whole blood ex 
vivo with LPS results in TNF-α and IL-1β concentrations that are much higher when compared with 
the maximum levels that were achieved during human endotoxemia. Another possible explanation 
for the observed difference is that TNF-α and IL-1β may (also) indirectly increase permeability by 
sensitizing endothelial cells to respond to other mediators such as VEGF. It has been demonstrated 
that the presence of TNF-α is required to modulate the VEGF-mediated increase in permeability.10 
Neutralization of TNF-α may therefore abrogate the VEGF-induced permeability response rather 
than prevent direct stimulation. Our finding that VEGF is induced during human endotoxemia 
confirms a previous study.18 Although our finding that the levels of VEGF in plasma obtained during 
human experimental endotoxemia correlated with the permeability increase does not necessarily 
reflect a cause-and-effect relation, the possible role of VEGF in mediating endothelial permeability 
is in accordance with the pathophysiologic effects of VEGF.9,19 We have recently demonstrated that 
increased VEGF concentrations correlate with fluid balance in patients with septic shock,20 which 
further supports the idea that VEGF is a mediator of microvascular permeability in patients with sepsis. 
More direct evidence was obtained from plasma of patients with adult respiratory distress syndrome, 
which also increased endothelial permeability in vitro  - an effect that could be abrogated by the 
addition of a soluble VEGF inhibitor.21 Recently, an anti-VEGF antibody became available for human 
use.22 Combined with the finding that inflammation-mediated capillary leakage is associated with 
elevated VEGF concentrations, this is of particular interest because VEGF may be considered as a new 
therapeutic target for the treatment with anti-VEGF antibodies. 
In addition to VEGF, the anti-inflammatory cytokine IL-10 also correlated significantly with 
endothelial permeability. Although high concentrations of IL-10 are associated with an increase in 
mortality in patients with sepsis,23,24 there is abundant evidence that IL-10 does not induce but protects 
against microvascular leakage.25-27 Apparently, this observation is caused by an epiphenomenon or 
larger increases of microvascular permeability which may induce a stronger IL-10 increase to protect 
the vasculature against further damage. 
In view of the moderate correlations between VEGF and IL-10 levels on the one hand and 
endothelial permeability on the other, we do not exclude the possibility that plasma obtained from 
human endotoxemia contains other yet unidentified inflammatory mediators that may follow the same 
kinetic profile as VEGF and IL-10 and are involved in the increase in permeability. 
In conclusion, the present study shows that plasma obtained during human experimental 
endotoxemia increases endothelial permeability in vitro. This response was independent of the 
incubation time (45 minutes to 6 hours) of endotoxic plasma on the endothelial monolayers. The 
largest increase in endothelial permeability was induced after incubation with plasma that was 
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obtained 4 h after the administration of LPS when plasma TNF-α and IL-1β levels had returned to 
baseline. The increase in endothelial permeability was moderately correlated with VEGF and IL-
10 levels in plasma. Our observations may facilitate future experiments that try to elucidate the 
pathophysiology of increased vascular permeability during systemic inflammation.
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Abstract
Although endothelial dysfunction is central to the pathogenesis of sepsis, no specific and clinically 
applicable marker for endothelial dysfunction is currently available. Endocan, a proteoglycan excreted 
by endothelial cells in response to inflammatory cytokines, may serve as such a marker. Our objective 
was to investigate the kinetics of endocan and its relationship with inflammation-induced endothelial 
dysfunction during experimental human endotoxemia. Endothelial function was assessed in 17 
healthy male volunteers before and 4 h after the administration of 2 ng/kg lipopolysaccharide (LPS) 
by determination of the vasodilatory response of forearm blood vessels to intra-arterial infusion 
of endothelium-dependent (acetylcholine) or endothelium-independent (nitroglycerin/sodium 
nitroprusside) vasodilators using venous occlusion plethysmography. Plasma levels of endocan, 
inflammatory cytokines, intercellular adhesion molecule (ICAM), and vascular cell adhesion molecule 
(VCAM) were measured, and correlations with endothelial dysfunction were explored. Plasma levels 
of all measured cytokines, endocan, ICAM, and VCAM concentrations significantly increased after 
LPS administration. Furthermore, LPS administration resulted in a significantly blunted response to 
acetylcholine (mean ± SD increase in forearm blood flow [FBF] of 383% ± 320% before LPS vs. 173% 
± 134% after LPS, P = 0.03), whereas the response to nitroglycerin/sodium nitroprusside was not 
affected (mean ± SD increase in FBF of 174% ± 120% before LPS vs. 110% ± 82% after LPS, P = 0.11). 
Furthermore, there was a significant correlation between the increase in plasma endocan levels and 
the attenuation of vasodilatory responses to acetylcholine (r = -0.48, P < 0.05). No correlation existed 
between plasma levels of ICAM or VCAM and the attenuation of the acetylcholine-induced vasodilatory 
response. Endocan levels are related to endothelial dysfunction in humans in vivo during systemic 
inflammation evoked by experimental endotoxemia. Therefore, this study suggests that endocan could 
be a novel marker of endothelial dysfunction in inflammatory conditions.
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Introduction
Sepsis is the leading cause of death in intensive care units (ICUs), accounting for more casualties than 
breast cancer, lung cancer, and prostate cancer combined.1 The endothelium plays a central role in the 
pathophysiology of sepsis. In sepsis, several factors such as intercellular adhesion molecule (ICAM) and 
vascular cell adhesion molecule (VCAM) 2 are released from the endothelium. Furthermore, endothelial 
dysfunction, reflected by vasodilatation and consequently hypotension, is a hallmark of sepsis.3 The 
latter contributes to decreased organ perfusion and development of multiple organ failure.4 An easy 
to obtain, early, specific, and clinically applicable marker that can identify the extent of endothelial 
dysfunction is not available. 
Endocan is a soluble proteoglycan that is secreted by endothelial cells in response to 
proinflammatory cytokines, lipopolysaccharide (LPS), and angiogenic factors.5 The exact functions of 
this proteoglycan have not been completely elucidated; however, endocan has been shown to increase 
the production of proinflammatory cytokines by endothelial cells, enhance microvascular permeability, 
and modulate leukocyte migration.6,7 Moreover, endocan might have a predictive value in inflammatory 
conditions such as community-acquired pneumonia,8 acute respiratory distress syndrome,9 and 
sepsis.5,7 Although its value is not yet well established, plasma endocan levels are increased in septic 
patients and are related with sepsis severity, the development of organ failure, and mortality.5,7 
Whereas it is possible that the relation between endocan and severity of disease is mediated through 
endothelial dysfunction, the direct relationship between endocan and endothelial function has not yet 
been investigated. 
Herein, we examined the kinetics of endocan during experimental human endotoxemia, a 
standardized controlled model to study acute systemic inflammation in humans that is associated with 
endothelial dysfunction.10 Furthermore, we investigated the relationship between endocan, plasma 
cytokines, ICAM, VCAM, and inflammation-induced endothelial dysfunction measured by venous 
occlusion plethysmography. We hypothesized that plasma endocan levels are related to endothelial 
dysfunction measured by venous occlusion plethysmography during human endotoxemia.
Materials and methods
Subjects and study design
Plasma endocan was measured in samples that were obtained during three previously performed 
human endotoxemia trials in which endothelial function was assessed. As such, this study is a post hoc 
analysis of previous data, in which additional endocan measurements were performed. The studies 
are registered under ClinicalTrial.gov identifier NCT01091571, NCT01349699, and NCT00916448, and 
two of them were recently published.11,12 For the current study, only data of subjects in the placebo 
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groups of these previous endotoxemia studies were used. All trials were approved by the local ethics 
committee of the Radboud University Medical Center and carried out according to Good Clinical 
Practice standards and the Declaration of Helsinki including current revisions. Samples of 17 healthy 
male volunteers were available for additional measurements for the current study. Unfortunately, 
no plasma samples were left of the other 13 subjects who were enrolled in the placebo arms of the 
previously mentioned endotoxemia studies. A screening visit before study enrollment revealed no 
abnormalities in medical history, physical examination, electrocardiogram, and routine laboratory tests. 
All subjects provided informed consent for the study procedures, including the storage of plasma 
samples for future analyses. 
Experimental human endotoxemia 
An overview of the study procedures on the experimental endotoxemia day is depicted in Figure 1. 
On the morning of the endotoxemia experiment, subjects were admitted to the Research Unit of 
the Intensive Care Department of the Radboud University Medical Center. They had refrained from 
ingestion of alcohol and caffeine for 24 h before the experiment and had fasted for 8 h before 
the experiment. All subjects received an arterial catheter in the brachial artery that was used for 
the administration of vasoactive drugs, blood sampling, and the continuous monitoring of blood 
pressure. A second cannula was placed in an antecubital vein to allow the administration of hydration 
fluids and endotoxin during the experiment. Heart rate was continuously monitored using a 5-lead 
electrocardiogram. Before any tests were performed, subjects were prehydrated with 1.5 L NaCl 
0.45%/glucose 2.5% solution. Thereafter, hydration was continued by a rate of 150 mL/h until T = 6 h 
after endotoxin administration and then 75 mL/h until the end of the experiment.13 At T = 0 h, 2 ng/
kg purified endotoxin (Escherichia coli LPS) was administered intravenously (serotype O:113, Clinical 
Center Reference Endotoxin; National Institutes of Health, Bethesda, Md), followed by 5 mL NaCl 0.9% 
to ensure complete delivery. 
Forearm blood flow measurements 
Forearm blood flow (FBF) was measured before and 4 h after LPS administration using venous 
occlusion plethysmography (Filtrass Domed, Munich, Germany) according to methods described 
previously.14 Forearm blood flow and drug infusions were normalized to forearm volume as measured 
with the water displacement method (placement of arm in a graduated cylinder filled with water) 
and FBFs were expressed in milliliters per minute per deciliter forearm volume (mL · min-1 · dL-1). The 
vasodilatory responses of forearm vessels to the incremental intra-arterial infusion of endothelium-
dependent vasodilator acetylcholine (0.5, 2, 8 µg · min-1 · dL-1) and endotheliumindependent 
vasodilators sodium nitroprusside (0.06, 0.2, 0.6 µg · min-1 · dL-1) or nitroglycerin (0.125, 0.25, 0.5 µg · 
min-1 · dL-1) were measured sequentially. Two of the three trials (NCT01522794, NCT00916448) used 
nitroglycerin as endothelium-independent vasodilator whereas, in one study (NCT01091571), sodium 
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nitroprusside was used. The changes in FBF in response to both these endothelium-independent 
vasodilatory agents were combined in the results. Each dose-response curve started with a 5-min 
period of baseline measurements, followed by 5-min intervals in which incremental dosages of 
vasoactive medication were administered. Forearm blood flow data were recorded continuously 
throughout the infusion of vasoactive drugs. The mean of FBF data obtained during the last 3 min of 
each 5-min infusion interval was used for the calculations. This way, for each measurement, a dose-
response curve could be constructed. Forearm blood flow measurements were adjusted for possible 
systemic changes unrelated to the local stimulus by expressing flow in the experimental arm as the 
ratio of concurrent flow in the non-infused (control) arm (FBF ratio). At baseline, this ratio was set at 
100%. Four hours after LPS administration, the protocol was repeated to determine the LPS-induced 
effects on vascular reactivity. 
Figure 1. Schematic overview of the endotoxemia experiments. 
The concentrations of vasoactive medication are in micrograms per minute per deciliter (µg · min-1 · dL-1). HR indicates 
heart rate; MAP, mean arterial pressure.
Determination of leukocyte counts and plasma levels of cytokines, 
VCAM, ICAM, and endocan 
Leukocyte counts were determined by flow cytometry (Sysmex XE-2100; Goffin Meyvis, Etten-Leur, 
The Netherlands). EDTA-anticoagulated blood samples were obtained at baseline and at various 
time points during the experiment to determine the time course of several inflammatory parameters 
and endocan. Plasma was processed immediately by centrifugation at 2,000g at 4°C for 15 min and 
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was stored at -80°C before analyses. Concentrations of cytokines (tumor necrosis factor-α [TNF- α], 
interleukin-6 [IL-6], IL-10, and IL-1RA), ICAM, and VCAM were determined using simultaneous Luminex 
assays (cytokines: Milliplex, Millipore, Billerica, Mass; VCAM and ICAM: Bioplex, Bio-Rad, Hercules, Calif). 
Endocan was measured using a sandwich enzyme-linked immunosorbent assay (Lunginnov, Lille, 
France) as previously described.15,16
Data analysis, calculations, and statistics 
Data are presented as mean ± SD or median and interquartile range based on their distribution. 
Normality of the data distribution was tested using D’Agostino and Pearson omnibus normality test. 
Increases/decreases in concentrations of the different mediators across time were calculated using 
repeated-measures one-way analysis of variance or Friedman tests as appropriate, depending on the 
distribution of the data. Spearman (rs) or Pearson (rp) was used as appropriate for correlation analyses, 
depending on the distribution of the data. To assess endothelial dysfunction, we compared the FBF 
dose-response curves before and after endotoxemia using repeated-measures two-way analysis 
of variance (interaction term). Baseline FBF ratios (before infusion of vasoactive agents) before and 
after LPS administrations were analyzed using a paired Student T test. For correlation analyses, the 
area under the dose-response curve at T = 4 divided by the area under the dose-response curve at 
baseline (ratio) was used as the endotoxin-induced difference in forearm vascular responsiveness. 
Furthermore, maximum increases of endocan, ICAM, VCAM, IL-6, TNF-α, IL-10, and IL-1RA per individual 
subject (delta) were used for correlation analyses. Analyses were performed using GraphPad Prism 5 
(GraphPad Software, La Jolla, Calif). A value of P < 0.05 was considered statistically significant.
Results
Effects of LPS administration on hemodynamic parameters, 
cytokines, ICAM, VCAM, and endocan levels
Demographic characteristics are listed in Table 1. As expected, LPS administration resulted in a 
vasodilatory state that occurred 4 to 6 h after LPS administration and resulted in a decrease in mean 
arterial blood pressure of 20 ± 6.6 mmHg and an increase in FBF from 4.6 ± 1.8 mL/min per dL at 
baseline to 8.0 ± 3.2 mL/min per dL at T = 4 h. 
Furthermore, a marked increase in plasma levels of proinflammatory cytokines TNF-α and IL-6 (Fig. 2A), 
anti-inflammatory cytokines IL-10 and IL-1RA (peaking at T = 3 h, 702 ± 518 pg/mL, and 7,332 ± 2,008 
pg/mL, respectively), and ICAM and VCAM (Fig. 2B) was observed. Although plasma endocan levels 
showed considerable interindividual variation, a transient increase after endotoxin administration to 
levels comparable to those observed during severe sepsis and septic shock was found (Fig. 2C).5 
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Table 1. Demographic characteristics
Mean ± SD
Age 22 ± 2
Weight (kg) 81 ± 10
BMI (kg/m2) 24 ± 4
Baseline MAP (mmHg) 98 ± 9
Baseline forearm volume (mL) 1188 ± 167
Baseline blood flow (mL·min-1·dL-1) 4.4 ± 1.8
Data are presented as mean ± SD of 17 male subjects.
Figure 2. Plasma concentrations of cytokines, ICAM/VCAM, and endocan during endotoxemia. 
A, TNF-α (dashed line) and IL-6 levels (solid line) during endotoxemia. B, VCAM (dashed line) and ICAM (solid line) 
levels during endotoxemia. C, Levels of endocan during endotoxemia. Data are expressed as mean ± SD (A and B) or 
median with interquartile range (C).
Endothelial dysfunction
Before LPS administration, the intra-arterial infusion of acetylcholine in the brachial artery increased 
FBF ratio by 383% ± 320%, whereas this response was attenuated after LPS administration to a 
maximum increase of 173% ± 134% (Fig. 3A). The response to nitroglycerin/sodium nitroprusside was 
not significantly blunted after LPS administration, although a trend toward impaired responsiveness 
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was observed (maximum increase in FBF ratio of 174% ± 120% before LPS vs. 110% ± 82% at T = 4; 
Fig. 3B). There were no differences in baseline FBF ratio (before infusion of vasoactive agents) before 
and after LPS administration (1.4 ± 0.9 and 1.1 ± 0.3,respectively; P = 0.13), indicating that baseline was 
achieved again at the start of post-LPS FBF measurements.
Figure 3. Forearm blood flow in response to the different vasoactive medications before  
and during endotoxemia. 
A, FBF ratio (%) in response to different acetylcholine concentrations before (solid line) and after (dashed line) the 
administration of LPS. B, FBF ratio (%) in response to different nitroglycerine/sodium nitroprusside concentrations 
before (solid line) and after (dashed line) administration of LPS. Data are expressed as mean T SD.
Correlation analysis
The proinflammatory cytokine IL-6 correlated positively with endocan levels (IL-6, rp = 0.76, P < 0.01). 
A similar positive correlation was found between TNF-α and endocan, although it did not reach 
statistical significance (rs = 0.43, P = 0.09), whereas the anti-inflammatory cytokine IL-10 tended 
to correlate negatively with endocan (rs = -0.43, P = 0.08). Interleukin-1RA did not correlate with 
endocan levels (rp = 0.12, P = 0.65). Furthermore,IL-6 and ICAM levels were correlated (rp = 0.68, P 
= 0.003), whereas no correlations between other cytokines and ICAM or VCAM levels were found 
(IL-10-ICAM, rs = j0.40, P = 0.12; TNF-α-ICAM, rs =-0.16, P = 0.54; IL-1RA-ICAM, rp =-0.09, P = 0.74; IL-6-
VCAM, rs = 0.30, P = 0.25; IL-10-VCAM, rs = 0.002, P = 0.99; TNF-α-VCAM, rs = 0.41, P = 0.10; IL-1RA-
VCAM, rp = 0.28, P = 0.29). Endocan concentrations correlated negatively with the response to the 
endothelium-dependent vasodilator acetylcholine (rp = -0.49, P = 0.049). In contrast, no significant 
correlation was found between endocan and the response to the endothelium-independent 
vasodilator nitroglycerin/sodium nitroprusside (rp = -0.34, P = 0.18). Furthermore, no association 
was found between ICAM and VCAM and the response to the endothelium-dependent vasodilator 
acetylcholine (rp = 0.06, P = 0.87 and rs = 0.05, P = 0.85, respectively). Finally, endocan did not 
correlate with ICAM and VCAM levels (ICAM, rp = 0.40, P = 0.11; VCAM, rs = 0.22, P = 0.41).
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Discussion
In the present study, we combined the experimental human endotoxemia model with the perfused 
forearm technique to investigate the effects of inflammation on endothelial function and release of 
markers related to endothelial dysfunction. We demonstrate a relation between endocan levels and 
endothelial dysfunction during systemic inflammation induced by experimental endotoxemia, reflected 
by a significant correlation between endocan and endothelium-dependent vascular dysfunction but 
not between endocan and endothelium-independent vascular dysfunction. In contrast, endothelial 
factors ICAM and VCAM showed no correlation with the extent of endothelial dysfunction, indicating 
that endocan could represent a marker of impaired endothelial function during systemic inflammation 
in humans. 
Systemic inflammation is associated with damage to the endothelium, which plays a central role 
in the deterioration of the clinical syndrome of sepsis into shock and multiple organ failure. Hence, 
endothelial dysfunction is related to impaired outcome in sepsis patients.17 Endocan could represent a 
marker for endothelial dysfunction in sepsis as it seems to be related to sepsis severity and outcome,5,7 
is secreted by endothelial cells in response to proinflammatory cytokines, and contributes to the 
inflammatory process itself.6 However, investigating the relation between endocan and endothelial 
dysfunction in sepsis patients is difficult because of the high heterogeneity of the septic patient 
population and difficulties related to functional endothelium measurements. The experimental human 
endotoxemia model enabled us to study systemic inflammation in healthy volunteers in a controlled 
and reproducible way and to investigate the possible relation between endocan and endothelial 
dysfunction. We want to emphasize that the endocan levels we measured in a highly homogeneous 
population and well-controlled model still showed considerable interindividual variations. Furthermore, 
the correlation we found between endocan levels and endotheliumdependent vascular dysfunction is 
modest and, concerning effect size, not much stronger than that between endocan and endothelium-
independent vascular dysfunction. These findings question the usefulness of this marker in actual 
patients. Therefore, additional studies in similar or alternative models of inflammation are needed 
first to firmly establish the relation between endocan and endothelial dysfunction. In case of positive 
results, it should be determined whether these findings can be extended to patients with inflammatory 
conditions, where many confounding factors are present. 
Next to its possible use as a marker of endothelial dysfunction, beneficial effects of a neutralizing 
antibody against endocan on survival in a murine cecal ligation and puncture model of sepsis6 suggest 
that endocan could also represent a viable therapeutic target. Unfortunately, the mechanisms 
behind the beneficial effects of neutralizing endocan were not evaluated in the cecal ligation and 
punctureYsepsis model.6 It would be of interest to determine whether antibodies or other approaches 
to neutralize endocan, such as siRNA,6 result in improved endothelial function during inflammatory 
conditions. To investigate this, mice could be administered LPS in combination with antibodies/siRNA 
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against endocan followed by ex vivo evaluation of endothelial function in aortas and/or mesenteric 
arteries using myography.18 
A potential limitation of our study is the fact that we used data from three different LPS studies. 
In one of these studies, sodium nitroprusside was used as the endothelium-independent vasodilator 
whereas, in the two others, nitroglycerin was used. However, we feel that this has not confounded our 
results to a significant extent for the following reasons. First, we corrected for potency effects between 
the two agents by using a higher dose of nitroglycerin compared with nitroprusside.Nitroglycerin acts 
mainly on the venous vasculature and to a lesser extent on the arterial system. Therefore, its effects 
on the forearm arteries are less pronounced. Our dose correction resulted in a comparable increase 
in arterial vasodilatation between the two agents. Related to this, we measured forearm circumference 
in the early phase of the vasodilatory response, which is solely dependent on vasodilatation of 
arterial resistance vessels. This means that the increase in forearm circumference is not influenced 
by effects on the venous vasculature, which differ between the two agents. Second, the intra-arterial 
infusion of drugs in our study did not result in systemic effects. This is also not expected because 
the forearm volume accounts for approximately only 1% of total body weight. Therefore, on cuff 
deflation, vasoactive agents are diluted 1:100 and are therefore not expected to exert systemic effects. 
Therefore, potential differences between modes of action or differential effects on venous and arterial 
vasculature between the two agents will not have resulted in different systemic effects in our study. 
Finally, we compared the response of these vasodilators before and after LPS administration within 
the same subject, so that they serve as their own control. Effects were similar in subjects infused with 
nitroprusside compared with nitroglycerin. 
In conclusion, whereas endocan has been suggested to be a marker for sepsis severity and 
outcome, we extend these findings by showing that endocan levels are associated with endothelial 
dysfunction in humans in vivo during systemic inflammation  evoked by experimental endotoxemia. 
However, in light of the
interindividual variability in endocan levels and the relatively moderate correlation found, 
additional studies are warranted to strengthen the relationship between endocan and endothelial 
dysfunction.
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Abstract
Background
Hyperalgesia is a well recognized hallmark of disease. Pro-inflammatory cytokines have been 
suggested to be mainly responsible, but human data are scarce. Changes in pain threshold during 
systemic inflammation evoked by human endotoxemia, were evaluated with three quantitative sensory 
testing methods.
Methods and results
Pressure pain thresholds, electrical pain thresholds and tolerance to the cold pressor test were 
measured before and 2 hours after the intravenous administration of 2 ng/kg purified E. coli endotoxin 
in 27 healthy volunteers. Another 20 subjects not exposed to endotoxemia served as controls. 
Endotoxemia led to a rise in body temperature and inflammatory symptom scores and a rise in 
plasma TNF-α, IL-6, IL-10 and IL-1RA. During endotoxemia, pressure pain thresholds and electrical pain 
thresholds were reduced with 20±4 % and 13±3 %, respectively. In controls only a minor decrease in 
pressure pain thresholds (7±3 %) and no change in electrical pain thresholds occurred. Endotoxin-
treated subjects experienced more pain during the cold pressor test, and fewer subjects were able to 
complete the cold pressor test measurement, while in controls the cold pressor test results were not 
altered. Peak levels and area under curves of each individual cytokine did not correlate to a change in 
pain threshold measured by one of the applied quantitative sensory testing techniques.
Conclusions and significance
In conclusion, this study shows that systemic inflammation elicited by the administration of endotoxin 
to humans, results in lowering of the pain threshold measured by 3 quantitative sensory testing 
techniques. The current work provides additional evidence that systemic inflammation is accompanied 
by changes in pain perception.
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Introduction
Pain is a major source of suffering in intensive care patients and commonly involves patients with 
concurrent inflammatory conditions like trauma, auto-immune diseases, or infectious diseases. Highly 
organized neural circuits existing in the brain and spinal cord regulate pain. These circuits in turn 
are influenced by a number of pathological states, including inflammation. Inflammation leads to a 
broad constellation of adaptive changes, called the ‘sickness response’. Features of this response 
include fever, increased sleep, decreased locomotion, decreased food and water intake, and hormonal 
changes.1 Furthermore, the pain threshold for painful stimuli is lowered, resulting in hyperalgesia, and 
normally non-painful stimuli can become painful (allodynia). Hyperalgesia constitutes an underexposed 
clinical problem on the intensive care, which deserves specific attention, since e.g. opiates that are 
frequently used in everyday practice can actually worsen hyperalgesia.2 Animal studies have shown 
that inflammatory cytokines contribute to the development of hyperalgesia.3-6 
However, data in humans in vivo are scarce. Quantitative sensory testing (QST) provides 
a standardized way of pain threshold quantification, as a result of which it is increasingly used 
in clinical and research settings. QST comprises several techniques to measure the intensity of 
stimuli needed to produce specific sensory perceptions. Common stimuli employed are touch or 
pressure, vibration, electrical stimulation or exposure to heat or cold.7 Intravenous administration of 
endotoxin in healthy volunteers, a well-characterized standardized model of systemic inflammation, 
results in an acute systemic inflammatory response characterized by high cytokine levels and 
flu-like symptoms.8 In the present study, pain thresholds, measured by three separate methods 
of QST, were investigated before and after the administration of 2 ng/kg of E. Coli endotoxin in 
healthy volunteers to quantify the difference in pain perception caused by systemic inflammation. 
Additionally, we assessed the relation between circulating levels of inflammatory cytokines and pain 
thresholds to gain further insight in the pathophysiological mechanisms linking inflammation and 
pain perception.
Materials and methods
Design
The study consisted of two parts. In the first part 27 healthy young males were subjected to 
experimental human endotoxemia, during which quantitative sensory testing was performed before 
and two hours after endotoxin administration. In the second part, 20 healthy young males underwent 
the same QST measurement regimen without endotoxemia, to identify any possible carry-over or 
time-dependent effects (control experiments). The study was not designed as a randomized controlled 
trial, as it was considered unethical to expose subjects in the control experiments to the risks and 
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discomfort of the placement of an arterial and venous catheter, while no fluid was administered and 
no blood was sampled from them.
Experimental human endotoxemia
The study was approved by the local ethics committee Commissie Mensgebonden Onderzoek 
(CMO) regio Arnhem – Nijmegen, The Netherlands and the study was conducted according to the 
principles expressed in the Declaration of Helsinki. After written informed consent was obtained, 27 
healthy male volunteers participated in the endotoxemia treated study group, which was part of a 
larger endotoxemia trial (NCT 01349699). Pre-study screening revealed no abnormalities in medical 
history, physical examination, routine laboratory tests and ECG. At 7:30 AM subjects were admitted 
to the research unit of our intensive care department. A cannula was placed in an antecubital vein 
to permit the infusion of 1.5 litre of 2.5%glucose/0.45% saline solution in 1 hour prior to endotoxin 
administration, followed by 150 ml/h until 6 h after endotoxin infusion and 75 ml/h until the end of the 
experiment to ensure optimal hydration.9 A 5-lead ECG and an arterial catheter in the brachial artery 
of preferably the non-dominant arm, enabled continuous monitoring of hemodynamics as well as the 
regular drawing of blood for cytokine measurements. At T=0 h, 2 ng/kg U.S. Reference Escherichia coli 
endotoxin (E. coli O:113, Clinical Center Reference Endotoxin, National
Institute of Health, Bethesda, USA) was administered intravenously over 1 minute. Subjects were 
asked to rate each of their inflammatory symptoms (headache, backache, muscle ache, shivering 
and nausea) on a 0–5 Likert scale every 30 minutes following endotoxin administration. Also, body 
temperature was taken every 30 minutes throughout the experiment using an automatic infrared 
tympanic thermometer (Genius 2, Tyco healthcare group LP, Mansfield, MA, USA). EDTA anti-
coagulated blood for the determination of IL-6, TNF-α, IL-10 and IL-1RA was drawn one hour before 
endotoxine administration, and at t=0, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours afterwards. Blood samples 
were immediately centrifuged at 2.000 g for 10 minutes at 4°C and supernatants were stored at –80 
°C until batch wise determination of cytokine concentrations using a simultaneous Luminex assay 
according to the manufacturer’s instructions (Bio-plex cytokine assay; Bio-Rad, Hercules, California, 
USA).
Quantitative sensory testing
Somatic Pressure Pain Thresholds (PPT) and Electrical Pain Thresholds (EPT) were determined in 
dermatome C5, T10 and L3, one hour before and two hours after LPS administration. Measurements 
in dermatome C5 took place at the site of the greater tubercle of the upper arm, in dermatome T10 
at the location of the iliac crest, and in L3 at the vastus lateralis muscle, half way the upper leg. All 
measurements were carried out contra-laterally to the side where the arterial cannula was placed. 
The subjects were asked to indicate thresholds for pain detection (stimulus just becoming painful), 
after which the stimulus was interrupted immediately. Both electrical and pressure pain thresholds 
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were determined 3 times consecutively in each dermatome. The instructions given to the subjects 
were repeated after every 3 stimuli. All tests were performed in a highly standardized fashion by 
2 members of our group to minimize interobserver variability. PPT measurement was performed 
by gradually increasing pressure with a pressure algometer (Somedic, Hörby, Sweden) until the 
subject indicated to experience the applied pressure as pain by saying ‘stop’. Electrical stimuli were 
administered transcutaneously in a gradually increasing mode (JNI Biomedical APS, Aalborg, Denmark) 
via self-adhesive electrodes. The current was gradually increased from 0 to 50 milliamperes until the 
subject ended the measurement himself by lifting his thumb from a metal handle at the moment the 
feeling just started to get painful, thereby automatically stopping the electric stimulus. For both PPT 
and EPT the measurements in different dermatomes were analysed separately, but to give a more 
general estimate of the pain threshold also a mean value of the three dermatomes was calculated 
which will be referred to as ‘combined PPT’ and ‘combined EPT’. The Cold Pressor Test (CPT) was 
carried out as previously described.10 Briefly, one hand of the subject was submerged to the wrist in 
water with melting crushed ice (0 °C). From the start of ice immersion, the subject was asked to rate 
the pain severity on a 0-10 Numeric Rating Scale (NRS) every 10 seconds. The subject was free to 
remove his hand from the ice water at any time by himself if he could not tolerate the cold any longer. 
The measurement was stopped by the investigators after 90 seconds or if the subject rated the pain 
severity as 10. Both the NRS scores as well as the time to removal of the hand (latency) from the ice 
water were analyzed.
Control experiments
To correct for possible time-dependent effects or the development of tolerance to the pain stimuli, 
20 healthy subjects were subjected to QST measurements without administration of endotoxin. The 
protocol and timing of the QST measurements were identical to the measurements in the endotoxin-
treated subjects, but subjects did not fast 12 hours before the start of the experiments, did not receive 
a venous or arterial cannula, no hydration fluid was administered, and no blood samples were drawn.
Statistical analysis
For the PPT and EPT, the average of three consecutive threshold measurements was calculated at 
each time point. Students paired T-test was used to compare mean pain thresholds within subjects. 
Correlation analysis was performed using Spearman rank R correlation or Pearson’s R correlation 
according to the distribution of the parameters tested Spearman rank R for change in pain threshold 
(i.e. ΔPT = PT after–PT before) versus cytokine induction, and Pearson’s R for Correlations between 
the different QST methods). Differences in tolerance to the cold pressor test were evaluated with 
McNemar’s test for paired comparisons for binominal data, survival analyses using the Log-rank test 
and repeated measures two- way ANOVA (interaction term). Differences in proportions were analyzed 
with Fisher’s exact test. Statistical calculations were performed using Graphpad Prism V5.0 (Graphpad 
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software) and SPSS 18.0 (PASW Statistics). Data are represented as mean ± SEM, unless otherwise 
stated. Because of the anticipated large variation in baseline pain perception between subjects, data 
were analyzed as % change from baseline per subject. Results were considered statistically significant 
at P<0.05.
Results
Baseline characteristics
There were no significant differences in demographic characteristics between the subjects in the 
endotoxin treated group (n=27, age 22±0.6 years, BMI 22.8±0.4 kg/m2) and control subjects (n=20, age 
22±0.5 years, BMI 22.2±0.7 kg/m2). All subjects were of European descent. There was a difference in 
baseline pain perception between controls and subjects; Baseline PPT was significantly higher in the 
endotoxin-treated group (Combined PPT 701±49 versus 491±46 N, p=0.004), while the baseline EPT 
was similar in both groups (Combined EPT 15.5±1.4 versus 12.1±1.4 mV, p=0.1). Also, no difference in 
baseline tolerance to the cold pressure test was observed, the % of subjects that could tolerate the ice 
immersion for the entire duration of the measurement was 63 % (LPS group) and 50 % (control group), 
p=0.77.
Experimental human endotoxemia
LPS administration caused a marked inflammatory response characterized by flu-like symptoms, an 
increase in body temperature of 2.0±0.1 °C and a marked rise in circulating cytokines in all 27 subjects. 
Symptoms ranging from headache, nausea, backache, muscle ache and shivering first occurred around 
1 hour after endotoxin administration and peaked at T=90 minutes. Thereafter symptoms gradually 
declined and at discharge (T=9 h after endotoxin administration) all subjects had fully recovered. Peak 
levels were detected for TNF-α at 1.5 h and IL-6 at 2 h, measuring 580±47 pg/ml and 1286±114 pg/ml, 
respectively, while IL-10 (435±67 pg/ml) and IL-RA (6063±282 pg/ml) peaked at 3 h (Figure 1A-D).
Quantitative sensory testing
Pain thresholds were tested 1 hour before and 2 hours after LPS administration (Figure 2A-B, Table 1). 
In the endotoxin treated group a significant decrease in PPTs was noted at T=2h for each dermatome 
separately (C5: -20±5 %, T10: -15±5 %, L3: -23±4 %) as well as for the combined PPT (-20±4 %). In 
control subjects, a statistically significant, but less pronounced reduction in PPT at T=2 h was observed 
in dermatome C5 (-17±4 %) and combined PPT (-7±3 %). Electrical pain thresholds were significantly 
decreased in the endotoxin treated group (C5: -8±7 %, T10: -14±4 %, L3: -16±3 %, Combined: -13±3 
%), but no significant changes were observed in control subjects. Subjective pain perception measured 
by NRS scores in response to the cold pressor test was highly reproducible (Figure 3A-B) showing 
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identical curves for the measurements at t=-1 and T=2 h in control subjects. Two hours after endotoxin 
administration, significantly more pain was reported during the cold pressor test (p<0.0001). Also, the 
period that subjects could withstand the exposure to cold was significantly decreased after endotoxin 
administration, only 26 % of the subjects completed the 90 second duration of the measurement 
during endotoxemia compared to 63% at T=-1 h (Figure 3C). The mean time to withdrawal from the 
ice was 76±4 seconds before endotoxin treatment and 54±5 seconds after (Figure 3D, p=0.0001). 
In control subjects there was no difference between the two measurements (55 % fulfilled the 
measurement at T=-1 hr versus 50 % at T=2 h, p=1.00). Mean time to withdrawal was 77±4 seconds at 
T=-1 and 75±4 seconds at T=2 h, p=0.51).
Figure 1. Plasma cytokine levels during human endotoxemia. 
Data expressed as mean±SEM. At T=0 h endotoxin was administered. A: TNF-α, B: IL-10, C: IL-6, D: IL-1RA. h: hours.
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Figure 2. Relative change in pain thresholds during human endotoxemia. 
A: combined pain pressure threshold (PPT) and B: combined electrical pain threshold (EPT) measured 2 hours after 
endotoxin administration. Values are depicted as percentage change from baseline (-1 h), where baseline was set at 
100%. White bars: control subjects, black bars: endotoxin treated subjects. Data expressed as mean±SEM. h: hours.
41481 van Eijk.indd   276 18-08-16   16:17
Systemic inflammation decreases pain threshold in humans in vivo
277
18
Ta
bl
e 
1.
 P
ai
n 
th
re
sh
ol
ds
 b
ef
or
e 
an
d 
af
te
r 
en
do
to
xe
m
ia
En
do
to
xe
m
ia
 (N
=2
7)
Co
nt
ro
ls
 (N
=2
0)
D
iff
er
en
ce
 
be
tw
ee
n
 g
ro
u
ps
T=
-1
 h
r
T=
2 
hr
s
D
el
ta
P 
va
lu
e
T=
-1
 h
r
T=
2 
hr
s
D
el
ta
P-
va
lu
e
P-
va
lu
e
PP
T 
 (N
)
C5
63
6±
45
50
1±
44
-1
36
±3
7
0.
00
1
48
3±
52
40
2±
48
-8
1±
22
0.
00
2
0.
24
7
T1
0
63
9±
50
53
4±
48
-1
05
±3
4
0.
00
5
43
3±
40
43
0±
46
-3
±1
4
0.
84
9
0.
01
8
L3
82
8±
68
61
2±
51
-2
16
±4
3
<0
.0
00
1
55
6±
53
54
5±
62
-1
1±
30
0.
72
2
0.
00
1
Co
m
bi
ne
d
70
1±
49
54
9±
45
-1
52
±2
7
<0
.0
00
1
49
1±
46
45
9±
49
-3
1±
14
0.
03
4
0.
00
1
EP
T 
(m
Am
p)
C5
15
.5
±1
.7
12
.9
±1
.4
-2
.6
±1
.2
0.
04
6
12
.8
±1
.3
12
.1
±1
.4
-0
.7
±0
.7
0.
30
8
0.
23
0
T1
0
17
.7
±1
.9
14
.6
±1
.4
-3
.1
±0
.9
0.
00
2
11
.8
±1
.6
11
.7
±1
.7
-0
.1
±1
.4
0.
94
1
0.
06
6
L3
13
.3
±1
.2
11
.0
±1
.1
-2
.3
±0
.6
0.
00
04
11
.8
±1
.6
11
.9
±1
.7
0.
1±
0.
6
0.
85
9
0.
00
7
Co
m
bi
ne
d
15
.5
±1
.4
12
.9
±1
.2
-2
.6
±0
.7
0.
00
04
12
.1
±1
.4
11
.9
±1
.5
-0
.2
±0
.7
0.
75
3
0.
01
6
PP
T:
 P
re
ss
ur
e 
Pa
in
 T
hr
es
ho
ld
. E
PT
: E
le
ct
ric
al
 P
ai
n 
Th
re
sh
ol
d.
 N
: n
ew
to
n.
 m
Am
p:
 m
ill
ia
m
pe
re
s
41481 van Eijk.indd   277 18-08-16   16:17
PART II  |  Methodological considerations
278
Figure 3. Change in tolerance to the cold pressor test during human endotoxemia. 
A and B: Amount of discomfort in response to immersion of one hand in ice water, rated on a 0-10 numeric rating 
scale (NRS). C and D: Percentage of subjects with hand in ice water. Open circles: T=-1 hour (before endotoxin 
treatment), black dots: T=2 hours, (after endotoxin treatment). A and C: results in endotoxin treated group, B and D: 
results in control group.
Correlation analyses
There was a good correlation between pain threshold determinations on different dermatomes and 
a modest, though statistically significant correlation between pain thresholds measured by PPT and 
EPT (Combined PPT vs Combined EPT: r=0.43, p<0.0001). Correlation analyses revealed no significant 
correlations between cytokine levels and changes in PPT or EPT (Table 2), except for weak correlations 
of peak IL-10 and delta PPT C5, IL-10 at T=2 h and delta PPT C5 and IL-6 at T=2 h and delta CPT. All 
these correlations lost significance following Bonferroni’s correction for multiple testing. Apart from 
the absence of clinically relevant correlations between cytokines and differences in pain thresholds, 
also no correlations between total symptom score or separate symptom scores (headache, backache, 
muscle ache, shivering and nausea) and changes in EPT, PPT or tolerance to CPT were found (data not 
shown).
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Table 2. Spearman correlations of changes in pain thresholds and cytokines
TNF-α IL-6 IL-10 IL-1RA
Peak Value 
at t=2 
h
Peak Value 
at t=2 
h
Peak Value 
at t=2 
h
Peak Value 
at t=2 
h
ΔPPT  (N)
C5 r 0.187 0.013 -0.062 -0.111 0.455 * 0.412 * 0.064 0.100
P-value 0.342 0.949 0.755 0.575 0.015 0.029 0.746 0.614
T10 r 0.017 -0.059 0.164 0.102 -0.034 -0.092 -0.299 0.002
P-value 0.932 0.767 0.404 0.606 0.864 0.641 0.122 0.993
L3 r -0.083 -0.167 0.121 0.144 0.030 0.067 0.050 -0.044
P-value 0.674 0.394 0.540 0.465 0.879 0.736 0.799 0.823
Combined r 0.155 0.056 0.200 0.173 0.223 0.164 0.026 0.093
P-value 0.430 0.776 0.308 0.379 0.255 0.404 0.894 0.638
ΔEPT (mAmp)
C5 r 0.218 0.131 -0.003 -0.129 -0.045 -0.094 -0.286 -0.265
P-value 0.275 0.516 0.988 0.522 0.825 0.641 0.148 0.181
T10 r -0.128 0.052 0.053 -0.020 -0.181 -0.184 -0.009 -0.380
P-value 0.525 0.797 0.792 0.919 0.365 0.357 0.965 0.051
L3 r 0.194 0.170 -0.022 -0.119 0.009 -0.089 -0.093 -0.245
P-value 0.333 0.398 0.914 0.554 0.963 0.660 0.646 0.219
Combined r 0.194 0.170 -0.022 -0.119 0.009 -0.089 -0.093 -0.245
P-value 0.333 0.398 0.914 0.554 0.963 0.660 0.646 0.219
ΔCPT (NRS)
r -0.038 -0.063 0.293 0.415 * 0.102 0.166 0.249 0.248
P-value 0.848 0.749 0.130 0.028 0.606 0.399 0.201 0.203
Δ: Delta. Pressure Pain Threshold. EPT: Electrical Pain Threshold. CPT: Cold Pressor Test. VAS: Visual Analog Scale. N: 
Newton. mAmp: milliamperes. *:p<0.05
Discussion
This study reports a clear change in pain perception during human experimental endotoxemia, 
and supports previous findings that suggest a close interrelation between the immune response 
and hyperalgesia. A profound difference in pain perception was found 2 hours after endotoxin 
administration which was not found in a group of subjects that did not receive endotoxin. Although 
human endotoxemia is a well–validated, standardized model of inflammation suitable to find possible 
correlations between cytokine release and altered pain thresholds, no such direct correlations were 
found. It has been long recognized that substances released by immune cells can modulate pain 
perception. The modulation of pain perception is part of the brain-mediated sickness response that 
enhances host survival. Pro-inflammatory cytokines are thought to initiate this response as they are 
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the key mediators of immune to brain communication.11,12 These cytokines can be produced locally at 
the site of tissue injury, leading to a local change in pain threshold. However, in the case of systemic 
inflammation, cytokines can induce a generalized change in pain perception. These cytokines act 
on signal transduction at the peripheral nerve terminals, along the nerve bundles, within the spinal 
cord and within the brain. In addition they can activate the vagus nerve which is also involved in 
pain perception and the sickness response.13 IL-1 is regarded as the most important and potent 
cytokine in modulation of pain perception. Hyperalgesia can (at least in part) be blocked by anti-IL-1 
directed therapies, while other pro-inflammatory cytokines such as TNF-alpha, and IL-6 are thought 
to influence pain perception mainly through IL-1 induction, illustrated by the fact that hyperalgesia 
caused by pro-inflammatory cytokines other than IL-1 is attenuated by blocking IL-1 signalling.14,15 In 
contrast with the hyperalgesic effects of pro-inflammatory cytokines, the anti-inflammatory cytokine 
IL-1 receptor antagonist (IL-1RA) and IL-10 have shown to increase pain thresholds when administered 
intrathecally.16-19 Not only systemic production of IL-1 is associated with hyperalgesia, also de novo 
production and release of IL-1 in the brain and the dorsal ganglia of the spinal cord are involved in 
sickness-induced hyperalgesia.20 In addition, nerve growth factor (NGF) may represent a final common 
pathway, as NGF is synergistically induced by both IL-1 and TNF- alpha.21,22 As IL-1 plays a pivotal role 
in changes of pain perception, it appears logical to measure IL-1 production in the current study as 
well. However, during human endotoxemia plasma IL-1 is not or only marginally elevated.23 In contrast, 
IL-1RA, the natural inhibitor of IL-1, is markedly elevated after endotoxin administration, suggesting 
that there is a significant induction of IL-1 within the tissues, which is not reflected in the circulation, 
but which could modulate pain perception. This may be a explanation for the fact that no correlation 
between changes in pain thresholds and measured circulating cytokines was found. An alternative 
explanation is that the effects of bacterial-derived inflammatory stimuli on pain perception are not 
mediated by inflammatory cytokines but by these bacterial products themselves, as hyperalgesia 
in mice was recently shown to be dependent on bacterial load rather than immune activation.24 In 
agreement, bacterial products, including LPS, can directly activate nociceptor neurons.24,25 Systemic 
inflammation has previously been shown to alter pain perception in animals and humans. Recently, 
Benson and colleagues reported altered pain perception after the administration of a very low dose 
of endotoxin (0.4 ng/kg) to healthy volunteers, mimicking low grade systemic inflammation.26 The 
current work provides additional evidence that systemic inflammation is accompanied by changes in 
pain perception. However, in contrast to the study of Benson et al. [26] no correlations were found 
between plasma levels of cytokines and changes in pain perception. A possible explanation might 
be that Benson et al.26 used a 5 times lower dose of endotoxin, only inducing a mild inflammatory 
reaction. Furthermore, the reported correlations are difficult to interpret: similarly to the present 
study, no correlations between changes in pain thresholds and peak or area under curve cytokine 
levels were found. The only significant correlations were found at time points either before or after 
peak levels of the respective cytokines. This implies that a type-1 error may have occurred, as no 
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correction for multiple testing was performed. Based on their and our observations, we suggest that 
cytokines may lower the pain threshold, but that this effect is likely modulated by one or more other 
downstream mechanisms. A possible mechanism could be the regulation of pain by glia cells of the 
CNS.27 In addition, activation of the vagus nerve by other substances apart from cytokines 13 as well as 
local production of IL-1 in peripheral tissues and the central nervous system may play an important 
role. A limitation to the study is that the group not treated with  endotoxin did not receive a venous 
and arterial catheter, did not receive (pre)hydration solution and did not fast 12 hours before the start 
of the experiments. Possibly one of these factors resulted in the baseline differences as were found in 
PPT and EPT. Because paired observations within the same subject were obtained, data were analyzed 
as change from baseline per subject, and no direct statistical comparisons between the endotoxemia 
group and non-endotoxemia were made, this should have no influence on the interpretation of the 
study results. Strong aspects of the present study are the fact that we used a validated, standardized 
model of systemic inflammation, in which purified endotoxin elicited a pronounced inflammatory 
response, reflected by high levels of circulating cytokines, even compared with septic patients.8 
Furthermore, time-dependent bias was excluded by the inclusion of a nonendotoxin treated study 
group. Also, three different domains of QST measurements were used; electrical stimulation, pressure 
algometry, and cold pressor testing, providing solid evidence that multiple measures of somatic pain 
perception are altered by systemic inflammation.
The findings of this and previous studies, indicating a clear relation between inflammation and 
pain perception, contribute to our understanding of pain in systemically inflamed patients such as 
those suffering from sepsis. Furthermore this study shows that experimental human endotoxemia 
offers a valuable model to study inflammation-induced hyperalgesia that may facilitate development of 
new therapies aimed at modulating inflammation-related pain perception.
In conclusion, this study shows that systemic inflammation elicited by the administration of 
endotoxin to human results in a decreased pressure pain threshold, a decreased electrical pain 
threshold and decreased tolerance to the cold pressor test. In the absence of a correlation with 
circulating cytokines, the nature of the link between inflammation and pain sensation needs further 
study.
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Introduction
Iron is essential to many basic physiological processes in animal and microbial life. Iron homeostasis 
is carefully regulated during health and disease states, to optimize oxygen transport while immunity 
is preserved. This delicate balance is profoundly disturbed by inflammation and infection. In general, 
systemic inflammation leads to reduced availability of iron, which further deprives pathogens from iron 
in the already hostile environment constituted by human plasma. However, depriving the bone marrow 
from iron leads to iron restricted erythropoiesis, ultimately resulting in anemia of inflammation. The 
interplay between iron and immunity is further unraveled in this thesis, using in vitro and in vivo studies 
in cells, animals, and humans.
Part 1: Iron metabolism and innate immunity
Although it is clear that iron homeostasis is profoundly affected by inflammation, it is much less evident 
what the effects of iron on the innate immune response are. The putative immune modulatory effects 
of iron are mainly attributed to the formation of reactive oxygen species (ROS), causing oxidative 
stress, which is associated with propagation of the innate immune response and organ damage. 
Previous animal experiments have shown that iron supplementation potentiates the innate immune 
response and associated mortality, while iron chelation exerts the opposite effect.1-5 In children living 
in areas where malaria is endemic, iron deficiency may protect against episodes of clinical malaria,6 
whereas iron supplementation has been reported to increase the risk of hospitalization and death.7 
The latter findings were refuted in a later meta-analysis,8 but the debate is still continuing as a more 
recent study not included in the meta-analysis shows a strong positive relationship between iron and 
susceptibility to malaria.9 In addition, iron status can be difficult to assess and is often poorly defined, 
particularly when infections are prevalent. As a consequence, studies investigating the effect of iron 
status on risk of infection are difficult to compare. Data from experimental human studies investigating 
the effect of iron administration or chelation on innate immunity were lacking, as were data on the role 
of hepcidin in inflammation-induced anemia. 
The effects of iron on innate immunity
Following a review on the existing literature on iron and immunity in critically ill patients in Chapter 2, 
we show in Chapter 3 that iron loading during experimental human endotoxemia indeed increases 
oxidative stress, but does not affect the innate immune response, and the subsequent hemodynamic, 
vascular, and renal effects. On the other hand, iron chelation did not show protective effects. In a 
subgroup of subjects however, iron loading led to an increase in labile plasma iron (LPI) for a short 
period of time. LPI was mainly elevated in subjects with a transferrin saturation above 90%. The 
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subjects that showed an increase in LPI had a reduced vascular response to norepinephrine after 
endotoxin challenge, whereas this was not the case in subjects without increased LPI levels. We 
therefore conclude that, although iron loading may result in worsening of vascular damage when 
LPI is formed during systemic inflammation, single pharmacologically relevant doses of both iron 
and iron chelation are unlikely to exert direct immune-related adverse effects. This is a comforting 
finding given the fact that propagation of the immune response may theoretically worsen diseases 
that underlie anemia of inflammation, such as auto-immune diseases. Our findings suggest that 
intravenous iron administration can be safely performed in these patients in case of anemia. This is in 
accordance with a recent meta-analysis of 632 articles in 2906 patients, in which oral and intravenous 
iron supplementation were investigated for the treatment of anemia in inflammatory bowel disease. 
This meta-analysis revealed that neither oral nor intravenous iron administration exacerbated the 
clinical course of inflammatory bowel disease.10 Analogous to these findings, no flares occurred in a 
group of 40 rheumatoid arthritis patients that were treated with intravenous iron.11 Of note, during 
active inflammation, the absorption of iron from the gut is compromised due to the effects of hepcidin. 
Therefore, intravenous iron administration would be preferable in these patients. 
We did not investigate the effect of iron on inflammation during infection. Endotoxin is a 
component of dead bacterial material, which is capable of inducing a inflammatory response, but 
unlike living bacteria will not replicate in favorable conditions. Theoretically, iron supplementation 
may propagate pathogen growth during an infection and may thereby worsen outcome. Current 
guidelines for anemia in chronic kidney disease (CKD) therefore recommend to withhold intravenous 
iron administration in the case of active infection.12 However, in a retrospective observational study 
in close to 23000 CKD patients admitted to the hospital for bacterial infection, no adverse effects of 
intravenous iron supplementation on the clinical course of the disease were observed.13 In contrast, 
a meta-analysis investigation on the efficacy of intravenous iron supplementation in reducing 
the requirement for blood transfusions did find an increased risk of all cause infections following 
intravenous iron therapy.14 However, these findings may be biased by the fact that infection was not 
a predefined endpoint in many of the investigated studies. Clinical trials investigating the effect of 
intravenous iron supplementation during anemia of inflammation in the presence of active infection 
are therefore warranted.
The effects of hepcidin on innate immunity
Next to direct iron supplementation or chelation, we intervened in iron homeostasis by investigating 
the effect of hepcidin on innate immunity (Chapter 4). Earlier in vitro and animal experiments have 
suggested that hepcidin exerts direct anti-inflammatory effects.15-18 These were shown to be mediated 
by JAK2-dependent internalization and degradation of ferroportin.15 JAK2 activation results in 
phosphorylation of ferroportin, but also phosphorylation of transcription factor STAT3, resulting in an 
altered expression of a variety of genes, including cytokines. Supposedly, this results in suppression of 
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the innate immune response, characterized by the reduced production of IL-6 and TNF-α, and reduced 
morbidity and mortality in inflammatory models using LPS, poly(I:C) and turpentine.15-18 Moreover, 
pretreatment with hepcidin was shown to protect mice from a lethal dose of LPS, and hepcidin-
knockout mice could be rescued from LPS toxicity by hepcidin administration.15 These beneficial 
effects attributed to hepcidin are of particular relevance for the development of hepcidin-targeting 
therapies as a new treatment for anemia of inflammation. Theoretically, antagonizing hepcidin could 
exacerbate the underlying inflammatory condition, next to treating anemia. However, the data from 
reference 15 supporting anti-inflammatory effects of hepcidin are clouded by scientific misconduct 
(paper # 3  in the report by McCormack et al. 2013 19) and all studies to date were carried out using cell 
lines and (knockout) mouse models and extremely high dosages of hepcidin. The question emerges 
whether hepcidin-mediated anti-inflammatory effects are relevant for the human in vivo situation. We 
therefore investigated whether physiological suppression of hepcidin in healthy volunteers by means 
of phlebotomy (withdrawal of 500 ml of blood) resulted in an altered immune response. Moreover, we 
investigated the effects of hepcidin on innate immunity in a mouse model and ex vivo human whole 
blood stimulation model (Chapter 4). Surprisingly, we did not find any effect of hepcidin on the innate 
immune response in the 3 models used. Based on our findings, we suggest that changes in hepcidin 
concentrations within the (patho)physiological range do not exert intrinsic immune modulatory effects 
to a relevant extent. The fact that phlebotomy exerted no immune modulatory effects rules out 
the possibility that the absence of effects in the other models was due to the hepcidin preparation. 
Although it is difficult to devise an explanation for the observed difference between our study and 
the earlier reports, it appears plausible that antagonizing hepcidin as a treatment for anemia of 
inflammation will not exacerbate the inflammatory response in a clinically relevant manner. This is 
further confirmed by our finding that antagonizing hepcidin using lexaptepid pegol, an anti-hepcidin 
l-oligoribonucleotide, did not exacerbate inflammation in animal and human models of systemic 
inflammation (Chapter 6 and 7a).  
Hepcidin in septic patients
Anemia of inflammation was previously known as anemia of chronic disease. Anemia of inflammation is 
the preferred term, as the mechanisms underlying anemia of chronic disease are also active during 
acute systemic inflammation such as during sepsis. In 2005, it was already shown that experimental 
human endotoxemia was associated with a rapid increase of hepcidin production followed by a 
decrease in serum iron concentration,20 suggesting that hypoferremia is likely to be present in patients 
that are admitted to the hospital with acute systemic inflammation. However, the association between 
inflammation, hepcidin release and anemia was not previously demonstrated in septic patients. In 
Chapter 5 we show that circulating hepcidin concentrations in septic patients are associated with the 
development of anemia and the amount of blood transfusions required. These findings shed new light 
on the clinical dilemma of treating the anemic inflamed patient. Our study suggests that treatment 
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options may also include targeting the hepcidin-induced iron restriction, e.g. by intravenous iron 
administration (of which the safety during active infection still needs further investigation), or possibly 
in the future by interfering in the hepcidin-ferroportin axis. 
Pharmacological inhibition of hepcidin using lexaptepid pegol
It has become clear that the pathophysiologic changes in hepcidin concentrations are central 
to the development of anemia of inflammation. Therefore, inhibition of hepcidin represents a 
potentially attractive therapeutic strategy to improve the utilization of iron from intracellular 
stores in patients suffering from anemia of inflammation. Effects of hepcidin can be counteracted 
by decreasing hepcidin production, neutralizing the biologic activity of hepcidin or by interfering 
with hepcidin binding to ferroportin.21 Lexaptepid pegol (lexaptepid) is a structured mirror-image 
l-oligoribonucleotide, a so called Spiegelmer, conjugated to 40 kDa polyethylene glycol (PEG), 
that blocks its target hepcidin in a manner similar to aptamers or protein-based scaffolds. In two 
studies (Chapter 6 and 7a) we showed that it is possible to inhibit hepcidin-mediated effects during 
systemic inflammation using lexaptepid pegol, also known as NOX-H94. First, we showed that the 
high binding affinity of lexaptepid pegol for human hepcidin translates into functional inhibition 
of hepcidin-induced ferroportin degradation and ferritin expression in two in vitro bioassays in 
macrophages, and that hepcidin can be effectively targeted in two in vivo models in Cynomolgus 
monkeys. Next, we investigated the effects of lexaptepid in healthy volunteers. In this experimental 
endotoxemia proof-of-principle study, lexaptepid was well-tolerated and proved effective in blocking 
the inflammation-induced reduction in serum iron during systemic inflammation. With this study, 
lexaptepid is the first hepcidin-targeted therapy that was proven effective in humans in terms of its 
capacity to increase serum iron levels during inflammation. Meanwhile, lexaptepid has been tested 
in a pilot phase IIa trial in anemic cancer patients. Lexaptepid treatment resulted in ferritin decrease, 
illustrating increased ferroportin expression as a consequence of effective hepcidin inhibition, 
in 10 out of 12 patients and hemoglobin increases of 1 g/dL or more in 5 out of 12 patients. The 
responding patients showed an increase in reticulocyte cell hemoglobin content and a decrease 
of soluble Transferrin Receptor (sTfR) levels.22 Since these observations offer proof of concept that 
hepcidin inhibition may represent a promising strategy to treat anemia caused by hepcidin-induced 
functional iron deficiency,22 a safety, PK/PD and efficacy study of NOX-H94 in dialysis patients with 
ESA hyporesponsive anemia is currently ongoing (ClinicalTrials.gov Identifier: NCT02079896). A 
potential disadvantage of the compound however, is the fact that it is only available for intravenous 
administration, and its use is therefore limited to hospitalized patients, or patients that frequently 
visit the hospital, among which are patients with end stage renal disease on hemodialysis. 
Furthermore, the price of the drug is not yet known and future studies should evaluate how its  
efficacy and costs relate to alternative treatments such as intravenous iron supplementation, the use 
of erythropoiesis stimulating agents, blood transfusion and other new treatments that are currently 
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under development, such as hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors.23-25 
In Chapter 7b, we suggest that that hepcidin inhibition may also represent a complementary treatment 
for anemia of inflammation in critically ill trauma patients or patients suffering from anemia after major 
surgery.
Effect of short-term hypoxia on iron homeostasis during  
human endotoxemia
As previously alluded to, anemia of inflammation occurs in both chronic as well as in acute 
inflammatory diseases, conditions which are often complicated by tissue hypoxia. This combination may 
further contribute to organ injury and failure. It was unclear to what extent hypoxia and inflammation, 
representing opposite signals for hepcidin production, interact with each other in humans in vivo. 
In Chapter 8 we demonstrate that the marked changes in hepcidin and iron homeostasis following 
intravenous endotoxin administration are not influenced by short-term hypoxia. These findings are 
in agreement with the hypothesis that hepcidin-induced redistribution of iron during inflammation 
or infection is an important part of the innate immune response.26 Apparently, tissue hypoxia is 
subordinate to acute inflammation with regard to hepcidin signaling. These findings may be of special 
relevance to patients on the intensive care, in whom inflammation and tissue hypoxia often coincide. 
As hypoxia does not appear to result in downregulation of hepcidin under inflammatory conditions 
and these patients are likely to suffer from a low hemoglobin level that may further compromise 
oxygen transport, pharmacological inhibition of hepcidin to prevent the development of anemia of 
inflammation may prove to be a valuable adjuvant therapy. 
Sepsis-associated changes in erythrocyte membrane composition
Anemia during systemic inflammation is the result of many factors that lead to a reduced number of 
erythrocytes in the circulation. In Chapter 9 we investigated the erythrocyte itself, as inflammation-
induced changes to the erythrocyte membrane may contribute to erythrocyte removal by the 
spleen. More specifically, we investigated the involvement of lipase activity in the erythrocyte-related 
pathophysiology of patients with severe sepsis. Using a sensitive matrix-assisted laser desorption 
and ionization time-of-flight (MALDI-TOF) mass spectrometry (MS) approach, we investigated the lipid 
composition of erythrocytes after incubation with the plasma of patients suffering from septic shock 
and with plasma of subjects that underwent experimental human endotoxemia. In this study we show 
for the first time that the plasma of patients with severe sepsis triggers erythrocyte membrane lipid 
remodeling illustrated by enhanced lysophosphatidylcholine (LPC) formation. Furthermore we observed 
an increase in the percentage of phosphatidylserine (PS)-exposing erythrocytes in healthy volunteers 
after endotoxin infusion. PS exposure on the outer side of the plasma membrane alters rheologic 
and hemostatic properties of the erythrocyte,27 and is a recognition signal for removal by spleen 
macrophages.28,29 Although we hypothesized that secretory phopholipase A2 (sPLA2) IIA was responsible 
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for the observed changes, no relations between sPLA2 IIA levels and the observed changes were found. 
This study stresses the need for further evaluation of the development of anemia of inflammation from 
the perspective of the erythrocyte; although it is recognized that the clearance of erythrocytes during 
systemic inflammation is enhanced, the mechanisms underlying this process are far from understood. 
Intravenous iron supplementation in iron-refractory iron 
deficiency anemia
In Chapter 10, we describe the remarkable case of a young female Turkish patient who suffered 
from anemia. Genetic investigation revealed defects in the TMPRSS6-gene leading to  matriptase-2 
deficiency as the cause for her condition. Matriptase-2 deficiency causes hepcidin concentrations 
that are inappropriately high for the body iron levels resulting in a chronic form of iron deficiency 
anemia. Oral iron supplementation typically has little or no effect in this form of anemia, and 
therefore it is commonly termed ‘iron-refractory iron deficiency anemia’ (IRIDA). Intravenous iron 
supplementation partly restored her hemoglobin level, and surprisingly, changed her hair color. 
Such hair color changes as a result of iron treatment were never described before. Of note in 
relation to this thesis, the patient did not report an abnormal history of infectious diseases before 
and after treatment had commenced.
 
Synthesis: answers to the main research questions
The first part of the thesis was based on 4 main research questions:
1)  Does iron administration or iron chelation have a direct effect on the innate systemic 
inflammatory response in humans?
2) Does hepcidin have a direct effect on the innate immune response?
3) Is hepcidin associated with the development of anemia in sepsis patients?
4) Can hepcidin be pharmacologically targeted in the setting of acute systemic inflammation?
Regarding research question 1) 
Several investigations have explored the effect of iron on the systemic inflammatory response, mostly 
in in vitro and animal studies, some of which show detrimental effects of iron supplementation on 
oxidative stress and inflammation, contributing to higher morbidity and mortality. This fed the idea 
that iron supplementation during systemic inflammation is deleterious. Our observations during 
experimental human endotoxemia offer evidence that iron supplementation with intravenous 
iron sucrose does not modulate the innate immune response. The intravenous iron formulations 
available nowadays for the treatment of anemia, such as iron sucrose or ferric carboximaltose, are 
much safer than the iron dextran formulations used in the past, that carried a risk of anaphylactoid 
responses, including the development of cardiovascular collapse and shock. Currently, intravenous 
iron supplementation may be a valuable, safe and cost-effective way of treating anemia in patients 
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that are unresponsive to oral iron treatment as a result of inflammation-induced hepcidin production. 
We therefore welcome any further studies in patients that investigate the treatment of anemia using 
intravenous iron administration, even in the presence of infection.  
In answer to question 1, we did not find evidence for an effect of iron administration or iron 
chelation on the innate systemic inflammatory response in humans.
Regarding research question 2) 
In 2010, a study into the immune modulatory effects of hepcidin was published, revealing that 
hepcidin exerted anti-inflammatory effects, both in vitro in macrophages as well as in vivo in mice.15 
With the prospect of performing a study in healthy volunteers in which hepcidin would be targeted 
with lexaptepid pegol during experimental endotoxemia, we too investigated the possible immune 
modulatory effects of hepcidin in three different experimental setups as described above. In all three 
setups, we did not find a hepcidin-related effect on the innate immune response. Furthermore, 
antagonizing hepcidin using lexaptepid (as described in Chapter 6 and 7) did not have an effect on 
inflammatory parameters as well. 
In answer to question 2, we state that hepcidin does not exert a relevant effect on innate 
immunity in a (patho)physiological dose range. Therefore, the immune modulatory effect of hepcidin 
appears to be of minor importance in humans during systemic inflammation. 
Regarding research question 3) 
Also in acute systemic inflammatory conditions such as sepsis, anemia is frequently encountered. 
Many factors are involved in the development of anemia, such as blood loss (through surgery, 
or withdrawal for diagnostic purposes), and the enhanced clearance of red blood cells from the 
circulation (as investigated in Chapter 9). However, many factors causing anemia during critical illness, 
resemble those causing anemia of chronic disease. It is therefore increasingly recognized that anemia 
of inflammation is the better term, and that it can also occur in the acute setting, such as in intensive 
care conditions including sepsis. As explained in Chapter 5, there is a relation between the degree of 
inflammation reflected by the concentration of IL-6, the increased concentration of hepcidin in plasma, 
and the development of anemia.
In answer to question 3, we state that changes in hepcidin concentrations are indeed associated 
with the development of anemia and the amount of blood transfusions required in sepsis patients.
Regarding research question 4) 
As it is recognized that hepcidin is the principle regulator of iron homeostasis, it has become a target 
for the development of novel therapeutics for iron disorders.21 Decreased hepcidin production can 
be achieved by preventing the production of hepcidin (by targeting hepcidin regulatory pathways or 
hepcidin mRNA), neutralizing the hepcidin peptide itself, or intervening in its effect on ferroportin (by 
41481 van Eijk.indd   294 18-08-16   16:17
Summary, general discussion, and future perspectives
295
19
preventing hepcidin-mediated ferroportin endocytosis or by stimulating ferroportin production). 
The efficacy of pharmaceutical inhibition of hepcidin has previously been demonstrated in 
preclinical models using an anti-hepcidin antibody in mice and non-human primates,30,31 as well 
as by indirect approaches that reduce hepcidin expression, such as anti-IL-6 receptor antibody,32 
bone morphogenetic protein receptor antagonist (LDN-193189),33 soluble hemojuvelin-Fc,34 or 
hypoxia-inducible factor prolyl hydroxylase inhibitors.24,25 Currently, two hepcidin-targeted drugs are in 
an advanced stage of clinical development. The first is a fully human anti-hepcidin antibody developed 
by Eli Lilly, called LY2787106. It is currently being evaluated in cancer patients with anemia (NCT 
01340976). The second drug is a synthetically generated PEGylated l-stereoisomeric RNA aptamer, 
called lexaptepid pegol (lexaptepid) and developed by NOXXON Pharma. It belongs to the Spiegelmers 
and consists of a synthetic l-oligoribonucleotide with a 3-dimensional structure. Due to the unnatural 
mirror-image structure, it is of higher biological stability compared with natural d-aptamers. Lexaptepid 
binds hepcidin conceptually similar to antibodies, thereby neutralizing its effect on ferroportin. In 
Chapter 6 and 7a we were indeed able to show that lexaptepid binds to hepcidin with high affinity, 
thereby inhibiting its effect, not only in vitro and in animal models of inflammation, but also during 
controlled systemic inflammation in humans in vivo. Furthermore, lexaptepid treatment did not 
influence the immune response.
In answer to question 4 we therefore state that hepcidin indeed can be pharmacologically 
targeted in the setting of acute systemic inflammation.
Future perspective regarding the treatment anemia of inflammation
The discovery of hepcidin has given an enormous impulse to research regarding anemia during 
inflammation. Several pathways of hepcidin induction and suppression have been unraveled and these 
new data have provided insight in the pathofysiology of a variety of disease states. Moreover, it has led 
to the development of several treatments for anemia of inflammation. Next to conventional treatments 
of anemia like (intravenous) supplementation of iron, the administration of erythropoiesis stimulating 
agents or transfusion of red blood cells, new treatments are being developed and are likely to become 
available within the next decade. Hepcidin-targeting therapies may of special benefit, considering the 
relative resistance to conventional therapies during inflammatory conditions: orally administered iron 
is hardly absorbed from the gut. Intravenous iron to avoid this problem is also hardly effective, yet 
results in high ferritin concentrations as most of the iron is redistributed into iron storing cells instead 
of being used for erythryopoiesis.35 Furthermore erythropoiesis stimulating agents are less effective 
during inflammation, and have been reported not to reduce the incidence of red-cell transfusion 
among critically ill patients,36,37 while it is associated with an increase in thrombotic events.36 Therapies 
directed directly against hepcidin, like lexaptepid (Chapter 7a) may be of benefit, although it still 
needs further evaluation in clinical studies. Another newly developed therapy that targets hepcidin 
indirectly is HIF-prolyl hydroxylase inhibitor GSK1278863. It may be more effective, as it acts upstream 
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of hepcidin and has recently been shown to decreases hepcidin concentrations in chronic kidney 
disease patients, whereas it increases EPO concentrations at the same time, resulting in increased 
erythropoiesis and hemoglobin levels.25
A combination of therapies will probably be most effective, at the one hand suppressing hepcidin 
and its effects (directly or indirectly), while at the other hand erythropoiesis can be stimulated with 
erythropoiesis stimulating agents and - in the case of iron deficiency - iron supplementation. The 
ideal strategy remains to be elucidated in the next decades. Interestingly, it was recently shown 
that ferroportin can be downregulated during inflammation via an alternative pathway not involving 
hepcidin.38 This means that hepcidin is not the only regulator of systemic iron homeostasis, and 
demands further investigation. 
Part 2: Methodological considerations
The experimental human endotoxemia model enables intervention studies in humans during transient 
controlled systemic inflammation. It consists of the intravenous administration of a low dose of 
purified E. Coli endotoxin to healthy volunteers, which results in a profound inflammatory response 
characterized by clinical, biochemical and vascular effects that are comparable to the clinical situation 
of sepsis. The model originates from fever-inducing therapies that were exploited some 150 years 
ago to treat a variety of diseases. Several microbial preparations were used to induce fever, until it 
was discovered that is was the endotoxin from the bacterial wall that was mainly responsible for the 
observed inflammatory reaction. As the potency of the several endotoxin preparations used varied, a 
need emerged for standardization of the formulation. This led to the development of a standardized 
batch of E. Coli endotoxin by the FDA in 1976, resulting in a series of batches of E. Coli endotoxin that 
since then serve as worldwide standard reference material.39  
Experimental human endotoxemia has proven to be a useful and safe model to study the 
pathophysiology of systemic inflammatory diseases, such as sepsis. Sepsis is defined as the systemic 
inflammatory response to an infection, and can progress to severe sepsis or septic shock, with an 
associated mortality of approximately 20-30%.40 Despite huge efforts to reduce the burden of sepsis 
during the last decades, it is still the most common cause of death on the intensive care. Systemic 
inflammation can also occur in the absence of infection, e.g. after major surgery, trauma, burns or 
auto-inflammatory diseases. Furthermore, low-grade systemic inflammation is present in many chronic 
diseases, such as chronic kidney disease, cancer, and atherosclerosis. As a consequence, systemic 
inflammation affects many millions of people worldwide. It is clear that, when too pronounced or 
inappropriate, the systemic inflammatory response can result in organ injury, and ultimately death. 
At the same time, this response is required for adequate immunity against invading pathogens. 
Therefore, intervening in the inflammatory response can have beneficial as well as detrimental effects. 
41481 van Eijk.indd   296 18-08-16   16:17
Summary, general discussion, and future perspectives
297
19
For sepsis, it has become increasingly clear that simultaneous with the initial pro-inflammatory phase, 
immune suppressive mechanisms set in as well. When these supposedly compensatory mechanisms 
get the upper hand, a severe immunosuppressed state known as “sepsis-induced immunoparalysis” 
develops. It appears that this state is a major contributor to the devopment of secondary or 
opportunistic infections that impair the recovery of sepsis patients, and thus mortality.41 Therefore, in 
sharp contrast to earlier trials that aimed to suppress inflammation in sepsis, recent trials focused on 
immune stimulatory treatments.42 Clearly, further studies are warranted, and given the complicated 
nature of (intervening in) the inflammatory response, an adequate in vivo model of the systemic 
inflammatory response is required. 
Most of the treatments that ultimately failed to show an advantage in sepsis patients, initially 
proved successful in animal models of sepsis. Apparently, animal models only partly reflect the 
clinical syndrome of sepsis in humans. Most pre-clinical studies are carried out in mice. The poorness 
of murine models in replicating human sepsis is well-illustrated by a recent study that shows the 
profound differences in gene expression induced by infection in mice and men.43 Apparently the 
step from mice to patients is too large, and calls for an intermediate step. As alluded to before, the 
experimental human endotoxemia model provides such a model to study the pathophysiology of 
sepsis and systemic inflammation, and offers a way to study interventions in this setting. Since 2003, 
the model is in use on the department of intensive care of the Radboudumc. During this period, the 
model has evolved in such a way that it is safe, highly reproducible, and generally well-tolerated by 
the studied subjects. Through the years, several aspects have been elucidated that have helped us 
improving the model. A number of these aspects have been addressed in this thesis. 
Human endotoxemia as a model for systemic inflammation  
and sepsis
Human endotoxemia is comparable to sepsis or systemic inflammation in patients in the sense 
that is accompanied by clinical symptoms, fever, the profound induction of cytokines, activation of 
the coagulation cascade and hemodynamic effects (increase in heart rate and cardiac output, and 
decrease in vascular resistance and blood pressure) that are also observed in sepsis patients. Although 
the model has many features that resemble the clinical situation of systemic inflammation in patients, 
the model also has important limitations, that are extensively discussed later on in this chapter.  
Safety of the model 
Ever since we started using the endotoxemia model in our institution, we have measured safety as 
a primary or key secondary endpoint of all our studies, to continuously reestablish the safety of the 
model. This became especially relevant after two subjects experienced a period of severe bradycardia 
and asystole approximately 1 hour after endotoxin administration in our first series of experiments 
(Chapter 11). Until that time, apart from 1 case report of a subject who experienced a severe vagal 
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response after endotoxin administration,44 no such effects had been described in literature. Soon 
after the events took place, personal communication with investigators in The Netherlands and 
America revealed that these events have occurred in at least 4 individuals including ours (described 
in Chapter 11), and that severe bradycardia had not occurred in 2200 endotoxemia subjects that 
were parenterally or orally prehydrated. We therefore concluded that hydration status is of crucial 
importance for the risk of such events. The decrease in ventricular preload resulting from a relative 
volume depletion due to fasting prior to the experiment in combination with the enhanced inotropic 
state caused by the increase of catacholamines following endotoxin administration, may lead to a 
deformation of the ventricular wall during contraction, thereby stimulating vagal afferent nerve endings 
in the left ventricle. This vago-vagal loop results in bradycardia in a similar way as the Bezold-Jarisch 
reflex.45 In addition, 2 out of 4 cases tested positive on a head tilt test, suggesting a supranormal vagal 
tonus. This was further illustrated by the fact that 3 out of 4 described individuals had experienced 
syncopes in the past. In addition to the cases described by us, an additional case of brady-asystole 
after endotoxin administration was described in reaction to our publication.46 The author suggests 
that based on our combined reports, the estimated incidence of this adverse event is approximately 
1 in every 600 individuals. However, this number may be an underestimation as there may have been 
events in other centers that were not published. Most notably, all subjects described recovered fully 
and uneventfully. Temporary cardiac effects of endotoxin have been described in human subjects 
similar to those observed in septic shock, consisting of a depression of left ventricular function, defined 
by the ratio of the peak systolic pressure to the end-systolic volume index, compared to controls.47 
These effects may be due to cardiotoxic effects of the pro-inflammatory cytokine TNF-α,48 levels of 
which are profoundly increased after endotoxin administration. However, the described cardiotoxic 
effects during human endotoxemia are minor and short-lived. Also, the time of occurrence of these 
effects is 5 hours after endotoxin administration,47 while the observed cases of brady-asystole 
described by us mostly occurred approximately 1 hour after endotoxin administration. Therefore, 
we do not think that direct cardiotoxic effects of TNF-α are responsible, although pro-inflammatory 
cytokines are likely involved. 
From that time on, for reasons of safety, subjects were routinely pre-hydrated with 1,5 L 
glucose/saline solution prior to endotoxin administration in all the following protocols. Surprisingly, 
standardized prehydration itself had an immune modulating effect, as is described in Chapter 12. 
Interestingly, pre-hydration shifted the cytokine response towards a more anti-inflammatory pattern, 
characterized by attenuation of the pro-inflammatory cytokine response and preservation of anti-
inflammatory IL-10 production. Furthermore, the symptoms associated with endotoxin administration 
were markedly reduced in the pre-hydrated group. The question emerges how our findings relate 
to observations from clinical practice, as fluid therapy has been the subject of investigation ever 
since publication of the study of Rivers et al. on early goal directed therapy in sepsis patients that 
showed a clear advantage of early goal directed fluid administration.49 It is tempting to speculate 
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that the observed beneficial effects were in part mediated by damping of the systemic inflammatory 
response. Meanwhile, it has become increasingly clear that fluid administration can be harmful to 
patients during sepsis as well as in patients undergoing major surgery. Fluids should be administered 
early and adequately in a goal-directed manner, to improve microcirculation and possibly dampen 
the inflammatory cascade,50 but liberal fluid administration in the later phase can be harmful and 
should be avoided.51,52 Probably, human endotoxemia is not a suitable model for sepsis with regard 
to fluid status. However, it might be a better model for healthy patients undergoing moderate-risk 
surgery. These patients indeed have a better recovery profile when fluids are administered liberally 
compared with patients who received restricted amounts of the same crystalloid,53,54 which might be 
the result of a reduced inflammatory reaction in response to the operation. As fluid status apparently 
has important immune modulatory effects, the standardized pre-hydration protocol as we use it 
today has another important advantage, being that all subjects have a comparable fluid status after 
pre-hydration. All subjects have adequate diuresis before the first endotoxin-induced effects are 
observed. Those who are relatively over-hydrated can quickly compensate by extra diuresis, while 
those who were hypovolemic prior to endotoxin challenge reach a normal fluid status in time, further 
standardizing the endotoxemia model.
In addition to applying the pre-hydration protocol in every volunteer subjected to experimental 
endotoxemia, a series of safety measures are taken to ensure the safety of participating subjects. All 
subjects are carefully screened, including a history of vasovagal collapse. They receive an intra-arterial 
cannula to enable the continuous measurement of intra-arterial blood pressure as well as blood 
sampling. A trained physician is continuously present in the room were the experiments take place and 
the experiments are supervised by an experienced intensivist. The study team can rely on the backup 
of experienced ICU nurses and staff in the unlikely event of an emergency. Furthermore a protocol is 
followed in the case of bradycardia or asystole, consisting of physically activating the subject, putting 
the subject in Trendelenburg position, administering intravenous fluids and if necessary atropine.
Since the described events took place in 2003, no such events have occurred ever since. In 
some subjects bradycardia developed, but with the additional measures described above no events 
of severe protracted bradycardia or asystole have taken occured. The exact number of subjects 
participating in endotoxemia studies worldwide since the existence of standard reference endotoxin 
is not known, but is estimated to be in the range of several thousands of subjects.55 Serious adverse 
events apart from those described by us and Jilma et al.,46 were never reported. We therefore 
conclude that the model is safe, especially when the aforementioned safety measures are respected. 
Interestingly, a case was reported of a laboratory worker who self-administered 1 mg of Salmonella 
endotoxin intravenously (a dose which is equivalent to 7500 times the dose that we administer to 
healthy volunteers), after which hypotension and shock developed and the patient needed treatment 
on an intensive care unit.56 However, despite the very large endotoxin dose administered, the patient 
could be released from the hospital after 8 days without unfavorable sequelae.
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Body mass index
Similar to patients, body mass index (BMI) differs considerably between subjects participating in 
endotoxemia experiments. Obesity in relation to systemic inflammation has gained a lot of interest 
the recent years, since various studies have shown a protective effect of obesity in intensive care 
patients,57-67 called the obesity paradox.68 In Chapter 13, the effect of BMI on the innate immune 
response was investigated, using samples of 7 human endotoxemia trials performed between 2005 
and 2010. No correlation was found between BMI and the systemic inflammatory cytokine response. 
Despite the relatively large number of studied individuals, extrapolation of the study findings is 
hampered by the relatively low number of overweight and obese subjects and lack of subjects with 
a BMI>35 kg/m2. Nevertheless, ICU mortality has been shown to gradually decrease with increasing 
BMI, with beneficial effects already found in patients with a BMI of 25 to 30 kg/m2,66 suggesting that 
our sample population was appropriate to detect a possible difference. We therefore suggest that the 
better prognosis of obese patients during critical illness is unlikely to be mediated through an altered 
cytokine response. A second drawback of the study is the fact that a high BMI in young healthy males 
can also result from high muscle mass, instead of fat tissue. We have not measured the percentage 
of fat to discriminated between those individuals with pronounced muscule mass and the ones with a 
high BMI due to fat tissue. In relation to the reproducibility of the endotoxemia model, we have shown 
that the consistency of the model is not influenced by BMI, in the range of BMIs from 18 to 28. At the 
same time, we cannot exclude possible effects in subjects with a BMI above 30. Next to direct effects 
of high levels of fat tissue on inflammation, such high BMIs are associated with metabolic changes (e.g. 
chances in cholesterol spectrum and insulin resistance), low grade inflammation, and life style aspects 
(such as high alcohol intake) that may also influence the response to endotoxin. 
Gender differences
Sepsis is less prevalent and also has a better prognosis in females compared to males.69 In Chapter 
14a we have evaluated the effect of gender on the innate immune response. We found a more 
pronounced pro-inflammatory response in women compared with men, while a trend towards lower 
concentrations of anti-inflammatory IL-10 were found. Interestingly, the pro-inflammatory pattern 
in females, was not associated with increased endothelial injury reflected by the response of fore-
arm vessels to the intra-arterial administration of norepinephrine. On the contrary; the response to 
norepinephrine was preserved in females, while it was attenuated in males. The observed differences 
correspond to the clinical observation that women are less likely to develop bacterial sepsis,69,70 and 
that women have a better prognosis once sepsis has developed.71,72 Numerous animal experiments 
show that sex hormones exert immunomodulatory effects, with estrogen having a pro-inflammatory 
effect, while testosterone suppresses the inflammatory response.73,74 
Our findings were recently confirmed in another human endotoxemia study in which a low dose 
of endotoxin was administered (0.4 ng/kg), with the aim to study the endotoxin-associated visceral 
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and musculoskeletal hyperalgesia. Similar to our study, endotoxemia resulted in a more pronounced 
inflammatory response in females.75 However, two other human endotoxemia studies did not show 
a difference in the cytokine response following the administration of respectively 2 and 1 ng/kg E Coli 
endotoxine.76,77 In the first study, cytokine analyses were performed in a relatively small subset of 
participants and a trend toward higher IL-8 levels was observed in women. In the second study the 
authors did not account for timing relative to the menstrual cycle in women, which may account for the 
difference with our findings. However, as suggested by others, the effects of gender on inflammatory 
responses to endotoxin, may be confounded by many more factors other than sex hormones,78 and 
further studies are therefore of great importance. Regardless of the fact that the exact role of gender 
on the innate immune response still needs further investigation, it is clear that including both males 
and females in endotoxemia studies may introduce a higher variation in cytokine levels. Therefore, 
unless there is a specific need to include women in a trial, such as in a pharmaceutical phase 1 or 2a 
trial in which safety in men and women is a primary endpoint, we have not included women in our 
endotoxemia experiments ever since we found the effects described in Chapter 14a. 
In Chapter 14b we comment on an article describing  gender-based differences in patient 
outcome after severe trauma.79 Women were found to be more likely to die in the first days after 
trauma, but upon extended hospital stay, women had a higher survival rate than men, because of a 
lower incidence of sepsis. We suggest that this higher survival rate in women may be explained by 
differences in immunity, with a more pronounced innate immune response in females, resulting in 
more effective bacterial killing and clearance of septic foci and protection against secondary infections. 
Microvascular permeability and endothelial damage
Proper functioning of the endothelium during health and disease is essential for the regulation of 
oxygen transport, hemostasis, vasomotor control, osmotic balance, solute transport,  and immunity. 
Sepsis is associated with severe damage to the endothelium resulting in capillary leakage and shock. 
In Chapter 15 we investigated whether experimental human endotoxemia is also associated 
with increased microvascular permeability. Microvascular permeability was assessed before and 5 hrs 
after the administration of endotoxin or placebo using the transcapillary escape rate of I125-albumin, 
venous occlusion strain-gauge plethymography, and Bioelectrical Impedance Analysis. None of these 
methods showed a change in capillary permeability after endotoxin administration, rendering the 
human endotoxemia model not suitable to study microvascular permeability as observed during 
sepsis or acute systemic inflammation. Possibly, the insult of the single administration of a low dose 
of endotoxin was not sufficient to cause an increase in capillary permeability. However, as described 
in Chapter 16, plasma obtained during these experiments did trigger an increase in endothelial 
permeability in vitro using cultured monolayers of endothelial cells, suggesting that an increase in 
permeability would have occurred if endotoxemia subjects had been exposed to a more prolonged 
inflammatory insult. Therefore a continuous infusion of a low dose of endotoxin might better reflect 
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the clinical scenario. Another explanation might be that the methods we used to measure capillary 
permeability were not sensitive enough to detect a change in permeability during experimental human 
endotoxemia. Disruption of endothelial barrier integrity is central to the pathofysiology of sepsis,80 and 
mitigation of capillary leak is associated with improved survival in pre-clinical models.81 Therefore we 
suggest to investigate whether continuous infusion of endotoxin, rather than a bolus injection, induces 
capillary leakage in humans. If so, the human endotoxemia model could provide a means to study 
interventions targeted at permeability, which is, although central to the pathophysiology of sepsis, still 
a largely unstudied aspect.
Next to an increase in microvascular permeability, endothelial dysfunction characterized by 
hypotension and shock with a relative resistance to vasopressor therapy, is a hallmark of the clinical 
syndrome of sepsis. Previous studies of our group and others, have indicated that experimental 
human endotoxemia is also associated with endothelial dysfunction that is characterized by 
insensitivity to vasoactive medication.82,83 Endothelial function can be assessed in humans in vivo 
by measuring the vasodilatory or vasoconstrictive response of forearm vessels to the intra-brachial 
infusion of vasoactive medication using venous occlusion plethysmography. In Chapter 17, we have 
investigated whether endothelial dysfunction measured during experimental human endotoxemia is 
correlated to the plasma concentration of various inflammatory cytokines and markers of endothelial 
dysfunction. We found that the blunted response to acetylcholine after endotoxin administration  was 
significantly correlated to increase in plasma endocan levels. We therefore suggest that endocan could 
be a novel marker of endothelial dysfunction is inflammatory conditions like sepsis.
Pain threshold during endotoxemia
A well recognized feature of systemic inflammation is a decreased threshold for the perception 
of pain, resulting in hyperalgesia and allodynia. Although most healthcare workers are well aware 
of the magnitude of the clinical problem of pain, little is known about the exact pathofysiology of 
hyperalgesia. Next to inflammatory cytokines, iatrogenic causes can contribute to the development 
of hyperalgesia, as e.g. opiates that are frequently used in everyday practice can actually worsen 
hyperalgesia. Research into the possible mechanisms is hampered by the fact that a suitable 
human in vivo model is lacking. In Chapter 18 we have investigated whether experimental human 
endotoxemia is associated with a decrease in pain thresholds measured by quantitative sensory 
testing (QST), and possible correlations with plasma cytokines were evaluated. We showed that the 
threshold for pressure-, electrical stimulus- and cold-induced pain was lowered after endotoxin 
administration compared with controls. No correlation with plasma cytokine concentrations could 
be found. Besides the clear relation we show between inflammation and pain perception, this study 
shows that experimental human endotoxemia offers a valuable model to study inflammation-induced 
hyperalgesia that may facilitate development of new therapies aimed at modulating inflammation-
related pain perception.
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Limits of the model and future perspectives
The human experimental endotoxemia model offers the unique way to study numerous 
pathophysiological aspects of systemic inflammation in humans, and provides a model to investigate 
new (pharmacological) interventions during controlled systemic inflammation. However, the model also 
has its limitations. During experimental human endotoxemia a purified dead bacterial wall component 
is used, which is a pure TLR-4 agonist, while in patients, often several types of living bacteria are 
present, triggering various pattern recognition receptors. Furthermore, studies subjects are usually 
young, healthy and male, whereas patients are usually old, are of both sexes and mostly have several 
comorbidities and receive different kinds of medication and other forms of supportive care (e.g. renal 
replacement therapy, ventilation support). Finally, in patients there is in most cases a continuous 
exposure to molecular patterns triggering the immune response with an unknown time of onset, 
whereas during human endotoxemia a single bolus of LPS is administered at a defined time point. It 
may be argued that a single bolus of endotoxin administration is more suitable as a model of trauma 
or SIRS than as a model of sepsis (or septic shock). Models of continuous infusion of endotoxin for up 
to 4 hours have also been described 84,85 and probably resemble the clinical the pathophysiology of 
actual infection to a greater extent. A model of continuous endotoxin administration has very recently 
been developed within our department, and future studies may therefore utilize either a single bolus 
of endotoxin administration, or a continuous infusion of endotoxin for up to 4 hours, depending on 
the objective of the study. 
In conclusion, the experimental human endotoxemia model has facilitated the investigation 
of many immune modulatory interventions and (patho)physiological mechanisms that occur during 
systemic inflammation in a variety of disease states including sepsis. Although the model has several 
limitations, it offers a very valuable intermediate step to translate findings from animal studies to 
patients.
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IJzermetabolisme, hepcidine en inflammatie
IJzer is in grote hoeveelheden op aarde aanwezig. De kern van de aarde bestaat bijna volledig uit ijzer, 
maar ook 5 à 6 % van de aardkorst bestaat uit dit element. IJzer is een transitiemetaal, wat betekent 
dat een ijzeratoom gemakkelijk een electron kan opnemen op afstaan. Daarmee fungeert het als een 
belangrijke katalysator van talloze chemische reacties die organismen nodig hebben om te leven, 
zoals DNA replicatie, zuurstof transport en metabolisme, en immunologische reacties. IJzer vormt dus 
een belangrijk voedingselement voor vrijwel alle organismen, inclusief planten en dieren, maar ook 
voor ziektekiemen. IJzer is onmisbaar, maar tegelijkertijd gevaarlijk. Ten eerste kan ijzer oxidatieve 
stressreacties katalyseren, wat schade aan weefsel en organen tot gevolg kan hebben. Daarnaast 
kan ijzer de groei van micro-organismen bevorderen en daarmee dus een infectie veroorzaken of 
onderhouden. Daarom is praktisch al het ijzer in het lichaam gebonden aan specifieke eiwitten en 
wordt de concentratie van het  vrije ijzer in de bloedbaan extreem laag gehouden, in de orde van 10-18 
mol/L. Daarnaast worden de opname, het transport en de opslag van ijzer in het lichaam zeer precies 
gereguleerd. 
Eén van de belangrijkste hormonen in de ijzerhomeostase is hepcidine. Rond het jaar 2000 
werd hepcidine voor het eerst beschreven als defensine; een eiwit met anti-microbiële effecten. 
Echter, al snel bleek uit onderzoek bij muizen dat het ontbreken van het gen voor hepcidine leidt tot 
ernstige ijzerstapeling. Hepcidine bleek de centrale regulator te zijn van systemische ijzerhomeostase. 
Hepcidine wordt voornamelijk geproduceerd in de lever, en bindt aan het ijzerkanaaltje ferroportine, 
wat voornamelijk tot expressie wordt gebracht op de celmembraan van hepatocyten, duodenale 
darmcellen en macrofagen van het reticulo-endotheliale systeem. Het binden van hepcidine aan 
ferroportine leidt tot internalisatie en degradatie van ferroportine, waardoor er geen ijzer meer 
vanuit de cel naar het plasma getransporteerd kan worden. Een verhoogd hepcidine leidt dus tot 
een verminderde opname van ijzer uit de darm, en tot redistributie van ijzer in het lichaam van 
het bloed naar macrofagen van het reticulo-endotheliale systeem. Hoewel er vaak geen absoluut 
ijzertekort is, kan er toch te weinig ijzer via het bloed naar het beenmerg getransporteerd worden, 
waardoor er na verloop van tijd anemie (bloedarmoede) ontstaat. De productie van hepcidine in de 
lever wordt onderdrukt door ijzertekort, hypoxie en actieve erythropoëse, en wordt gestimuleerd 
door ijzer, en inflammatoire stimuli zoals endotoxine en pro-inflammatoire cytokines (b.v. IL-6,  TNFα 
en INF-γ). Tijdens systemische inflammatie kan er dus na verloop van tijd een anemie ontstaan, 
doordat er ten gevolge van de inflammatoire stimulus continu hepcidine wordt geproduceerd, 
waardoor ijzer zijn weg niet kan vinden naar het beenmerg. Daarbij is tijdens systemische inflammatie 
de erythrocytenproductie van het beenmerg als respons op erythropoëtine afgenomen en ook de 
erythropoëtineproductie zelf is afgenomen, waardoor de anemie wordt verergerd. Deze situatie wordt 
‘anemie van de chronische ziekte’ genoemd. Echter, omdat dit mechanisme ook bij acute systemische 
inflammatie een rol speelt bij de ontwikkeling van anemie is ‘anemie van inflammatie’ een betere term. 
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Anemie is één van de grote wereldwijde gezondheidsproblemen. Naar schatting 2 miljard mensen 
hebben een vorm van anemie. De meest voorkomende oorzaak is ijzerdeficiëntie. Anemie 
van inflammatie staat op nummer twee als oorzaak, en bij patiënten die in het ziekenhuis zijn 
opgenomen is het zelfs de meest voorkomende oorzaak van anemie. Dit leidt tot een hogere 
morbiditeit en mortaliteit en gaat gepaard met aanzienlijke kosten, bijvoorbeeld ten gevolge van 
een langere opnameduur in het ziekenhuis, frequentere noodzaak tot opname op de intensive care, 
bloedtransfusies, etc. Het nader onderzoeken van anemie van inflammatie, inclusief de ontwikkeling 
van nieuwe behandelmethoden, is derhalve van groot klinisch en maatschappelijk belang.
Interveniëren in het mechanisme van anemie van inflammatie, betekent in feite dat men het 
lage ijzergehalte in het bloed tijdens infectie of inflammatie zou willen tegengaan. Dit zou men 
bijvoorbeeld kunnen bewerkstelligen door intraveneus ijzer toe te dienen, of de effecten van hepcidine 
te blokkeren. Theoretisch zou dit echter tot problemen kunnen leiden, aangezien aangenomen 
wordt dat het ijzergehalte in het bloed doelbewust laag wordt gehouden om de uitgroei van micro-
organismen tijdens infectie te voorkomen, en de schade door oxidatieve stressreacties te beperken. 
Tal van experimenten in in vitro- en dier-studies laten daar aanwijzigen voor zien. Zo wordt het 
bacteriostatische effect van humaan plasma teniet gedaan door ijzer toe te voegen, en kan de 
verhoogde infectiegevoeligheid van muizen met ijzerstapeling worden tegengegaan met ijzerbinders. 
Muizen die worden blootgesteld aan systemische inflammatie door de injectie met endotoxine, laten 
meer oxidatieve stress en een hogere mortaliteit zien als er tegelijkertijd een ijzerpreparaat wordt 
toegediend, terwijl het omgekeerde het geval is wanneer een ijzerbinder wordt gegeven. Onderzoek 
bij mensen laat zien dat de ijzerstapelingsziekte hemochromatose, kan leiden tot een hogere kans op 
infectie. Ook is gerapporteerd dat ijzersuppletie bij kinderen in een gebied waar malaria endemisch 
is, kan leiden tot een hogere kans op sterfte. (Intraveneuze) ijzersuppletie ter correctie van anemie 
van inflammatie zou derhalve ongunstig kunnen zijn. Anderzijds laten de eerste onderzoeken met 
intraveneuze ijzertoediening tijdens chronische systemische inflammatie bij inflammatoire darmziekten 
of reumatoïde artritis geen toename zien van infecties. Er is dus duidelijk behoefte dit nader te 
onderzoeken. Echter, experimentele studies in mensen ontbraken tot dit proefschrift. Ten aanzien 
van het antagoneren van hepcidine zijn ook kanttekeningen te maken. Bij muizen zijn namelijk anti-
inflammatoire effecten van hepcidine beschreven. Het antagoneren van hepcidine als behandeling 
van anemie van inflammatie zou theoretisch dus de onderliggende inflammatoire ziekte kunnen 
verergeren. Ook hier ontbraken de nodige experimentele studies.
Met behulp van het experimentele humane endotoxinemie model, hebben we deze vragen 
nader onderzocht. Dit model bestaat eruit dat gezonde vrijwilligers  een lage dosis endotoxine, een 
gezuiverd bestanddeel uit de membraan van Escherichia Coli bacteriën, intraveneus krijgen ingespoten. 
Hier reageert het lichaam op met een sterke kortdurende inflammatoire respons die gekenmerkt 
wordt door klinische, biochemische en vasculaire effecten die vergelijkbaar zijn met sepsis. Het model 
is voortgevloeid uit koorts-inducerende therapieën die anderhalve eeuw geleden (met wisselend 
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succes) werden gebruikt om diverse ziekten te behandelen. In de jaren 40 van vorige eeuw werd 
ontdekt dat het de endotoxine van de gebruikte bacteriële preparaten was die de sterke systemische 
ontstekingsrespons teweeg bracht, en leidde later tot de productie van één gestandaardiseerde batch 
E. Coli endotoxine, die wereldwijd gebruikt wordt om humane endotoxinestudies mee te doen. Het 
model van experimentele humane endotoxinemie wordt sinds 2003 ook in het Radboudumc gebruikt. 
Wij hebben het model aangewend om in deel 1 van dit proefschrift de volgende onderzoeksvragen te 
beantwoorden.
1)  Heeft ijzersuppletie of ijzerchelatie een direct effect op de aangeboren immuunrespons bij 
mensen?
2) Heeft hepcidine een direct effect op de aangeboren immuunrespons?
3) Is hepcidine geassocieerd met de ontwikkeling van anemie bij sepsispatiënten?
4)  Kan hepcidine farmacologisch worden geantagoneerd tijdens acute systemische 
inflammatie?
In deel twee van het proefschrift worden diverse methodologische aspecten van het experimentele 
humane endotoxinemie model behandeld. 
Deel 1: IJzermetabolisme en de aangeboren 
immuunrespons
Na een algehele introductie van het proefschrift in hoofdstuk 1, worden in hoofdstuk 2 enerzijds de 
effecten van het immuunsysteem op de ijzerhomeostase beschreven, en anderzijds de effecten van 
ijzer op het immuunsysteem. De ijzervoorraad in het lichaam (± 40-50 mg/kg lichaamsgewicht) bevindt 
zich voor het grootste deel in erythocyten waar het gebonden is aan haem. Daarnaast bevindt zich 
een deel van het ijzer in het beenmerg (300-500 mg) en een deel in de lever en macrophagen van 
het reticulo-endotheliale systeem (RES) (± 500 mg). Niet meer dan 0.1 % van het ijzer bevindt zich in 
het plasma, waar het hoofdzakelijk gebonden is aan de ijzertransporter transferrine. Per dag wordt 
normaliter slechts 1 tot 2 mg per dag aan ijzer opgenomen uit de darm. Een veel groter deel, 20 tot 
25 mg per dag, wordt gerecycled uit verouderde rode bloedcellen, die worden gefagocyteerd in het 
RES. Het ijzer uit deze erythrocyten wordt tijdelijk opgeslagen in het RES in de vorm van ferritine, en 
wordt als via ferroportine weer naar het plasma getransporteerd wanneer daar behoefte aan is. Het 
vrijkomen van ijzer uit duodenale enterocyten en macrophagen van het RES wordt gereguleerd door 
hepcidine. Zoals al eerder beschreven bindt hepcidine aan ferroportine en zorgt voor de destructie 
van dit ijzerkanaaltje, waardoor er geen ijzer-efflux uit de cellen meer mogelijk is. In hoofdstuk 2 
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wordt dieper ingegaan op de manieren waarop hepcidineproductie in de lever wordt gestimuleerd 
of juist geremd. De belangrijkste stimuli voor hepcidineproductie zijn de lichaamsijzervoorraad (en 
zorgt daarmee dus voor negatieve terugkoppeling) en inflammatie. De belangrijkste onderdrukkers 
van hepcidineproductie zijn erythropoëse en hypoxie. Als, tengevolge van inflammatie, de 
hepcidineproductie langer verhoogd blijft, ontstaat er derhalve een functioneel ijzertekort. Samen met 
een verminderde erythropoëtine (EPO)-productie en onderdrukte respons op EPO in het beenmerg 
leidt dit tot anemie van inflammatie. Dat het verlagen van plasma-ijzer tijdens inflammatie of infectie 
evolutionair gezien een extra verdediging is tegen micro-organismen wordt aannemelijk gemaakt aan 
de hand van een aantal voorbeelden. Bacteriën en schimmels hebben diverse manieren ontwikkeld 
om in hun gastheer, waar het beschikbare ijzer dus zo laag mogelijk wordt gehouden, toch aan ijzer 
te komen zoals het produceren van siderophoren, een soort sterke ijzerchelatoren die ijzer kunnen 
afvangen van transferrine ten behoeve van het pathogeen. Het zou dus van nut kunnen zijn dat de 
inflammatoire respons van de gastheer, door inductie van hepcidine, het ijzer in het plasma nog 
lager maakt. In het geval van intracellulaire pathogenen vindt echter juist het omgekeerde plaats; 
upregulatie van ferroportine in de geïnfecteerde cel, leidt tot verlaging van het intracellulaire ijzer 
en vormt daarmee een extra vorm van aangeboren immuniteit. Tot slot wordt dieper ingegaan op 
anemie bij patiënten met sepsis, waar anemie zeer frequent voorkomt. Mogelijkerwijs is er een rol 
voor intraveneus ijzer of anti-hepcidine bij de behandeling van anemie bij patiënten met systemische 
inflammatie op de intensive care, maar dit moet nader onderzocht worden, aangezien een verhoging 
van het plasma ijzer mogelijk het beloop van de infectie of oxidatieve stress kan verergeren. De tot nu 
toe beschikbare data uit patiëntenstudies zijn echter hoopgevend te noemen.
In hoofdstuk 3 wordt het effect van een ijzertoediening of ijzerchelatie op de aangeboren 
immuunrespons bij de mens beschreven. Hiertoe werden 30 gezonde mannelijke vrijwilligers 
geïncludeerd, die ofwel een intraveneuze bolusinjectie met ijzersucrose (venofer 1.25 m/kg), of een 
orale toediening van een ijzerchelator (deferasirox 30 mg/kg), of placebo kregen toegediend. Al deze 
vrijwilligers ondergingen na deze toedieningen experimentele humane endotoxinemie. Intraveneuze 
ijzertoediening leidde wel tot een toename in malondialdehyde als maat voor oxidatieve stress, 
maar niet tot een verandering van de cytokinerespons ten gevolgde van endotoxinetoediening. Ook 
ijzerchelatie had geen immunomodulerend effect. Tevens was er geen effect te zien van ijzer of 
ijzerchelatie op de endotoxine-geïnduceerde vasculaire schade en subklinische nierschade. Echter, in 
een subgroep van proefpersonen waar het ‘labiele plasma ijzer’ (LPI) korte tijd verhoogd was werd wel 
een verminderde vasculaire response op noradrenaline gevonden na endotoxine toediening, terwijl 
dit niet het geval was bij diegenen die geen verhoogd LPI hadden. LPI was met name verhoogd bij 
proefpersonen met een transferrineverzadiging van boven de 90%. Derhalve concluderen we dat een 
eenmalige dosis van intraveneus ijzer de aangeboren immuunrespons niet beïnvloedt, maar dat het 
wel de vasculaire schade zou kunnen verergeren als er LPI gevormd wordt tijdens acute systemische 
inflammatie.  
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Net zoals van ijzer, is er ook van hepcidine in dierexperimenteel onderzoek beschreven dat het directe 
immunomodulerende effecten zou kunnen hebben. Dit is relevant in het licht van de ontwikkeling 
van nieuwe therapieën voor anemie van inflammatie die gericht zijn tegen hepcidine. Theoretisch zou 
je met een anti-hepcidine therapie de onderliggende inflammatoire aandoening kunnen verergeren, 
door het anti-inflammatoire effect van hepcidine weg te nemen. Echter, er zijn maar weinig studies 
waarin het veronderderstelde immunomudulerende effect van hepcidine is aangetoond. Bovendien 
is één van deze studies in een kwaad daglicht komen te staan door een vermoeden van fraude. In 
hoofdstuk 4 hebben we op drie manieren het mogelijke immunomodulerende effect van hepcidine 
onderzocht. Ten eerste werden muizen ingespoten met hepcidine (of placebo) voorafgaand aan een 
injectie met endotoxine (of placebo), waarna we keken naar de cytokineproductie 90 minuten na 
endotoxine toediening. Ten tweede werd bloed van gezonde vrijwilligers geïncubeerd met hepcidine 
in een concentratierange van 0 tot 500 nM. Eén uur later werd endotoxine toegevoegd en een dag 
later werd de cytokineproductie gemeten. Ten derde hebben we gedurende 3 weken op verschillende 
tijdstippen gekeken naar de ex vivo cytokineproductie van bloed van gezonde vrijwilligers, van wie het 
hepcidine werd onderdrukt door 500 ml bloed af te nemen. Met geen van de drie methoden werd 
een immunomodulerend effect van hepcidine gevonden. Deze bevindingen bevestigen niet dat anti-
hepcidine therapieën systemische inflammatie mogelijk zouden kunnen verergeren, en geven dus 
groen licht met betrekking tot de toediening van dergelijke therapieën aan patiënten.
Inflammatie is een sterke stimulus voor hepcidineproductie. Met name van IL-6 is beschreven 
dat het de hepcidineproductie stimuleert. Het meeste onderzoek is gedaan bij patiënten met een 
chronische inflammatoire ziekte. In hoofdstuk 5 werd onderzocht of er ook een relatie is tussen 
inflammatie, hepcidineproductie en het ontwikkelen van een anemie bij patiënten met een acute 
systemische inflammatoire aandoening, namelijk sepsis. Van 92 patiënten die in het ziekenhuis werden 
opgenomen met sepsis, werd op de eerste 3 dagen van opname plasma concentraties van hepcidine 
en IL-6 gemeten. Tevens werd het verloop van het hemoglobinegehalte gedurende de eerste twee 
weken na opname in kaart gebracht. Vervolgens hebben we gekeken of er een correlatie was tussen 
IL-6 en hepcidineconcentraties, en ook of er een correlatie was tussen hepcidineconcentraties en 
het verloop in hemoglobine. We vonden dat IL-6 correleerde met hepcidineconcentraties, en dat 
ziekere patiënten een hogere hepcidineconcentratie hadden. De toegenomen hepcidineconcentratie 
correleerde met de afname in hemoglobinegehalte, en patiënten met een hoger hepcidine leken vaker 
en bloedtransfusie nodig te hebben. We denken op grond van deze data dat ook bij sepsispatiënten 
acute inflammatie-geïnduceerde hepcidineproductie bijdraagt aan de ontwikkeling van anemie.
Aangezien anemie van inflammatie veel voorkomt en een grote maatschappelijke impact 
heeft, zijn er tal van onderzoeksgroepen bezig met het ontwikkelen van een therapie om het 
pathofysiologische mechanisme van inflammatie-geïnduceerde hepcidineproductie te antagoneren. 
Een van de manieren om dit te doen is door middel van het nieuwe geneesmiddel NOX-H94 
(lexaptepid pegol). NOX-H94 is een synthetisch ‘spiegelbeeld’ L-oligoribonucleatide, een zogenaamd 
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‘Spiegelmeer’, dat met hoge affiniteit aan hepcidine bindt en het daarmee inactiveert. In hoofdstuk 6 
hebben we in vitro aangetoond dat binding van NOX-H94 aan hepcidine inderdaad leidt tot remming 
van hepcidine-geïnduceerde ferroportine-degradatie en ferritine-expressie. Tevens hebben we, 
gebruik makend van een in vivo model met makaken, aangetoond dat IL-6-geïnduceerde hypoferremie 
en anemie inderdaad te remmen is door toediening van NOX-H94. Op basis van dit hoofdstuk 
concluderen we dat NOX-H94 mogelijk een nieuwe therapie is voor de behandeling van anemie van 
inflammatie.
Voordat NOX-H94 ook daadwerkelijk bij patiënten getest kon worden, was het eerst nodig 
om bij gezonde vrijwilligers aan te tonen dat NOX-H94 effectief was. Het experimentele humane 
endotoxinemie model leent zich bij uitstek om deze vraag te beantwoorden, vanwege de mogelijkheid 
om een gecontroleerde inflammatoire stimulus toe te dienen bij mensen zonder co-morbiditeit, 
waarvan eerder is aangetoond dat dit gepaard gaat met inflammatie-geïnduceerde hepcidineproductie 
en hypoferremie. In hoofdstuk 7a wordt een gerandomiseerde, dubbelblinde, placebo-gecontroleerde 
studie beschreven, waarin we systemische inflammatie induceerden bij 24 gezonde vrijwilligers 
door gebruik te maken van het experimentele humane endotoxinemie model. Dertig minuten 
na endotoxinetoediening werd het middel lexaptepid (of placebo) toegediend. Negen uur na 
endotoxinetoediening was er een duidelijk en zeer significant verschil tussen de behandelgroepen 
te zien: In de lexaptepid-behandelde groep was het serum ijzergehalte toegenomen ten opzicht 
van baseline, terwijl het sterk was afgenomen in de placebogroep. Dit was de eerste studie waarin 
hepcidine farmacologisch werd geantagoneerd tijdens systemische inflammatie in vivo bij de mens. 
Deze studie toont voor het eerst aan dat hepcidine inderdaad op een klinische relevante manier 
geantagoneerd kan worden, en heeft de weg geopend voor studies bij patiënten, die momenteel 
worden verricht.
In hoofdstuk 7b suggereren we dat het antagoneren van hepcidin ook een aanvullende 
therapie zou kunnen zijn voor de behandeling van anemie bij traumapatienten of patiënten die grote 
chirurgische ingrepen hebben ondergaan.
Bij patiënten met acute ernstige inflammatie, zoals tijdens sepsis, kunnen er tegelijkertijd 
conflicterende signalen zijn met betrekking tot hepcidineproductie. Enerzijds wordt hepcidineproductie 
door inflammatie gestimuleerd, anderzijds kan er bijvoorbeeld in het geval van septische shock sprake 
zijn van weefselhypoxie, hetgeen hepcidineproductie juist onderdrukt. In hoofdstuk 8 hebben we 
gekeken of hypoxie inderdaad inflammatie-geïnduceerde hepcidineproductie  beïnvloedt. Bij gezonde 
vrijwilligers werd gedurende 3,5 uur een staat van hypoxie geïnduceerd door een speciaal daartoe 
ontwikkelde helm op de zetten, waarin we de fractie inspiratoire zuurstof (FiO2) konden titreren tot 
een gewenst niveau. In de interventiegroep werd de FiO2 zo ingesteld dat de zuurstofsaturatie bij de 
proefpersonen daalde tot 80-85%. De controlegroep ademde normale buitenlucht. Een uur na het 
initiëren van deze zuurstofstatus, werd een systemische inflammatoire response geïnduceerd door 
toediening van endotoxine. In de daarop volgende uren werden plasmacontentraties gemeten van 
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erytropoëtine, cytokines, hepcidine en ijzer. Hypoxie leidde tot een significant lagere pro-inflammatoire 
respons, terwijl het anti-inflammatoire IL-10 juist een hogere trend liet zien in de interventiegroep. 
Er was echter geen verschil te zien in hepcidine- en ijzerconcentraties tussen de groepen. We 
concluderen dat tijdens acute inflammatie de inflammatoire stimulus die leidt tot hepcidineproductie 
sterker is dan de hepcidine-onderdrukkende stimulus door hypoxie. Deze bevindingen zijn met name 
van belang voor intensive care-patiënten, die gedurende de systemische inflammatie dus waarschijnlijk 
niet in staat zijn om hepcidine te onderdrukken in geval van hypoxie. Daardoor lopen ze meer risico 
om de negatieve gevolgen te ondervinden van anemie van inflammatie.
In hoofdstuk 9 wordt de anemie van inflammatie nader onderzocht vanuit het perspectief van de 
erytrocyt. Tijdens acute systemische inflammatie zoals sepsis neemt de vervormbaarheid van erytrocyten 
af. Dit draagt bij aan verslechtering van de microcirculatie, hetgeen op zijn beurt leidt tot een slechtere 
prognose voor de patiënt met sepsis. Tevens leidt de verandering van membraaneigenschappen van de 
erytrocyten tot een versnelde klaring van erytrocyten uit de bloedbaan door de milt, wat bijdraagt aan de 
ontwikkeling van anemie in deze patiëntengroep. De lipidencompositie van de erythrocytenmembraan 
is van belang van voor de structuur van de membraan. Fosfatidylcholine (PC) en sfingomyeline (SM) 
zijn twee belangrijke fosfolipiden op de buitenmembraan van de erythrocyt. We hebben onderzocht 
of deze membraan-lipidencompositie verandert door een verandering van lipidenmetabolisme in 
de circulatie van septische patiënten. Erythrocyten van gezonde O-negatieve bloeddonoren werd 
geïncubeerd met plasma van patiënten met septische shock, of plasma van gezonde vrijwilligers die 
deelnamen aan een humaan endotoxine experiment. Plasma van septische shockpatiënten veroorzaakte 
een verhoogde hydrolyse van PC tot lyso-PC (LPC) en een toename van fosfatidylserine-expositie 
op de erytrocytenmembraan. De verhoogde LPC-formatie kon niet toegeschreven worden aan  het 
onderzochte secretoire fosfoslipase A2 IIA. Experimentele endotoxinemie leidde wel tot een verhoogde 
expositie van fosfatidylserine expositie op erythrocyten, maar niet tot een toename van LPC-vorming. De 
rol van membraanlipiden-metabolisme bij de verhoogde klaring van erythrocyten tijdens sepsis moet nog 
nader worden onderzocht.
In hoofdstuk 10 wordt een opmerkelijke casus beschreven van een jonge Turkse patiënte 
die geanalyseerd werd voor haar anemie, die ze al sinds jonge leeftijd had gehad. We vonden 
middels genetisch onderzoek twee mutaties in het gen coderend voor matriptase, wat bij de 
patiënte resulteerde matriptasedeficientie. Dit leidt tot een continue inadequaat verhoogde 
hepcidineproductie, waardoor er te weinig ijzer kan worden opgenomen uit de darm en er een 
ijzergebreksanemie ontstaat. Dit ziektebeeld staat bekend als ‘iron refractory iron deficiency anemia’ 
(IRIDA), hetgeen zoveel betekent als een anemie op basis van ijzer-deficientie die niet reageert op 
orale ijzersuppletie. De behandeling bestaat uit intraveneuze ijzertoediening en deze patiënte werd 
ook zo behandeld. Opmerkelijk was dat zij blond haar had (een relatief lichte kleur voor iemand van 
Turkse afkomst), wat donker begon te kleuren nadat de intraveneuze ijzertherapie was begonnen. Dit 
was nooit eerder beschreven. In relatie tot dit proefschrift is meldenswaardig dat ze geen abnormale 
anamnese had voor wat betreft (het beloop van) infectieziekten. 
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De antwoorden op de onderzoeksvragen gesteld in de introductie van het proefschrift zijn als volgt: 
1)  We hebben geen bewijs gevonden voor een effect van ijzer of ijzerchelatie op de 
aangeboren systemische inflammatoire respons bij de mens. Derhalve zou de mogelijkheid 
van intraveneuze ijzersuppletie verder onderzocht moeten worden als aanvullende therapie 
tegen anemie tijdens (acute) systemische inflammatie.  
2)  Tevens hebben we geen immunomodulerend effect kunnen aantonen van hepcidine in 
drie verschillende experimenten. Bovendien leidde het antagoneren van hepcidine tijdens 
endotoxinemie bij gezonde vrijwilligers niet tot een verandering van de inflammatoire 
respons. Het veronderstelde immunomodulerende effect van hepcidine lijkt niet van belang 
te zijn tijdens acute systemische inflammatie bij de mens. Dat betekent dat het antagoneren 
van hepcidine als nieuwe therapie ter bestrijding van anemie van inflammatie veilig kan 
gebeuren, zonder te hoeven vrezen voor verergering van de onderliggende inflammatoire 
aandoening. 
3)  Inflammatie-geïnduceerde hepcidineproductie is inderdaad geassocieerd met de 
ontwikkeling van anemie bij sepsispatiënten. Interveniëren in de inflammatie-hepcidine-
anemie pathway zou van nut kunnen zijn ter bestrijding van anemie bij deze patiëntengroep, 
waar anemie zeer frequent voorkomt.
4)  Hepcidine kan inderdaad farmacologisch worden geantagoneerd tijdens acute systemische 
inflammatie. Het feit dat dit mogelijk is, toont aan dat therapieën die gericht zijn tegen de 
werking van hepcidine, zinvol zouden kunnen zijn ter bestrijding van anemie van inflammatie. 
Momenteel worden er studies bij patiënten gedaan die dit verder onderzoeken. 
In de nabije toekomst zullen er verdere onderzoeken verricht moeten worden naar therapiën 
voor anemie van inflammatie. Met name voor kritisch zieke patiënten zijn conventionele therapiën 
zoals ijzersuppletie, erytropoese stimulerende middelen of bloedtransfusie ineffectief gebleken. 
Nieuwe therapiën gericht tegen hepcidin (zoals lexaptepid), of middelen die upstream werken van 
hepcidin, zoals HIF-prolyl hydroxylase inhibitors, zijn thans in ontwikkeling en worden getest in 
patiënten. Toekomstig onderzoek zal moeten uitwijzen wat de optimale behandeling is voor anemie 
van inflammatie. Mogelijkerwijs is een combinatie van therapiën het meest effectief, waarbij aan 
de ene kant het effect van hepcidin direct of indirect wordt geremd, terwijl aan de andere kant de 
erythropoiese wordt gestimuleerd.    
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Deel 2: Methodologische overwegingen
Het experimentele humane endotoxinemie model wordt beschouwd als een geaccepteerd en veilig 
in vivo model van systemische inflammatie. Het gaat gepaard met griepachtige verschijnselen, en 
biochemische en vasculaire effecten die vergelijkbaar zijn met sepsis. Dit model wordt al ruim 40 
jaar lang op min of meer dezelfde manier toegepast, waarbij nooit ernstige bijwerkingen waren 
beschreven. In hoofdstuk 11 worden een viertal proefpersonen beschreven waarbij een ernstige 
bradycardie of asystolie optrad na toediening van endotoxine. Twee van de beschreven casus vonden 
plaats tijdens onze eigen experimenten, en twee andere casus werden daaraan toegevoegd na 
overleg met internationale experts op het gebied van endotoxine-onderzoeken. We concludeerden 
dat de bradycardiën mogelijk het gevolg waren van een combinatie van de effecten van endotoxine 
in combinatie met relatieve ondervulling van de proefpersonen. Derhalve hebben we naar aanleiding 
van deze reacties het onderzoeksprotocol aangepast en worden proefpersonen sindsdien standaard 
ge-prehydreerd voorafgaand aan toediening van endotoxine. Mits bepaalde monitoringsmaatregelen 
in acht worden genomen blijven wij van mening dat het experimentele humane endotoxinemodel een 
veilig model is. 
Nadat we naar aanleiding van bovenstaande casus het protocol hadden aangepast en de 
proefpersonen standaard zijn gaan pre-hydreren, bleek dat de pre-hydratie op zichzelf een anti-
inflammatoir effect had. Dit is beschreven in hoofdstuk 12. Zowel de ziekteverschijnselen bij de 
proefpersonen, als de pro-inflammatoire cytokinerespons waren veel minder uitgesproken bij de 
proefpersonen die van tevoren waren geprehydreerd, terwijl de respons van het anti-inflammatoire 
cytokine IL-10 intact bleef. De hemodynamische veranderingen na endotoxinetoediening waren 
vergelijkbaar in beide groepen. 
In hoofdstuk 13 werd onderzocht of de body mass index (BMI) van de proefpersonen 
samenhangt met de aangeboren immuunrespons tijdens experimentele humane endotoxinemie. 
Bij patiënten op de intensive care is een hoge BMI geassocieerd met een lagere betere overleving. 
Wij vroegen ons af of dit mogelijk te verklaren zou kunnen zijn vanuit een verandering van de 
inflammatoire respons door een hoog BMI. Samples van 7 verschillende endotoxinestudies werden 
opnieuw geanalyseerd en er werd gekeken of er een relatie was tussen het BMI van de proefpersonen 
en de cytokinerespons tijdens experimentele endotoxinemie. Een dergelijke correlatie werd echter 
voor geen van de cytokines gevonden. Het is dus de vraag of de verschillen die bij patiënten werden 
geobserveerd te verklaren zijn vanuit een relatie tussen BMI en de acute inflammatoire reactie in 
kritisch zieke patiënten. Onze data suggereren van niet, maar omdat het aantal proefpersonen met 
een sterk verhoogde BMI klein was, moeten we een slag om de arm houden.  
In de eerste serie experimenten met humane endotoxinemie vonden we belangrijke 
verschillen in de inflammatoire respons tussen mannen en vrouwen. Dit staat beschreven in 
hoofdstuk 14a. De inflammatoire respons op endotoxine werd onderzocht bij 15 mannen en 15 
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vrouwen. Vrouwen lieten een meer uitgesproken pro-inflammatoire respons zien dan mannen, 
geïllustreerd door een hoger CRP, een meer uitgesproken leukopenie en een hogere stijging van 
pro-inflammatoire cytokines. Concentraties van het anti-inflammatoire cytokine IL-10 was niet 
statistisch verschillend. Lipopolysaccharide-bindend eiwit (LPB) was hoger in vrouwen voorafgaand 
aan endotoxinetoediening en liet ook een sterkere stijging zien na endotoxinetoediening. LBP 
faciliteert de binding van endotoxine aan Toll-like receptor 4 (TLR-4), en de hogere concentratie zou 
wellicht een deel van de verklaring kunnen zijn van de meer uitgesproken inflammatoire respons bij 
vrouwen. De bloeddrukdaling na endotoxinetoediening was ook meer uitgesproken bij vrouwen en 
endotoxinetoediening leidde bij mannen wel tot een afgenomen gevoeligheid van de vasculatuur 
voor noradrenaline, terwijl er bij vrouwen geen verschil werd gevonden na endotoxinetoediening ten 
opzichte van baseline. Ook in de incidentie en het beloop van sepsis zijn er in de literatuur verschillen 
gerapporteerd ten faveure van vrouwen. Wellicht spelen hormonale verschillen hierin een belangrijke 
rol. Voor onze onderzoeksgroep hebben deze verschillen er in elk geval toe geleid dat we alleen nog 
mannen includeren in onze endotoxine onderzoeken om de variabiliteit te beperken.
In hoofdstuk 14b reageren we op een artikel waarin een betere overleving wordt gerapporteerd 
van vrouwen ten opzichte van mannen na een trauma. Direct na het trauma gaan vrouwen vaker 
dood, maar als de ziekenhuis opname langer duurt doen vrouwen het beter. We suggeren we dat de 
hogere overleving van vrouwen in deze fase verklaard zou kunnen worden uit geslachtsverschillen in 
de immuunrespons, waardoor vrouwen beter in staat zijn pathogenen te klaren en daardoor minder 
kans hebben op het optreden van opportunistische infecties.
In hoofdstuk 15 wordt het effect van experimentele endotoxinemie op de microvasculaire 
permeabiliteit beschreven. Toename van de capillaire permeabiliteit staat centraal in de pathogenese 
van septische shock. Onderzocht werd of toename van microvasculaire permeabiliteit ook optrad 
tijdens experimentele humane endotoxinemie. Daartoe werd zowel vóór, als 5 uur na toediening 
van endotoxine de microvasculaire permeabiliteit gemeten met een drietal methoden, te weten; 1) 
de transcapillaire verdwijning van I125-gelabeld albumine,  2) veneuze occlusie plethysmografie en 
3) bio-elektrische impedantie analyse. Met geen van de toegepaste technieken werd toename van 
capillaire permeabiliteit aangetoond. Wellicht is het insult van eenmalige endotoxinetoediening te 
mild of te kortdurend om een toename van permeabiliteit te bewerkstelligen. Het experimentele 
humane endotoxinemie model is derhalve in zijn huidige vorm geen geschikt model om de toename in 
permeabiliteit tijdens sepsis en septische shock te onderzoeken. Echter, in hoofdstuk 16 beschrijven 
we dat plasma wat afgenomen is tijdens experimentele endotoxinemie, in vitro wel leidt tot een 
verhoogde permeabiliteit van gekweekte endotheelcellen. Dit suggereert dat er mogelijk wel een 
toename van microvasculaire permeabiliteit in vivo zou kunnen optreden tijdens endotoxinemie als 
het insult langer zou duren, bijvoorbeeld in een model waarbij endotoxine als continue infusie wordt 
toegediend.
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Naast een toename van microvasculaire permeabiliteit, is er bij kritisch zieke patiënten vaak sprake 
van endotheeldysfunctie, die onder andere gekenmerkt wordt door ongevoeligheid voor vasoactieve 
medicatie. Tijdens experimentele humane endotoxinemie is er ook sprake van een dergelijke 
endotheeldysfunctie die gemeten kan worden door de respons van de bloedvaten in de onderarm 
te meten als reactie op de intra-arteriele toediening van vasoactieve medicamenten. In hoofdstuk 
17 wordt beschreven dat de mate van endotheeldysfunctie na endotoxinetoediening, gecorreleerd 
is aan de stijging in plasmaspiegels van endocan. Endocan zou derhalve mogelijk kunnen dienen als 
biomarker van endotheelschade. 
In hoofdstuk 18 wordt het effect van endotoxine toediening op de pijndrempel onderzocht. 
Bij vrijwilligers werd vóór, en enkele uren na endotoxine toediening met behulp van drie 
gestandaardiseerde methoden de pijndrempel gemeten. De pijndrempel bleek significant afgenomen 
te zijn in vergelijking met een controle groep die geen endotoxine kreeg toegediend. Er kon geen 
correlatie worden gevonden met plasma cytokines. 
Het experimentele humane endotoxinemie model biedt de unieke mogelijkheid om bij de mens in vivo 
talloze pathofysiologische aspecten van systemische inflammatie te onderzoeken en (farmacologische) 
interventies tijdens systemische inflammatie te testen. Beperkingen van het model zijn gelegen in het 
feit dat de proefpersonen doorgaans jonge, gezonde mannen zijn, terwijl patiënten doorgaans oudere 
mensen van beide geslachten zijn met diverse co-morbiditeiten waar ze vaak diverse behandelingen 
voor krijgen. Bovendien is de eenmalige toediening van een lage dosis gezuiverd E. Coli endotoxine 
zeer anders dan de continue expositie aan talloze pathogene en inflammatoire mediatoren zoals bij 
patiënten met een infectie het geval is. Een continue toediening van endotoxine is wellicht een klinisch 
relevanter model van infectie, en derhalve is er op de afdeling intensive care van het Radboudumc 
een model met continue toediening van endotoxine ontwikkeld en is recent de eerste trial met dit 
aangepast protocol succesvol uitgevoerd. 
Concluderend is het experimentele humane endotoxinemie model een prachtig humaan in 
vivo model om (patho)fysiologische mechanismen te onderzoeken die optreden tijdens systemische 
inflammatie in het kader van diverse ziektebeelden, waaronder sepsis. Hoewel het model 
enkele belangrijke beperkingen kent, biedt het een waardevolle tussenstap tussen resultaten uit 
dierexperimenteel onderzoek en klinisch onderzoek bij patiënten.
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Promotor, internationale ijzergrootheid, kritisch luisteraar, wandelende bibliotheek en vraagbaak
Dorine Swinkels
Copromotor, collega en leidinggevende, getalenteerd onderzoeker, met goed gevoel voor statistiek en 
waarheidsvinding, schrijver, amateur historicus, reisgenoot, mede-avonturier, vriend
Matthijs Kox
Leidinggevenden van afdeling Intensive Care, bouwers en managers van een geweldige afdeling
Hans van der Hoeven en Anne-Miek Broods
Bron van inspiratie, creëerder van kansen 
Paul Smits
Collega (ex-)promovendi van de afdeling Intensive Care, brainstormers en denktank van de research IC, 
mede-borrelaars en kroeggenoten, lotgenoten, klankborden, sparringpartners, helpende handen en 
redders in nood
Bart Ramakers, Suzanne Heemskerk, Mirrin Dorresteijn, Benno Lansdorp, Rebecca Koch, Mark 
van den Boogaard, Jenneke Leentjens, Linda Hamers, Dorien Kiers, Lisanne Roesthuis, Jonne 
Doorduin, Paul Rood, Guus Leijte, Jelle Zwaag, Roger van Groenendael, Annelies Wassenaar, Lex 
van Loon, Eline Oppersma, Quirine Habes, Roel Stolk, Christopher Geven en Marloes Witjes
met in het bijzonder mijn kamergenoten
Kim Timmermans en Esther Peters
Alle researchverpleegkundigen die in de loop der jaren betrokken zijn (geweest) bij het onderzoek op 
de Intensive care, steunpilaren van vrijwel alle trials op onze afdeling 
met in het bijzonder
Marieke van der A, Chantal Luijten, Hellen van Wezel, Aarnout Jansen van Rosendaal, 
Hetty van der Eng en Tijn Bouw (mede-oprichter en lange tijd hoofd van de research IC)
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Analisten
Rian Roelofs, Siem Klaver, Coby Laarakkers, Trees Jansen, Hennie Roelofs en Faustin Mbuyi 
met in het bijzonder
Jelle Gerretsen
Biotechnici 
Ilona van den Brink en Francien van de Pol
Studenten / stagiaires, steun en toeverlaten 
Susanne van Wijk, Sanne van Lith, Els Rengers, Rob van der Pluijm, Joanne van den Wildenberg, 
Tim Verhaak, Ebru Çevik, Aaron John en Karin Dautzenberg
Alle mede-onderzoekers en mede-auteurs (zie individuele hoofdstukken)
Alle artsen van de afdeling Intensive Care van het Radboudumc
Alle verpleegkundigen van de afdeling Intensive Care van het Radboudumc
Alle proefpersonen die hebben deelgenomen aan de experimenten
Secretariële ondersteuning
Rachel Quibell, Jennie Wegh, Sjoukje van Wanroij en Nelly Gerrits 
met in het bijzonder 
Yvonne Kaspers
Onafhankelijk arts bij alle humane experimenten
Alexander Rennings
Afdelingen Anesthesiologie van het Bernhoven Ziekenhuis en het Radboudumc 
met in het bijzonder
Dr. Braak, Hester Hoogenboom, Prof. dr. Scheffer, Christiaan Keijzer, Frans ten Have en 
Monique de Groot
Alle mede-AIOS Anesthesiologie van het Radboudumc
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Sponsoren
ZonMw en NOXXON pharma AG 
met in het bijzonder 
Frank Schwoebel, Kai Riecke en Luciana Summo
Mijn (studie-)vrienden, met in het bijzonder 
Marc Awater, Martijn van der Eijk, Karen Cnossen, Berry Brinke, 
Maartje de Hosson, Carlijn Hooijmans, Ine Delemarre, Lianne Wennekes, 
Janske Rohof en Sven Dinslage (tevens ontwerper van kaft en binnenwerk)
Mijn familie en schoonfamilie, met in het bijzonder mijn ouders en zussen
Theo & Ans van Eijk, Roos van Eijk en Marijke van Eijk
Mijn grote liefdes
Sanne Kroft (tevens ex-proefpersoon) en Thijmen & Hugo van Eijk
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Curriculum Vitae
Curriculum Vitae
Lucas van Eijk werd geboren op 31 januari 1980 in ’s-Hertogenbosch. Na het behalen van zijn VWO-
diploma en het maken van een reis door Australië studeerde hij Biomedische Wetenschappen aan 
de Radboud Universiteit Nijmegen. Zijn afsluitende wetenschappelijke stage deed hij aan de afdeling 
Intensive Care van het Radboudumc onder begeleiding van prof. dr. Pickkers. Het klinische onderzoek 
en de patiëntenzorg spraken hem dermate aan dat hij vervolgens ook de studie Geneeskunde 
heeft gedaan. In de tussentijd bleef hij betrokken bij het onderzoek op de afdeling Intensive Care. 
Na zijn studie werkte hij enkele jaren als arts-assistent bij de afdeling Interne Geneeskunde van het 
Radboudumc. Met behulp van een subsidie van ZonMw heeft hij vervolgens zijn promotie onderzoek 
gedaan op de afdeling Intensive Care. Inmiddels is hij in opleiding tot anesthesioloog aan het 
Radboudumc.
De bevindingen uit het medisch wetenschappelijk onderzoek werden gepresenteerd op diverse 
congressen in binnen- en buitenland en hebben geresulteerd in meerdere prijzen.
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